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Abbreviations and Acronyms
2D ¼ 2-dimensional
3D ¼ 3-dimensional
ACE ¼ angiotensin-converting enzyme
AF ¼ atrial fibrillation
ARB ¼ angiotensin-receptor blocker
aPTT ¼ activated partial thromboplastin time
AR ¼ aortic regurgitation
AS ¼ aortic stenosis
AVR ¼ aortic valve replacement
BP ¼ blood pressure
CABG ¼ coronary artery bypass graft
CAD ¼ coronary artery disease
CMR ¼ cardiac magnetic resonance
COR ¼ Class of Recommendation
CT ¼ computed tomography
ECG ¼ electrocardiogram
HF ¼ heart failure
HIV ¼ human immunodeficiency virus
IE ¼ infective endocarditis
INR ¼ international normalized ratio
LA ¼ left atrium
LMWH ¼ low-molecular-weight heparin
LOE ¼ Level of Evidence
LV ¼ left ventricular
LVEF ¼ left ventricular ejection fraction
LVESD ¼ left ventricular end-systolic dimension
MI ¼ myocardial infarction
MR ¼ mitral regurgitation
MS ¼ mitral stenosis
MVR ¼ mitral valve replacement
NYHA ¼ New York Heart Association
NVE ¼ native valve endocarditis
PR ¼ pulmonic regurgitation
PROM ¼ predicted risk of mortality
PVE ¼ prosthetic valve endocarditis
RCT ¼ randomized controlled trial
RV ¼ right ventricular
TAVR ¼ transcatheter aortic valve replacement
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The medical profession should play a central role in evalu-
ating evidence related to drugs, devices, and procedures for
detection, management, and prevention of disease. When
properly applied, expert analysis of available data on the
benefits and risks of these therapies and procedures
can improve the quality of care, optimize patient outcomes,
and favorably affect costs by focusing resources on the most
effective strategies. An organized and directed approache4 The Journal of Thoracic and Cardiovascular Surgeto a thorough review of evidence has resulted in the produc-
tion of clinical practice guidelines that assist clinicians in
selecting the best management strategy for an individual pa-
tient. Moreover, clinical practice guidelines can provide
a foundation for other applications, such as performance
measures, appropriate use criteria, and both quality
improvement and clinical decision support tools.
The American College of Cardiology (ACC) and the
American Heart Association (AHA) have jointly engaged
in the production of guidelines in the area of cardiovascular
disease since 1980. The ACC/AHATask Force on Practice
Guidelines (Task Force) directs this effort by developing,
updating, and revising practice guidelines for cardiovascu-
lar diseases and procedures.
Experts in the subject under consideration are selected from
both ACC and AHA to examine subject-specific data and
write guidelines.Writing committees are specifically charged
with performing a literature review; weighing the strength of
evidence for or against particular tests, treatments, or proce-
dures; and including estimates of expected health outcomes
where such data exist. Patient-specific modifiers, comorbid-
ities, and issues of patient preference that may influence the
choice of tests or therapies are considered, as well as fre-
quency of follow-up and cost effectiveness. When available,
information from studies on cost is considered; however, a re-
view of data on efficacy and outcomes constitutes the primary
basis for preparing recommendations in this guideline.
In analyzing the data and developing recommendations
and supporting text, the writing committee uses evidence-
based methodologies developed by the Task Force.1 The
Class of Recommendation (COR) is an estimate of the
size of the treatment effect, with consideration given to risks
versus benefits, as well as evidence and/or agreement that a
given treatment or procedure is or is not useful/effective or in
some situations may cause harm. The Level of Evidence
(LOE) is an estimate of the certainty or precision of the treat-
ment effect. The writing committee reviews and ranks evi-
dence supporting each recommendation, with the weight
of evidence ranked as LOE A, B, or C, according to specific
definitions. The schema for the COR and LOE is summa-
rized in Table 1, which also provides suggested phrases for
writing recommendations within each COR. Studies are
identified as observational, retrospective, prospective, or
randomized, as appropriate. For certain conditions forwhich
inadequate data are available, recommendations are based
on expert consensus and clinical experience and are ranked
as LOE C. When recommendations at LOE C are supported
by historical clinical data, appropriate references (including
clinical reviews) are cited if available. For issues with sparse
available data, a survey of current practice among the clini-
cian members of the writing committee is the basis for LOE
C recommendations and no references are cited.
A new addition to this methodology is separation of
the Class III recommendations to delineate whether thery c July 2014
TABLE 1. Applying classification of recommendations and level of evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend
themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective. *Data
available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes mellitus, history of prior myocardial infarc-
tion, history of heart failure, and prior aspirin use. yFor comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use
of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.
Nishimura et al Clinical Guidelinesrecommendation is determined to be of ‘‘no benefit’’ or is
associated with ‘‘harm’’ to the patient. In addition, in
view of the increasing number of comparative effectiveness
studies, comparator verbs and suggested phrases for writing
recommendations for the comparative effectiveness of one
treatment or strategy versus another are included for COR
I and IIa, LOE A or B only.
In view of the advances in medical therapy across the
spectrum of cardiovascular diseases, the Task Force has
designated the term guideline-directed medical therapy
(GDMT) to represent optimal medical therapy as definedThe Journal of Thoracic and Cby ACC/AHA guideline (primarily Class I)-recommended
therapies. This new term, GDMT, is used herein and
throughout subsequent guidelines.
Because the ACC/AHA practice guidelines address pa-
tient populations (and clinicians) residing in North Amer-
ica, drugs that are not currently available in North
America are discussed in the text without a specific COR.
For studies performed in large numbers of subjects outside
North America, each writing committee reviews the poten-
tial impact of different practice patterns and patient popula-
tions on the treatment effect and relevance to the ACC/AHAardiovascular Surgery c Volume 148, Number 1 e5
Clinical Guidelines Nishimura et altarget population to determine whether the findings should
inform a specific recommendation.
The ACC/AHA practice guidelines are intended to assist
clinicians in clinical decision making by describing a range
of generally acceptable approaches to the diagnosis, man-
agement, and prevention of specific diseases or conditions.
The guidelines attempt to define practices that meet the
needs of most patients in most circumstances. The ultimate
judgment about care of a particular patient must be made by
the clinician and patient in light of all the circumstances
presented by that patient. As a result, situations may arise
in which deviations from these guidelines may be appro-
priate. Clinical decision making should involve consider-
ation of the quality and availability of expertise in the
area where care is provided. When these guidelines are
used as the basis for regulatory or payer decisions, the
goal should be improvement in quality of care. The Task
Force recognizes that situations arise in which additional
data are needed to inform patient care more effectively;
these areas are identified within each respective guideline
when appropriate.
Prescribed courses of treatment in accordance with
these recommendations are effective only if followed.
Because lack of patient understanding and adherence
may adversely affect outcomes, clinicians should make
every effort to engage the patient’s active participation
in prescribed medical regimens and lifestyles. In addition,
patients should be informed of the risks, benefits, and al-
ternatives to a particular treatment and should be involved
in shared decision making whenever feasible, particularly
for COR IIa and IIb, for which the benefit-to-risk ratio
may be lower.
The Task Force makes every effort to avoid actual, poten-
tial, or perceived conflicts of interest that may arise as a
result of relationships with industry and other entities
(RWI) among the members of the writing committee. All
writing committee members and peer reviewers of the
guideline are required to disclose all current healthcare-
related relationships, including those existing 12 months
before initiation of the writing effort.
In December 2009, the ACC and AHA implemented
a new RWI policy that requires the writing committee
chair plus a minimum of 50% of the writing committee to
have no relevant RWI (Appendix 1 includes the ACC/
AHA definition of relevance). The Task Force and all
writing committee members review their respective RWI
disclosures during each conference call and/or meeting of
the writing committee, and members provide updates to
their RWI as changes occur. All guideline recommendations
require a confidential vote by the writing committee and
require approval by a consensus of the voting members. Au-
thors’ and peer reviewers’ RWI pertinent to this guideline
are disclosed in Appendixes 1 and 2. Members may not
draft or vote on any recommendations pertaining to theire6 The Journal of Thoracic and Cardiovascular SurgeRWI. Members who recused themselves from voting are
indicated in the list of writing committee members with
specific section recusals noted in Appendix 1. In addition,
to ensure complete transparencys’ comprehensive disclo-
sure information—including RWI not pertinent to this
document—is available as an online supplement.
Comprehensive disclosure information for the Task
Force is also available online at http://www.cardiosource.
org/en/ACC/About-ACC/Who-We-Are/Leadership/Guide
lines-and-Documents-Task-Forces.aspx. The ACC and
AHA exclusively sponsor the work of the writing commit-
tee without commercial support. Writing committee mem-
bers volunteered their time for this activity. Guidelines are
official policy of both the ACC and AHA.
In an effort to maintain relevance at the point of care for
clinicians, the Task Force continues to oversee an ongoing
process improvement initiative. As a result, several
changes to these guidelines will be apparent, including
limited narrative text, a focus on summary and evidence
tables (with references linked to abstracts in PubMed),
and more liberal use of summary recommendation tables
(with references that support LOE) to serve as a quick
reference.
In April 2011, the Institute of Medicine released 2 re-
ports: Finding What Works in Health Care: Standards for
Systematic Reviews and Clinical Practice Guidelines We
Can Trust.2,3 It is noteworthy that the Institute of
Medicine cited ACC/AHA practice guidelines as being
compliant with many of the proposed standards. A
thorough review of these reports and of our current
methodology is under way, with further enhancements
anticipated.
The recommendations in this guideline are considered
current until they are superseded by a focused update,
the full-text guideline is revised, or until a published
addendum declares it out of date and no longer official
ACC/AHA policy.
Jeffrey L. Anderson, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines1. INTRODUCTION
1.1. Methodology and Evidence Review
The recommendations listed in this document are, when-
ever possible, evidence based. An extensive review was
conducted on literature published through November
2012, and other selected references through October
2013 were reviewed by the guideline writing committee.
Searches were extended to studies, reviews, and other evi-
dence conducted on human subjects and that were pub-
lished in English from PubMed, EMBASE, Cochrane,
Agency for Healthcare Research and Quality Reports, and
other selected databases relevant to this guideline. Key
search words included but were not limited to the following:ry c July 2014
Nishimura et al Clinical Guidelinesvalvular heart disease, aortic stenosis, aortic regurgitation,
bicuspid aortic valve, mitral stenosis, mitral regurgitation,
tricuspid stenosis, tricuspid regurgitation, pulmonic steno-
sis, pulmonic regurgitation, prosthetic valves, anticoagula-
tion therapy, infective endocarditis, cardiac surgery, and
transcatheter aortic valve replacement. Additionally, the
committee reviewed documents related to the subject matter
previously published by the ACC and AHA. The references
selected and published in this document are representative
and not all-inclusive.
1.2. Organization of the Writing Committee
The committee was composed of clinicians, who
included cardiologists, interventionalists, surgeons, and an-
esthesiologists. The committee also included representa-
tives from the American Association for Thoracic
Surgery, American Society of Echocardiography (ASE),
Society for Cardiovascular Angiography and Interventions,
Society of Cardiovascular Anesthesiologists, and Society
of Thoracic Surgeons (STS).
1.3. Document Review and Approval
This document was reviewed by 2 official reviewers each
nominated by both the ACC and the AHA, as well as 1
reviewer each from the American Association for Thoracic
Surgery, ASE, Society for Cardiovascular Angiography and
Interventions, Society of Cardiovascular Anesthesiologists,
and STS and 39 individual content reviewers (which
included representatives from the following ACC commit-
tees and councils: Adult Congenital and Pediatric Cardiol-
ogy Section, Association of International Governors,
Council on Clinical Practice, Cardiovascular Section Lead-
ership Council, Geriatric Cardiology Section Leadership
Council, Heart Failure and Transplant Council, Interven-
tional Council, Lifelong Learning Oversight Committee,
Prevention of Cardiovascular Disease Committee, and Sur-
geon Council). Reviewers’ RWI information was distrib-
uted to the writing committee and is published in this
document (Appendix 2).
This document was approved for publication by the gov-
erning bodies of the ACC and AHA and endorsed by the
American Association for Thoracic Surgery, ASE, Society
for Cardiovascular Angiography and Interventions, Society
of Cardiovascular Anesthesiologists, and STS.
1.4. Scope of the Guideline
The focus of this guideline is the diagnosis and manage-
ment of adult patients with valvular heart disease (VHD). A
full revision of the original 1998 VHD guideline was made
in 2006, and an update was made in 2008.4 Some recom-
mendations from the earlier VHD guidelines have been
updated as warranted by new evidence or a better
understanding of earlier evidence, whereas others that
were inaccurate, irrelevant, or overlapping were deletedThe Journal of Thoracic and Cor modified. Throughout, our goal was to provide the
clinician with concise, evidence-based, contemporary rec-
ommendations and the supporting documentation to
encourage their use.
This guideline was created in a different format from
prior VHD guidelines to facilitate access to concise, rele-
vant bytes of information at the point of care when clinical
knowledge is needed the most. Thus, each COR is followed
by a brief paragraph of supporting text and references.
Where applicable, sections were divided into subsections
of: (1) diagnosis and follow-up; (2) medical therapy; and
(3) intervention. The purpose of these subsections was to
categorize the COR according to the clinical decision-
making pathways that caregivers use in the management
of patients with VHD. New recommendations for assess-
ment of the severity of valve lesions have been proposed,
based on current natural history studies of patients with
VHD.
The present document applies to adult patients with
VHD. Management of patients with congenital heart dis-
ease and infants and children with valve disease are not ad-
dressed here. The document recommends a combination of
lifestyle modifications and medications that constitute
GDMT. Both for GDMT and other recommended drug
treatment regimens, the reader is advised to confirm dos-
ages with product insert material and to carefully evaluate
for contraindications and drug–drug interactions. Table 2
is a list of associated guidelines that may be of interest
to the reader. The table is intended for use as a resource
and obviates the need to repeat extant guideline
recommendations.2. GENERAL PRINCIPLES
2.1. Evaluation of the Patient With Suspected VHD
Patients with VHD may present with a heart murmur,
symptoms, or incidental findings of valvular abnormalities
on chest imaging or noninvasive testing. Irrespective of
the presentation, all patients with known or suspected
VHD should undergo an initial meticulous history and
physical examination. A careful history is of great impor-
tance in the evaluation of patients with VHD, because deci-
sions about treatment are based on the presence or absence
of symptoms. Due to the slow, progressive nature of many
valve lesions, patients may not recognize symptoms
because they may have gradually limited their daily activity
levels. A detailed physical examination should be per-
formed to diagnose and assess the severity of valve lesions
based on a compilation of all findings made by inspection,
palpation, and auscultation. The use of an electrocardio-
gram (ECG) to confirm heart rhythm and use of a chest
x-ray to assess the presence or absence of pulmonary
congestion and other lung pathology may be helpful in
the initial assessment of patients with known or suspectedardiovascular Surgery c Volume 148, Number 1 e7
TABLE 2. Associated guidelines and statements
Title Organization
Publication
year/reference
Recommendations for Evaluation of the Severity of Native Valvular RegurgitationWith Two-Dimensional
and Doppler Echocardiography
ASE 20035
Guidelines for the Management of Adults With Congenital Heart Disease ACC/AHA 20087
Echocardiographic Assessment of Valve Stenosis: EAE/ASE Recommendations for Clinical Practice EAE/ASE 20098
Recommendations for Evaluation of Prosthetic Valves With Echocardiography and Doppler Ultrasound ASE 20099
Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy ACCF/AHA 201110
Guidelines on the Management of Cardiovascular Diseases During Pregnancy ESC 201111
Antithrombotic and Thrombolytic Therapy for Valvular Disease: Antithrombotic Therapy and Prevention
of Thrombosis
ACCP 201212
Guidelines on the Management of Valvular Heart Disease ESC/EACTS 201213
Guideline for the Management of Heart Failure ACCF/AHA 201314
Guideline for the Management of Patients With Atrial Fibrillation AHA/ACC/HRS 201415
ACC, American College of Cardiology; ACCF, American College of Cardiology Foundation; ACCP, American College of Chest Physicians; AF, atrial fibrillation; AHA, Amer-
ican Heart Association; ASE, American Society of Echocardiography; EACTS, European Association for Cardio-Thoracic Surgery; EAE, European Association of Echocardi-
ography; ESC, European Society of Cardiology; VHD, valvular heart disease.
Clinical Guidelines Nishimura et alVHD. A comprehensive transthoracic echocardiogram
(TTE) with 2–dimensional (2D) imaging and Doppler inter-
rogation should then be performed to correlate findings with
initial impressions based on the initial clinical evaluation.
The TTE will also be able to provide additional informa-
tion, such as the effect of the valve lesion on the cardiac
chambers and great vessels, and to assess for other concom-
itant valve lesions. Other ancillary testing such as transeso-
phageal echocardiography (TEE), computed tomography
(CT) or cardiac magnetic resonance (CMR) imaging, stress
testing, and diagnostic hemodynamic cardiac catheteriza-
tion may be required to determine the optimal treatment
for a patient with VHD. An evaluation of the possible sur-
gical risk for each individual patient should be performed
if intervention is contemplated, as well as other contributing
factors such as the presence and extent of comorbidities
and frailty. Follow-up of these patients is important
and should consist of an annual history and physical
examination in most stable patients. An evaluation of the
patient may be necessary sooner than annually if there is
a change in the patient’s symptoms. In some valve lesions,
there may be unpredictable adverse consequences on
the left ventricle in the absence of symptoms necessitating
more frequent follow-up. The frequency of repeat
testing, such as echocardiography, will be dependent on
the severity of the valve lesion and its effect on the left or
right ventricle, coupled with the known natural history of
the valve lesion.
2.2. Definitions of Severity of Valve Disease
Classification of the severity of valve lesions should be
based on multiple criteria, including the initial findings on
the physical examination, which should then be correlated
with data from a comprehensive TTE. Intervention should
primarily be performed on patients with severe VHD in
addition to other criteria outlined in this document.e8 The Journal of Thoracic and Cardiovascular SurgeThis document provides a classification of the progres-
sion of VHD with 4 stages (A to D) similar to that proposed
by the ‘‘2013 ACCF/AHA Guideline for the Management
of Heart Failure.’’ Indication for intervention in patients
with VHD is dependent on (1) the presence or absence of
symptoms; (2) the severity of VHD; (3) the response of
the left and/or right ventricle to the volume or pressure over-
load caused by VHD; (4) the effect on the pulmonary or sys-
temic circulation; and (5) a change in heart rhythm. The
stages take into consideration all of these important factors
(Table 3). The criteria for the stages of each individual valve
lesion are listed in Section 3 (Table 8), Section 4.2
(Table 11), Section 6.1 (Table 13), Section 7.2 (Tables 15
and 16), and Section 8.1 (Table 19), Section 8.3
(Table 20), Section 9.1 (Table 21), and Section 9.2
(Table 22).
The purpose of valvular intervention is to improve symp-
toms and/or prolong survival, as well as to minimize the risk
of VHD-related complications such as asymptomatic irre-
versible ventricular dysfunction, pulmonary hypertension,
stroke, and atrial fibrillation (AF). Thus, the criteria for ‘‘se-
vere’’ VHD are based on studies describing the natural his-
tory of patients with unoperated VHD, as well as
observational studies relating the onset of symptoms to
measurements of severity. In patients with stenotic lesions,
there is an additional category of ‘‘very severe’’ stenosis
based on studies of the natural history showing that prog-
nosis becomes poorer as the severity of stenosis increases.
Supporting References: 14.
2.3. Diagnosis and Follow-up
Diagnostic testing is very important for the diagnosis
and treatment of patients with VHD. TTE provides
morphological and hemodynamic information for diag-
nosis and quantitation of VHD, as well as for determining
optimal timing for intervention. In selected patients,ry c July 2014
TABLE 3. Stages of progression of VHD
Stage Definition Description
A At risk Patients with risk factors for development of
VHD
B Progressive Patients with progressive VHD (mild-to-
moderate severity and asymptomatic)
C Asymptomatic
severe
Asymptomatic patients who have the criteria
for severe VHD:
C1: Asymptomatic patients with severe VHD
in whom the left or right ventricle remains
compensated
C2: Asymptomatic patients with severe VHD
with decompensation of the left or right
ventricle
D Symptomatic
severe
Patients who have developed symptoms as a
result of VHD
VHD, Valvular heart disease.
Nishimura et al Clinical Guidelinesadditional testing such as stress testing, TEE, cardiac cath-
eterization, and CT or CMR imaging might be indicated.
However, both the performance and interpretation of these
diagnostic tests require meticulous attention to detail as
well as expertise in cardiac imaging and evaluation of
hemodynamics.
2.3.1. Diagnostic Testing–Initial Diagnosis: Recommen-
dation
Class I
1. TTE is recommended in the initial evaluation of patients with
known or suspected VHD to confirm the diagnosis, establish etiol-
ogy, determine severity, assess hemodynamic consequences, deter-
mine prognosis, and evaluate for timing of intervention.17-32
(Level of Evidence: B)
TTE is now the standard diagnostic test in the initial eval-
uation of patients with known or suspected VHD. Echocar-
diographic imaging can accurately assess the morphology
and motion of valves and can usually determine the etiology
of the VHD. TTE can also assess for concomitant disease in
other valves and associated abnormalities such as aortic
dilation. Left ventricular (LV) chamber size and function
can be reliably assessed. It is the LV linear dimensions
from echocardiography, either from 2D images or 2D-
directed M-mode, that have been used in studies to deter-
mine timing of valve operation. Until further studies are
available using LV volumes, the recommendations in this
guideline will refer to LV dimensions. It is also important
to understand the variability in measurements of LV dimen-
sions so that decisions on intervention are based on sequen-
tial studies rather than a single study, especially in
asymptomatic patients. A semiquantitative assessment of
right ventricular (RV) size and function is usually made
by a visual subjective analysis. Doppler TTE is used for
noninvasive determination of valve hemodynamics. In ste-
notic lesions, measurements of the peak velocity, as well
as calculation of valve gradients and valve area, charac-
terize the severity of the lesion. Hemodynamic measure-
ments can be performed at rest and during provocation.
The quantitation of the severity of valve regurgitation is
based on multiple hemodynamic parameters using color
Doppler imaging of jet geometry, continuous wave Doppler
recordings of the regurgitant flow, and pulsed wave Doppler
measures of transvalvular volume flow rates and flow rever-
sals in the atria and great vessels. The hemodynamic effect
of valve lesions on the pulmonary circulation can be deter-
mined using tricuspid regurgitation (TR) velocity to provide
a noninvasive measurement of RV systolic pressure. TTE
quantitation of valve stenosis and valve regurgitation has
been validated against catheterization data, in animal
models with direct measures of disease severity, and in pro-
spective clinical studies using valve replacement and mor-
tality as the primary endpoint. On the basis of their value
in predicting clinical outcomes, these echocardiographicThe Journal of Thoracic and Cparameters are now used to determine timing of valve inter-
vention in conjunction with symptom status.
Supporting References: 17-32
2.3.2. Diagnostic Testing—Changing Signs or Symptoms:
Recommendation
Class I
1. TTE is recommended in patients with known VHD with any
change in symptoms or physical examination findings. (Level of
Evidence: C)
Patients with VHD should be instructed to always report
any change in symptomatic status. Patients with known
VHD who have a change in symptoms should undergo a
repeat comprehensive TTE study to determine whether
the etiology of the symptoms is due to a progression in
the valve lesion, deterioration of the ventricular response
to the volume or pressure overload, or another etiology.
New signs on physical examination also warrant a repeat
TTE. The findings on TTE will be important in determining
the timing of intervention.
Supporting References: 33-40
2.3.3. Diagnostic Testing—Routine Follow-up: Recom-
mendation
Class I
1. Periodic monitoring with TTE is recommended in asymptomatic
patients with known VHD at intervals depending on valve lesion,
severity, ventricular size, and ventricular function. (Level of Evi-
dence: C)
After initial evaluation of an asymptomatic patient with
VHD, the clinician may decide to continue close follow-
up. The purpose of close follow-up is to prevent the irrevers-
ible consequences of severe VHD that primarily affect the
status of the ventricles and pulmonary circulation and
may also occur in the absence of symptoms. At a minimum,
the follow-up should consist of a yearly history and physicalardiovascular Surgery c Volume 148, Number 1 e9
Clinical Guidelines Nishimura et alexamination. Periodic TTE monitoring also provides
important prognostic information. The frequency of a
repeat 2D and Doppler echocardiogram is based on the
type and severity of the valve lesion, the known rate
of progression of the specific valve lesion, and the effect
of the valve lesion on the affected ventricle (Table 4).
This table does not refer to patients with stage D VHD,
who will usually undergo intervention, as will other select
patient populations with stage C VHD.
Supporting References: 22,29,32-35,37-41
2.3.4. Diagnostic Testing—Cardiac Catheterization:
Recommendation
Class I
1. Cardiac catheterization for hemodynamic assessment is recommen-
ded in symptomatic patients when noninvasive tests are inconclu-
sive or when there is a discrepancy between the findings on
noninvasive testing and physical examination regarding severity
of the valve lesion. (Level of Evidence: C)
Although TTE (and in some instances TEE) is now able
to provide the required anatomic and hemodynamic infor-
mation in most patients with VHD, there is still a subset
of patients in whom hemodynamic catheterization is neces-
sary to ensure that the proper decision about treatment is
made. TTE may provide erroneous or inadequate informa-
tion in some patients. Severity of stenosis may be underes-
timated when imaging is difficult or when the Doppler beam
is not directed parallel to the valvular jet velocities. TTE
quantitation of valve regurgitation shows considerable vari-
ability in measurement, and severity of disease may be
overestimated or underestimated if image or Doppler data
quality is suboptimal. If there are inconclusive, noninvasive
data, particularly in the symptomatic patient, or if there is a
discrepancy between the noninvasive tests and clinical find-
ings, a hemodynamic cardiac catheterization is indicated.
The measurements of valve gradients and cardiac output
are important for assessing valve stenosis. Contrast angiog-
raphy is still useful for a semiquantitative assessment of the
severity of regurgitation in those instances in which the
noninvasive results are discordant with the physical exami-
nation. A major advantage of cardiac catheterization is the
measurement of intracardiac pressures and pulmonary
vascular resistance, which may further aid in decision mak-
ing about valve intervention. Diagnostic interventions that
can be performed in the catheterization laboratory include
the use of dobutamine in low-flow states, pulmonary vaso-
dilators in pulmonary hypertension, and exercise hemody-
namics in patients with discrepant symptoms. It must be
emphasized that there is no longer a ‘‘routine’’ cardiac cath-
eterization. Patients who come to the catheterization labora-
tory present complex diagnostic challenges because the
noninvasive testing in these patients has not provided all
pertinent information. Thus, hemodynamic catheterization
needs to be done with meticulous attention to detail ande10 The Journal of Thoracic and Cardiovascular Surgperformed by persons with knowledge and expertise in as-
sessing patients with VHD.
Supporting References: 42,43
2.3.5. Diagnostic Testing—Exercise Testing: Recommen-
dation
Class IIa
1. Exercise testing is reasonable in selected patients with asymptom-
atic severe VHD to 1) confirm the absence of symptoms, or 2) assess
the hemodynamic response to exercise, or 3) determine prognosis.44-
48 (Level of Evidence: B)
In a subset of patients, exercise stress testing will be of
additional value in determining optimal therapy. Because
of the slow, insidious rate of progression of many
valve lesions, patients may deny symptoms as they gradu-
ally limit their activity level over years to match the gradual
limitation imposed by the valve lesion. In patients
with an equivocal history of symptoms, exercise testing
helps identify those who are truly symptomatic. There
may be patients in whom resting hemodynamics do not
correlate with symptoms. In these patients, exercise hemo-
dynamics may be helpful in determining the etiology of the
symptoms, specifically in patients with mitral VHD. Exer-
cise stress testing is of prognostic value in patients with
asymptomatic severe aortic stenosis (AS) and provides
further information about timing of intervention. Exercise
testing in patients with severe VHD should always be per-
formed by trained operators with continuous monitoring
of the ECG and blood pressure (BP).
Supporting References: 44-48
2.4. Basic Principles of Medical Therapy
All patients being evaluated for VHD should also un-
dergo GDMT for other risk factors associated with cardiac
disease. These include hypertension, diabetes mellitus, and
hyperlipidemia. The safety and efficacy of an exercise pro-
gram for patients with VHD has not been established, but
patients will benefit from an exercise prescription in which
a regular aerobic exercise program is followed to ensure
cardiovascular fitness. Although heavy isometric repetitive
training will increase the afterload on the LV, resistive
training with small free weights or repetitive isolated mus-
cle training may be used to strengthen individual muscle
groups.
Most patients with LV systolic dysfunction and severe
VHD should undergo intervention for the valve itself. How-
ever, if the decision has been made for medical therapy,
these patients should receive the GDMT drug therapy for
LV systolic dysfunction, including angiotensin-converting
enzyme (ACE) inhibitors or angiotensin-receptor blockers
(ARBs) and beta-adrenergic blockers. Care must be taken
to not abruptly lower BP in patients with stenotic lesions.
Rheumatic fever prophylaxis and infective endocarditis
(IE) prophylaxis should be given to appropriate groupsery c July 2014
TABLE 4. Frequency of echocardiograms in asymptomatic patients with VHD and normal left ventricular function
Stage Valve lesion
Stage Aortic stenosis* Aortic regurgitation Mitral stenosis Mitral regurgitation
Progressive
(stage B)
Every 3–5 y
(mild severity Vmax 2.0–2.9 m/s)
Every 3–5 y (mild severity)
Every 1–2 y (moderate severity)
Every 3–5 y
(MVA>1.5 cm2)
Every 3–5 y (mild severity)
Every 1–2 y (moderate severity)
Every 1–2 y
(moderate severity Vmax 3.0–3.9 m/s)
Severe
(stage C)
Every 6–12 mo
(Vmax 4 m/s)
Every 6–12 mo
Dilating LV: more frequently
Every 1–2 y
(MVA 1.0–1.5 cm2)
Once every year
(MVA<1.0 cm2)
Every 6–12 mo
Dilating LV: more frequently
Patients with mixed valve disease may require serial evaluations at intervals earlier than recommended for single valve lesions. LV, Left ventricule;MVA, mitral valve area; VHD,
valvular heart disease; Vmax, maximum velocity. *With normal stroke volume.
Nishimura et al Clinical Guidelinesof patients as outlined in Sections 2.4.1 and 2.4.2.
The maintenance of optimal oral health remains the
most important component of an overall healthcare program
in preventing IE. Influenza and pneumococcal vaccinations
should be given to appropriate patient groups with VHD.
Supporting Reference: 49
2.4.1. Secondary Prevention of Rheumatic Fever: Recom-
mendation
Rheumatic fever is an important cause of VHD. In the
United States, acute rheumatic fever has been uncommon
since the 1970s. However, there has been an increase in
the number of cases of rheumatic fever since 1987. Under-
standing of the causative organism, group A Streptococcus,
has been enhanced by the development of kits that allow
rapid detection of this organism. Prompt recognition and
treatment of streptococcal pharyngitis constitute primary
prevention of rheumatic fever. For patients with previous
episodes of well-documented rheumatic fever or in those
with evidence of rheumatic heart disease, long-term anti-
streptococcal prophylaxis is indicated for secondary
prevention.
Supporting Reference: 50
Class I
1. Secondary prevention of rheumatic fever is indicated in patients
with rheumatic heart disease, specifically mitral stenosis (MS)
(Tables 5 and 6).50 (Level of Evidence: C)
Recurrent rheumatic fever is associated with a worsening
of rheumatic heart disease. However, infection with group
A Streptococcus does not have to be symptomatic to trigger
a recurrence, and rheumatic fever can recur even when the
symptomatic infection is treated. Prevention of recurrent
rheumatic fever requires long-term antimicrobial prophy-
laxis rather than recognition and treatment of acute episodes
of group A Streptococcus pharyngitis. The recommended
treatment regimens and duration of secondary prophylaxis
are shown in Tables 5 and 6. In patients with documented
VHD, the duration of rheumatic fever prophylaxis should
be at least 10 years or until the patient is 40 years of age
(whichever is longer).The Journal of Thoracic and Ca2.4.2. IE Prophylaxis: Recommendations
Because of the lack of published evidence on the use of
prophylactic antibiotics to prevent IE, the value of antibiotic
prophylaxis has been questioned by several national and in-
ternational medical societies. Antibiotic prophylaxis is now
indicated for only a subset of patients who are at high risk
for developing IE and at highest risk for an adverse outcome
if IE occurs. Themaintenance of optimal oral health care re-
mains the most effective intervention to prevent future valve
infection.
Supporting References: 51-53
Class IIa
1. Prophylaxis against IE is reasonable for the following patients at
highest risk for adverse outcomes from IE before dental procedures
that involve manipulation of gingival tissue, manipulation of the
periapical region of teeth, or perforation of the oral mucosa54-56
(Level of Evidence: B):
 Patients with prosthetic cardiac valves;
 Patients with previous IE;
 Cardiac transplant recipients with valve regurgitation due to a
structurally abnormal valve; or
 Patients with congenital heart disease with:rdiovB Unrepaired cyanotic congenital heart disease, including
palliative shunts and conduits;
B Completely repaired congenital heart defect repaired with
prosthetic material or device, whether placed by surgery or
catheter intervention, during the first 6 months after the pro-
cedure; or
B Repaired congenital heart disease with residual defects at the
site or adjacent to the site of a prosthetic patch or prosthetic
device.The risk of IE is significantly higher in patients with a his-
tory of prosthetic valve replacement. Even in those patients
at high risk for IE, the evidence for significant reduction in
events with prophylaxis is conflicting. This lack of support-
ing evidence along with the risk of anaphylaxis and
increasing bacterial resistance to antimicrobials led to a sig-
nificant revision in the AHA recommendations for prophy-
laxis so that only those patients at the highest risk of
developing IE (eg, those with prosthetic valves) should be
treated. Furthermore, evidence for prophylaxis has onlyascular Surgery c Volume 148, Number 1 e11
TABLE 6. Duration of secondary prophylaxis for rheumatic fever
Type Duration after last attack
Rheumatic fever with carditis and
residual heart disease
(persistent VHD*)
10 y or until patient is 40 y of age
(whichever is longer)
Rheumatic fever with carditis but no
residual heart disease (no valvular
disease*)
10 y or until patient is 21 y of age
(whichever is longer)
Rheumatic fever without carditis 5 y or until patient is 21 y of age
(whichever is longer)
VHD, Valvular heart disease. *Clinical or echocardiographic evidence. Adapted from
Gerber et al.50
Clinical Guidelines Nishimura et albeen found to be reasonable in dental procedures that
involve manipulation of gingival tissue, manipulation of
the periapical region of teeth, or perforation of the oral
mucosa. In the case of other prosthetic material
(excluding surgically created palliative systemic-
pulmonary shunts or conduits) such as annuloplasty
rings, neochords, Amplatzer devices, and MitraClips, there
have been only sporadic case reports of infected devices.
Given the low infection rate and scarcity of data, there is
no definitive evidence that prophylaxis in these patients is
warranted in the absence of the patient having other high
risks of intracardiac infection.
There are no randomized controlled trials (RCTs) or
large observational cohort studies for prophylaxis in
patients with a previous episode of IE, but given the cu-
mulative risks of mortality with repeated infection, the
potentially disabling complications from repeated infec-
tions, and the relatively low risk of prophylaxis, prophy-
laxis for IE has been recommended in this high-risk
group of patients. IE is substantially more common in
heart transplant recipients than in the general population.
The risk of IE is highest in the first 6 months after trans-
plantation due to endothelium disruption, high-intensity
immunosuppressive therapy, frequent central venous cath-
eter access, and endomyocardial biopsies. If there is a
structurally abnormal valve, IE prophylaxis should be
continued indefinitely, given the high risk of IE in post-
transplant patients.
In patients in whom IE prophylaxis is reasonable, give
prophylaxis before dental procedures that involve manipu-
lation of gingival tissue or the periapical region of teeth
or cause perforation of the oral mucosa. Bacteremia
commonly occurs during activities of daily living such as
routine brushing of the teeth or chewing. Persons at risk
for developing bacterial IE should establish and maintain
the best possible oral health to reduce potential sources of
bacterial seeding. Optimal oral health is maintained through
regular professional dental care and the use of appropriate
dental products, such as manual, powered, and ultrasonic
toothbrushes; dental floss; and other plaque-removal de-
vices. There is no evidence for IE prophylaxis inTABLE 5. Secondary prevention of rheumatic fever
Agent Dosage
Penicillin G benzathine 1.2 million units IM
every 4 wk*
Penicillin V potassium 200 mg orally BID
Sulfadiazine 1 g orally once daily
Macrolide or azalide antibiotic (for patients
allergic to penicillin and sulfadiazine)y
Varies
BID, Twice daily; HIV, human immunodeficiency; IM, intramuscular. *Administra-
tion every 3 wk is recommended in certain high-risk situations. yMacrolide antibiotics
should not be used in persons taking other medications that inhibit cytochrome P450
3A, such as azole antifungal agents, HIV protease inhibitors, and some selective se-
rotonin reuptake inhibitors. Adapted from Gerber et al.50
e12 The Journal of Thoracic and Cardiovascular Surggastrointestinal procedures or genitourinary procedures ab-
sent known enterococcal infection.
Multiple epidemiological studies show no increase in
the rate of IE since adoption of the AHA and European So-
ciety of Cardiology guidelines recommending more restric-
tive use of IE prophylaxis. The NICE (National Institute for
Health and Clinical Excellence, United Kingdom) guide-
lines took an even more radical departure from the previous
prophylaxis standards in not recommending antibiotic pro-
phylaxis for dental or nondental procedures (eg, respiratory,
gastrointestinal, and genitourinary). Similarly, subsequent
epidemiological studies performed in the wake of the
NICE guideline revisions have demonstrated no increase
in clinical cases or deaths from IE. For the recommended
choice of antibiotic regimen when IE prophylaxis is
recommended, see http://www.heart.org/idc/groups/heart-
public/@wcm/@hcm/documents/downloadable/ucm_3076
44.pdf.
Supporting References: 50-59
Class III: No Benefit
1. Prophylaxis against IE is not recommended in patients with VHD
who are at risk of IE for nondental procedures (eg, TEE, esophago-
gastroduodenoscopy, colonoscopy, or cystoscopy) in the absence of
active infection.60 (Level of Evidence: B)
The incidence of IE followingmost procedures in patients
with underlying cardiac disease is low, and there is a lack of
controlled data supporting the benefit of antibiotic prophy-
laxis. Furthermore, the indiscriminate use of antibiotics
can be associated with the development of resistant organ-
isms, Clostridium difficile colitis, unnecessary expense,
and drug toxicity. The risk of IE as a direct result of a flexible
endoscopic procedure is small. Transient bacteremia may
occur during or immediately after endoscopy; however,
there are few reports of IE attributable to endoscopy. For
most gastrointestinal endoscopic procedures, the rate of
bacteremia is 2% to 5%, and organisms typically identified
are unlikely to cause IE. The rate of bacteremia does not in-
crease with mucosal biopsy, polypectomy, or sphincterot-
omy. There are no data to indicate that deep biopsy, such
as that performed in the rectum or stomach, leads to a higher
rate of bacteremia. The rate of transient bacteremia is moreery c July 2014
Nishimura et al Clinical Guidelinescommonly seen in routine activities such as brushing teeth
and flossing (20% to 68%), using toothpicks (20% to
40%), and simply chewing food (7% to 51%). Somegastro-
intestinal procedures, such as esophageal dilation (as high as
45%), sclerotherapy (31%), and endoscopic retrograde
cholangiopancreatography (6% to 18%) have higher rates
of bacteremia than simple endoscopy. However, no studies
indicate reduced rates of IE with antibiotic prophylaxis.
Surgery, instrumentation, or diagnostic procedures
that involve the genitourinary tract may cause bacteremia.
The rate of bacteremia following urinary tract procedures
is high in the presence of urinary tract infection. Steriliza-
tion of the urinary tract with antimicrobial therapy in pa-
tients with bacteriuria should be attempted before elective
procedures, including lithotripsy. Results of a preprocedure
urine culture will allow the clinician to choose antibiotics
appropriate for the recovered organisms.
Supporting References: 61-73
2.5. Evaluation of Surgical and Interventional Risk
The decision to intervene, as well as the type of interven-
tion for a patient with severe VHD, should be based on an
individual risk–benefit analysis. The risk of the procedure
and intermediate-term mortality must be weighed against
the benefits of the procedure in altering the natural history
of the disease and acknowledging the long-term conse-
quences of the intervention. Operative mortality can be esti-
mated from a number of different scoring systems by using
a combination of risk factors such as the STS risk estimate
or Euroscore (http://www.euroscore.org/). There are limita-
tions to these scores, including that they derive only from
surgical patients and that they do not take into consideration
procedure-specific impediments, major organ system
compromise, comorbidities, or the frailty of the patient. A
risk-assessment scheme combining these factors is pre-
sented in Table 7. The STS risk estimate is an accepted
tool to predict the risk of a surgical operation. In an analysis
of aortic valve operations in the STS database from 2002 to
2010, 80% of patients had a predicted risk of mortality
(PROM) of <4% and an actual mean mortality rate of
1.4%. Fourteen percent had a PROM of 4% to 8% and
an actual mean mortality rate of 5.1%, and 6% of patients
had a PROM of>8% and an actual mortality rate of 11.1%.
Other factors such as the frailty of the patient, major organ
system compromise, and procedure-specific impediments
must be taken into consideration. A number of mechanisms
to evaluate frailty assess the ability to perform activities of
daily living (independence in feeding, bathing, dressing,
transferring, toileting, urinary continence, etc.) and mea-
surements of gait speed, grip strength, and muscle mass.
Published frailty scores are available, but a limited evalua-
tion may use the following: no frailty (able to perform all
activities of daily living and perform a 5–meter walk
in<6 seconds), mild degree of frailty (unable to performThe Journal of Thoracic and Ca1 activity of daily living or unable to perform a 5–meter
walk in <6 seconds), and moderate-to-severe degree of
frailty (unable to perform 2 activities of daily living).
Further research is required to enhance the predictive accu-
racy of current risk scores, particularly in patients undergo-
ing transcatheter therapy. The overall risks versus benefits
should then be discussed with the patient and family using
a shared decision-making process.
In addition to the risk classification in Table 7, it is appro-
priate to defer any type of intervention in patients who will
not benefit in terms of symptoms or improved life span from
the procedure. This group of patients in whom surgical or
transcatheter intervention for severe VHD is futile are those
with 1) a life expectancy of<1 year, even with a successful
procedure, and 2) those who have a chance of ‘‘survival
with benefit’’ of<25% at 2 years. Survival with benefit
means survival with improvement by at least 1 New York
Heart Association (NYHA) or Canadian Cardiovascular So-
ciety class in heart failure (HF) or angina symptoms,
improvement in quality of life, or improvement in life ex-
pectancy. Those patients with severe frailty may fall into
this category.
Supporting References: 41,74-78
2.6. The Heart Valve Team and Heart Valve Centers
of Excellence: Recommendations
The number of patients presenting with VHD in devel-
oped countries is growing, primarily due to the increasing
age of the population. In addition, more patients with
VHD are referred to cardiovascular specialists due to
enhanced awareness of various treatments, as well as
improved noninvasive imaging tests. When patients with
VHD are referred for intervention in a timely manner, there
is an improved outcome in preservation of ventricular func-
tion as well as enhanced survival. However, the manage-
ment of patients with VHD is becoming increasingly
complex, due to the use of more sophisticated noninvasive
imaging modalities and technological advances in thera-
pies. These advances result in changing thresholds for valve
interventions. There remain a number of patients who are
referred for intervention too late in the course of their dis-
ease or not referred at all, either of which results in poor
long-term outcomes. Alternatively, intervention in the
asymptomatic patient requires expertise in evaluation and
noninvasive imaging assessment. The advent of transcath-
eter valve therapies has transformed the treatment of elderly
high-risk patients with severe VHD but imposes difficult
decision making in terms of risk–benefit analysis. Patient
care should be customized to the patient’s needs, values,
and expectations.
A competent practicing cardiologist should have the
ability to diagnose and direct the treatment of most pa-
tients with VHD. For instance, otherwise healthy pa-
tients with severe VHD who become symptomaticrdiovascular Surgery c Volume 148, Number 1 e13
TABLE 7. Risk assessment combining STS risk estimate, frailty, major organ system dysfunction, and procedure-specific impediments
Low risk (must meet
all criteria in this column)
Intermediate risk
(any 1 criterion in
this column)
High risk
(any 1 criterion in
this column)
Prohibitive risk
(any 1 criterion in
this column)
STS PROM* <4%
AND
4%-8%
OR
>8%
OR
Predicted risk with surgery of death
or major morbidity (all-cause)
>50% at 1 y
OR
Frailtyy None
AND
1 Index (mild)
OR
2 Indices (moderate to severe)
OR
Major organ system
compromise not to
be improved
postoperativelyz
None
AND
1 Organ system
OR
No more than 2 organ systems
OR
3 Organ systems
OR
Procedure-specific
impedimentx
None Possible procedure-
specific impediment
Possible procedure-specific
impediment
Severe procedure-specific
impediment
CKD, Chronic kidney disease; CNS, central nervous system; CVA, stroke; DLCO2, diffusion capacity for carbon dioxide; FEV1, forced expiratory volume in 1 s; GI, gastroin-
testinal; INR, international normalized ratio; LV, left ventricular; PROM, predicted risk of mortality; RV, right ventricular; STS, Society of Thoracic Surgeons; VKA, vitamin K
antagonist. *Use of the STS PROM to predict risk in a given institution with reasonable reliability is appropriate only if institutional outcomes are within 1 standard deviation of
STS average observed/expected ratio for the procedure in question. ySeven frailty indices: Katz Activities of Daily Living (independence in feeding, bathing, dressing, trans-
ferring, toileting, and urinary continence) and independence in ambulation (no walking aid or assist required or 5-meter walk in<6 s). Other scoring systems can be applied
to calculate no, mild-, or moderate-to-severe frailty. zExamples of major organ system compromise: Cardiac—severe LV systolic or diastolic dysfunction or RV dysfunction,
fixed pulmonary hypertension; CKD stage 3 or worse; pulmonary dysfunction with FEV1<50% or DLCO2<50% of predicted; CNS dysfunction (dementia, Alzheimer’s dis-
ease, Parkinson’s disease, CVAwith persistent physical limitation); GI dysfunction—Crohn’s disease, ulcerative colitis, nutritional impairment, or serum albumin<3.0; cancer—
active malignancy; and liver—any history of cirrhosis, variceal bleeding, or elevated INR in the absence of VKA therapy. xExamples: tracheostomy present, heavily calcified
ascending aorta, chest malformation, arterial coronary graft adherent to posterior chest wall, or radiation damage.
Clinical Guidelines Nishimura et alshould nearly always be considered for intervention.
However, more complex decision-making processes
may be required in select patient populations, such as
those who have asymptomatic severe VHD, those who
are at high risk for intervention, or those who could
benefit from specialized therapies such as valve repair
or transcatheter valve intervention.
The management of patients with complex severe VHD
is best achieved by a Heart Valve Team composed primarily
of a cardiologist and surgeon (including a structural valve
interventionist if a catheter-based therapy is being consid-
ered). In selected cases, there may be a multidisciplinary,
collaborative group of caregivers, including cardiologists,
structural valve interventionalists, cardiovascular imaging
specialists, cardiovascular surgeons, anesthesiologists, and
nurses, all of whom have expertise in the management
and outcomes of patients with complex VHD. The Heart
Valve Team should optimize patient selection for available
procedures through a comprehensive understanding of the
risk–benefit ratio of different treatment strategies. This is
particularly beneficial in patients in whom there are several
options for treatment, such as the elderly high-risk patient
with severe symptomatic AS being considered for trans-
catheter aortic valve replacement (TAVR) or surgical aortic
valve replacement (AVR). The patient and family should be
sufficiently educated by the Heart Valve Team about all al-
ternatives for treatment so that their expectations can be met
as fully as possible using a shared decision-making
approach.
The optimal care of the patient with complex heart dis-
ease is best performed in centers that can provide all avail-
able options for diagnosis and management, including thee14 The Journal of Thoracic and Cardiovascular Surgexpertise for complex aortic or mitral valve repair, aortic
surgery, and transcatheter therapies. This has led to the
development of Heart Valve Centers of Excellence. Heart
Valve Centers of Excellence (1) are composed of experi-
enced healthcare providers with expertise from multiple
disciplines; (2) offer all available options for diagnosis
and management, including complex valve repair, aortic
surgery, and transcatheter therapies; (3) participate in
regional or national outcome registries; (4) demonstrate
adherence to national guidelines; (5) participate in
continued evaluation and quality improvement processes
to enhance patient outcomes; and (6) publicly report their
available mortality and success rates. Decisions about inter-
vention at the Heart Valve Centers of Excellence should be
dependent on the centers’ publicly available mortality rates
and operative outcomes. It is recognized that some Heart
Valve Centers of Excellence may have expertise in select
valve problems.Class I
1. Patients with severe VHD should be evaluated by a multidisci-
plinary Heart Valve Team when intervention is considered. (Level
of Evidence: C)
Decisions about selection and timing of interventions
for patients with severe VHD are best done through the
Heart Valve Team. The Heart Valve Team is composed
primarily of a cardiologist and surgeon (including a struc-
tural valve interventionist if a catheter-based therapy is be-
ing considered). In selected cases, there may be a
multidisciplinary, collaborative group of caregivers,
including cardiologists, structural valve interventionalists,ery c July 2014
Nishimura et al Clinical Guidelinescardiovascular imaging specialists, cardiovascular sur-
geons, anesthesiologists, and nurses, many of whom
have expertise in the management and outcomes of pa-
tients with complex VHD. For patients with infections
of the heart, infectious disease specialists should be
involved. For pregnant women, high-risk obstetrics should
be involved. The Heart Valve Team (1) reviews the pa-
tient’s medical condition and valve abnormality, (2) deter-
mines the possible interventions that are indicated,
technically feasible, and reasonable, and (3) discusses
the risks and outcomes of these interventions with the pa-
tient and family. This approach has been used for patients
with complex coronary artery disease (CAD) and is sup-
ported by reports that patients with complex CAD referred
specifically for percutaneous coronary intervention (PCI)
or coronary artery bypass graft (CABG) surgery in concur-
rent trial registries using a heart team approach have lower
mortality rates than those randomly assigned to PCI or
CABG in controlled trials.
Supporting References: 35,79-84Class IIa
1. Consultation with or referral to a Heart Valve Center of Excellence
is reasonable when discussing treatment options for 1) asymptom-
atic patients with severe VHD, 2) patients who may benefit from
valve repair versus valve replacement, or 3) patients with multiple
comorbidities for whom valve intervention is considered. (Level of
Evidence: C)
With the advent of newer surgical techniques and
lower rates of operative mortality, it is reasonable to lower
the threshold for valve intervention to prevent the adverse
consequences of severe VHD, particularly in the asymp-
tomatic patient with severe VHD. However, the overall
benefit of operating on these patients requires that the
patient be evaluated by those with expertise in assessment
of VHD and that they undergo operation in a center
with low operative mortality and excellent patient out-
comes. If a ‘‘watchful waiting’’ approach is taken in
asymptomatic patients with severe VHD, a Heart Valve
Center of Excellence may be beneficial in ensuring proper
follow-up.
Surgical outcomes depend on the expertise and experi-
ence of the surgeons, especially with highly specialized
operations such as complex mitral valve repair and surgi-
cal treatment of aortic disease. It is well documented that
operative risks and outcomes are better for patients un-
dergoing mitral valve repair versus mitral valve replace-
ment (MVR) in patients with primary mitral
regurgitation (MR) and morphology suitable for repair.
Although the rate of mitral valve repair has increased,
a number of patients with primary MR will still undergo
MVR. The rate of successful mitral valve repair in pa-
tients with primary MR is dependent on the experience
of the surgeon as well as the surgical volume. OptimalThe Journal of Thoracic and Caoutcomes are best achieved in Heart Valve Centers of
Excellence dedicated to the management and treatment
of patients with VHD and that offer all available treat-
ment options, including complex valve repair, aortic sur-
gery, and transcatheter therapies. At Heart Valve Centers
of Excellence, healthcare providers have experience and
expertise from multiple disciplines, demonstrate adher-
ence to national guidelines, participate in regional or na-
tional outcome registries, and publicly report their
available mortality and success rates with a continued
quality improvement program in place. Decisions on
early operation in the asymptomatic patient can then be
made based on the reported data from the specific Heart
Valve Center of Excellence, including mortality
and morbidity statistics as well as durable repair rates
for patients with primary MR. Heart Valve Centers of
Excellence have also been shown to increase the propor-
tion of patients managed according to GDMT, decrease
unnecessary testing, optimize timing of intervention,
and best handle other problems such as operations for
complex multivalve disease, multiple reoperations, and
complex IE. Heart Valve Centers of Excellence can
play an important role in patient and clinician education
to help ensure timely referral for evaluation and proper
protocol for follow-up.
Supporting References: 35,85-883. AORTIC STENOSIS
See Table 8 for the stages of valvular AS and Tables 9 and
10 for a summary of recommendations for choice and
timing of intervention.3.1. Stages of Valvular AS
Medical and interventional approaches to the manage-
ment of patients with valvular AS depend on accurate diag-
nosis of the cause and stage of the disease process. Table 8
shows the stages of AS ranging from patients at risk of AS
(stage A) or with progressive hemodynamic obstruction
(stage B) to severe asymptomatic (stage C) and symptom-
atic AS (stage D). Each of these stages is defined by valve
anatomy, valve hemodynamics, the consequences of valve
obstruction on the left ventricle and vasculature, as well
as by patient symptoms. Hemodynamic severity is best
characterized by the transaortic maximum velocity (or
mean pressure gradient) when the transaortic volume flow
rate is normal. However, some patients with AS have a
low transaortic volume flow rate due to either LV systolic
dysfunction with a low LV ejection fraction (LVEF) or
due to a small hypertrophied left ventricle with a low stroke
volume. These categories of severe AS pose a diagnostic
and management challenge distinctly different from the
challenges faced by the majority of patients with AS, who
have a high gradient and velocity when AS is severe. Theserdiovascular Surgery c Volume 148, Number 1 e15
Clinical Guidelines Nishimura et alspecial subgroups with low-flow AS are designated D2
(with a low LVEF) and D3 (with a normal LVEF).
The definition of severe AS is based on natural history
studies of patients with unoperated AS, which show that
the prognosis is poor once there is a peak aortic valve veloc-
ity of>4 m per second, corresponding to a mean aortic
valve gradient>40 mm Hg. In patients with low forward
flow, severe AS can be present with lower aortic valve ve-
locities and lower aortic valve gradients. Thus, an aortic
valve area should be calculated in these patients. The prog-
nosis of patients with AS is poorer when the aortic valve
area is<1.0 cm2. At normal flow rates, an aortic valve
area of <0.8 cm2 correlates with a mean aortic valve
gradient >40 mm Hg. However, symptomatic patients
who have a calcified aortic valve with reduced opening
and an aortic valve area between 0.8 cm2 and 1.0 cm2 should
be closely evaluated to determine whether they would
benefit from valve intervention. Meticulous attention to
detail is required when assessing aortic valve hemody-
namics, either with Doppler echocardiography or cardiac
catheterization, and the inherent variability of the measure-
ments and calculations should always be considered in
clinical-decision making.
3.2. Aortic Stenosis
3.2.1. Diagnosis and Follow-up
The overall approach to the initial diagnosis of VHD is
discussed in Section 2.3, and additional considerations spe-
cific to patients with AS are addressed here.
3.2.1.1. Diagnostic testing—initial diagnosis: Recommen-
dations
Class I
1. TTE is indicated in patients with signs or symptoms ofAS or a bicuspid
aortic valve for accurate diagnosis of the cause of AS, hemodynamic
severity, LV size, and systolic function, and for determining prognosis
and tim-ing of valve intervention.24,25,89 (Level of Evidence: B)
Most patients with AS are first diagnosed when cardiac
auscultation reveals a systolic murmur or after a review of
TTE requested for other indications. Physical examination
findings are specific but not sensitive for evaluation of ste-
nosis severity. The classic findings of a loud (grade 3/6),
late-peaking systolic murmur that radiates to the carotid ar-
teries, a single or paradoxically split second heart sound,
and a delayed and diminished carotid upstroke confirm
the presence of severe AS. However, carotid upstroke
may be normal in elderly patients because of the effects
of aging on the vasculature, and the murmur may be soft
or may radiate to the apex. The only physical examination
finding that is reliable in excluding the possibility of severe
AS is a normally split second heart sound.
TTE is indicated when there is an unexplained systolic
murmur, a single second heart sound, a history of a bicuspid
aortic valve, or symptoms that might be due to AS.e16 The Journal of Thoracic and Cardiovascular SurgEchocardiographic imaging allows reliable identification
of the number of valve leaflets along with qualitative assess-
ment of valve motion and leaflet calcification. In nearly all
patients, the hemodynamic severity of the stenotic lesion
can be defined with Doppler echocardiographic measure-
ments of maximum transvalvular velocity, mean pressure
gradient, and continuity equation valve area, as discussed
in the European Association of Echocardiography (EAE)/
ASE guidelines for evaluation of valve stenosis. Doppler
evaluation of severity of AS has been well validated in
experimental and human studies compared with direct mea-
surements of intracardiac pressure and cardiac output. In
addition, Doppler measures of severity of AS are potent pre-
dictors of clinical outcome. However, Doppler may under-
estimate or overestimate aortic velocity and disease
severity in some patients, so clinical evaluation should
include symptoms, physical examination findings, and re-
sults of other diagnostic testing as well.
TTE is also useful for determining the LV response to
pressure overload. Systolic function is evaluated using 2D
or 3–dimensional (3D) measurement of LVEF. LV diastolic
function can be evaluated using standard Doppler ap-
proaches and an estimate of pulmonary systolic pressure
derived from the TR jet. In addition, TTE allows diagnosis
and evaluation of concurrent valve lesions, with MR being
common in patients with AS.
Supporting References: 8,19,24,25,27,89-94Class IIa
1. Low-dose dobutamine stress testing using echocardiographic
or invasive hemodynamic measurements is reasonable in
patients with stage D2 AS with all of the following95-97 (Level of
Evidence: B):
a. Calcified aortic valve with reduced systolic opening;
b. LVEF less than 50%;
c. Calculated valve area 1.0 cm2 or less; and
d. Aortic velocity less than 4.0 m per second or mean pressure
gradient less than 40 mm Hg.
Patients with severe AS and concurrent LV systolic
dysfunction often present with a relatively low transvalvular
velocity and pressure gradient (ie, mean pressure
gradient<40 mm Hg) but with a small calculated valve
area. In some of these patients, severe AS is present with
LV systolic dysfunction due to afterload mismatch. In
others, primary myocardial dysfunction is present with
only moderate AS and reduced aortic leaflet opening due
to a low transaortic volume flow rate. In these patients
with low-flow/low-gradient AS and LV systolic dysfunction
(LVEF<50%), it may be useful to measure aortic velocity
(or mean pressure gradient) and valve area during a baseline
state and again during low-dose pharmacological (ie, dobut-
amine infusion) stress testing to determine whether AS is
severe or only moderate and to evaluate for contractile or
flow reserve.ery c July 2014
TABLE 8. Stages of valvular AS
Stage Definition Valve anatomy Valve hemodynamics
Hemodynamic
consequences Symptoms
A At risk of AS  Bicuspid aortic valve
(or other congenital
valve anomaly)
 Aortic valve sclerosis
 Aortic Vmax<2 m/s  None  None
B Progressive AS  Mild-to-moderate leaflet
calcification of a bicuspid
or trileaflet valve with
some reduction in
systolic motion or
 Rheumatic valve
changes with
commissural fusion
 Mild AS: Aortic Vmax
2.0–2.9 m/s or mean
DP<20 mm Hg
 Moderate AS: Aortic
Vmax 3.0–3.9 m/s or mean
DP 20–39 mm Hg
 Early LV diastolic
dysfunction may
be present
 Normal LVEF
 None
C: Asymptomatic severe AS
C1 Asymptomatic
severe AS
 Severe leaflet calcification
or congenital stenosis
with severely reduced
leaflet opening
 Aortic Vmax 4 m/s or
mean DP 40 mm Hg
 AVA typically is 1.0 cm2
(or AVAi 0.6 cm2/m2)
 Very severe AS is an aortic
Vmax 5 m/s or mean
DP 60 mm Hg
 LV diastolic dysfunction
 Mild LV hypertrophy
 Normal LVEF
 None: Exercise testing
is reasonable to confirm
symptom status
C2 Asymptomatic
severe AS with
LV dysfunction
 Severe leaflet calcification
or congenital stenosis
with severely reduced
leaflet opening
 Aortic Vmax 4 m/s or
mean DP 40 mm Hg
 AVA typically 1.0 cm2
(or AVAi 0.6 cm2/m2)
 LVEF<50%  None
D: Symptomatic severe AS
D1 Symptomatic
severe high-
gradient AS
 Severe leaflet calcification
or congenital stenosis
with severely reduced
leaflet opening
 Aortic Vmax 4 m/s or
mean DP 40 mm Hg
 AVA typically 1.0 cm2
(or AVAi 0.6 cm2/m2) but
may be larger with mixed
AS/AR
 LV diastolic dysfunction
 LV hypertrophy
 Pulmonary hypertension
may be present
 Exertional dyspnea or
decreased exercise
tolerance
 Exertional angina
 Exertional syncope
or presyncope
D2 Symptomatic severe
low-flow/low-gradient
AS with reduced
LVEF
 Severe leaflet calcification
with severely reduced
leaflet motion
 AVA 1.0 cm2 with resting
aortic Vmax<4 m/s or mean
DP<40 mm Hg
 Dobutamine stress
echocardiography shows
AVA 1.0 cm2 with Vmax
4 m/s at any flow rate
 LV diastolic dysfunction
 LV hypertrophy
 LVEF<50%
 HF
 Angina
 Syncope or presyncope
D3 Symptomatic severe
low-gradient AS
with normal LVEF or
paradoxical low-flow
severe AS
 Severe leaflet calcification
with severely reduced
leaflet motion
 AVA 1.0 cm2 with aortic
Vmax<4 m/s or mean DP
<40 mm Hg
 Indexed AVA 0.6 cm2/m2
and
 Stroke volume index<35
mL/m2
 Measured when patient is
normotensive (systolic
BP<140 mm Hg)
 Increased LV relative
wall thickness
 Small LV chamber with
low stroke volume
 Restrictive diastolic filling
 LVEF 50%
 HF
 Angina
 Syncope or presyncope
AR, Aortic regurgitation; AS, aortic stenosis; AVA, aortic valve area; AVAi, aortic valve area indexed to body surface area; BP, blood pressure;HF, heart failure; LV, left ventricular;
LVEF, left ventricular ejection fraction; DP, pressure gradient; Vmax, maximum aortic velocity.
Nishimura et al Clinical GuidelinesDobutamine is infused in progressive stages, begin-
ning at 5 mcg/kg per minute and increasing in incre-
ments of 5 mcg/kg per minute to a maximum dose of
20 mcg/kg per minute with appropriate clinical and he-
modynamic monitoring. Echocardiographic and Doppler
data (or hemodynamic data) are recorded at each dose
of dobutamine for measurement of aortic velocity,The Journal of Thoracic and Camean pressure gradient, valve area, and LVEF. Patients
who do not have true anatomically severe AS will
exhibit an increase in valve area with only a modest in-
crease in transaortic velocity or gradient as transaortic
stroke volume increases. In contrast, patients with severe
AS have a relatively fixed valve area even with an in-
crease in LV contractility and transaortic volume flowrdiovascular Surgery c Volume 148, Number 1 e17
TABLE 9. Summary of recommendations for AS: timing of intervention
Recommendations COR LOE References
AVR is recommended for symptomatic patients with severe high-gradient AS who have symptoms by
history or on exercise testing (stage D1)
I B 9,91,134,135
AVR is recommended for asymptomatic patients with severe AS (stage C2) and LVEF<50% I B 136,137
AVR is indicated for patients with severe AS (stage C or D) when undergoing other cardiac surgery I B 108,138
AVR is reasonable for asymptomatic patients with very severe AS (stage C1, aortic velocity5.0 m/s) and
low surgical risk
IIa B 139,140
AVR is reasonable in asymptomatic patients (stage C1) with severe AS and decreased exercise tolerance or
an exercise fall in BP
IIa B 25,47
AVR is reasonable in symptomatic patients with low-flow/low-gradient severe AS with reduced LVEF
(stage D2) with a low-dose dobutamine stress study that shows an aortic velocity 4.0 m/s (or mean
pressure gradient 40 mm Hg) with a valve area 1.0 cm2 at any dobutamine dose
IIa B 43,141,142
AVR is reasonable in symptomatic patients who have low-flow/low-gradient severe AS (stage D3) who are
normotensive and have an LVEF 50% if clinical, hemodynamic, and anatomic data support valve
obstruction as the most likely cause of symptoms
IIa C N/A
AVR is reasonable for patients with moderate AS (stage B) (aortic velocity 3.0–3.9 m/s) who are
undergoing other cardiac surgery
IIa C N/A
AVR may be considered for asymptomatic patients with severe AS (stage C1) and rapid disease
progression and low surgical risk
IIb C N/A
AS, Aortic stenosis; AVR, aortic valve replacement by either surgical or transcatheter approach; BP, blood pressure; COR, Class of Recommendation; LOE, Level of Evidence;
LVEF, left ventricular ejection fraction; N/A, not applicable.
Clinical Guidelines Nishimura et alrate. The document ‘‘Echocardiographic Assessment of
Valve Stenosis: EAE/ASE Recommendations for Clinical
Practice’’ defines severe AS on low-dose dobutamine
stress testing as a maximum velocity 4.0 m per second
with a valve area 1.0 cm2 at any point during the test
protocol. In addition to moderate AS and true severe
AS, low-dose dobutamine stress testing helps identify a
third group of patients who fail to show an increase in
stroke volume 20% with dobutamine, referred to as
‘‘lack of contractile reserve’’ or ‘‘lack of flow reserve.’’
This subgroup of patients appears to have a very poor
prognosis with either medical or surgical therapy. Low-
dose dobutamine stress testing in patients with AS re-
quires center experience in pharmacological stress
testing as well as continuous hemodynamic and electro-
cardiographic monitoring with a cardiologist in
attendance.
Supporting References: 8,43,95,96,98-101TABLE 10. Summary of recommendations for AS: Choice of surgical or t
Recommendations
Surgical AVR is recommended in patients who meet an indication for AVR (Sect
low or intermediate surgical risk
For patients in whom TAVR or high-risk surgical AVR is being considered, mem
Valve Team should collaborate to provide optimal patient care
TAVR is recommended in patients who meet an indication for AVR for AS wh
prohibitive surgical risk and a predicted post-TAVR survival>12 mo
TAVR is a reasonable alternative to surgical AVR in patients who meet an indic
(Section 3.2.3) and who have high surgical risk (Section 2.5)
Percutaneous aortic balloon dilation may be considered as a bridge to surgical o
AVR in severely symptomatic patients with severe AS
TAVR is not recommended in patients in whom existing comorbidities would p
expected benefit from correction of AS
AS, Aortic stenosis; AVR, aortic valve replacement; COR, Class of Recommendation; LOE,
e18 The Journal of Thoracic and Cardiovascular SurgSee Online Data Supplement 1 for more information on
outcomes in patients with low-flow/low-gradient AS with
reduced LVEF.
3.2.1.2. Diagnostic testing—changing signs or symptoms
In patients with known valvular AS, repeat TTE is appro-
priate when physical examination reveals a louder systolic
murmur or a change in the second heart sound orwhen symp-
tomsoccur thatmight be due toASbecausevalve obstruction
may have progressed since the last evaluation. Repeat TTE is
also appropriate in patients with AS who are exposed to
increased hemodynamic demands either electively, such as
noncardiac surgery or pregnancy, or acutely, such as with a
systemic infection, anemia, or gastrointestinal bleeding. In
these clinical settings, knowledge of the severity of valve
obstruction andLV function is critical for optimizing loading
conditions and maintaining a normal cardiac output.
Supporting References: 24,25,89,102,103ranscatheter intervention
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Timing of periodic clinical evaluation of patients with se-
vere asymptomatic AS depends on comorbidities and
patient-specific factors. TTE for re-evaluation of asymp-
tomatic patients with AS with normal LV systolic function
who have no change in signs or symptoms is performed at
intervals of 6 months to 1 year when aortic velocity
is4.0 m per second (stage C), 1 to 2 years when aortic ve-
locity is between 3.0 m per second and 3.9 m per second
(stage B), and 3 to 5 years when aortic velocity is 2.0 m
per second to 2.9 m/s (stage B) (Table 4).
ValvularAS is a progressive disease, and an increase in he-
modynamic severity is inevitable once even mild AS is pre-
sent. The rate of progression of the stenotic lesion has been
estimated in a variety of invasive and noninvasive studies.
When severe AS is present (aortic velocity 4.0 m per sec-
ond), the rate of progression to symptoms is high, with an
event-free survival of only 30% to 50% at 2 years. There-
fore, patients with asymptomatic severe AS require frequent
monitoring for progressive disease because symptom onset
may be insidious and not recognized by the patient.
Once even moderate AS is present (aortic velocity be-
tween 3.0 m per second and 3.9 m per second), the average
rate of progression is an increase in velocity of 0.3 m per
second per year, an increase in mean pressure gradient of
7 mm Hg per year, and a decrease in valve area of
0.1 cm2 per year. There is marked individual variability in
the rate of hemodynamic change. Progression of AS can
be more rapid in older patients and in those with more se-
vere leaflet calcification. Because it is not possible to predict
the exact rate of progression in an individual patient, regular
clinical and echocardiographic follow-up is mandatory in
all patients with asymptomatic mild-to-moderate AS.
In patients with aortic sclerosis, defined as focal areas of
valve calcification and leaflet thickening with an aortic
velocity<2.5 m per second, progression to severe AS oc-
curs in about 10% of patients within 5 years. Patients
with bicuspid aortic valve disease are also at risk for pro-
gressive valve stenosis, with AS being the most common
reason for intervention in patients with a bicuspid aortic
valve (Section 5.1.1).
Supporting References: 28,104-115
See Online Data Supplement 2 for more information on
hemodynamic progression of AS.
3.2.1.4. Diagnostic testing—cardiac catheterization
Diagnostic TTE and Doppler data can be obtained in
nearly all patients, but severity of AS may be underesti-
mated if image quality is poor or if a parallel intercept angle
is not obtained between the ultrasound beam and aortic jet.
CMR imaging shows promise for evaluation of severity of
AS but is not widely available. Cardiac CT imaging is useful
for quantitation of valve calcification (severe calcification is
considered to be present with an aortic valve calcificationThe Journal of Thoracic and Cascore>1,000 Agatston units) and in patients undergoing
TAVR for measurement of annulus area, leaflet length,
and the annular to coronary ostial distance. However, CT
imaging is less useful for evaluation of severity of AS.
When noninvasive data are nondiagnostic or if there is a
discrepancy between clinical and echocardiographic evalu-
ation, cardiac catheterization for determination of severity
of AS is recommended. Transaortic pressure gradients
should be recorded for measurement of mean transaortic
gradient, based on simultaneous LV and aortic pressure
measurements. Aortic valve area should be calculated
with the Gorlin formula, using a Fick or thermodilution car-
diac output measurement. See Section 14.1 for recommen-
dations on coronary angiography in patients with AS.
Supporting References: 42,116
3.2.1.5. Diagnostic testing—exercise testing: Recommen-
dations
Class IIa
1. Exercise testing is reasonable to assess physiological changes with
exercise and to confirm the absence of symptoms in asymptomatic
patients with a calcified aortic valve and an aortic velocity 4.0 m
per second or greater or mean pressure gradient 40 mm Hg or
higher (stage C).25,46,47,117 (Level of Evidence: B)
When performed under the direct supervision of an expe-
rienced clinician, with close monitoring of BP and ECG, ex-
ercise testing in asymptomatic patients is relatively safe and
may provide information that is not evident during the initial
clinical evaluation, particularlywhen the patient’s functional
capacity is unclear. Patients with symptoms provoked by ex-
ercise testing should be considered symptomatic, even if the
clinical history is equivocal. Although it can be challenging
to separate normal exercise limitations from abnormal symp-
toms due to AS, particularly in elderly sedentary patients,
exercise-induced angina, excessive dyspnea early in exer-
cise, dizziness, or syncope are consistent with symptoms of
AS. In 1 series, exercise testing brought out symptoms in
29% of patients who were considered asymptomatic before
testing; in these patients, spontaneous symptoms developed
over the next year in 51% of patients, compared with only
11% of patients who had no symptoms on exercise testing.
Exercise testing can also identify a limited exercise capac-
ity, abnormal BP response, or arrhythmia. An abnormal he-
modynamic response (eg, hypotension or failure to increase
BP with exercise) in patients with severe AS is considered
a poor prognostic finding. In another series, patients with
AS who manifested symptoms, an abnormal BP response
(<20mmHg increase), or ST-segment abnormalitieswith ex-
ercise had a significantly reduced symptom-free survival at 2
years (19% compared with 85%). However, electrocardio-
graphic ST-segment depression is seen in>80% of patients
with AS with exercise and is nonspecific for diagnosis of
CAD. Ventricular tachycardia was reported in early exercise
studies but has not been reported in contemporary series.rdiovascular Surgery c Volume 148, Number 1 e19
Clinical Guidelines Nishimura et alSome studies suggest additional value for measuring
changes in valve hemodynamics with exercise. In a series
of 186 patients with moderate-to-severe AS, stress testing
was normal in 73% of patients; however, adverse cardiac
events occurred in 67 of these patients at a mean follow-up
interval of 20 14 months. Predictors of cardiac events, pri-
marily symptom onset requiring AVR, were age>65 years,
diabetes mellitus, LV hypertrophy, a resting mean pressure
gradient>35 mm Hg, and an increase of>20 mm Hg in
mean pressure gradient with exercise. However, a prospec-
tive study of 123 patients with asymptomatic AS did not
show additive value for exercise hemodynamics for predict-
ing clinical outcome when baseline measures of hemody-
namic severity and functional status were considered.
Recording hemodynamics with exercise is challenging,
and simpler parameters are adequate in most patients.
Supporting References: 25,28,46,47,117-121
See Online Data Supplement 3 for more information on
exercise testing in patients with AS.
Class III: Harm
1. Exercise testing should not be performed in symptomatic patients
with AS when the aortic velocity is 4.0 m per second or greater or
mean pressure gradient is 40 mm Hg or higher (stage D).122 (Level
of Evidence: B)
As reported in several prospective and retrospective
studies, the risk of exercise testing is low in asymptomatic
patients with AS. However, even in asymptomatic patients,
complications include exertional hypotension in up to 10%
of patients, exercise-induced symptoms, and ventricular pre-
mature beats. A retrospective study of 347 patients with AS
who underwent cardiopulmonary exercise testing showed no
deaths or major complications. Most of these patients had no
(78%) or equivocal (16%) symptoms at baseline, with only
20 symptomatic patients (6%) with AS in this series.123
Exercise testing should not be performed in symptomatic
patients with AS owing to a high risk of complications,
including syncope, ventricular tachycardia, and death. In
a prospective survey of 20 medical centers in Sweden that
included 50,000 exercise tests done over an 18–month
period, the complication rate was 18.4; morbidity rate, 5.2;
andmortality rate, 0.4 per 10,000 tests. Although the number
of patients with AS was not reported, 12 of the 92 complica-
tions occurred in patients with AS: 8 had an exercise decline
in BP, 1 had asystole, and 3 had ventricular tachycardia.
Supporting References: 46,47,117-120,122,123
3.2.2. Medical Therapy: Recommendations
Class I
1. Hypertension in patients at risk for developing AS (stage A) and in
patients with asymptomatic AS (stages B and C) should be treated
according to standard GDMT, started at a low dose, and gradually
titrated upward as needed with frequent clinical monitoring.124-126
(Level of Evidence: B)e20 The Journal of Thoracic and Cardiovascular SurgHypertension is common in patients with AS, may be a
risk factor for AS, and adds to the total pressure overload
on the left ventricle in combination with valve obstruction.
Concern that antihypertensive medications might result in a
fall in cardiac output has not been corroborated in studies of
medical therapy, including 2 small RCTs, likely because AS
does not result in ‘‘fixed’’ valve obstruction until late in the
disease process. In 1,616 patients with asymptomatic AS in
the SEAS (Simvastatin Ezetimibe in Aortic Stenosis) study,
hypertension (n¼1,340) was associated with a 56% higher
rate of ischemic cardiovascular events and a 2-fold
increased mortality rate (both P < .01) compared with
normotensive patients with AS, although no impact on
AVR was seen. Medical therapy for hypertension should
follow standard guidelines, starting at a low dose and grad-
ually titrating upward as needed to achieve BP control.
There are no studies addressing specific antihypertensive
medications in patients with AS, but diuretics should be
avoided if the LV chamber is small, because even smaller
LV volumes may result in a fall in cardiac output. In theory,
ACE inhibitors may be advantageous due to the potential
beneficial effects on LV fibrosis in addition to control of hy-
pertension. Beta blockers are an appropriate choice in pa-
tients with concurrent CAD.
Supporting References: 124-128
Class IIb
1. Vasodilator therapy may be reasonable if used with invasive hemo-
dynamic monitoring in the acute management of patients with se-
vere decompensated AS (stage D) with NYHA class IV HF
symptoms. (Level of Evidence: C)
In patients who present with severe AS and NYHA class
IV HF, afterload reduction may be used in an effort to sta-
bilize the patient before urgent AVR. Invasive monitoring
of LV filling pressures, cardiac output, and systemic
vascular resistance is essential because of the tenuous he-
modynamic status of these patients, in whom a sudden
decline in systemic vascular resistance might result in an
acute decline in cardiac output across the obstructed aortic
valve. However, some patients do benefit with an increase in
cardiac output as systemic vascular resistance is slowly
adjusted downward due to the reduction in total LV after-
load. AVR should be performed as soon as feasible in these
patients.
Supporting Reference: 129
Class III: No Benefit
1. Statin therapy is not indicated for prevention of hemodynamic pro-
gression of AS in patients with mild-to-moderate calcific valve dis-
ease (stages B to D).109,130,131 (Level of Evidence: A)
Despite experimental models and retrospective clinical
studies that suggest that lipid-lowering therapy with a statin
might prevent disease progression of calcific AS, 3 large
well-designed RCTs failed to show a benefit either in terms
of changes in hemodynamic severity or in clinical outcomesery c July 2014
Nishimura et al Clinical Guidelinesin patients with mild-to-moderate valve obstruction. Thus,
at the time of publication, there are no data to support the
use of statins for prevention of progression of AS. However,
concurrent CAD is common in patients with AS, and all pa-
tients should be screened and treated for hypercholesterole-
mia using GDMT for primary and secondary prevention of
CAD.
Supporting References: 109,130-133
See Online Data Supplement 4 for more information on
clinical trials of lipid-lowering therapy to slow progression
of AS (stage B) and prevent cardiovascular outcomes.3.2.3. Timing of Intervention: Recommendations
See Table 9 for a summary of recommendations from
this section and Figure 1 for indications for AVR in pa-
tients with AS. These recommendations for timing of
intervention for AS apply to both surgical and transcath-
eter AVR. The integrative approach to assessing risk of
surgical or transcatheter AVR is discussed in Section
2.5. The specific type of intervention for AS is discussed
in Section 3.2.4.
Class I
1. AVR is recommended in symptomatic patients with severe AS (stage
D1) with9,91,134,135 (Level of Evidence: B):
a. Decreased systolic opening of a calcified or congenitally stenotic
aortic valve; and
b. An aortic velocity 4.0 m per second or greater or mean pressure
gradient 40 mm Hg or higher; and
c. Symptoms of HF, syncope, exertional dyspnea, angina, or pre-
syncope by history or on exercise testing.
Hemodynamic progression eventually leading to symp-
tom onset occurs in nearly all asymptomatic patients with
AS. However, survival during the asymptomatic phase is
similar to age-matched controls with a low risk of sudden
death (<1% per year) when patients are followed prospec-
tively and promptly report symptom onset. The rate of
symptom onset is strongly dependent on severity of AS,
with an event-free survival rate of about 75% to 80% at 2
years in those with a jet velocity <3.0 m per second
compared with only 30% to 50% in those with a jet
velocity 4.0 m per second. Patients with asymptomatic
AS require periodic monitoring for development of symp-
toms and progressive disease, but routine AVR is not recom-
mended (Section 3.1).
However, once even mild symptoms caused by severe
AS are present, outcomes are extremely poor unless
outflow obstruction is relieved. Typical initial symptoms
are dyspnea on exertion or decreased exercise tolerance.
The classical symptoms of syncope, angina, and HF are
late manifestations of disease, most often seen in patients
in whom early symptom onset was not recognized and
intervention was inappropriately delayed. In patients
with severe, symptomatic, and calcific AS, the onlyThe Journal of Thoracic and Caeffective treatment is surgical or transcatheter AVR, re-
sulting in improved survival rates, reduced symptoms,
and improved exercise capacity. In the absence of serious
comorbid conditions that limit life expectancy or quality
of life, AVR is indicated in virtually all symptomatic pa-
tients with severe AS and should be performed promptly
after onset of symptoms. Age alone is not a contraindica-
tion to surgery, with several series showing outcomes
similar to age-matched normal subjects in the very
elderly.
Severe AS is defined as an aortic velocity 4.0 m per
second or mean pressure gradient 40 mm Hg based on
outcomes in a series of patients with AS of known hemo-
dynamic severity. Although transaortic velocity and mean
pressure gradient are redundant measures of AS severity—
with native valve AS there is a close linear correlation be-
tween velocity and mean pressure gradient whether
measured by catheterization or Doppler methods—both
are included in this guideline so that either Doppler or
invasive measurements can be used in decision making.
There is substantial overlap in hemodynamic severity be-
tween asymptomatic and symptomatic patients, and there
is no single parameter that indicates the need for AVR.
Instead, it is the combination of symptoms, valve anat-
omy, and hemodynamics (Table 8) that provides
convincing evidence that AVR will be beneficial in an in-
dividual patient. Many patients with a high transaortic ve-
locity/pressure gradient will remain asymptomatic for
several years and do not require AVR until symptom
onset. However, if symptoms are present, a high veloc-
ity/gradient confirms valve obstruction as the cause
of symptoms. With mixed stenosis and regurgitation, a
high velocity/gradient indicates severe mixed aortic valve
disease. Calculation of valve area is not necessary when a
high velocity/gradient is present and the valve is calcified
and immobile; most patients will have a valve area 1.0
cm2 or an indexed valve area 0.6 cm2/m2, but some
will have a larger valve area due to a large body size or
coexisting aortic regurgitation (AR). Thus, the primary
criterion for the definition of severity of AS is based on
aortic velocity or mean pressure gradient. Calculations
of valve area may be supportive but are not necessary
when a high velocity or gradient is present. In contrast,
valve area calculations are essential for patients with AS
and a low ejection fraction or stroke volume as defined
for stages D2 and D3.
Supporting References: 24,25,29,89,92,94,108,109,134,
135,139,140,143-148
See Online Data Supplements 5, 6, and 7 for more infor-
mation on clinical outcomes with asymptomatic AS (stages
B and C) of known hemodynamic severity, incidence of sud-
den death in asymptomatic patients with AS (stages B and
C), and clinical outcomes with symptomatic AS of known
hemodynamic severity, respectively.rdiovascular Surgery c Volume 148, Number 1 e21
FIGURE 1. Indications for AVR in patients with AS. Arrows show the decision pathways that result in a recommendation for AVR. Periodic monitoring is
indicated for all patients in whomAVR is not yet indicated, including those with asymptomatic AS (stage D or C) and those with low-gradient AS (stage D2
or D3) who do not meet the criteria for intervention. AS, Aortic stenosis; AVA, aortic valve area; AVR, aortic valve replacement by either surgical or trans-
catheter approach; BP, blood pressure; DSE, dobutamine stress echocardiography; ETT, exercise treadmill test; LVEF, left ventricular ejection fraction;
DPmean, mean pressure gradient; Vmax, maximum velocity. *AVR should be considered with stage D3 AS only if valve obstruction is the most likely cause
of symptoms, stroke volume index is<35 mL/m2, indexed AVA is0.6 cm2/m2, and data are recorded when the patient is normotensive (systolic BP<140
mm Hg).
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2. AVR is recommended for asymptomatic patients with severe AS
(stage C2) and an LVEF less than 50%with decreased systolic open-
ing of a calcified aortic valve with an aortic velocity 4.0m per second
or greater or mean pressure gradient 40 mm Hg or higher.136,137
(Level of Evidence: B)
In patients with a low LVEF and severe AS, survival
is better in those who undergo AVR than in those
treated medically. The depressed LVEF in many patients
is caused by excessive afterload (afterload mismatch),
and LV function improves after AVR in such patients.
If LV dysfunction is not caused by afterload mismatch,
survival is still improved, likely because of the reduced
afterload with AVR, but improvement in LV functione22 The Journal of Thoracic and Cardiovascular Surgand resolution of symptoms might not be complete after
AVR.
Supporting References: 98,136,141,142,149-153
See Online Data Supplement 1 for more information on
outcomes in patients with low-flow/low-gradient AS with
reduced LVEF.
Class I
3. AVR is indicated for patients with severe AS (stage C or D) when un-
dergoing cardiac surgery for other indications when there is
decreased systolic opening of a calcified aortic valve and an aortic
velocity 4.0 m per second or greater or mean pressure gradient 40
mm Hg or higher.108,138 (Level of Evidence: B)
Prospective clinical studies demonstrate that disease
progression occurs in nearly all patients with severeery c July 2014
Nishimura et al Clinical Guidelinesasymptomatic AS. Symptom onset within 2 to 5 years is
likely when aortic velocity is 4.0 m per second or mean
pressure gradient is 40 mm Hg. The additive risk of
AVR at the time of other cardiac surgery is less than the
risk of reoperation within 5 years.
Supporting References: 108,138,154,155
Class IIa
1. AVR is reasonable for asymptomatic patients with very severe AS
(stage C1) with139,140 (Level of Evidence: B):
a. Decreased systolic opening of a calcified valve;
b. An aortic velocity 5.0 m per second or greater or mean pressure
gradient 60 mm Hg or higher; and
c. A low surgical risk.
In patientswith very severeAS and an aortic velocity5.0
mper second ormean pressure gradient60mmHg, the rate
of symptom onset is approximately 50% at 2 years. Several
observational studies have shown higher rates of symptom
onset and major adverse cardiac events in patients with
very severe, compared with severe, AS. In addition, a study
comparing early surgery with surgery at symptom onset in
57 propensity scorematched pairs showed a lower all-
cause mortality risk with early surgery (hazard ratio [HR]:
0.135; 95% confidence interval [CI]: 0.030 to 0.597;
P ¼ .008). Thus, it is reasonable to consider elective AVR
in patients with very severe asymptomatic AS if surgical
risk is low rather than waiting for symptom onset. A low sur-
gical risk is defined as an STS PROM score of<4.0 in the
absence of other comorbidities or advanced frailty. At Heart
ValveCenters of Excellence, this corresponds to an operative
mortality of<1.5% (Section 2.5). Patient age, avoidance of
patient-prosthesis mismatch, anticoagulation issues, and pa-
tient preferences should be taken into account in a decision to
proceed with AVR or continue watchful waiting.
Supporting References: 115,139,140,145,156-158
Class IIa
2. AVR is reasonable in apparently asymptomatic patients with severe
AS (stage C1) with25,47 (Level of Evidence: B):
a. A calcified aortic valve;
b. An aortic velocity of 4.0 m per second to 4.9 m per second or
mean pressure gradient of 40 mm Hg to 59 mm Hg; and
c. An exercise test demonstrating decreased exercise tolerance or a
fall in systolic BP.
Exercise testing may be helpful in clarifying symptom
status in patients with severe AS. When symptoms are pro-
voked by exercise testing, the patient is considered symp-
tomatic and meets a Class I recommendation for AVR. In
patients without overt symptoms who demonstrate 1) a
decrease in systolic BP below baseline or a failure of BP
to increase by at least 20 mmHg or 2) a significant decrease
in exercise tolerance compared with age and sex normal
standards, symptom onset within 1 to 2 years is high (about
60% to 80%). Thus, it is reasonable to consider electiveThe Journal of Thoracic and CaAVR in these patients when surgical risk is low, taking
into account patient preferences and clinical factors such
as age and comorbid conditions.
Supporting References: 25,46,47,117,119-121
See Online Data Supplement 3 for more information on
exercise testing.
Class IIa
3. AVR is reasonable in symptomatic patients with low-flow/low-
gradient severe AS with reduced LVEF (stage D2) with a43,141,142
(Level of Evidence: B):
a. Calcified aortic valve with reduced systolic opening;
b. Resting valve area 1.0 cm2 or less;
c. Aortic velocity less than 4 m per second or mean pressure
gradient less than 40 mm Hg;
d. LVEF less than 50%; and
e. A low-dose dobutamine stress study that shows an aortic velocity
4 m per second or greater or mean pressure gradient 40 mm Hg
or higher with a valve area 1.0 cm2 or less at any dobutamine
dose.
Mean pressure gradient is a strong predictor of outcome
after AVR, with better outcomes with higher gradients. Out-
comes are poor with severe low-gradient AS but are still
improvedwithAVRcomparedwithmedical therapy in those
with a low LVEF, particularly when contractile reserve is
present. The document ‘‘Echocardiographic Assessment of
Valve Stenosis: EAE/ASE Recommendations for Clinical
Practice’’ defines severe AS on dobutamine stress testing
as a maximum velocity>4.0 m per second with a valve
area 1.0 cm2 at any point during the test protocol, with a
maximum dobutamine dose of 20 mcg/kg per minute. On
the basis of outcome data in several prospective nonrandom-
ized studies, AVR is reasonable in these patients. LVEF typi-
cally increases by 10 LVEF units andmay return to normal if
afterload mismatch was the cause of LV systolic dysfunc-
tion. Some patients without contractile reserve may also
benefit from AVR, but decisions in these high-risk patients
must be individualized because there are no data indicating
who will have a better outcome with surgery.
Supporting References: 43,99,137,141,142,150,151
See Online Data Supplement 1 for more information on
outcomes in patients with low-flow/low-gradient AS with
reduced LVEF.
Class IIa
4. AVR is reasonable in symptomatic patients with low-flow/low-
gradient severe AS (stage D3) with an LVEF 50% or greater, a calci-
fied aortic valve with significantly reduced leaflet motion, and a
valve area 1.0 cm2 or less only if clinical, hemodynamic, and
anatomic data support valve obstruction as the most likely cause
of symptoms and data recorded when the patient is normotensive
(systolic BP<140 mm Hg) indicate (Level of Evidence: C):
a. An aortic velocity less than 4 m per second or mean pressure
gradient less than 40 mm Hg; and
b. A stroke volume index less than 35 mL/m2; and
c. An indexed valve area 0.6 cm2/m2 or less.rdiovascular Surgery c Volume 148, Number 1 e23
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valvular gradient and velocity. However, a subset present
with severe AS despite a low gradient and velocity
due either to concurrent LV systolic dysfunction
(LVEF<50%) or a low transaortic stroke volume with pre-
served LV systolic function. Studies suggest that low-flow/
low-gradient severe AS with preserved LVEF occurs in 5%
to 25% of patients with severe AS. Some studies suggest
that even asymptomatic patients with low-flow/low-
gradient severe AS with a normal LVEF have a poor prog-
nosis and might benefit from AVR. Other studies suggest
that many of these asymptomatic patients have only moder-
ate AS with outcomes similar to other patients with moder-
ate AS and normal transaortic flow rates. However, both
case-control and prospective studies suggest that outcomes
are worse in symptomatic patients with low-flow/low-
gradient AS with a normal LVEF compared with patients
with high-gradient severe AS. Although no RCTs have
been done, a post hoc subset analysis of an RCT suggests
that survival may be improved with TAVR or AVR versus
medical management in the symptomatic patient with
low-flow severe AS.
The clinical approach to patients with low-flow AS relies
on integration of multiple sources of data. Low-flow/low-
gradient severe AS with preserved LVEF should be consid-
ered in patients with a severely calcified aortic valve, an
aortic velocity <4.0 m per second (mean pressure
gradient<40 mmHg), and a valve area1.0 cm2. However,
even with low flow, severe AS is unlikely with
a velocity<3.0 m per second or mean pressure gradient
<20 mm Hg. Typically, there is a small left ventricle with
thick walls, diastolic dysfunction, and a normal LVEF
(50%). The first diagnostic step is to ensure that data
have been recorded and measured correctly. If the patient
was hypertensive, repeat evaluation after control of BP
should be considered. Next, the valve area should be in-
dexed to body size because an apparent small valve area
may be only moderate AS in a small patient; an aortic valve
area index 0.6 cm2/m2 suggests severe AS. Transaortic
stroke volume should be calculated from the LV outflow
tract diameter and Doppler velocity time integral; a stroke
volume indexed to body surface area<35 mL/m2 is consis-
tent with low flow. If the degree of valve calcification cannot
be adequately assessed on TTE, TEE, CT imaging, or fluo-
roscopymay be considered. The patient should be evaluated
for other potential causes of symptoms to ensure that symp-
toms are most likely due to valve obstruction. The risk of
surgery and patient comorbidities should also be taken
into account.
Supporting References: 8,146,159-166
See Online Data Supplement 8 for more information on
outcomes in patients with low-flow/low-gradient AS with
preserved LVEF.e24 The Journal of Thoracic and Cardiovascular SurgClass IIa
5. AVR is reasonable for patients with moderate AS (stage B) with an
aortic velocity between 3.0 m per second and 3.9 m per second or
mean pressure gradient between 20 mm Hg and 39 mm Hg who
are undergoing cardiac surgery for other indications. (Level of Ev-
idence: C)
Calcific AS is a progressive disease, and once moderate
AS is present, the likelihood of symptom onset within 5
years is significant. When the risk of progressive VHD is
balanced against the risk of repeat surgery within 5 years,
it is reasonable to perform AVR at the time of other cardiac
surgery when moderate AS is present (Sections 4.3.3. and
10). This decision must be individualized based on the spe-
cific operative risk in each patient, clinical factors such as
age and comorbid conditions, valve durability, and patient
preferences.
Supporting References: 25,92,138,154,155
Class IIb
1. AVR may be considered for asymptomatic patients with severe
AS (stage C1) with an aortic velocity 4.0 m per second or
greater or mean pressure gradient 40 mm Hg or higher if the
patient is at low surgical risk and serial testing shows an in-
crease in aortic velocity 0.3 m per second or greater per year.
(Level of Evidence: C)
Predictors of rapid disease progression include older age,
more severe valve calcification, and a faster rate of hemody-
namic progression on serial studies. In patients with severe
AS and predictors of rapid disease progression, elective
AVR may be considered if the surgical risk is low and after
consideration of other clinical factors andpatient preferences.
Supporting References: 115,167,168
3.2.4. Choice of Intervention: Recommendations
See Table 10 for a summary of recommendations from
this section.
These recommendations for choice of intervention for
AS apply to both surgical and transcatheter AVR; indica-
tions for AVR are discussed in Section 3.2.3. The integrative
approach to assessing risk of surgical or transcatheter AVR
is discussed in Section 2.5. The choice of proceeding with
surgical versus transcatheter AVR is based on multiple pa-
rameters, including the risk of operation, patient frailty,
and comorbid conditions. Concomitant severe CAD may
also affect the optimal intervention because severe multi-
vessel coronary disease may best be served by AVR and
CABG.
Class I
1. Surgical AVR is recommended in patients who meet an indication
for AVR (Section 3.2.3) with low or intermediate surgical risk
(Section 2.5).74,148 (Level of Evidence: A)
AVR is indicated for survival benefit, improvement in
symptoms, and improvement in LV systolic function in pa-
tients with severe symptomatic AS (Section 3.2.3.). Givenery c July 2014
Nishimura et al Clinical Guidelinesthe magnitude of the difference in outcomes between
those undergoing AVR and those who refuse AVR in his-
torical series, an RCT of AVR versus medical therapy
would not be appropriate in patients with a low to interme-
diate surgical risk (Section 2.5). Outcomes after surgical
AVR are excellent in patients who do not have a high pro-
cedural risk. Surgical series demonstrate improved symp-
toms after AVR, and most patients have an improvement
in exercise tolerance as documented in studies with pre-
and post-AVR exercise stress testing. The specific choice
of prosthetic valve type is discussed in Section 11.1. Sur-
gical AVR should be considered over TAVR in patients
who are at higher surgical risk but have severe multivessel
coronary disease.
Supporting References: 74,93,173-176
Class I
2. For patients in whom TAVR or high-risk surgical AVR is being
considered, a Heart Valve Team consisting of an integrated, multi-
disciplinary group of healthcare professionals with expertise in
VHD, cardiac imaging, interventional cardiology, cardiac anes-
thesia, and cardiac surgery should collaborate to provide optimal
patient care. (Level of Evidence: C)
Decision making is complex in the patient at high sur-
gical risk with severe symptomatic AS. The decision to
perform surgical AVR, TAVR, or to forgo intervention re-
quires input from a Heart Valve Team. The primary cardi-
ologist is aware of coexisting conditions that affect risk
and long-term survival, the patient’s disease course, and
the patient’s preferences and values. Cardiac imaging spe-
cialists who are knowledgeable about AS and TAVR pro-
vide evaluation of aortic valve anatomy and hemodynamic
severity, vascular anatomy, aortic annulus size, and coro-
nary anatomy, including the annular-ostial distance. Inter-
ventional cardiologists help determine the likelihood of a
successful transcatheter procedure. The cardiac surgeon
can provide a realistic estimate of risk with a conventional
surgical approach, at times in conjunction with a cardiac
anesthesiologist. An expert in VHD, typically a cardiolo-
gist or cardiac surgeon with expertise in imaging and/or
intervention, provides the continuity and integration
needed for the collaborative decision-making process.
Nurses and other members of the team coordinate care
and help with patient education. The cardiac surgeon
and interventional cardiologist are the core of the Heart
Valve Team for patients being considered for AVR or
TAVR.
Supporting References: 79,177
Class I
3. TAVR is recommended in patients who meet an indication for AVR
(Section 3.2.3) who have a prohibitive risk for surgical AVR (Section
2.5) and a predicted post-TAVR survival greater than 12
months.169,170 (Level of Evidence: B)
TAVR has been studied in numerous observational
studies and multicenter registries that include largeThe Journal of Thoracic and Canumbers of high-risk patients with severe symptomatic
AS. These studies demonstrated the feasibility, excellent
hemodynamic results, and favorable outcomes of the pro-
cedure. In addition, TAVR was compared with standard
therapy in a prospective RCT of patients with severe
symptomatic AS who were deemed inoperable. Severe
AS was defined as an aortic valve area <0.8 cm2 plus
a mean pressure gradient 40 mm Hg or a maximum
aortic velocity 4.0 m per second. All patients had
NYHA class II to IV symptoms. Patients were considered
to have a prohibitive surgical risk when predicted 30–day
surgical morbidity and mortality were 50% due to co-
morbid disease or a serious irreversible condition. Pa-
tients were excluded if they had a bicuspid aortic
valve, acute myocardial infarction (MI), significant
CAD, an LVEF<20%, an aortic annulus diameter<18
mm or>25 mm, severe AR or MR, a transient ischemic
attack within 6 months, or severe renal insufficiency.
TAVR was performed by either the transfemoral or trans-
apical approach using the SAPIEN heart-valve system
(Edwards Lifesciences LLC, Irvine, CA). Standard ther-
apy included percutaneous aortic balloon dilation in
84%.
All-cause death at 2 years was lower with TAVR (43.3%)
compared with standard medical therapy (68%), with an
HR for TAVR of 0.58 (95% CI: 0.36 to 0.92; P ¼ .02).
There was a reduction in repeat hospitalization with
TAVR (55% versus 72.5%; P< .001). In addition, only
25.2% of survivors were in NYHA class III or IV 1 year af-
ter TAVR, compared with 58% of patients receiving stan-
dard therapy (P<.001). However, the rate of major stroke
at 30 days was higher with TAVR (5.05% versus 1.0%;
P ¼ .06) and remained higher at 2 years with TAVR
compared with standard therapy (13.8% versus 5.5%;
P ¼ .01). Major vascular complications occurred in
16.2% with TAVR versus 1.1% with standard therapy
(P<.001).
Thus, in high-risk patients with severe symptomatic
AS who are unable to undergo surgical AVR due to a pro-
hibitive surgical risk and who have an expected survival
of>1 year after intervention, TAVR is recommended to
improve survival and reduce symptoms. This decision
should be made only after discussion with the patient
about the expected benefits and possible complications of
TAVR and surgical AVR. Patients with severe AS are
considered to have a prohibitive surgical risk if they have
a predicted risk with surgery of death or major morbidity
(all cause) of>50% at 1 year; disease affecting 3 major
organ systems that is not likely to improve postoperatively;
or anatomic factors that preclude or increase the risk of car-
diac surgery, such as a heavily calcified (eg, porcelain)
aorta, prior radiation, or an arterial bypass graft adherent
to the chest wall.
Supporting References: 169,170,178rdiovascular Surgery c Volume 148, Number 1 e25
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1. TAVR is a reasonable alternative to surgical AVR in patients who
meet an indication for AVR (Section 3.2.3) and who have high sur-
gical risk for surgical AVR (Section 2.5).171,172 (Level of Evidence: B)
TAVR has been studied in numerous observational
studies andmulticenter registries that include large numbers
of high-risk patients with severe symptomatic AS. These
studies demonstrated the feasibility, excellent hemody-
namic results, and favorable outcomes of the procedure.
In addition, TAVR was compared with standard therapy in
a prospective RCT of patients with severe symptomatic
AS who were deemed high risk for surgery. Severe symp-
tomatic calcific AS was defined as aortic valve area<0.8
cm2 plus a mean transaortic gradient 40 mm Hg or aortic
velocity 4.0 m per second with NYHA class II to IV
symptoms. Patients were deemed at high surgical risk if
risk of death was15%within 30 days after the procedure.
An STS score 10% was used for guidance, with an actual
mean STS score of 11.8% 3.3%. Exclusions included
bicuspid aortic valve anatomy, acute MI, significant CAD,
an LVEF<20%, an aortic annulus diameter<18 mm or
>25mm, severe AR orMR, transient ischemic attack within
6 months, or severe renal insufficiency. On an intention-to-
treat analysis, all-cause death was similar in those random-
ized to TAVR (n¼ 348) compared with surgical AVR
(n¼ 351) at 30 days, 1 year, and 2 years (P¼ .001) for non-
inferiority of TAVR compared with surgical AVR. The com-
posite endpoint of all-cause death or stroke at 2 years was
35% with surgical AVR compared with 33.9% with
TAVR (P¼ .78). TAVR was performed by the transfemoral
approach in 244 patients and the transapical approach in
104 patients. Only limited data on long-term durability of
bioprosthetic valves implanted by the transcatheter
approach are available.
Given the known long-term outcomes and valve dura-
bility with surgical AVR, TAVR currently remains restricted
to patients with prohibitive or high surgical risk. High sur-
gical risk is defined as an STS PROM score of 8% to
15%, anatomic factors that increase surgical risk, or signif-
icant frailty (Section 14.2).
Supporting References: 171,172,179,180
See Online Data Supplement 9 for more information on
choice of intervention.
Class IIb
1. Percutaneous aortic balloon dilation may be considered as a bridge
to surgical AVR or TAVR in patients with severe symptomatic AS.
(Level of Evidence: C)
Percutaneous aortic balloon dilation has an important
role in treating children, adolescents, and young adults
with AS, but its role in treating older patients is very limited.
The mechanism by which balloon dilation modestly re-
duces the severity of stenosis in older patients is by fracture
of calcific deposits within the valve leaflets and, to a minore26 The Journal of Thoracic and Cardiovascular Surgdegree, stretching of the annulus and separation of the
calcified or fused commissures. Immediate hemodynamic
results include a moderate reduction in the transvalvular
pressure gradient, but the postdilation valve area rarely ex-
ceeds 1.0 cm2. Despite the modest change in valve area, an
early symptomatic improvement usually occurs. However,
serious acute complications, including acute severe AR
and restenosis and clinical deterioration, occur within 6 to
12 months in most patients. Therefore, in patients with
AS, percutaneous aortic balloon dilation is not a substitute
for AVR.
Some clinicians contend that despite the procedural
morbidity and mortality and limited long-term results,
percutaneous aortic balloon dilation can have a temporary
role in the management of some symptomatic patients
who are not initially candidates for surgical AVR or
TAVR. For example, patients with severe AS and refractory
pulmonary edema or cardiogenic shock might benefit from
percutaneous aortic balloon dilation as a ‘‘bridge’’ to AVR;
an improved hemodynamic state may reduce the risks of
TAVR or surgery. In some patients, the effects of percuta-
neous aortic balloon dilation on symptoms and LV function
may be diagnostically helpful as well, but many clinicians
recommend proceeding directly to AVR in these cases.
The indications for palliative percutaneous aortic balloon
dilation in patients in whom AVR cannot be recommended
because of serious comorbid conditions are even less well
established, with no data to suggest improved longevity;
however, some patients do report a decrease in symptoms.
Most asymptomatic patients with severe AS who require ur-
gent noncardiac surgery can undergo surgery at a reason-
ably low risk with anesthetic monitoring and attention to
fluid balance. Percutaneous aortic balloon dilation is not
recommended for these patients. If preoperative correction
of AS is needed, they should be considered for AVR.
Supporting References: 171,172,181-183
Class III: No Benefit
1. TAVR is not recommended in patients in whom existing comorbid-
ities would preclude the expected benefit from correction of AS.169
(Level of Evidence: B)
The survival and symptom reduction benefit of TAVR is
only seen in appropriately selected patients. Baseline clin-
ical factors associated with a poor outcome after TAVR
include advanced age, frailty, smoking or chronic obstruc-
tive pulmonary disease, pulmonary hypertension, liver dis-
ease, prior stroke, anemia, and other systemic conditions.
The STS estimated surgical risk score provides a useful
measure of the extent of patient comorbidities and may
help identify which patients will benefit from TAVR. In pa-
tients with a prohibitive surgical risk for AVR in the PART-
NER (Placement of Aortic Transcatheter Valve) study, the
survival benefit of TAVR was seen in those with an STS
score <5% (n¼ 40, HR: 0.37; 95% CI: 0.13 to 1.01;ery c July 2014
Nishimura et al Clinical GuidelinesP ¼ .04) and in those with an STS score between 5% and
14.9% (n¼ 227, HR: 0.58; 95% CI: 0.41 to 0.8;
P ¼ .002) but not in those with an STS score 15%
(n¼ 90, HR: 0.77; 95%CI: 0.46 to 1.28; P¼ .31). The rela-
tive prevalence of oxygen- dependent lung disease was
similar in all 3 groups. However, the other reasons for inop-
erability were quite different, with a porcelain aorta or prior
chest radiation damage being most common in those with
an STS score of<5% and frailty being most common in
those with an STS score 15%. These data emphasize
the importance of evaluating the likely benefit of TAVR,
as well as the risks, in weighing the risk–benefit ratio of
intervention in an individual patient. TAVR is not recom-
mended in patients with 1) a life expectancy of<1 year,
even with a successful procedure, and 2) those with a
chance of ‘‘survival with benefit’’ of<25% at 2 years.
Supporting References: 115,169,178,1844. AORTIC REGURGITATION
4.1. Acute AR
Acute AR may result from abnormalities of the valve,
primarily IE, or abnormalities of the aorta, primarily aortic
dissection. Acute AR may also occur from iatrogenic com-
plications, such as following percutaneous aortic balloon
dilation or TAVR or following blunt chest trauma. The acute
volume overload on the left ventricle usually results in se-
vere pulmonary congestion as well as a low forward cardiac
output. Urgent diagnosis and rapid intervention can be
lifesaving.
4.1.1. Diagnosis
TTE is indispensable in confirming the presence,
severity, and etiology of AR, estimating the degree of pul-
monary hypertension, and determining whether there is
rapid equilibration of aortic and LV diastolic pressure. Short
deceleration time on the mitral flow velocity curve and early
closure of the mitral valve on M-mode echocardiography
are indicators of markedly elevated LV end-diastolic pres-
sure. A short half-time of<300 milliseconds on the AR ve-
locity curve indicates rapid equilibration of the aortic and
LV diastolic pressures. Assessing reversed flow during dias-
tole in the aortic arch in comparison with the forward sys-
tolic flow provides a quick semiquantitative estimate of
regurgitant fraction.
Acute severe AR caused by aortic dissection is a surgical
emergency that requires particularly prompt identification
and management. However, the presence of new, even
mild, AR, diagnosed by auscultation of a diastolic murmur
or findings on echocardiography, may be a sign of acute
aortic dissection. The sensitivity and specificity of TTE
for diagnosis of aortic dissection are only 60% to 80%,
whereas TEE has a sensitivity of 98% to 100% and a spec-
ificity of 95% to 100%. CT imaging is also very accurateThe Journal of Thoracic and Caand may provide the most rapid approach to diagnosis at
many centers. CMR imaging is useful with chronic aortic
disease but is rarely used in unstable patients with suspected
dissection. Angiography should be considered only when
the diagnosis cannot be determined by noninvasive imaging
and when patients have suspected or known CAD, espe-
cially those with previous CABG.
4.1.2. Intervention
In patients with acute severe AR resulting from IE or
aortic dissection, surgery should not be delayed, especially
if there is hypotension, pulmonary edema, or evidence of
low flow (Section 12). Numerous studies have demonstrated
improved in-hospital and long-term survival in such pa-
tients if they are treated with prompt AVR, as long as there
are no complications (such as severe embolic cerebral dam-
age) or comorbid conditions that make the prospect of re-
covery remote. In a prospectively enrolled multinational
cohort of 1,552 patients with definite native valve endocar-
ditis (NVE), evidence of new ARwas present in 37% of pa-
tients. HF (HR: 2.33; 95% CI: 1.65 to 3.28; P<.001) and
pulmonary edema (HR: 1.51; 95% CI: 1.04 to 2.18;
P ¼ .029) were associated with increased in-hospital mor-
tality. Early surgery was associated with reduced in-
hospital mortality (HR: 0.56; 95% CI: 0.38 to 0.82;
P¼ .003). The effect of early surgery on in-hospital mortal-
ity was also assessed by propensity-based matching adjust-
ment for survivor bias and by instrumental variable
analysis. Compared with medical therapy, early surgery in
the propensity-matched cohort after adjustment for survivor
bias was associated with an absolute risk reduction of 5.9%
(P<.001) for in-hospital mortality.
Intra-aortic balloon counterpulsation is contraindicated
in patients with acute severe AR. Augmentation of aortic
diastolic pressure will worsen the severity of the acute re-
gurgitant volume, thereby aggravating LV filling pressures
and compromising forward output.
Beta blockers are often used in treating aortic dissection.
However, these agents should be used very cautiously, if
at all, for other causes of acute AR because they will block
the compensatory tachycardia and could precipitate a
marked reduction in BP.
Supporting References: 185-195
4.2. Stages of Chronic AR
The most common causes of chronic AR in the United
States and other developed countries are bicuspid aortic
valve and calcific valve disease. In addition, AR frequently
arises from primary diseases causing dilation of the
ascending aorta or the sinuses of Valsalva. Another cause
of AR is rheumatic heart disease (the leading cause in
many developing countries). In the majority of patients
with AR, the disease course is chronic and slowly progres-
sive with increasing LV volume overload and LVadaptationrdiovascular Surgery c Volume 148, Number 1 e27
Clinical Guidelines Nishimura et alvia chamber dilation and hypertrophy. Management of pa-
tients with AR depends on accurate diagnosis of the cause
and stage of the disease process. Table 11 shows the stages
of AR ranging from patients at risk of AR (stage A) or with
progressive mild-to-moderate AR (stage B) to severe
asymptomatic (stage C) and symptomatic AR (stage D).
Each of these stages is defined by valve anatomy, valve he-
modynamics, severity of LV dilation, and LV systolic func-
tion, as well as by patient symptoms.
4.3. Chronic AR
See Figure 2 for indications for AVR for chronic AR.
4.3.1. Diagnosis and Follow-up
4.3.1.1. Diagnostic testing—initial diagnosis: Recommen-
dations
Class I
1. TTE is indicated in patients with signs or symptoms of AR (stages A
to D) for accurate diagnosis of the cause of regurgitation, regurgi-
tant severity, and LV size and systolic function, and for determining
clinical outcome and timing of valve intervention.32,196-205 (Level of
Evidence: B)
The clinical stages that characterize the severity of
chronic AR (Table 11) are defined by symptomatic status,
severity of regurgitation, and LV volume and systolic func-
tion. TTE is an indispensable imaging test for evaluating pa-
tients with chronic AR and guiding appropriate
management decisions. It provides diagnostic information
about the etiology and mechanism of AR (including valve
reparability), severity of regurgitation, morphology of the
ascending aorta, and LV response to the increases in preload
and afterload. Quantitative measures of regurgitant volume
and effective regurgitant orifice area were strong predictors
of clinical outcome in a prospective study of 251 asymp-
tomatic patients with isolated AR and normal LV function
(stages B and C). This was confirmed in a subsequent study
involving 294 patients. Observation of diastolic flow
reversal in the aortic arch or more distally can help identify
patients with severe AR. Numerous studies involving a total
of>1,150 patients have consistently shown that measures of
LV systolic function (LVEF or fractional shortening) and
LV end-systolic dimension (LVESD) or volume are associ-
ated with development of HF symptoms or death in initially
asymptomatic patients (stages B and C1). Moreover, in
symptomatic patients undergoing AVR (stage D), preopera-
tive LV systolic function and end-systolic dimension or vol-
ume are significant determinants of survival and functional
results after surgery. Symptomatic patients (stage D) with
normal LVEF have significantly better long-term postoper-
ative survival than those with depressed systolic function.
Supporting References: 17,32,196-220
See Online Data Supplement 10 for more information on
the natural history of asymptomatic AR.e28 The Journal of Thoracic and Cardiovascular SurgClass I
2. TTE is indicated in patients with dilated aortic sinuses or
ascending aorta or with a bicuspid aortic valve (stages A and
B) to evaluate the presence and severity of AR.221 (Level of Evi-
dence: B)
A diastolic regurgitant murmur is not always audible
in patients with mild or moderate AR. TTE is more sensitive
than auscultation in detecting AR in patients at risk for
development of AR. In a series of 100 patients referred
for echocardiographic evaluation of a systolic murmur, 28
had AR on echocardiography. Auscultation had high spec-
ificity (96%) for detecting AR but low sensitivity (21%),
and diagnostic accuracy was only 75%.
Supporting Reference: 221
Class I
3. CMR is indicated in patients with moderate or severe AR
(stages B, C, and D) and suboptimal echocardiographic images
for the assessment of LV systolic function, systolic and dia-
stolic volumes, and measurement of AR severity.222,223 (Level
of Evidence: B)
CMR imaging provides accurate measures of regurgitant
volume and regurgitant fraction in patients with AR, as well
as assessment of aortic morphology, LV volume, and LV
systolic function. In addition to its value in patients with
suboptimal echocardiographic data, CMR is useful for eval-
uating patients in whom there is discordance between clin-
ical assessment and severity of AR by echocardiography.
CMR measurement of regurgitant severity is less variable
than echocardiographic measurement.
Supporting References: 222-228
4.3.1.2. Diagnostic testing—changing signs or symptoms
Symptoms are the most common indication for AVR in
patients with AR. In patients with previous documenta-
tion of mild or moderate AR, new-onset dyspnea or
angina may indicate that AR has progressed in severity.
If AR remains mild, further investigation for other etiol-
ogies is indicated. In patients with previous documenta-
tion of severe AR, onset of symptoms is an indication
for surgery and repeat TTE is indicated to determine
the status of the aortic valve, aorta, and left ventricle
preoperatively.
Supporting References: 31,214,220,229,230
4.3.1.3. Diagnostic testing—routine follow-up
Patients with asymptomatic severe AR with normal LV
systolic function are at risk for progressive increases in
LV end-diastolic and end-systolic volumes and reduction
in systolic function. In a series of asymptomatic patients
with AR and normal LV systolic function who underwent
serial echocardiograms, predictors of death or symptoms
in a multivariate analysis were age, initial end-systolic
dimension, and rate of change in end-systolic dimensionery c July 2014
TABLE 11. Stages of chronic AR
Stage Definition Valve anatomy Valve hemodynamics
Hemodynamic
consequences Symptoms
A At risk of
AR
 Bicuspid aortic valve (or other
congenital valve anomaly)
 Aortic valve sclerosis
 Diseases of the aortic
sinuses or ascending aorta
 History of rheumatic fever or
known rheumatic heart
disease
 IE
 AR severity: none or trace  None  None
B Progressive
AR
 Mild-to-moderate calcification
of a trileaflet valve bicuspid
aortic valve (or other
congenital valve anomaly)
 Dilated aortic sinuses
 Rheumatic valve changes
 Previous IE
 Mild AR:
B Jet width<25% of LVOT;
B Vena contracta<0.3 cm;
B RVol<30 mL/beat;
B RF<30%;
B ERO<0.10 cm2;
B Angiography grade 1þ
 Moderate AR:
B Jet width 25%–64% of
LVOT;
B Vena contracta 0.3–0.6 cm;
B RVol 30–59 mL/beat;
B RF 30%–49%;
B ERO 0.10–0.29 cm2;
B Angiography grade 2þ
 Normal LV systolic
function
 Normal LV volume or
mild LV dilation
 None
C Asymptomatic
severe AR
 Calcific aortic valve disease
 Bicuspid valve (or other
congenital abnormality)
 Dilated aortic sinuses or
ascending aorta
 Rheumatic valve changes
 IE with abnormal leaflet
closure or perforation
 Severe AR:
B Jet width 65% of LVOT;
B Vena contracta>0.6 cm;
B Holodiastolic flow reversal
in the proximal abdominal
aorta
B RVol 60 mL/beat;
B RF 50%;
B ERO 0.3 cm2;
B Angiography grade 3þ to
4þ;
B In addition, diagnosis of
chronic severe AR requires
evidence of LV dilation
C1: Normal LVEF (50%)
and mild-to-moderate LV
dilation (LVESD 50 mm)
C2: Abnormal LV systolic
function with depressed
LVEF (<50%) or severe
LV dilatation (LVESD
>50 mm or indexed
LVESD>25 mm/m2)
 None; exercise
testing is reasonable
to confirm symptom
status
D Symptomatic
severe AR
 Calcific valve disease
 Bicuspid valve (or other
congenital abnormality)
 Dilated aortic sinuses or
ascending aorta
 Rheumatic valve changes
 Previous IE with abnormal
leaflet closure or perforation
 Severe AR:
B Doppler jet width 65%
of LVOT;
B Vena contracta>0.6 cm,
B Holodiastolic flow reversal
in the proximal abdominal
aorta,
B RVol 60 mL/beat;
B RF 50%;
B ERO 0.3 cm2;
B Angiography grade 3þ
to 4þ;
B In addition, diagnosis of
chronic severe AR requires
evidence of LV dilation
 Symptomatic severe AR
may occur with normal
systolic function (LVEF
50%), mild-to-moderate
LV dysfunction (LVEF
40%–50%), or severe
LV dysfunction (LVEF
<40%);
 Moderate-to-severe LV
dilation is present.
 Exertional dyspnea
or angina or more
severe HF symptoms
AR, Aortic regurgitation; ERO, effective regurgitant orifice; HF, heart failure; IE, infective endocarditis; LV, left ventricular; LVEF, left ventricular ejection fraction; LVESD, left
ventricular end-systolic dimension; LVOT, left ventricular outflow tract; RF, regurgitant fraction; RVol, regurgitant volume.
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FIGURE 2. Indications for AVR for Chronic AR. AR, Aortic regurgitation; AVR, aortic valve replacement (valve repair may be appropriate in selected
patients); ERO, effective regurgitant orifice; LV, left ventricular; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction;
LVESD, left ventricular end-systolic dimension; RF, regurgitant fraction; RVol, regurgitant volume.
Clinical Guidelines Nishimura et aland rest LVEF during serial studies. In asymptomatic pa-
tients who do not fulfill the criteria for AVR, serial imaging
is indicated to identify thosewho are progressing toward the
threshold for surgery (Table 4).
Supporting Reference: 32
4.3.1.4. Diagnostic testing—cardiac catheterization
When there is discordance between clinical assessment
and noninvasive tests about the severity of AR, additional
testing is indicated. Under most circumstances, another
noninvasive test such as CMR is used when TTE and
clinical findings are discordant. Invasive assessment is indi-
cated when CMR is not available or there are contraindica-
tions for CMR, such as implanted devices. In symptomatic
patients with equivocal echocardiographic evidence
of severity of AR, cardiac catheterization is useful to
assess hemodynamics, coronary artery anatomy, and severity
of AR.
Supporting References: 222,224-228e30 The Journal of Thoracic and Cardiovascular Surg4.3.1.5. Diagnostic testing—exercise testing
Exercise stress testing can be used to assess symptomatic
status and functional capacity in patients with AR. Such
testing is helpful in confirming patients’ reports that they
have no symptoms with daily life activities and in assessing
objective exercise capacity and symptom status in those
with equivocal symptoms.4.3.2. Medical Therapy: Recommendations
Class I
1. Treatment of hypertension (systolic BP>140 mmHg) is recommen-
ded in patients with chronic AR (stages B and C), preferably with
dihydropyridine calcium channel blockers or ACE inhibitors/
ARBs.204,209 (Level of Evidence: B)
Vasodilating drugs are effective in reducing systolic BP
in patients with chronic AR. Beta blockers may be less
effective because the reduction in heart rate is associated
with an even higher stroke volume, which contributesery c July 2014
Nishimura et al Clinical Guidelinesto the elevated systolic pressure in patients with chronic
severe AR.
Supporting References: 204,209,231-233
Class IIa
1. Medical therapy with ACE inhibitors/ARBs and beta blockers is
reasonable in patients with severe AR who have symptoms and/or
LV dysfunction (stages C2 and D) when surgery is not performed
because of comorbidities.232,234 (Level of Evidence: B)
Vasodilating drugs improve hemodynamic abnormalities
in patients with AR and improve forward cardiac output.
However, 2 small RCTs yielding discordant results did
not conclusively show that these drugs alter the natural his-
tory of asymptomatic patients with chronic severe AR and
normal LV systolic function. Thus, vasodilator therapy is
not recommended routinely in patients with chronic asymp-
tomatic AR and normal LV systolic function.
In symptomatic patients who are candidates for surgery,
medical therapy is not a substitute for AVR. However, med-
ical therapy is helpful for alleviating symptoms in patients
who are considered at very high risk for surgery because
of concomitant comorbid medical conditions. In a cohort
study of 2,266 patients with chronic AR, treatment with
ACE inhibitors or ARBs was associated with a reduced
composite endpoint of AVR, hospitalization for HF, and
death from HF (HR: 0.68; 95% CI: 0.54 to 0.87; P<.01).
In that study, 45% had evidence of LV systolic impairment.
In another retrospective cohort study of 756 patients with
chronic AR, therapy with beta-adrenergic blockers was
associated with improved survival (HR: 0.74; 95% CI:
0.58 to 0.93; P<.01). Also, 33% of patients had associated
CAD, 64% had hypertension, 20% had renal insufficiency,
70% had HF, and 25% had AF. Patients treated with beta
blockers were more likely to also be taking ACE inhibitors
(53% vs 40%; P < .001) and dihydropyridine calcium
channel blockers (22% vs 16%; P ¼ .03). Importantly,
more patients receiving beta blockers in that study under-
went AVR (49% vs 29%; P<.001), but this was accounted
for in the multivariate model. When patients were censored
at the time of surgery, beta-blocker therapy remained asso-
ciated with higher survival rates (P<.05).
Supporting References: 204,209,231,232,234-239
See Online Data Supplement 11 for more information on
vasodilator therapy in AR.
4.3.3. Timing of Intervention: Recommendations
See Table 12 for a summary of recommendations from
this section.
The vast majority of patients who require surgery for
chronic severe ARwill require AVR. Valve-sparing replace-
ment of the aortic sinuses and ascending aorta is a possible
strategy in patients with AR caused by aortic dilation in
whom a trileaflet or bicuspid valve is not thickened,
deformed, or calcified. Despite advances in primary aortic
valve repair, especially in young patients with bicuspidThe Journal of Thoracic and Caaortic valves, the experience at a few specialized centers
has not yet been replicated at the general community level,
and durability of aortic valve repair remains a major
concern. Performance of aortic valve repair should be
concentrated in those centers with proven expertise in the
procedure.
Supporting References: 244-247
Class I
1. AVR is indicated for symptomatic patients with severe AR regard-
less of LV systolic function (stage D).31,229,230 (Level of Evidence: B)
Symptoms are an important indication for AVR in pa-
tients with chronic severe AR, and the most important
aspect of the clinical evaluation is taking a careful, detailed
history to elicit symptoms or diminution of exercise capac-
ity. Patients with chronic severe ARwho develop symptoms
have a high risk of death if AVR is not performed. In a series
of 246 patients with severe AR followed without surgery,
those who were NYHA class III or IV had a mortality rate
of 24.6% per year; even NYHA class II symptoms were
associated with increased mortality (6.3% per year).
Numerous other studies indicate that survival and func-
tional status after AVR are related to severity of preopera-
tive symptoms assessed either subjectively or objectively
with exercise testing, with worse outcomes in patients
who undergo surgery after development of moderately se-
vere (NYHA class III) symptoms or impaired exercise ca-
pacity. In a series of 289 patients followed after AVR,
long-term postoperative survival was significantly higher
in patients who were in NYHA class I or II at the time of
surgery compared with those in NYHA class III or IV
(10–year survival rates 78%7% versus 45%4%,
respectively; P< .001). The importance of preoperative
symptoms in the study was observed for both patients
with normal LV systolic function and thosewith LV systolic
dysfunction. Postoperative survival is significantly higher in
symptomatic patients with normal LVEF compared with
those with impaired systolic function, but even in symptom-
atic patients with severely depressed systolic function, sur-
gery is recommended over medical therapy. In a
postoperative series of 450 patients undergoing AVR from
1980 to 1995, patients with markedly low LVEF incurred
high short- and long-term mortality after AVR. However,
postoperative LV function improved significantly, and
most patients survived without recurrence of HF. This was
confirmed in a series of 724 patients who underwent AVR
from 1972 to 1999, in which long-term survival was signif-
icantly reduced in the 88 patients with severe LV dysfunc-
tion (LVEF<30%) compared with the 636 patients with
either less severe LV dysfunction or normal LVEF (81%
vs 92% at 1 year, 68% vs 81% at 5 years, 46% vs 62%
at 10 years, 26% vs 41% at 15 years, and 12% versus
24% at 20 years, respectively; P ¼ .04). Among
propensity-matched patients operated on in the latter timerdiovascular Surgery c Volume 148, Number 1 e31
TABLE 12. Summary of recommendations for AR intervention
Recommendations COR LOE References
AVR is indicated for symptomatic patients with severe AR regardless of LV systolic function (stage D) I B 31,229,230
AVR is indicated for asymptomatic patients with chronic severe AR and LV systolic dysfunction
(LVEF<50%) (stage C2)
I B 211,229,240,241
AVR is indicated for patients with severe AR (stage C or D) while undergoing cardiac surgery for other
indications
I C N/A
AVR is reasonable for asymptomatic patients with severe ARwith normal LV systolic function (LVEF50%)
but with severe LV dilation (LVESD>50 mm, stage C2)
IIa B 225,242,243
AVR is reasonable in patients with moderate AR (stage B) who are undergoing other cardiac surgery IIa C N/A
AVR may be considered for asymptomatic patients with severe AR and normal LV systolic function
(LVEF50%, stage C1) but with progressive severe LV dilation (LVEDD>65 mm) if surgical risk is low*
IIb C N/A
AR, Aortic regurgitation; AVR, aortic valve replacement; COR, Class of Recommendation; LOE, Level of Evidence; LV, left ventricular; LVEDD, left ventricular end-diastolic
dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; N/A, not applicable. *Particularly in the setting of progressive LVenlarge-
ment.
Clinical Guidelines Nishimura et alframe since 1985, these trends were no longer significant
(survival at 1, 5, and 10 years after surgery was 92%,
79%, and 51%, respectively for patients with severe LV
dysfunction and 96%, 83%, and 55% for the others,
respectively; P ¼ .9).
Supporting References: 31,211-221,229,230,240,241,
248,249
See Online Data Supplement 12 for more information on
outcome after surgery for AR.
Class I
2. AVR is indicated for asymptomatic patients with chronic severe AR
and LV systolic dysfunction (LVEF<50%) at rest (stage C2) if no
other cause for systolic dysfunction is identified.211,229,240,241
(Level of Evidence: B)
After AVR, LV systolic function is an important deter-
minant of survival and functional status for chronic severe
AR. Optimal outcomes are obtained when surgery is per-
formed before LVEF decreases below 50%. However,
among patients with LV systolic dysfunction, LV function
will improve in many after surgery, especially those with
minimal or no symptoms, mild versus severe LV systolic
dysfunction, and a brief duration of LV dysfunction. A se-
ries of 37 patients with severe AR who underwent AVR
were studied, all of whom had preoperative LV dysfunc-
tion but preserved exercise capacity (including 8 asymp-
tomatic patients). In the 10 patients in whom LV
dysfunction had developed <14 months preoperatively,
there was a greater improvement in LV systolic function
and regression of LV dilatation compared with those pa-
tients who had a longer duration of LV dysfunction. Pa-
tients with preserved exercise capacity had higher
survival rates, a shorter duration of LV dysfunction, and
a persistent improvement in LV size and systolic function
at late postoperative studies at 3 to 7 years. Thus, once LV
systolic dysfunction (LVEF<50%) is demonstrated, re-
sults are optimized by referring for surgery rather than
waiting for onset of symptoms or more severe LV
dysfunction.e32 The Journal of Thoracic and Cardiovascular SurgSupporting References: 17,211-220,229,240-242,249,
250
Class I
3. AVR is indicated for patients with severe AR (stage C or D) while
undergoing cardiac surgery for other indications. (Level of Evi-
dence: C)
Patients with chronic severe AR should undergo AVR if
they are referred for other forms of cardiac surgery, such
as CABG, mitral valve surgery, or replacement of the
ascending aorta. This will prevent both the hemodynamic
consequences of persistent AR during the perioperative
period and the possible need for a second cardiac operation
in the near future.
Class IIa
1. AVR is reasonable for asymptomatic patients with severe AR with
normal LV systolic function (LVEF50%) but with severe LV dila-
tion (LVESD >50 mm or indexed LVESD >25 mm/m2) (stage
C2).225,242,243 (Level of Evidence: B)
LVESD in patients with chronic AR reflects both the
severity of the LV volume overload and the degree of
LV systolic shortening. An elevated end-systolic dimen-
sion often reflects LV systolic dysfunction with a
depressed LVEF. If LVEF is normal, an increased LVESD
indicates a significant degree of LV remodeling and is
associated with subsequent development of symptoms
and/or LV systolic dysfunction. In a series of 104 initially
asymptomatic patients with normal LV systolic function
followed for a mean of 8 years, an LVESD >50 mm
was associated with a risk of death, symptoms, and/or
LV dysfunction of 19% per year. In a second study of
101 similar patients followed for a mean of 5 years, this
risk was 7% per year. In a third study of 75 similar pa-
tients followed for a mean of 10 years, the risk was
7.6% per year. Among patients undergoing AVR, a
smaller LVESD is associated with both better survival
and improvement in LV systolic function after surgery.
Most studies used unadjusted LV dimension, with moreery c July 2014
Nishimura et al Clinical Guidelinesrecent data suggesting that indexing for body size may be
appropriate, particularly in women or small patients. A
study of 246 patients that adjusted end-systolic dimension
for body size suggested that an end-systolic dimension
25 mm/m2 is associated with a poor outcome in asymp-
tomatic patients. This has been confirmed by a subsequent
study of 294 asymptomatic patients in which an end-
systolic dimension>24 mm/m2 was an independent pre-
dictor of LV systolic dysfunction, symptoms, or death,
and an earlier study of 32 patients in which an end-
systolic dimension >26 mm/m2 was associated with
persistent LV dilation after AVR. Other studies have sug-
gested that end-systolic volume index is a more sensitive
predictor of cardiac events than end-systolic dimension
in asymptomatic patients, but values of end-systolic vol-
ume index identifying high-risk patients have varied be-
tween 35 mL/m2 and 45 mL/m2 in 2 studies. Thus, more
data are needed to determine threshold values of end-
systolic volume index with which to make recommenda-
tions for surgery in asymptomatic patients.
Supporting References: 17,31,32,196,197,199,203-205,
208,212-216,218,242,243,249,251-254
See Online Data Supplement 12 for more information on
AVR in asymptomatic patients.
Class IIa
2. AVR is reasonable in patients with moderate AR (stage B) while un-
dergoing surgery on the ascending aorta, CABG, or mitral valve
surgery. (Level of Evidence: C)
Because of the likelihood of progression of AR and the
need for future AVR in patients with moderate AR, it is
reasonable to replace the aortic valve in patients who
have evidence of primary aortic valve leaflet disease or sig-
nificant aortic dilation if they are referred for other forms of
cardiac surgery, such as CABG, mitral valve surgery, or
replacement of the ascending aorta.
Class IIb
1. AVR may be considered for asymptomatic patients with severe AR
and normal LV systolic function at rest (LVEF50%, stage C1) but
with progressive severe LV dilatation (LV end-diastolic dimension
>65 mm) if surgical risk is low. (Level of Evidence: C)
LV end-diastolic dimension is indicative of the severity
of LV volume overload in patients with chronic AR. It is
significantly associated with development of symptoms
and/or LV systolic dysfunction in asymptomatic patients
but less so than LVESD. Similarly, end-diastolic volume
index is less predictive than end-systolic volume index
in asymptomatic patients. However, especially in young
patients with severe AR, progressive increases in end-
diastolic dimension are associated with a subsequent
need for surgery. In a series of 104 initially asymptomatic
patients with normal LV systolic function followed for a
mean of 8 years, an LV end-diastolic dimension of 70
mm was associated with a risk of death, symptoms,The Journal of Thoracic and Caand/or LV dysfunction of 10% per year. In a second study
of 101 patients followed for a mean of 5 years, this risk
was 6.3% per year; in a third study of 75 patients fol-
lowed for a mean of 10 years, the risk was 5.8% per
year. Marked increases in end-diastolic dimension (80
mm) have been associated with sudden death. The writing
committee thought that AVR may be considered for the
asymptomatic patient with severe AR, normal LV systolic
function, and severe LV dilatation (LV end-diastolic
dimension>65 mm) if there is a low surgical risk and
particularly if there is evidence of progressive LV
dilation.
New markers of severity of AR and its resultant LV vol-
ume overload are under investigation. These include mea-
sures of regurgitant fraction, regurgitant volume, and
effective regurgitant orifice area; LV volume assessment
with 3D echocardiography; noninvasive measures of LV
end-systolic stress and systolic and diastolic strain rates;
and biomarkers such as brain natriuretic peptide. Further
experience with these new markers pertaining to patient
outcomes is necessary before firm recommendations can
be proposed.
Supporting References: 32,196,197,203-2075. BICUSPID AORTIC VALVE AND AORTOPATHY
Patients with a bicuspid aortic valve may also have an
associated aortopathy consisting of aortic dilation, coarcta-
tion, or even aortic dissection.5.1. Bicuspid Aortic Valve
5.1.1. Diagnosis and Follow-up
5.1.1.1. Diagnostic testing—initial diagnosis: Recommen-
dations
Class I
1. An initial TTE is indicated in patients with a known bicuspid aortic
valve to evaluate valve morphology, to measure the severity of AS
and AR, and to assess the shape and diameter of the aortic sinuses
and ascending aorta for prediction of clinical outcome and to deter-
mine timing of intervention.255-260 (Level of Evidence: B)
Most patients with a bicuspid aortic valve will develop
AS or AR over their lifetime. Standard echocardiographic
approaches for measurement of stenosis and regurgitant
severity are key to optimal patient management as
detailed in the recommendations for AS and AR
(Sections 3 and 4).
Bicuspid aortic valves are frequently associated with
aortic dilation either at the level of the sinuses of Valsalva
or, more frequently, in the ascending aorta. In some patients,
severe aneurysmal aortic dilation may develop. The inci-
dence of aortic dilation is higher in patients with fusion of
the right and noncoronary cusps than the more common
phenotype of fusion of the right and left coronary cusps.
In a series of 191 patients with bicuspid aortic valvesrdiovascular Surgery c Volume 148, Number 1 e33
Clinical Guidelines Nishimura et alundergoing echocardiography, those with fusion of the right
or left coronary cusp and the noncoronary cusp had a greater
prevalence of aortic dilation than those with the fusion of
the right and left coronary cusps (68% vs 40%). This was
confirmed in a subsequent report of 167 patients with
bicuspid aortic valves studied with CT and echocardiogra-
phy. Patients with fusion involving the noncoronary cusp
are also more likely to have dilation of the ascending aorta,
rather than the sinuses, which often extends to the trans-
verse arch.
In nearly all patients with a bicuspid aortic valve, TTE
provides good quality images of the aortic sinuses with ac-
curate diameter measurements. Further cephalad segments
of the ascending aorta can be imaged in many patients by
moving the transducer up 1 or 2 interspaces to view the
arch from a suprasternal notch approach. The echocardio-
graphic report should include aortic measurements at the
aortic annulus, sinuses, sinotubular junction, and mid-
ascending aorta, along with an indicator of the quality and
completeness of aortic imaging in each patient with a
bicuspid aortic valve. Doppler interrogation of the proximal
descending aorta allows evaluation for aortic coarctation,
which is associated with the presence of a bicuspid aortic
valve.
In 20% to 30% of patients with bicuspid valves, other
family members also have bicuspid valve disease and/or
an associated aortopathy. A specific genetic cause has not
been identified, and the patterns of inheritance are variable,
so it is important to take a family history and inform patients
that other family members may be affected. Imaging of
first-degree relatives is clearly appropriate if the patient
has an associated aortopathy or a family history of VHD
or aortopathy. Many valve experts also recommend
screening all first-degree relatives of patients with bicuspid
aortic valve, although we do not yet have data addressing
the possible impact of screening on outcomes or the cost-
effectiveness of this approach.
Supporting References: 255-261
Class I
2. Aortic magnetic resonance angiography or CTangiography is indi-
cated in patients with a bicuspid aortic valve when morphology of
the aortic sinuses, sinotubular junction, or ascending aorta cannot
be assessed accurately or fully by echocardiography. (Level of Evi-
dence: C)
TTE can provide accurate assessment of the presence and
severity of aortic dilation inmost patients. However, in some
patients, only the aortic sinuses can be visualized, because
the ascending aorta is obscured by intervening lung tissue.
When echocardiographic images do not provide adequate
images of the ascending aorta to a distance 4.0 cm from
the valve plane, additional imaging is needed. TEE may be
considered but requires sedation and stillmaymiss segments
of the mid-ascending aorta. Magnetic resonance angiog-
raphy or chest CT angiography provide accurate diametere34 The Journal of Thoracic and Cardiovascular Surgmeasurements when aligned perpendicular to the long axis
of the aorta. Advantages ofmagnetic resonance angiography
and CT angiography compared with TTE include higher
spatial (but lower temporal) resolution and the ability to
display a 3D reconstruction of the entire length of the aorta.
Magnetic resonance angiography and CT angiography
aortic diameters typically are 1 mm to 2 mm larger than
echocardiographic measurements because of inclusion of
the aortic wall in the measurement and because echocardio-
graphic measurements are made at end-diastole, whereas
magnetic resonance angiography or CT angiography mea-
surements may represent an average value. Magnetic reso-
nance angiography imaging is preferred over CT
angiography imaging, when possible, because of the
absence of ionizing radiation exposure in patients who likely
will have multiple imaging studies over their lifetime.
Supporting References: 261-263
5.1.1.2. Diagnostic testing—routine follow-up: Recommen-
dation
Class I
1. Serial evaluation of the size and morphology of the aortic sinuses
and ascending aorta by echocardiography, CMR, or CT angiog-
raphy is recommended in patients with a bicuspid aortic valve
and an aortic diameter greater than 4.0 cm, with the examination
interval determined by the degree and rate of progression of aortic
dilation and by family history. In patients with an aortic diameter
greater than 4.5 cm, this evaluation should be performed annually.
(Level of Evidence: C)
Patients with bicuspid aortic valves who have docu-
mented dilation of the sinuses of Valsalva or ascending
aorta should have serial assessment of aortic morphology
because the aortopathy may progress with time. In a series
of 68 patients with bicuspid aortic valves, the mean rate of
diameter progression was 0.5 mm per year at the sinuses of
Valsalva (95% CI: 0.3 to 0.7), 0.5 mm per year at the sino-
tubular junction (95% CI: 0.3 to 0.7), and 0.9 mm per year
at the proximal ascending aorta (95%CI: 0.6 to 1.2). Others
have reported mean rates of increase of up to 2 mm per year.
Aortic imaging at least annually is prudent in patients with a
bicuspid aortic valve and significant aortic dilation (>4.5
cm), a rapid rate of change in aortic diameter, and in those
with a family history of aortic dissection. In patients with
milder dilation that shows no change on sequential studies
and a negative family history, a longer interval between im-
aging studies is appropriate.
Supporting References: 264-266
5.1.2. Medical Therapy
There are no proven drug therapies that have been shown
to reduce the rate of progression of aortic dilation in patients
with aortopathy associated with bicuspid aortic valve.
In patients with hypertension, control of BP with any effec-
tive antihypertensive medication is warranted. Beta
blockers and ARBs have conceptual advantages to reduceery c July 2014
Nishimura et al Clinical Guidelinesrate of progression but have not been shown to be beneficial
in clinical studies.
5.1.3. Intervention: Recommendations
Class I
1. Operative intervention to repair the aortic sinuses or replace the
ascending aorta is indicated in patients with a bicuspid aortic valve
if the diameter of the aortic sinuses or ascending aorta is greater
than 5.5 cm.113,267,268 (Level of Evidence: B)
In 2 large long-term retrospective cohort studies of pa-
tients with bicuspid aortic valves, the incidence of aortic
dissection was very low. In a study of 642 patients followed
for a mean of 9 years, there were 5 dissections (3 ascending
and 2 descending). In another bicuspid aortic valve study
of 416 patients followed for a mean of 16 years, there
were 2 dissections. In the latter report, the calculated inci-
dence of dissection was higher than the age-adjusted rela-
tive risk of the county’s general population (HR: 8.4;
95% CI: 2.1 to 33.5; P ¼ .003) but was only 3.1 (95%
CI: 0.5 to 9.5) cases per 10,000 patient-years. In patients
with bicuspid aortic valves, data are limited regarding the
degree of aortic dilation at which the risk of dissection is
high enough to warrant operative intervention in patients
who do not fulfill criteria for AVR on the basis of severe
AS or AR. Previous ACC/AHA guidelines have recommen-
ded surgery when the degree of aortic dilation is>5.0 cm at
any level, including sinuses of Valsalva, sinotubular junc-
tion, or ascending aorta. The current writing committee
considers the evidence supporting these previous recom-
mendations very limited and anecdotal and endorses a
more individualized approach. Surgery is recommended
with aortic dilation of 5.1 cm to 5.5 cm only if there is a fam-
ily history of aortic dissection or rapid progression of dila-
tion. In all other patients, operation is indicated if there is
more severe dilation (5.5 cm). The writing committee also
does not recommend the application of formulas to adjust
the aortic diameter for body size. Furthermore, prior recom-
mendations were frequently ambiguous with regard to the
level to which they apply (sinus segment versus tubular
ascending aorta) and did not acknowledge the normal dif-
ference in diameter at these levels, with the sinus segment
0.5 cm larger in diameter than the normal ascending aorta.
In Heart Valve Centers of Excellence, valve-sparing
replacement of the aortic sinuses and ascending aorta yields
excellent results in patients who do not have severely
deformed or dysfunctional valves.
Supporting References: 113,244,245,266-273
Class IIa
1. Operative intervention to repair the aortic sinuses or replace the
ascending aorta is reasonable in patients with bicuspid aortic valves
if the diameter of the aortic sinuses or ascending aorta is greater
than 5.0 cm and a risk factor for dissection is present (family history
of aortic dissection or if the rate of increase in diameter is 0.5 cm
per year). (Level of Evidence: C)The Journal of Thoracic and CaIn patients with bicuspid aortic valves, data are limited
regarding the degree of aortic dilation at which the risk of
dissection is high enough to warrant operative intervention
in patients who do not fulfill criteria for AVR on the basis of
severe AS or AR. In patients at higher risk of dissection
based on family history or evidence of rapid progression
of aortic dilation (0.5 cm per year), surgical intervention
is reasonable when the aortic diameter is>5.0 cm.
Supporting References: 266,268-270,274
Class IIa
2. Replacement of the ascending aorta is reasonable in patients with a
bicuspid aortic valve who are undergoing aortic valve surgery
because of severe AS or AR (Sections 3.2.3 and 4.3.3) if the diameter
of the ascending aorta is greater than 4.5 cm. (Level of Evidence: C)
In patients with bicuspid aortic valves, data are limited
regarding the degree of aortic dilation at which the risk
of dissection is high enough to warrant replacement of
the ascending aorta at the time of AVR. The risk of pro-
gressive aortic dilation and dissection after AVR in pa-
tients with bicuspid aortic valves has been the subject
of several studies, although definitive data are lacking.
In patients undergoing AVR because of severe AS or
AR, replacement of the ascending aorta is reasonable
when the aortic diameter is >4.5 cm. Replacement of
the sinuses of Valsalva is not necessary in all cases and
should be individualized based on the displacement of
the coronary ostia, because progressive dilation of the si-
nus segment after separate valve and graft repair is
uncommon.
Supporting References: 266,268-270,275-2796. MITRAL STENOSIS
6.1. Stages of MS
Medical and interventional approaches to the manage-
ment of patients with valvular MS depend on accurate diag-
nosis of the cause and stage of the disease process. Table 13
shows the stages of mitral valve disease ranging from pa-
tients at risk of MS (stage A) or with progressive hemody-
namic obstruction (stage B) to severe asymptomatic (stage
C) and symptomatic MS (stage D). Each of these stages is
defined by valve anatomy, valve hemodynamics, the conse-
quences of valve obstruction on the left atrium (LA) and
pulmonary circulation, and patient symptoms. The
anatomic features of the stages of MS are based on a rheu-
matic etiology for the disease. There are patients who have a
nonrheumatic etiology of MS due to senile calcific disease
(Section 6.3) in whom there is a heavily calcified mitral
annulus with extension of the calcium into the leaflets. He-
modynamic severity is best characterized by the planime-
tered mitral valve area and the calculated mitral valve
area from the diastolic pressure half-time. The definition
of ‘‘severe’’ MS is based on the severity at which symptomsrdiovascular Surgery c Volume 148, Number 1 e35
Clinical Guidelines Nishimura et aloccur as well as the severity at which intervention will
improve symptoms. Thus, a mitral valve area 1.5 cm2 is
considered severe. This usually corresponds to a transmitral
mean gradient of>5 mm Hg to 10 mm Hg at a normal heart
rate. However, the mean pressure gradient is highly depen-
dent on the transvalvular flow and diastolic filling period
and will vary greatly with changes in heart rate. The dia-
stolic pressure half-time is dependent not only on the degree
of mitral obstruction but also the compliance of the left
ventricle and the LA and other measures of mitral valve
area, such as the continuity equation or the proximal isove-
locity surface area, may be used if discrepancies exist.
Supporting References: 280-286
6.2. Rheumatic MS
See Figure 3 for indications for intervention for rheu-
matic MS.
6.2.1. Diagnosis and Follow-up
6.2.1.1. Diagnostic testing—initial diagnosis: Recommen-
dations
Class I
1. TTE is indicated in patients with signs or symptoms of MS to estab-
lish the diagnosis, quantify hemodynamic severity (mean pressure
gradient, mitral valve area, and pulmonary artery pressure), assess
concomitant valvular lesions, and demonstrate valve morphology
(to determine suitability for mitral commissurotomy).8,287-295
(Level of Evidence: B)
Suspicion for MS may arise from a childhood history of
rheumatic fever or a characteristic auscultatory finding of
an opening snap after the second heart sound and subse-
quent apical diastolic murmur, but such patients often pre-
sent with nonspecific complaints of exertional dyspnea
with an unrevealing physical examination. In the vast ma-
jority of cases, TTE can elucidate the anatomy and func-
tional significance of MS but must be undertaken with
great care. Use of 2D scanning from the parasternal long-
axis window can identify the characteristic diastolic dom-
ing of the mitral valve, whereas short-axis scanning will
demonstrate commissural fusion and allow planimetry of
the mitral orifice. This must be done carefully to obtain
the smallest orifice in space and the largest opening in
time. 3D echocardiography (either TTE or TEE) may allow
greater accuracy but is not yet routinely used. Doppler he-
modynamics are typically obtained from the apical 4–
chamber or long-axis view and should include peak and
mean transvalvular gradient as calculated by the simplified
Bernoulli equation, averaged from 3 to 5 beats in sinus
rhythm and 5 to 10 beats in AF. Heart rate should always
be included in the report because it greatly affects trans-
valvular gradient due to the differential impact of tachy-
cardia on diastolic versus systolic duration. Concomitant
MR should be sought and quantified as recommended,
along with other valve lesions (Section 7.3.1.1). RVe36 The Journal of Thoracic and Cardiovascular Surgsystolic pressure is typically estimated by continuous
wave Doppler of TR. Mitral valve morphology and feasi-
bility for percutaneous mitral balloon commissurotomy or
surgical commissurotomy can be assessed in several
ways, most commonly via the Wilkins score, which com-
bines valve thickening, mobility, and calcification with
subvalvular scarring in a 16–point scale. Characterization
of commissural calcification is also useful. Additional
echocardiographic tools for assessment of MS include the
mitral pressure half-time, which is inversely related to
mitral valve area. However, the mitral pressure half-time
is also affected by left atrial and LV compliance. Thus,
other methods for calculation of the mitral valve area,
such as the continuity method and proximal isovelocity
surface area method, could be used if necessary. Left atrial
dimension, area, and volume index should be measured,
with careful interrogation for possible left atrial thrombus
(although full exclusion of thrombus requires TEE). As
with any echocardiogram, full characterization of global
and regional LV and RV function should be reported.
Supporting References: 8,287-295
Class I
2. TEE should be performed in patients considered for percutaneous
mitral balloon commissurotomy to assess the presence or absence
of left atrial thrombus and to further evaluate the severity of
MR.288,296-298 (Level of Evidence: B)
TEE offers excellent visualization of the mitral valve
and LA and is an alternative approach to assessment of
MS in patients with technically limited transthoracic inter-
rogation. Three-dimensional datasets may be acquired,
from which optimal measurements of minimal orifice area
can be obtained offline. However, in the vast majority of pa-
tients withMS, valve morphology and lesion severity can be
obtained with TTE. A key exception is in patients being
considered for percutaneous mitral balloon commissurot-
omy, in whom left atrial cavity and appendage thrombi
must be excluded. Although TTE may identify risk factors
for thrombus formation, several studies show that TTE has
poor sensitivity for detecting such thrombi, thus mandating
a TEE before percutaneous mitral balloon commissurot-
omy. Although TTE is generally accurate in grading MR,
TEE may offer additional quantitation and assurance that
MR>2þ is not present, which generally precludes percuta-
neous mitral balloon commissurotomy.
Supporting References: 288,296-298
6.2.1.2. Diagnostic testing—changing signs or symptoms
Patients with an established diagnosis of MS may experi-
ence a change in symptoms from progressive narrowing of
the mitral valve, worsening of concomitant MR or other
valve lesions, or a change in hemodynamic state due to
such factors as AF, fever, anemia, hyperthyroidism, or post-
operative state. In such cases, a TTE examination should be
repeated to quantify the mitral valve gradient and area, asery c July 2014
TABLE 13. Stages of MS
Stage Definition Valve anatomy Valve hemodynamics
Hemodynamic
consequences Symptoms
A At risk of MS  Mild valve doming during
diastole
 Normal transmitral flow
velocity
 None  None
B Progressive MS  Rheumatic valve changes with
commissural fusion and
diastolic doming of the mitral
valve leaflets
 Planimetered MVA>1.5 cm2
 Increased transmitral flow
velocities
 MVA>1.5 cm2
 Diastolic pressure half-time
<150 ms
 Mild-to-moderate LA
enlargement
 Normal pulmonary pressure
at rest
 None
C Asymptomatic
severe MS
 Rheumatic valve changes with
commissural fusion and
diastolic doming of the mitral
valve leaflets
 Planimetered MVA 1.5 cm2
 (MVA 1.0 cm2 with very
severe MS)
 MVA 1.5 cm2
 (MVA 1.0 cm2 with very
severe MS)
 Diastolic pressure half-time
150 ms
 (Diastolic pressure half-time
220 ms with very severe MS)
 Severe LA enlargement
 Elevated PASP>30 mm Hg
 None
D Symptomatic
severe MS
 Rheumatic valve changes with
commissural fusion and
diastolic doming of the mitral
valve leaflets
 Planimetered MVA 1.5 cm2
 MVA 1.5 cm2
 (MVA 1.0 cm2 with very
severe MS)
 Diastolic pressure half-time
150 ms
 (Diastolic pressure half-time
220 ms with very severe MS)
 Severe LA enlargement
 Elevated PASP>30 mm Hg
 Decreased exercise
tolerance
 Exertional dyspnea
The transmitral mean pressure gradient should be obtained to further determine the hemodynamic effect of the MS and is usually>5 mmHg to 10 mmHg in severe MS; however,
due to the variability of the mean pressure gradient with heart rate and forward flow, it has not been included in the criteria for severity. LA, Left atrial; LV, left ventricular;MS,
mitral stenosis; MVA, mitral valve area; PASP, pulmonary artery systolic pressure.
Nishimura et al Clinical Guidelineswell as other parameters that may contribute to a change in
symptoms.
6.2.1.3. Diagnostic testing—routine follow-up
Rheumatic MS is a slowly progressive disease, character-
ized by a prolonged latent phase between the initial rheu-
matic illness and the development of valve stenosis. The
latent phase is an interval typically measured in decades
in the developed world but considerably shorter periods in
the developing world, likely due to recurrent carditis.
Once mild stenosis has developed, further narrowing is
typical, although the rate of progression is highly variable.
In 103 patients with MS followed for 3.3 2 years, valve
area decreased at 0.09 cm2 per year, although there was sig-
nificant interpatient variability. Larger valves decreased in
area more rapidly, although the same absolute decrease
would be expected to have greater impact in the more ste-
notic valves. Importantly, progressive enlargement in the
right ventricle and rise in RV systolic pressure were
observed, even in the absence of a decrease in mitral valve
area. Accordingly, repeat TTE at intervals dictated by valve
area is an important aspect of disease management, even in
patients without symptoms. TTE should be performed to re-
evaluate asymptomatic patients with MS and stable
clinical findings to assess pulmonary artery pressure and
valve gradient (very severe MS with mitral valve
area<1.0 cm2 every year, severe MS with mitral valve
area 1.5 cm2 every 1 to 2 years; and progressive MSThe Journal of Thoracic and Cawith mitral valve area >1.5 cm2 every 3 to 5 years)
(Table 4).
Supporting References: 299-301
6.2.1.4. Diagnostic testing—cardiac catheterization
In the contemporary era, adequate assessment of MS and
associated lesions can be obtained in the vast majority of pa-
tients by TTE, occasionally supplemented by TEE. Howev-
er, in those few patients with nondiagnostic studies or
whose clinical and echocardiographic findings conflict, it
is essential to further characterize MS hemodynamics and
catheterization as the next best approach. Catheterization
is also the only method available to measure absolute pres-
sures inside the heart, which may be important in clinical
decision making. Such studies must be carried out by
personnel experienced with catheterization laboratory he-
modynamics with simultaneous pressure measurements in
the left ventricle and LA, ideally via transseptal catheteriza-
tion. Although a properly performed mean pulmonary ar-
tery wedge pressure is an acceptable substitute for mean
LA pressure, the LV to pulmonary wedge gradient will
overestimate the true transmitral gradient due to phase
delay and delayed transmission of pressure changes. The
Gorlin equation is applied for calculation of mitral valve
area, using cardiac output obtained via thermodilution
(when there is no significant TR) or the Fick method.
Ideally, measured oxygen consumption should be used in
this calculation. Full right-heart pressures should berdiovascular Surgery c Volume 148, Number 1 e37
FIGURE 3. Indications for intervention for rheumatic MS. AF, Atrial fibrillation; LA, left atrial;MR, mitral regurgitation;MS, mitral stenosis;MVA, mitral
valve area; MVR, mitral valve surgery (repair or replacement); NYHA, New York Heart Association; PCWP, pulmonary capillary wedge pressure; PMBC,
percutaneous mitral balloon commissurotomy; T ½, pressure half-time.
Clinical Guidelines Nishimura et alreported. In cases where exertional symptoms seem out of
proportion to resting hemodynamic severity, data may be
obtained during exercise.
Supporting References: 302-304
6.2.1.5. Diagnostic testing—exercise testing: Recommen-
dation
Class I
1. Exercise testing with Doppler or invasive hemodynamic assessment
is recommended to evaluate the response of the mean mitral
gradient and pulmonary artery pressure in patients with
MS when there is a discrepancy between resting Doppler echocar-
diographic findings and clinical symptoms or signs. (Level of Evi-
dence: C)
Exercise testing with hemodynamics yields a number of
data points to help in the management of MS when a pa-
tient’s symptoms seem significantly greater or less than
would be expected from TTE. Results have been published
using both exercise and dobutamine with Doppler echocar-
diography, although exercise is preferred in general as thee38 The Journal of Thoracic and Cardiovascular Surgmore physiological test. Most experience is with treadmill
exercise, with images and Doppler obtained immediately
after stress, but bicycle exercise allows data acquisition at
various stages of exercise. Bicycle or arm ergometry exer-
cise testing during cardiac catheterization can also be per-
formed for direct measurements of pulmonary artery
wedge pressure and pulmonary pressures at rest and with
exercise. Simple functional capacity is important to help
quantify the patient’s symptoms and assess changes over
time. Changes in valve gradient are also helpful, as is the
presence of exercise-induced pulmonary hypertension.
Although exercise-induced pulmonary hypertension does
not have a formal place in these guidelines, a rise in RV sys-
tolic pressure to>60 mm Hg to 70 mm Hg should prompt
the clinician to carefully consider the patient’s symptoms.
Most patients can continue to be followed without exercise
testing by careful clinical assessment and periodic resting
echocardiograms as indicated above.
Supporting References: 305-308ery c July 2014
Nishimura et al Clinical Guidelines6.2.2. Medical Therapy: Recommendations
Class I
1. Anticoagulation (vitamin K antagonist [VKA] or heparin) is indi-
cated in patients with 1)MS andAF (paroxysmal, persistent, or per-
manent), 2) MS and a prior embolic event, or 3) MS and a left atrial
thrombus.309-315 (Level of Evidence: B)
In the presurgical era, patients with MS were at high
risk for arterial embolization, which was further elevated
in those with AF and prior embolic events. Anticoagula-
tion with VKA has long been recommended for patients
with MS with AF or prior embolism and has been so
well accepted that patients with MS have generally
been excluded from AF trials examining the utility of anti-
coagulation. One exception to trials excluding patients
with MS is the NASPEAF (National Study for Prevention
of Embolism in Atrial Fibrillation) trial. Of the 495 high-
risk patients in the cohort, 316 patients had MS. Of these
316 patients, 95 had a prior embolization. Patients in the
study were randomized to standard anticoagulation with
VKA (international normalized ratio [INR] goal 2 to 3)
versus the combination of an antiplatelet agent and VKA
anticoagulation with a lower INR goal (0.10 to 2.5). The
study demonstrated a highly significant increased risk
for embolism among those patients with VHD with prior
events versus those without (9.1% versus 2.3% over 3
years; P < .001). Further larger studies are required to
determine if antiplatelet agents should be used in patients
with AF and MS. Although no trial evidence exists for an-
ticoagulation when LA or left atrial appendage thrombi
are incidentally found (generally by TEE), it is well docu-
mented that even in sinus rhythm, such clots are predis-
posed to embolize, and so anticoagulation with VKA is
recommended. Anticoagulation should be given indefi-
nitely to patients with these indications. It is controversial
as to whether long-term anticoagulation should be given to
patients with MS in normal sinus rhythm on the basis of
left atrial enlargement or spontaneous contrast on TEE.
The efficacy of the novel oral anticoagulant agents in pre-
venting embolic events has not been studied in patients
with MS.
Supporting References: 309-315
Class IIa
1. Heart rate control can be beneficial in patients withMS and AF and
fast ventricular response. (Level of Evidence: C)
Patients with MS are prone to developing atrial arrhyth-
mias. Thirty percent to 40% of patients with severe MS
will develop AF. Significant detrimental hemodynamic con-
sequences may be associated with the acute development of
AF, primarily from the rapid ventricular response, which
shortens the diastolic filling period and increases left atrial
pressure. The treatment of acute AF is anticoagulation and
control of the heart rate response with negative dromotropicThe Journal of Thoracic and Caagents. If the rate cannot be adequately controlled with
medications, cardioversion may be necessary to improve
hemodynamics. In the stable patient, the decision for rate
control versus rhythm control is dependent on multiple fac-
tors, including the duration of AF, hemodynamic response
to AF, left atrial size, prior episodes of AF, and a history
of embolic events. It is more difficult to achieve rhythm
control in patients with MS because the rheumatic process
itself may lead to fibrosis of the intermodal and interatrial
tracts and damage to the sinoatrial node.
Supporting Reference: 316
Class IIb
1. Heart rate control may be considered for patients with MS in
normal sinus rhythm and symptoms associated with exercise.317,318
(Level of Evidence: B)
It is well known that the proportion of the cardiac cycle
occupied by diastole decreases with increasing heart rate,
thereby increasing themean flow rate across themitral valve
(assuming constant cardiac output) with a consequent rise in
meanmitral gradient inMS in proportion to the square of the
flow rate. A study of normal volunteers undergoing bicycle
exercise echocardiography demonstrated a reduction in the
diastolic interval from 604 milliseconds to 219milliseconds
as the heart rate increased from 60 beats per minute to 120
beats per minute indicating a 63% reduction in total dia-
stolic time. Maintaining the same cardiac output would
require a 38% increase in mean flow rate during diastole,
which, by squared relation of the Bernoulli equation, re-
quires an increase in mean mitral gradient of approximately
90%. Thus, it is rational to think that limiting tachycardia
with beta blockade might be beneficial in patients with MS
in normal sinus rhythm. Nevertheless, the only RCT on the
impact of beta blockade on exercise duration in MS failed
to show this salutary effect. One study looked at 15 patients
with an average mitral area of 1.0 cm2 (NYHA class II and
III) randomized in crossover fashion to atenolol or placebo.
Although the exercise heart rate was significantly reduced
and diastolic filling interval increased by 40%, there was
no increase in functional capacity, and maximal O2 con-
sumption actually fell by 11%, with cardiac index falling
by 20% when patients were treated with beta blockade.
One study had more neutral results in a trial of 17 patients
with NYHA class I and II MS, and 7 patients had improve-
ment in maximal oxygen consumption, whereas 4 had a
deterioration in symptoms. Overall, anaerobic threshold
was reduced by 11% with atenolol therapy, so these studies
do not support the general use of heart rate control in patients
withMS and normal sinus rhythm. Nevertheless, in selected
patients whose symptoms worsen markedly with exercise, a
trial of beta blockade might be considered. Other negative
chronotropic agents have not been evaluated in patients
with MS.
Supporting References: 317,318rdiovascular Surgery c Volume 148, Number 1 e39
Clinical Guidelines Nishimura et al6.2.3. Intervention: Recommendations
See Table 14 for a summary of recommendations from
this section.
Class I
1. Percutaneous mitral balloon commissurotomy is recommended for
symptomatic patients with severe MS (mitral valve area 1.5 cm2,
stage D) and favorable valvemorphology in the absence of left atrial
thrombus or moderate-to-severe MR.280-284,286,328 (Level of
Evidence: A)
Several RCTs have established the safety and efficacy of
percutaneous balloon mitral commissurotomy compared
with surgical closed or open commissurotomy. The tech-
nique is generally performed by advancing1 balloon cath-
eters across the mitral valve and inflating them, thereby
splitting the commissures. For the percutaneous approach
to have optimal outcome, it is essential that the valve
morphology be predictive of success, generally being mo-
bile, relatively thin, and free of calcium. This is usually as-
sessed by the Wilkins score, although other risk scores have
also shown utility. Clinical factors such as age, NYHA
class, and presence or absence of AF are also predictive
of outcome. Percutaneous mitral balloon commissurotomy
should be performed by experienced operators with imme-
diate availability of surgical backup for potential complica-
tions. Percutaneous mitral balloon commissurotomy is also
useful in patients with restenosis following prior commis-
surotomy if restenosis is the consequence of refusion of
both commissures.
Supporting References: 280-284,286,292,294,325,328-
331
See Online Data Supplement 13 for a summary of RCTs
that have established the safety and efficacy of percuta-
neous mitral balloon commissurotomy in comparison to
surgical closed or open commissurotomy.
Class I
2. Mitral valve surgery (repair, commissurotomy, or valve replace-
ment) is indicated in severely symptomatic patients (NYHA class
III to IV) with severe MS (mitral valve area 1.5 cm2, stage D)
who are not high risk for surgery and who are not candidates for
or who have failed previous percutaneous mitral balloon commis-
surotomy.319-324 (Level of Evidence: B)
Mitral valve surgery is an established therapy forMS, pre-
dating percutaneousmitral balloon commissurotomy. Surgi-
cal options may involve commissurotomy (either closed,
where the valve is opened blindly through the LA or left
ventricle, or open, which allows more extensive surgery un-
der direct visualization). MVRmay be preferred in the pres-
ence of severe valvular thickening and subvalvular fibrosis
with leaflet tethering. In addition to those who have subop-
timal valve anatomy (or failed percutaneous mitral balloon
commissurotomy), patients with moderate or severe TR
may also have a better outcome with a surgical approach
that includes tricuspid valve repair. Because the naturale40 The Journal of Thoracic and Cardiovascular Surghistory of MS is one of slow progression over decades and
MS does not have long-standing detrimental effects on the
left ventricle, surgery should be delayed until the patient
has severe limiting symptoms (NYHA class III to IV).
Supporting References: 283,319-324,332-334
Class I
3. Concomitant mitral valve surgery is indicated for patients
with severe MS (mitral valve area 1.5 cm2, stage C or D)
undergoing cardiac surgery for other indications. (Level of Evi-
dence: C)
Studies of the natural history of moderate-to-severe MS
demonstrate progressive decrement in valve area of 0.09
cm2 per year. For patients with other indications for open
heart surgery, mitral intervention should be undertaken,
particularly in those patients with valves amenable to
open commissurotomy or valve repair.
Supporting Reference: 300
Class IIa
1. Percutaneous mitral balloon commissurotomy is reasonable for
asymptomatic patients with very severe MS (mitral valve
area 1.0 cm2, stage C) and favorable valve morphology in the
absence of left atrial thrombus or moderate-to-severe
MR.293,325-327 (Level of Evidence: C)
Although it is a general rule in VHD not to intervene
before the onset of symptoms, there are patients who will
clearly benefit from intervention while still ostensibly
asymptomatic. Most patients with mitral valve area 1.0
cm2 will manifest a true reduction in functional capacity
even if the gradual onset is not obvious. In addition,
numerous studies have demonstrated a greater likelihood
of successful percutaneous mitral balloon commissurotomy
when the valve is less thickened and calcified, indicating
intervention before this state. Furthermore, it is preferable
to intervene before the development of severe pulmonary
hypertension, because those patients with near systemic
pulmonary pressure show reduced RV function and persis-
tent pulmonary hypertension following percutaneous mitral
balloon commissurotomy or MVR.
Supporting References: 293,325-327
Class IIa
2. Mitral valve surgery is reasonable for severely symptomatic pa-
tients (NYHA class III to IV) with severe MS (mitral valve
area 1.5 cm2, stage D), provided there are other operative indica-
tions (eg, aortic valve disease, CAD, TR, aortic aneurysm). (Level of
Evidence: C)
Asituationmay arise inwhich a patientwho is otherwise a
candidate for percutaneous mitral balloon commissurotomy
(favorable valve anatomy, no atrial thrombus or significant
MR) has other cardiac conditions that should be addressed
surgically. These patients should undergo a comprehensive
operation to address all lesions, including MS. However,
as percutaneous intervention has evolved, particularly that
involving the coronary arteries and aortic valve, there willery c July 2014
TABLE 14. Summary of recommendations for MS intervention
Recommendations COR LOE References
PMBC is recommended for symptomatic patients with severe MS (MVA1.5 cm2, stage D) and favorable
valve morphology in the absence of contraindications
I A 280-284,286
Mitral valve surgery is indicated in severely symptomatic patients (NYHA class III/IV) with severe MS
(MVA 1.5 cm2, stage D) who are not high risk for surgery and who are not candidates for or failed
previous PMBC
I B 319-324
Concomitant mitral valve surgery is indicated for patients with severe MS (MVA 1.5 cm2, stage C or D)
undergoing other cardiac surgery
I C N/A
PMBC is reasonable for asymptomatic patients with very severe MS (MVA 1.0 cm2, stage C) and
favorable valve morphology in the absence of contraindications
IIa C 293,325-327
Mitral valve surgery is reasonable for severely symptomatic patients (NYHA class III/IV) with severe MS
(MVA 1.5 cm2, stage D), provided there are other operative indications
IIa C N/A
PMBC may be considered for asymptomatic patients with severe MS (MVA 1.5 cm2, stage C) and
favorable valve morphology who have new onset of AF in the absence of contraindications
IIb C N/A
PMBC may be considered for symptomatic patients with MVA>1.5 cm2 if there is evidence of
hemodynamically significant MS during exercise
IIb C N/A
PMBC may be considered for severely symptomatic patients (NYHA class III/IV) with severe MS
(MVA 1.5 cm2, stage D) who have suboptimal valve anatomy and are not candidates for surgery or at
high risk for surgery
IIb C N/A
Concomitant mitral valve surgery may be considered for patients with moderate MS (MVA 1.6–2.0 cm2)
undergoing other cardiac surgery
IIb C N/A
Mitral valve surgery and excision of the left atrial appendage may be considered for patients with severe
MS (MVA1.5 cm2, stages C and D) who have had recurrent embolic events while receiving adequate
anticoagulation
IIb C N/A
AF, Atrial fibrillation; COR, Class of Recommendation; LOE, Level of Evidence; MS, mitral stenosis; MVA, mitral valve area; NYHA, New York Heart Association; PMBC,
percutaneous mitral balloon commissurotomy.
Nishimura et al Clinical Guidelinesbe circumstances in which an all-percutaneous approach
will be favored. This decision should take into account the
local expertise at the treating facility.
Class IIb
1. Percutaneous mitral balloon commissurotomy may be considered
for asymptomatic patients with severe MS (mitral valve area 1.5
cm2, stage C) and valve morphology favorable for percutaneous
mitral balloon commissurotomy in the absence of left atrial
thrombus or moderate-to-severe MR who have new onset of AF.
(Level of Evidence: C)
Patients with mild and asymptomatic MS may develop
AF as an isolated event that can be managed without mitral
valve intervention for many years. However, in many pa-
tients, the onset of AF may be a harbinger of a more symp-
tomatic phase of the disease. Percutaneous mitral balloon
commissurotomy may be considered in such cases, particu-
larly if rate control is difficult to achieve or if the mitral
valve area is 1.5 cm2. Lowering the left atrial pressure
by percutaneous mitral balloon commissurotomy may be
useful if a rhythm control approach is taken for AF.
Class IIb
2. Percutaneous mitral balloon commissurotomy may be considered
for symptomatic patients with mitral valve area greater than
1.5 cm2 if there is evidence of hemodynamically significant MS
based on pulmonary artery wedge pressure greater than 25 mm
Hg or mean mitral valve gradient greater than 15 mm Hg during
exercise. (Level of Evidence: C)The Journal of Thoracic and CaIt is recognized that there are patients with genuine symp-
toms fromMS, even with mitral valve area between 1.6 cm2
and 2.0 cm2, who would benefit from percutaneous mitral
balloon commissurotomy. This may occur for several rea-
sons. First, given the vagaries of clinical imaging, it is
possible that the valve is actually smaller than the reported
area. Second, for a given valve area, the transmitral gradient
will be higher in persons with a large body surface area or
those with other reasons to have an elevated cardiac output
(eg, arteriovenous fistulae). Third, there is a variable rela-
tion of pulmonary vascular resistance in comparison to
mitral valve area. Thus, patients may experience clinical
improvement in such cases. This procedure may
be performed for these indications in patients with valve
morphology suitable for percutaneous mitral balloon
commissurotomy.
Supporting Reference: 335
Class IIb
3. Percutaneous mitral balloon commissurotomy may be considered
for severely symptomatic patients (NYHA class III to IV) with se-
vere MS (mitral valve area 1.5 cm2, stage D) who have a subopti-
mal valve anatomy and who are not candidates for surgery or at
high risk for surgery. (Level of Evidence: C)
Both the Wilkins score and the presence of commissural
calcification predict successful percutaneous mitral balloon
commissurotomy. However in all such series, this predictive
ability is not absolute, with 42% of patients with a Wilkinsrdiovascular Surgery c Volume 148, Number 1 e41
Clinical Guidelines Nishimura et alscore >8 having an optimal outcome (25% increase in
mitral valve area to>1.5 cm2) and 38% of patients with
commissural calcium having event-free survival at 1.8
years. Accordingly, severely symptomatic patients who
are poor surgical candidates may benefit from percutaneous
mitral balloon commissurotomy even with suboptimal
valve anatomy. Patients who refuse surgery may also be
considered for percutaneous mitral balloon commissurot-
omy after discussion about the potential complications
associated with this procedure when performed in patients
with suboptimal valve anatomy.
Supporting References: 292-294
Class IIb
4. Concomitant mitral valve surgery may be considered for patients
withmoderateMS (mitral valve area 1.6 cm2 to 2.0 cm2) undergoing
cardiac surgery for other indications. (Level of Evidence: C)
Consideration of concomitant MVR at the time of other
heart surgery must balance several factors, including the
severity of MS (based on mitral valve area, mean pressure
gradient, and pulmonary arterial pressure); rate of progres-
sion; history of AF; skill of the surgeon; and perceived risk
of repeat cardiac surgery if the MS progresses to a symp-
tomatic state. Consideration should also include the suit-
ability of the valve for subsequent percutaneous mitral
balloon commissurotomy (echocardiogram score and pres-
ence of MR), as this might be a preferable method for treat-
ing worsening MS.
Class IIb
5. Mitral valve surgery and excision of the left atrial appendage may
be considered for patients with severe MS (mitral valve area 1.5
cm2, stages C and D) who have had recurrent embolic events while
receiving adequate anticoagulation. (Level of Evidence: C)
A large prospective study of patients with MS shows an
elevated risk of recurrent embolism among patients with
prior embolic events irrespective of the presence or absence
of AF. The risk is reduced, but not eliminated, by percuta-
neous mitral balloon commissurotomy. Another study of
205 patients who underwent mitral valve surgery, 58 with
ligation of the left atrial appendage, demonstrated that
lack of ligation was significantly associated with future
embolic events (odds ratio [OR]: 6.7). This study also noted
that in 6 of the 58 ligation patients, communication of the
left atrial appendage and LA cavity was still present. Resid-
ual communication between the left atrial appendage and
LA cavity was noted in 60% of patients undergoing left
atrial appendage ligation in a subsequent study, suggesting
that left atrial appendage excision and not ligation may be
the preferred approach in selected patients.
Supporting References: 336,337
See Online Data Supplements 14 and 15 for more infor-
mation on the outcomes of percutaneous mitral balloon
commissurotomy.e42 The Journal of Thoracic and Cardiovascular Surg6.3. Nonrheumatic MS
Although the vast majority of MS in the world results
from rheumatic heart disease, senile calcific MS is found
with increasing frequency in the elderly population in North
America. This is due to calcification of the mitral annulus
and calcification that extends into the leaflets, which cause
both a narrowing of the annulus and rigidity of the leaflets
without commissural fusion. Mitral annular calcification
has been associated with decreased renal function and in-
flammatory markers like C-reactive protein; however, se-
nile calcific MS is common in the elderly population with
normal renal function and is associated with senile AS.
Data are relatively sparse on the natural history of senile
calcific MS. A small study of 32 patients observed over a
mean of 2.6 years demonstrated progression in mean mitral
valve gradient in only half of the subjects. However, in those
with progression, the rate of change averaged 2 mm Hg per
year and changed as rapidly as 9 mm Hg per year. More
rapid progression was found in younger patients, but sur-
prisingly this was not predicted by a reduced glomerular
filtration rate. Although the mean pressure gradient from
Doppler echocardiography is accurate, the use of a mitral
valve area from diastolic half-time is uncertain in this pop-
ulation. Indications for intervention in patients with senile
calcific MS are different from those for rheumatic MS
for the following reasons. First, because calcification in-
volves the annulus and base of the leaflets without commis-
sural fusion, there is no role for percutaneous mitral balloon
or surgical commissurotomy. Second, the presence of se-
vere mitral annular calcification can be quite challenging
for the surgeon because it causes problems in securely at-
taching the prosthetic valve and narrowing of the orifice.
Supra-annular insertion and other innovative techniques
can be used, such as placement of a felt patch around the
valve orifice to anchor the prosthesis; however, this only
works if the mitral orifice is adequate. If the annular calci-
fication narrows the orifice, it has to be debrided. The other
alternative is left atrial to ventricular bypass with a valved
conduit in extreme cases of calcification both of the leaflet
and the annulus. Finally, patients with calcification are
often elderly and debilitated, have multiple comorbidities,
and are at high risk for surgery. For these reasons, interven-
tion should be delayed until symptoms are severely
limiting and cannot be managed with diuresis and heart
rate control.
A subset of patients have mitral inflow obstruction due to
other causes, such as congenital malformations, tumors, or
other masses. Congenital MS usually takes the form of a
parachute mitral valve, where the mitral chordae are
attached to a single or dominant papillary muscle and often
form a component of the Shone complex, which can include
supramitral rings, valvular or subvalvular AS, and aortic
coarctation. For MS caused by tumors or other obstructiveery c July 2014
Nishimura et al Clinical Guidelineslesions, intervention is aimed at reducing or removing the
mass, with efforts made to preserve the valve.
Supporting References: 338-3527. MITRAL REGURGITATION
7.1. Acute MR
Acute MR may be due to disruption of different parts of
the mitral valve apparatus. IE may cause leaflet perforation
or chordal rupture. Spontaneous chordal rupture may occur
in patients with degenerative mitral valve disease. Rupture
of the papillary muscle occurs in patients who have an acute
ST-segment elevationMI usually associated with an inferior
infarction. The acute volume overload on the left ventricle
and LA results in pulmonary congestion and low forward
cardiac output. Diagnosis of the presence and etiology of
acute MR and urgent intervention may be lifesaving.
7.1.1. Diagnosis and Follow-up
TTE is useful in patients with severe acute primary MR
for evaluation of LV function, RV function, pulmonary ar-
tery pressure, and mechanism of MR. The patient with se-
vere acute MR, which might occur from chordal rupture,
usually experiences acute decompensation with hemody-
namic embarrassment. The sudden volume overload in-
creases left atrial and pulmonary venous pressure,
leading to pulmonary congestion and hypoxia, whereas
decreased blood delivery to the aorta causes reduced car-
diac output, hypotension, or even shock. The rapid systolic
rise in LA pressure with a concomitant fall in LV systolic
pressure limits the pressure gradient driving MR to early
systole. Thus, the murmur may be short and unimpressive.
Some patients with severe torrential MR have no murmur
due to equalization of the LV and left atrial pressures. TTE
can usually clarify the diagnosis by demonstrating the
presence of severe MR, the mechanism causing MR, and
a hyperdynamic instead of a depressed left ventricle as
would be present in many other causes of hemodynamic
compromise. Likely mechanisms of acute MR detected
by TTE include valve disruption or perforation from IE,
chordal rupture, and/or papillary muscle rupture. If the
diagnosis of IE as the cause of acute MR is made, therapy
that includes antibiotic administration and early surgery
must be considered.
It may be difficult to diagnose severe acute MR with TTE
due to narrow eccentric jets of MR, tachycardia, and early
equalization of LV and LA pressures. In cases where TTE
is nondiagnostic but the suspicion of severe acute MR per-
sists, enhanced mitral valve imaging with TEE usually clar-
ifies the diagnosis. TEE can be especially helpful in
detecting valvular vegetations and annular abscesses that
may further accentuate the need for a more urgent surgical
approach. In the presence of sudden acute and hemody-
namic instability after MI with hyperdynamic LV functionThe Journal of Thoracic and Caby TTE and no other cause for the deterioration, TEE
should be performed as soon as possible, looking for severe
MR due either to a papillary muscle or chordal rupture.
7.1.2. Medical Therapy
Vasodilator therapy can be useful to improve hemody-
namic compensation in acuteMR. The premise of use of va-
sodilators in acute MR is reduction of impedance of aortic
flow, thereby preferentially guiding flow away from the
left ventricle to the left atrial regurgitant pathway,
decreasing MR while simultaneously increasing forward
output. This is usually accomplished by infusion of an
easily titratable agent such as sodium nitroprusside or nicar-
dipine. Use of vasodilators is often limited by systemic hy-
potension that is exacerbated when peripheral resistance is
decreased.
Intra-aortic balloon counterpulsation can be helpful
to treat acute severe MR. By lowering systolic aortic pres-
sure, intra-aortic balloon counterpulsation decreases LV
afterload, increasing forward output while decreasing re-
gurgitant volume. Simultaneously, intra-aortic balloon
counterpulsation increases diastolic and mean aortic pres-
sure, thereby supporting the systemic circulation. In almost
every case, intra-aortic balloon counterpulsation is a tempo-
rizing measure for achieving hemodynamic stability until
definitive mitral surgery can be performed. The use of a
percutaneous circulatory assist device may also be effective
to stabilize a patient with acute hemodynamic compromise
before operation.
Supporting References: 353,354
7.1.3. Intervention
Prompt mitral valve surgery is recommended for treat-
ment of the symptomatic patient with acute severe primary
MR. The severity of acute primary MR is variable, and
some patients with more moderate amounts of MR may
develop compensation as LV dilation allows for lower
filling pressure and increased forward cardiac output.
However, most patients with acute severe MR will require
surgical correction for re-establishment of normal hemody-
namics and for relief of symptoms. This is especially true
for a complete papillary muscle rupture that causes torren-
tial MR, which is poorly tolerated. Even if there is a partial
papillary muscle rupture with hemodynamic stability, ur-
gent surgery is indicated because this can suddenly progress
to complete papillary muscle rupture. In cases of ruptured
chordae tendineae, mitral repair is usually feasible and
preferred over MVR, and the timing of surgery can be deter-
mined by the patient’s hemodynamic status. If IE is the
cause of severe symptomatic MR, earlier surgery is gener-
ally preferred because of better outcomes over medical ther-
apy. However, this strategy should also be tempered by the
patient’s overall condition.
Supporting Reference: 355rdiovascular Surgery c Volume 148, Number 1 e43
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In assessing the patient with chronic MR, it is critical to
distinguish between chronic primary (degenerative) MR
and chronic secondary (functional) MR, as these 2 condi-
tions have more differences than similarities.
In chronic primary MR, the pathology of 1 of the
components of the valve (leaflets, chordae tendineae,
papillary muscles, annulus) causes valve incompetence
with systolic regurgitation of blood from the left ventricle
to the LA (Table 15). The most common cause of chronic
primaryMR in developed countries is mitral valve prolapse,
which has a wide spectrum of etiology and presentation.
Younger populations present with severe myxomatous
degeneration with gross redundancy of both anterior
and posterior leaflets and the chordal apparatus (Barlow’s
valve). Alternatively, older populations present with fibroe-
lastic deficiency disease, in which lack of connective tissue
leads to chordal rupture. The differentiation between these 2
etiologies has important implications for operative inter-
vention. Other less common causes of chronic primary
MR include IE, connective tissue disorders, rheumatic heart
disease, cleft mitral valve, and radiation heart disease. If the
subsequent volume overload of chronic primaryMR is pro-
longed and severe, it causes myocardial damage, HF, and
eventual death. Correction of the MR is curative. Thus,
MR is ‘‘the disease.’’
In chronic secondary MR, the mitral valve is usually
normal (Table 16). Instead, severe LV dysfunction is caused
either by CAD, related MI (ischemic chronic secondary
MR), or idiopathic myocardial disease (nonischemic
chronic secondary MR). The abnormal and dilated left
ventricle causes papillary muscle displacement, which in
turn results in leaflet tethering with associated annular dila-
tion that prevents coaptation. Because MR is only 1 compo-
nent of the disease (severe LV dysfunction, coronary
disease, or idiopathic myocardial disease are the others),
restoration of mitral valve competence is not by itself cura-
tive; thus, the best therapy for chronic secondary MR is
much less clear than it is for chronic primary MR. The
data are limited, and there is greater difficulty in defining
the severity of MR in patients with secondary MR than in
those with primary MR. In patients with secondary MR,
adverse outcomes are associated with a smaller calculated
effective regurgitant orifice compared to primary MR due
to multiple reasons. The MR will likely progress because
of the associated progressive LV systolic dysfunction and
adverse remodeling. In addition, there is an underestimation
of effective regurgitant orifice area by the 2D echocardiog-
raphyderived flow convergence method due to the cres-
centic shape of the regurgitant orifice. There are the
additional clinical effects of a smaller amount of regurgita-
tion in the presence of compromised LV systolic function
and baseline elevated filling pressures.e44 The Journal of Thoracic and Cardiovascular Surg7.3. Chronic Primary MR
7.3.1. Diagnosis and Follow-up
7.3.1.1. Diagnostic testing—initial diagnosis: Recommen-
dations
Class I
1. TTE is indicated for baseline evaluation of LV size and function, RV
function and left atrial size, pulmonary artery pressure, and mech-
anism and severity of primaryMR (stages A toD) in any patient sus-
pected of having chronic primary MR.5,21,39,356-371 (Level of
Evidence: B)
Images provided by TTE generate most of the diagnostic
data needed for clinical decision making in chronic primary
MR. The outcome of the patient with chronic primaryMR is
determined by lesion severity and the presence or absence
of negative prognostic features that include the presence
of symptoms, onset of LV dysfunction, and presence of pul-
monary hypertension; usually only severeMR leads to these
negative sequelae. Favorable loading conditions in MR
(increased preload and usually normal afterload) increase
ejection phase indexes of LV function, such as LVEF, but
do not affect the extent of shortening. Thus, a ‘‘normal’’
LVEF in MR is approximately 70%. In turn, the onset of
LV dysfunction is inferred when LVEF declines toward
60% or when the left ventricle is unable to contract
to<40 mm diameter at end systole. It is clear that properly
obtained and validated chamber volumes give more infor-
mation about detrimental cardiac remodeling than simple
chamber dimensions, as suggested by angiographically ob-
tained volume data. These techniques have been replaced
by newer noninvasive imaging techniques, which initially
used chamber dimensions for measurement of LV size
and function. Until more prognostic volumetric data are
available, most current prognostic data rely on chamber di-
mensions. Pulmonary artery systolic pressure approaching
50 mm Hg also worsens prognosis. Thus, when the murmur
of MR is first discovered, the clinician needs to know the
severity of the MR (Table 15) and the size and function of
the left ventricle, pulmonary artery pressure, and valve
pathoanatomy from which valve reparability can be pre-
dicted. Determination of the severity of MR should be
made on the basis of measurements of effective orifice
area, regurgitant volume, and regurgitant fraction using
the proximal isovelocity surface area or quantitative
Doppler flow measurements. However, there are limitations
to this technique, and multiple Doppler parameters,
including color jet area, vena contracta, continuous wave
Doppler intensity, and transmitral jet velocity curve should
be used to correlate with the quantitative measurements.
Once 1 of the above ‘‘triggers’’ is reached, indicating severe
MR and LV dysfunction, the patient should be considered
for mitral valve surgery. TTE serves to give this information
in most cases and also generates baseline data that can be
used to compare the patient’s progress on subsequentery c July 2014
TABLE 15. Stages of Primary MR
Grade Definition Valve anatomy Valve hemodynamics*
Hemodynamic
consequences Symptoms
A At risk of MR  Mild mitral valve prolapse
with normal coaptation
 Mild valve thickening and
leaflet restriction
 No MR jet or small central
jet area<20% LA on
Doppler
 Small vena contracta
<0.3 cm
 None  None
B Progressive MR  Severe mitral valve prolapse
with normal coaptation
 Rheumatic valve changes
with leaflet restriction and
loss of central coaptation
 Prior IE
 Central jet MR 20%–40%
LA or late systolic eccentric
jet MR
 Vena contracta<0.7 cm
 Regurgitant volume<60mL
 Regurgitant fraction<50%
 ERO<0.40 cm2
 Angiographic grade 1–2þ
 Mild LA enlargement
 No LV enlargement
 Normal pulmonary
pressure
 None
C Asymptomatic
severe MR
 Severe mitral valve prolapse
with loss of coaptation or
flail leaflet
 Rheumatic valve changes
with leaflet restriction and
loss of central coaptation
 Prior IE
 Thickening of leaflets with
radiation heart disease
 Central jet MR>40% LA
or holosystolic eccentric
jet MR
 Vena contracta 0.7 cm
 Regurgitant volume
60 mL
 Regurgitant fraction 50%
 ERO 0.40 cm2
 Angiographic grade 3–4þ
 Moderate or severe LA
enlargement
 LV enlargement
 Pulmonary hypertension
may be present at rest or
with exercise
 C1: LVEF>60% and
LVESD<40 mm
 C2: LVEF 60% and
LVESD 40 mm
 None
D Symptomatic
severe MR
 Severe mitral valve prolapse
with loss of coaptation or
flail leaflet
 Rheumatic valve changes
with leaflet restriction and
loss of central coaptation
 Prior IE
 Thickening of leaflets with
radiation heart disease
 Central jet MR>40% LA
or holosystolic eccentric
jet MR
 Vena contracta 0.7 cm
 Regurgitant volume
60 mL
 Regurgitant fraction 50%
 ERO 0.40 cm2
 Angiographic grade 3–4þ
 Moderate or severe LA
enlargement
 LV enlargement
 Pulmonary hypertension
present
 Decreased exercise
tolerance
 Exertional dyspnea
ERO, Effective regurgitant orifice; IE, infective endocarditis; LA, left atrium/atrial; LV, left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-
systolic dimension;MR, mitral regurgitation. *Several valve hemodynamic criteria are provided for assessment ofMR severity, but not all criteria for each category will be present
in each patient. Categorization ofMR severity as mild, moderate, or severe depends on data quality and integration of these parameters in conjunction with other clinical evidence.
Nishimura et al Clinical Guidelinesexaminations. Three-dimensional echocardiography, strain
imaging, or CMR may add more accurate assessment of
the LV response in the future. Symptom presence is a key
determinant of outcome, yet symptom status is highly sub-
jective. Studies have demonstrated a correlation between B-
type natriuretic peptide and outcome in MR. Although the
data are preliminary, the finding of a rising B-type natri-
uretic peptide could be helpful as another factor in deciding
the optimal timing of mitral surgery.
Supporting References: 5,21,39,356-371
Class I
2. CMR is indicated in patients with chronic primaryMR to assess LV
andRV volumes, function, orMR severity andwhen these issues are
not satisfactorily addressed by TTE.366,372,373 (Level of Evidence: B)
In most cases, TTE provides the data needed for adequate
evaluation of the MR patient. However, in cases where TTE
image quality is poor, CMR may be of value in MR evalu-
ation. CMR produces highly accurate data on LV volumes,
RV volumes, and LVEF, and an estimation of MR severity,The Journal of Thoracic and Cabut outcome data using CMR volumes is pending. CMR is
less helpful in establishing mitral pathoanatomy.
Supporting References: 366,372,373
Class I
3. Intraoperative TEE is indicated to establish the anatomic basis for
chronic primary MR (stages C and D) and to guide repair.374,375
(Level of Evidence: B)
Intraoperative TEE is a standard imagingmodality for the
surgical therapy of MR. Before the operative incision, TEE
may give the surgeon a better understanding of the valve
anatomy and type of repair that will likely be performed,
although this decision is ultimately made when the valve
is inspected visually. Three-dimensional TEE may be help-
ful in further visualizing the abnormal mitral valve anat-
omy. Because anesthesia lessens afterload, preload,
and mitral valve closing force, it is important that decisions
about severity of MR not be re-evaluated under these
artificial conditions, in which MR severity could be
underestimated.rdiovascular Surgery c Volume 148, Number 1 e45
TABLE 16. Stages of Secondary MR
Grade Definition Valve anatomy Valve hemodynamics* Associated cardiac findings Symptoms
A At risk of MR  Normal valve leaflets,
chords, and annulus in a
patient with coronary
disease or cardiomyopathy
 No MR jet or small central
jet area<20% LA on
Doppler
 Small vena contracta
<0.30 cm
 Normal or mildly dilated
LV size with fixed
(infarction) or inducible
(ischemia) regional wall
motion abnormalities
 Primary myocardial disease
with LV dilation and
systolic dysfunction
 Symptoms due to coronary
ischemia or HF may be
present that respond to
revascularization and
appropriate medical
therapy
B Progressive MR  Regional wall motion
abnormalities with mild
tethering of mitral leaflet
 Annular dilation with mild
loss of central coaptation of
the mitral leaflets
 ERO<0.20 cm2y
 Regurgitant volume
<30 mL
 Regurgitant fraction<50%
 Regional wall motion
abnormalities with reduced
LV systolic function
 LV dilation and systolic
dysfunction due to primary
myocardial disease
 Symptoms due to coronary
ischemia or HF may be
present that respond to
revascularization and
appropriate medical
therapy
C Asymptomatic
severe MR
 Regional wall motion
abnormalities and/or LV
dilation with severe
tethering of mitral leaflet
 Annular dilation with
severe loss of central
coaptation of the mitral
leaflets
 ERO 0.20 cm2y
 Regurgitant volume
30 mL
 Regurgitant fraction50%
 Regional wall motion
abnormalities with reduced
LV systolic function
 LV dilation and systolic
dysfunction due to primary
myocardial disease
 Symptoms due to coronary
ischemia or HF may be
present that respond to
revascularization and
appropriate medical
therapy
D Symptomatic
severe MR
 Regional wall motion
abnormalities and/or LV
dilation with severe
tethering of mitral leaflet
 Annular dilation with
severe loss of central
coaptation of the mitral
leaflets
 ERO 0.20 cm2y
 Regurgitant volume
30 mL
 Regurgitant fraction50%
 Regional wall motion
abnormalities with reduced
LV systolic function
 LV dilation and systolic
dysfunction due to primary
myocardial disease
 HF symptoms due to MR
persist even after
revascularization and
optimization of medical
therapy
 Decreased exercise
tolerance
 Exertional dyspnea
2D, 2-dimensional; ERO, effective regurgitant orifice; HF, heart failure; LA, left atrium; LV, left ventricular; MR, mitral regurgitation; TTE, transthoracic echocardiogram.
*Several valve hemodynamic criteria are provided for assessment of MR severity, but not all criteria for each category will be present in each patient. Categorization of MR
severity as mild, moderate, or severe depends on data quality and integration of these parameters in conjunction with other clinical evidence. yThe measurement of the proximal
isovelocity surface area by 2D TTE in patients with secondary MR underestimates the true ERO due to the crescentic shape of the proximal convergence.
Clinical Guidelines Nishimura et alIntraoperative TEE is especially helpful in gauging the
adequacy of repair. Because even mild residual MR
after repair increases the likelihood of later repair failure
necessitating reoperation, surgeons strive for near-perfect
operative repair. If MR is detected in the operating room
following repair, it is often an indication that the repair
should be revised. This assessment should be made during
conditions that approach those of normal physiology. The
left ventricle should be well filled and systemic BP should
be brought well into the normal range. A low preload with
underfilling of the left ventricle can lead to 1) systolic
anterior leaflet motion with outflow obstruction or 2) un-
derestimation of degree of residual MR. Thus, information
obtained by TEE when the ventricle is underfilled can lead
to an unneeded revision in the former case while overlook-
ing a needed revision in the latter. Intraoperative TEE is
also useful for diagnosing mitral inflow obstruction or
LV outflow obstruction as a result of the mitral valve
repair.
Supporting References: 374,375e46 The Journal of Thoracic and Cardiovascular SurgClass I
4. TEE is indicated for evaluation of patients with chronic primary
MR (stages B to D) in whom noninvasive imaging provides nondiag-
nostic information about severity of MR, mechanism of MR, and/or
status of LV function. (Level of Evidence: C)
TEE is not recommended for routine evaluation and
follow-up of patients with chronic primary MR but is indi-
cated in specific situations. Because TEE provides excel-
lent imaging of the mitral valve, it should be performed
when TTE images are inadequate. TEE is especially use-
ful in cases of MR due to IE, where additional information
about other potentially infected structures can be fully
evaluated by that technique. TEE allows more precise
quantitation of regurgitant severity and provides a better
estimate of the likelihood of a successful surgical valve
repair. Three-dimensional TEE may be helpful in further
visualizing the abnormal mitral valve anatomy. Mitral
valve repair is preferable to valve replacement because
of lower operative mortality and avoidance of the compli-
cations inherent to prosthetic valves that accrue over time.ery c July 2014
Nishimura et al Clinical GuidelinesThus, if repair can be accomplished, it might be performed
earlier in the course of disease. Alternatively,
if replacement is likely, strategy shifts toward performing
surgery later to avoid unwanted exposure time to
prosthetic-related complications.
7.3.1.2. Diagnostic testing—changing signs or symptoms
TTE is indicated in patients with primary MR (stages B
to D) to evaluate the mitral valve apparatus and LV func-
tion after a change in signs or symptoms. The onset of
symptoms (dyspnea on exertion, orthopnea, or declining
exercise tolerance) is by itself a negative prognostic event
even if LV function is preserved. Symptoms are the culmi-
nation of the pathophysiology of MR and may indicate
changes in LV diastolic function, left atrial compliance,
LV filling pressure and/or increases in pulmonary artery
pressure, and decreases in RV function or the coexistence
of TR. Therefore, symptoms add pathophysiological data
not readily available from imaging. Further, there is no ev-
idence that treatment with diuretics or other therapies that
might relieve symptoms changes the prognostic effect of
symptom onset. Once symptoms have occurred, the pa-
tient should be considered for mitral valve operation
even if medication has led to improvement. Repeat TTE
at the time of symptom onset is indicated to confirm
that symptoms are likely due to MR or its effect on the
left ventricle, which in turn supports surgical correction.
The new onset of AF is also an indication for repeat
TTE to look for changes in severity of MR and the status
of the left ventricle.
Supporting References: 365,376
7.3.1.3. Diagnostic testing—routine follow-up
TTE should be performed on an annual or semiannual
basis for surveillance of LV function (estimated by
LVEF and end-systolic dimension) and pulmonary artery
pressure in asymptomatic patients with severe primary
MR (stage C1). Chronic severe MR is tolerated poorly,
reaching a trigger for surgery at an average rate of about
8% per year. Because this progression varies from patient
to patient and because prognosis worsens if correction of
MR is delayed beyond the onset of these triggers, either
referral to a Heart Valve Center of Excellence for early
repair or very careful surveillance is mandatory. If a
watchful waiting approach is pursued, periodic TTE is
critical to examine the patient for changes in LV function
and pulmonary pressure in determining the proper timing
of surgery. For patients approaching the above bench-
marks, semiannual TTE is recommended. It should be
noted that echocardiographic measurements are variable,
and management decisions that rest on these measure-
ments should be confirmed by repeat TTE if the patient
is approaching or has reached the important triggers for
surgery noted above.The Journal of Thoracic and CaIn patients with chronic primaryMR that is less than se-
vere (stages A and B), TTE is indicated periodically to eval-
uate for changes in MR severity. MR is a progressive
disease. The LV volume overload induced by chronic pri-
mary MR causes eccentric cardiac remodeling with pro-
gressively increasing chamber volume, tending to reduce
valve leaflet coaptation. Advancing valve pathology leads
to further worsening of MR. This process may develop
slowly without dramatic changes in symptoms or physical
examination. Thus, MR could become severe and even
lead to LV dysfunction without the patient or clinician being
aware of it. Accordingly, periodic repeat TTE to examine
for changes in severity of MR and LV size and function
when baseline disease is less than severe is advisable. For
mild MR, follow-up every 3 to 5 years is adequate unless
the results of the physical examination or symptoms
change. For moderate MR, follow-up every 1 to 2 years is
recommended, again unless clinical status suggests a wors-
ening in severity (Table 4).
Supporting Reference: 39
7.3.1.4. Diagnostic testing—cardiac catheterization
Left ventriculography and/or hemodynamic measure-
ments are indicated when clinical assessment and/or nonin-
vasive tests are inconclusive or discordant regarding: (1)
severity of MR; (2) LV function; or (3) the need for surgery.
Imaging with these techniques is adequate for evaluation of
MR in the majority of cases. However, invasive hemody-
namic evaluationmay be necessary in some cases, especially
when there is a clinical discrepancy between symptomatic
status and noninvasive testing. Elevated filling pressures sup-
port a cardiac cause for dyspnea and/ormay indicate severely
abnormal pathophysiology even when the patient claims to
be asymptomatic. Conversely, a normal invasive hemody-
namic examination in a symptomatic patient with what ap-
pears to be less than severe MR suggests a noncardiac
cause for the symptoms. Hemodynamic evaluation can be
especially helpful in patients with concomitant lung disease.
Normal left atrial (or wedge) pressure and a large transpul-
monary gradient suggest pulmonary hypertension due to
lung disease rather thanmitral valve disease. Patients usually
complain of dyspnea with exertion, yet noninvasive evalua-
tion is usually made at rest. Hemodynamic measurement
made during either handgrip or dynamic exercise may be
very revealing. Increased load with exercise may bring out
severely disordered hemodynamics explaining the patient’s
exercise-related symptoms. Left ventriculography may also
be of diagnostic benefit. Whereas echo-Doppler interroga-
tion of the mitral valve measures flow velocity, ventriculog-
raphy uses the density of contrast to determine the amount of
bloodflow from the left ventricle to LA.Although only semi-
quantitative, a carefully performed ventriculogram can add
significantly to the diagnostic data pool.
Supporting Reference: 42rdiovascular Surgery c Volume 148, Number 1 e47
Clinical Guidelines Nishimura et al7.3.1.5. Diagnostic testing—exercise testing: Recommen-
dations
Class IIa
1. Exercise hemodynamics with either Doppler echocardiography or
cardiac catheterization is reasonable in symptomatic patients with
chronic primary MR where there is a discrepancy between symp-
toms and the severity of MR at rest (stages B and C).377,378 (Level
of Evidence: B)
The symptoms of chronic primary MR usually occur dur-
ing exercise. Thus, evaluation during exercise may be very
informative when resting TTE and symptomatic status are
discordant or when the magnitude of LV and LA enlarge-
ment seem out of proportion to the severity of resting MR.
In such cases, severity of MR and/or pulmonary artery pres-
sure may increase during exercise, both helping to explain
exercise-induced symptoms and indicating that mitral sur-
gerymay be in order. The change in pulmonary arterywedge
pressure and LV diastolic pressure during exercise can be
obtained during cardiac catheterization, which may further
aid in determining the etiology of symptoms.
Supporting References: 42,377,378
Class IIa
2. Exercise treadmill testing can be useful in patients with chronic pri-
maryMR to establish symptom status and exercise tolerance (stages
B and C). (Level of Evidence: C)
Theonset of symptoms represents a keydevelopment in se-
vere MR. However, some patients may not recognize their
symptoms, may deny them, or may alter their lifestyle to
remain asymptomatic. A formal treadmill exercise test can
establish true exercise tolerance and can also form the base-
line for future symptom assessment. Additional information
about a cardiac or noncardiac limitation canbeobtainedusing
oxygen consumption measurements during exercise. Exer-
cise echocardiography may add additional prognostic value
beyond conventional exercise treadmill testing in patients
with asymptomatic moderate or severe chronic primary MR.
Supporting References: 378-3817.3.2. Medical therapy: Recommendations
Class IIa
1. Medical therapy for systolic dysfunction is reasonable in symptom-
atic patients with chronic primary MR (stage D) and LVEF less
than 60% in whom surgery is not contemplated.382-386 (Level of
Evidence: B)
PatientswithMRandLVdysfunction experiencemyocar-
dial damage and HF. With onset of LV systolic dysfunction,
surgery is usually indicated. However, in those patients in
whom surgery is not performed or will be delayed, medical
therapy for systolic dysfunction should be implemented.
Although there are sparse data available specific to patients
with MR with LV dysfunction, it seems reasonable to treat
such patients with the standard regimen for HF, includinge48 The Journal of Thoracic and Cardiovascular Surgbeta-adrenergic blockade, ACE inhibitors or ARBs, and
possibly aldosterone antagonists. Perhaps the best data exist
for the use of beta blockers, which reverse LV dysfunction in
experimental MR. Patients who are receiving beta blockers
may have better surgical outcomes and delayed onset of LV
dysfunction compared with those not taking these medica-
tions. ACE inhibition has not been effective in experimental
MR with LV dysfunction but has caused reverse remodeling
in a study with a small number of patients. Because aldoste-
rone antagonism is thought to work in part by inhibiting
fibrosis, its role in MRwhere little fibrosis occurs is unclear.
Supporting References: 382-386
Class III: No Benefit
1. Vasodilator therapy is not indicated for normotensive asymptom-
atic patients with chronic primary MR (stages B and C1) and
normal systolic LV function.386-391 (Level of Evidence: B)
Because vasodilator therapy appears to be effective in
acute severe symptomatic MR, it seems reasonable to
attempt afterload reduction in chronic asymptomatic MR
with normal LV function in an effort to forestall the need
for surgery. However, the results from the limited number
of trials addressing this therapy have been disappointing,
demonstrating little or no clinically important benefit.
Conversely, becausevasodilators decreaseLV size andmitral
closing force, theymay increasemitral valve prolapse, wors-
ening rather than decreasing severity of MR. The foregoing
does not apply to patients with concomitant hypertension.
Hypertension must be treated because of the well-known
morbidity and mortality associated with that condition and
because increased LV systolic pressure by itself increases
the systolic transmitral gradient andworsens severity ofMR.
Supporting References: 386-391
7.3.3. Intervention: Recommendations
See Table 17 for a summary of recommendations from
this section.
Intervention for patients with primary MR consists of
either surgical mitral valve repair or MVR. Mitral valve
repair is preferred over MVR if a successful and durable
repair can be achieved. Repair success is dependent on
the mitral valve morphology as well as surgical expertise.
Percutaneous mitral valve repair provides a less invasive
alternative to surgery but is not approved for clinical use
in the United States.
Supporting Reference: 426
Class I
1. Mitral valve surgery is recommended for symptomatic patients
with chronic severe primary MR (stage D) and LVEF greater
than 30%.365,376 (Level of Evidence: B)
Primary MR is a mechanical problem of the leaflets that
has only a mechanical solution—that of mitral valve sur-
gery. The onset of symptoms that results from severe MR
worsens prognosis even when LV function appears to beery c July 2014
Nishimura et al Clinical Guidelinesnormal, and negative prognosis extends even to mild symp-
toms. Thus, the onset of symptoms is an indication for
prompt mitral valve surgery.
Supporting References: 365,376
Class I
2. Mitral valve surgery is recommended for asymptomatic patients
with chronic severe primary MR and LV dysfunction (LVEF 30%
to 60% and/or LVESD 40 mm, stage C2).359-362,392-394 (Level of
Evidence: B)
The goal of therapy in MR is to correct it before the onset
of LV systolic dysfunction and the subsequent adverse
effect on patient outcomes. Ideally, mitral valve surgery
should be performed when the patient’s left ventricle ap-
proaches but has not yet reached the parameters that indicate
systolic dysfunction (LVEF 60% or LVESD 40 mm).
Because symptoms do not always coincidewith LVdysfunc-
tion, imaging surveillance is used to plan surgery before se-
vere dysfunction has occurred. If moderate LV dysfunction
is already present, prognosis is reduced following mitral
valve operation. Thus, further delay (even though symptoms
are absent) will lead to greater LV dysfunction and a still
worse prognosis. Because the loading conditions in MR
allow continued late ejection into a lower-impedance LA,
a higher cutoff for ‘‘normal’’ LVEF is used in MR than in
other types of heart disease. Although it is clearly inadvis-
able to allow patients’ LV function to deteriorate beyond
the benchmarks of an LVEF 60% and/or LVESD 40
mm, some recovery of LV function can still occur even if
these thresholds have been crossed.
Supporting References: 359-362,392-394
Class I
3. Mitral valve repair is recommended in preference toMVRwhen sur-
gical treatment is indicated for patients with chronic severe primary
MR limited to the posterior leaflet.87,364,395-409 (Level of Evidence: B)
Mitral competence is only 1 function of the mitral valve
apparatus. The mitral valve apparatus is an integral part of
the left ventricle. It aids in LV contraction and helps main-
tain the efficient prolate ellipsoid shape of the left ventricle.
Destruction of the mitral apparatus causes immediate LV
dysfunction. Mitral valve repair is favored over MVR for 3
reasons:
1. Mitral valve repair is performed at a lower operative mor-
tality rate than MVR. Although no RCTs exist, virtually
every clinical report, including data from the STS data-
base, indicates that operative risk (30–day mortality)
for repair is about half that of MVR.
2. LV function is better preserved following repair preser-
ving the integrity of the mitral valve apparatus versus
following MVR.
3. Repair avoids the risks inherent to prosthetic heart valves,
that is, thromboembolism or anticoagulant-induced hem-
orrhage for mechanical valves or structural deterioration
for bioprosthetic valves.The Journal of Thoracic and CaBecause the success of repair increases with surgical vol-
ume and expertise, repair (which is the preferred treatment)
is more likely to be accomplished in centers with surgeons
who have expertise in this type of surgery. Mitral valve
repair over MVR is indicated even in patients>65 years
of age. When in doubt, MVR is preferable to a poor repair.
The results of a minimally invasive approach performed via
minithoracotomy/port access using direct vision, thoraco-
scopic, or robotic assistance versus a conventional sternot-
omy approach may be similar when performed by highly
experienced surgeons.
Surgical repair of MR has been remarkably successful in
the treatment of primary MR. When leaflet dysfunction is
sufficiently limited so that only annuloplasty and repair of
the posterior leaflet are necessary, repair of isolated degen-
erative mitral disease has led to outcomes distinctly supe-
rior to biological or mechanical valve replacement: an
operative mortality of<1%; long-term survival equivalent
to that of the age-matched general population; approxi-
mately 95% freedom from reoperation; and>80% freedom
from recurrent moderate or severe (3þ) MR at 15 to 20
years after operation. As much as one half of the posterior
leaflet may be excised, plicated, or resuspended. Posterior
leaflet repair has become sufficiently standardized so that
valve repair rather than valve replacement is the standard
of care in this situation. Execution of this procedure with
a success rate90% should be the expectation of every car-
diac surgeon who performs mitral valve procedures.
Supporting References: 87,364,395-409,427-432
Class I
4. Mitral valve repair is recommended in preference to MVR when
surgical treatment is indicated for patients with chronic severe pri-
mary MR involving the anterior leaflet or both leaflets when a suc-
cessful and durable repair can be accomplished.86,407-413 (Level of
Evidence: B)
Degenerative mitral valve disease consisting of more
than posterior leaflet disease requires a more complex and
extensive repair. When the anterior leaflet or both leaflets
require repair, durability of the repair is less certain, with
a freedom from reoperation of approximately 80% and a
freedom from recurrent moderate or severe MR of 60% at
15 to 20 years. These results are superior to the results of
MVR, even in elderly patients. Repair should also be at-
tempted if possible with other causes of severe MR, such
as papillary muscle rupture, IE, and cleft mitral valve. As
the repair becomes more complex, however, results of
very complex repair in younger patients may be matched
by results of durable mechanical MVR with careful man-
agement of anticoagulation.
More complex repair is not well standardized and is more
surgically demanding. The Heart Valve Team should assign
complex repairs to more experienced mitral valve surgeons
with established outcomes, including acute success rate asrdiovascular Surgery c Volume 148, Number 1 e49
TABLE 17. Summary of recommendations for chronic Primary MR
Recommendations COR LOE References
MV surgery is recommended for symptomatic patients with chronic severe primary MR (stage D) and LVEF
>30%
I B 365,376
MV surgery is recommended for asymptomatic patients with chronic severe primary MR and LV dysfunction
(LVEF 30%–60% and/or LVESD 40 mm, stage C2)
I B 359-362,392-394
MV repair is recommended in preference toMVRwhen surgical treatment is indicated for patients with chronic
severe primary MR limited to the posterior leaflet
I B 87,364,395-409
MV repair is recommended in preference toMVRwhen surgical treatment is indicated for patients with chronic
severe primary MR involving the anterior leaflet or both leaflets when a successful and durable repair can be
accomplished
I B 86,407-413
Concomitant MV repair or replacement is indicated in patients with chronic severe primary MR undergoing
cardiac surgery for other indications
I B 414
MV repair is reasonable in asymptomatic patients with chronic severe primary MR (stage C1) with preserved
LV function (LVEF>60% and LVESD<40 mm) in whom the likelihood of a successful and durable repair
without residual MR is>95% with an expected mortality rate of<1% when performed at a Heart Valve
Center of Excellence
IIa B 39,86,415-419
MV repair is reasonable for asymptomatic patients with chronic severe nonrheumatic primary MR (stage C1)
and preserved LV function in whom there is a high likelihood of a successful and durable repair with 1) new
onset of AF or 2) resting pulmonary hypertension (PA systolic arterial pressure>50 mm Hg)
IIa B 363,415,420-425
Concomitant MV repair is reasonable in patients with chronic moderate primary MR (stage B) undergoing
cardiac surgery for other indications
IIa C N/A
MV surgery may be considered in symptomatic patients with chronic severe primary MR and LVEF 30%
(stage D)
IIb C N/A
MV repair may be considered in patients with rheumatic mitral valve disease when surgical treatment is
indicated if a durable and successful repair is likely or if the reliability of long-term anticoagulation
management is questionable
IIb B 86,406,413
Transcatheter MV repair may be considered for severely symptomatic patients (NYHA class III/IV) with
chronic severe primary MR (stage D) who have a reasonable life expectancy but a prohibitive surgical risk
because of severe comorbidities
IIb B 426
MVR should not be performed for treatment of isolated severe primary MR limited to less than one half of the
posterior leaflet unless MV repair has been attempted and was unsuccessful
III: Harm B 87,407-409
AF, Atrial fibrillation; COR, Class of Recommendation; LOE, Level of Evidence; LV, left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic
dimension; MR, mitral regurgitation; MV, mitral valve; MVR, mitral valve replacement; N/A, not applicable; NYHA, New York Heart Association; PA, pulmonary artery.
Clinical Guidelines Nishimura et alwell as long-term durability. The probability of mitral valve
repair rather than MVR correlates with surgeon-specific
mitral volumes. In a 2007 analysis, hospitals that
performed<36 mitral operations per year had a 48% repair
rate, whereas hospitals that performed>140 mitral opera-
tions per year had a 77% repair rate. Hospital mortality
was also 50% lower, on average, in the highest-volume hos-
pitals. There was, however, considerable overlap in specific
hospital outcomes, with>25% of low-volume hospitals
outperforming the median high-volume hospitals. This
overlap suggests that hospital or surgeon-specific volumes
should not be used as a surrogate for actual surgeon-
specific repair rates and outcomes.
Supporting References: 86,407-413
Class I
5. Concomitant mitral valve repair or MVR is indicated in patients
with chronic severe primary MR undergoing cardiac surgery for
other indications.414 (Level of Evidence: B)
During coronary revascularization and in cases of IE or
other conditions where multiple valves may be involved,
it is prudent to correct severe primary MR at the time ofe50 The Journal of Thoracic and Cardiovascular Surgsurgery. This is especially true when mitral repair can be
performed in conjunction with AVR because operative
risk is lower than that of double valve replacement.
Supporting Reference: 414
Class IIa
1. Mitral valve repair is reasonable in asymptomatic patients with
chronic severe primary MR (stage C1) with preserved LV function
(LVEF>60% and LVESD<40 mm) in whom the likelihood of a
successful and durable repair without residual MR is greater than
95% with an expected mortality rate of less than 1% when per-
formed at a Heart Valve Center of Excellence.39,86,415-419 (Level of
Evidence: B)
The onset of symptoms, LV dysfunction, or pulmonary
hypertension worsens the prognosis for MR. Careful inten-
sive surveillance may result in timing of valve surgery
before these negative sequelae occur. However, an attractive
alternative strategy for treating severe chronic primary MR
is to perform early mitral repair before these triggers are
reached. Early mitral repair avoids the need for intensive
surveillance and also obviates the possibility that patients
might become lost to follow-up or delay seeing theirery c July 2014
Nishimura et al Clinical Guidelinesclinician until advanced LV dysfunction has already ensued.
This strategy requires expertise in clinical evaluation and
cardiac imaging to ensure that MR is severe. For this strat-
egy to be effective, a durable repair must be provided. An
unwanted valve replacement, exposing the patient to the un-
needed risks accrued from prosthetic valve replacement, or
a repair that fails, necessitating reoperation, should be
considered complications of this approach. Thus, there
must be a high degree of certainty that a durable repair
can be performed. In this regard, posterior leaflet repair is
usually more durable than anterior leaflet repair, especially
in less experienced hands, and high surgical volume is also
associated with better repair rates and more durable out-
comes. These operations on the asymptomatic patient
should be performed in Heart Valve Centers of Excellence
by experienced surgeons with expertise in mitral valve
repair. When performed by experienced surgeons in a Heart
Valve Center of Excellence, there is a lower risk of patients
developing HF and lower mortality rates in patients with se-
vere MR from flail leaflets who undergo early operation as
opposed to watchful waiting.
Supporting References: 39,86,415-419
Class IIa
2. Mitral valve repair is reasonable for asymptomatic patients with
chronic severe nonrheumatic primaryMR (stage C1) and preserved
LV function (LVEF>60% and LVESD<40 mm) in whom there is a
high likelihoodof a successful anddurable repairwith 1) newonset of
AFor 2) resting pulmonary hypertension (pulmonary artery systolic
arterial pressure>50 mm Hg).363,415,420-425 (Level of Evidence: B)
In nonrheumatic MR, the onset of AF is in part due to
enlarging left atrial size, and its presence worsens surgical
outcome. Furthermore, the longer AF is present, the more
likely it is to persist. Thus, it may be reasonable to restore
mitral competence by low-risk repair with the hope that
the ensuing reduction in left atrial size will help restore
and maintain sinus rhythm. However, restoration of sinus
rhythm following valve surgery is uncertain, and concomi-
tant AF ablation surgery may be warranted (Section 14.2.2).
This strategy does not apply to rheumatic MR, where active
atrial inflammation may make restoration of sinus rhythm
less likely and valve scarring reduces the likelihood of a
successful repair. The presence of pulmonary arterial hyper-
tension due to MR is associated with poorer outcome after
valve surgery. Thus, it is reasonable to consider surgery in
these patients if there is a high likelihood of a successful
and durable repair.
Supporting References: 363,420-425
Class IIa
3. Concomitant mitral valve repair is reasonable in patients with
chronic moderate primary MR (stage B) when undergoing cardiac
surgery for other indications. (Level of Evidence: C)
Because MR is a progressive lesion, it is reasonable to
address it at the time of other cardiac surgery. This isThe Journal of Thoracic and Caespecially true if the mitral valve can be repaired. However,
the added risk of mitral valve surgery must be weighed
against the potential for progression of MR. In such cases,
increased operative mortality might not be justified in treat-
ing moderate MR.
Supporting Reference: 433
Class IIb
1. Mitral valve surgery may be considered in symptomatic patients
with chronic severe primary MR and LVEF less than or equal to
30% (stage D). (Level of Evidence: C)
Most patients with decompensated MR and an
LVEF 30% have secondary rather than primary MR.
However in the rare cases where valve pathology indicates
a clear primary cause in a patient with far-advanced LV
dysfunction, surgery might be beneficial, especially in pa-
tients without severe comorbidities. Repair seems reason-
able in such patients because of the likelihood of
continued deterioration in LV function if surgery is not per-
formed. However, data regarding surgery in patients with
primary MR and a low LVEF are lacking.
Class IIb
2. Mitral valve repair may be considered in patients with rheumatic
mitral valve disease when surgical treatment is indicated if a dura-
ble and successful repair is likely or when the reliability of long-
term anticoagulation management is questionable.86,406,413 (Level
of Evidence: B)
Rheumatic mitral valve disease is less suitable for mitral
repair than complex degenerative disease. Durability of the
repair is limited by thickened or calcified leaflets, extensive
subvalvular disease with chordal fusion and shortening, and
progression of rheumatic disease. Freedom from reopera-
tion at 20 years, even in experienced hands, is in the 50%
to 60% range. In a large series from Korea, repair was
accomplished in 22% of patients operated on for rheumatic
disease. One third of these patients who underwent repair
had significant stenosis or regurgitation at 10 years. Repair
of rheumatic mitral valve disease should be limited to pa-
tients with less advanced disease in whom a durable repair
can be accomplished or to patients in whom a
mechanical prosthesis cannot be used because of anticoagu-
lation management concerns.
Supporting References: 434,435
Class IIb
3. Transcatheter mitral valve repair may be considered for severely
symptomatic patients (NYHA class III to IV) with chronic severe
primary MR (stage D) who have favorable anatomy for the
repair procedure and a reasonable life expectancy but who have a
prohibitive surgical risk because of severe comorbidities and
remain severely symptomatic despite optimal GDMT for HF.426
(Level of Evidence: B)
AnRCTof percutaneous mitral valve repair using theMi-
traClip device versus surgical mitral repair was conducted
in the United States. The clip was found to be safe butrdiovascular Surgery c Volume 148, Number 1 e51
Clinical Guidelines Nishimura et alless effective than surgical repair because residual MR was
more prevalent in the percutaneous group. However, the
clip reduced severity of MR, improved symptoms, and led
to reverse LV remodeling. Percutaneous mitral valve repair
should only be considered for patients with chronic primary
MRwho remain severely symptomatic with NYHA class III
to IV HF symptoms despite optimal GDMT for HF and who
are considered inoperable.
Supporting References: 426,436,437
Class III: Harm
1. MVR should not be performed for the treatment of isolated severe
primaryMR limited to less than one half of the posterior leaflet un-
less mitral valve repair has been attempted and was unsuccess-
ful.87,407-409 (Level of Evidence: B)
Surgical repair of MR has been remarkably successful,
particularly in the treatment of chronic primary MR. Repair
of isolated degenerative mitral disease, when leaflet
dysfunction is sufficiently limited that only annuloplasty
and repair of the posterior leaflet are necessary, has led to
outcomes distinctly superior to biological or mechanical
MVR: operative mortality of <1%; long-term survival
equivalent to that of age-matched general population;
approximately 95% freedom from reoperation; and
>80% freedom from recurrent moderate or severe (3þ)
MR at 15 to 20 years after operation. As much as one half
of the posterior leaflet may be excised, plicated, or resus-
pended. Posterior leaflet repair has become sufficiently
standardized in this situation that repair rather than MVR
is the standard of care. Execution of this procedure with a
success rate 90% should be the expectation of every car-
diac surgeon who performs mitral valve procedures.
Supporting References: 87,407-409
See Online Data Supplements 16 and 17 for more infor-
mation on intervention.
7.4. Chronic Secondary MR
7.4.1. Diagnosis and Follow-up: Recommendations
Class I
1. TTE is useful to establish the etiology of chronic secondary MR
(stages B to D) and the extent and location of wall motion abnormal-
ities and to assess global LV function, severity of MR, and magni-
tude of pulmonary hypertension. (Level of Evidence: C)
In general, the presence of chronic secondary MR
worsens the prognosis of patients with LV systolic dysfunc-
tion and symptoms of HF, and most patients with secondary
MR have severe global LV dysfunction. However, in some
patients, a limited but strategically placed wall motion ab-
normality may also cause chronic secondary MR, and prog-
nosis may be better in such patients. An initial TTE helps
establish the cause of chronic secondaryMR and also serves
as a baseline for future comparisons. In patients with sec-
ondary MR, outcome studies have shown poorer prognosise52 The Journal of Thoracic and Cardiovascular Surgwith effective regurgitant orifice 20 mm2. It is recognized
that there is difficulty assessing secondary MR in patients
with reduced LV systolic function and low forward flow.
Supporting References: 438,439
Class I
2. Noninvasive imaging (stress nuclear/positron emission tomography,
CMR, or stress echocardiography), cardiac CTangiography, or car-
diac catheterization, including coronary arteriography, is useful to
establish etiology of chronic secondaryMR (stages B to D) and/or to
assess myocardial viability, which in turn may influence manage-
ment of functional MR. (Level of Evidence: C)
Prognosis is poor for both ischemic and nonischemic
MR, but ischemicMR lends itself to the possibility of revas-
cularization and potential improvement in LV function if
CAD has led to large areas of hibernating viable myocar-
dium. CTangiography is usually adequate to rule out signif-
icant CAD and thus rule out ischemic MR. If CAD is
detected and noninvasive testing demonstrates areas of
viability, coronary arteriography is pursued to better define
the anatomy for potential revascularization.
Supporting Reference: 440
7.4.2. Medical Therapy: Recommendations
Class I
1. Patients with chronic secondary MR (stages B to D) and HF with
reduced LVEF should receive standard GDMT therapy for HF,
including ACE inhibitors, ARBs, beta blockers, and/or aldosterone
antagonists as indicated.310,441-445 (Level of Evidence: A)
Chronic secondary MR usually develops as a result of se-
vere LV dysfunction. Thus, standard GDMT for HF forms
the mainstay of therapy. Diuretics, beta blockers, ACE inhi-
bition or ARBs, and aldosterone antagonists help improve
symptoms and/or prolong life in HF in general and
probably do so even when HF is complicated by chronic
secondary MR.
Supporting References: 310,441-445
Class I
2. Cardiac resynchronization therapywith biventricular pacing is rec-
ommended for symptomatic patients with chronic severe secondary
MR (stages B to D) who meet the indications for device ther-
apy.446,447 (Level of Evidence: A)
Wall motion abnormalities are a common cause of
chronic secondary MR, and their presence worsens the con-
dition. The presence of conduction system abnormalities,
especially left bundle-branch block, causes disordered LV
contraction that exacerbates or is the primary cause of
wall motion abnormalities. Electrical resynchronization
may reduce or even eliminate wall motion abnormalities.
Cardiac resynchronization therapy may also improve LV
function and mitral valve closing force, which in turn leads
to a reduction in chronic secondary MR in some cases.
Thus, cardiac resynchronization therapy should beery c July 2014
TABLE 18. Summary of recommendations for chronic severe secondary MR
Recommendations COR LOE References
MV surgery is reasonable for patients with chronic severe secondary MR (stages C and D)
who are undergoing CABG or AVR
IIa C N/A
MV surgery may be considered for severely symptomatic patients (NYHA class III/IV)
with chronic severe secondary MR (stage D)
IIb B 439,448-458
MV repair may be considered for patients with chronic moderate secondary MR (stage B)
who are undergoing other cardiac surgery
IIb C N/A
AVR, Aortic valve replacement; CABG, coronary artery bypass graft; COR, Class of Recommendation; LOE, Level of Evidence;MR, mitral regurgitation;MV, mitral valve; N/A,
not applicable; NYHA, New York Heart Association.
Nishimura et al Clinical Guidelinesconsidered in symptomatic patients with chronic secondary
MR who meet the indications for device therapy as outlined
in the ACC/AHA guidelines for device-based therapy.
Supporting References: 446,447
7.4.3. Intervention: Recommendations
See Table 18 for a summary of recommendations for this
section and Figure 4 for indications for surgery for MR.
Chronic severe secondary MR adds volume overload to
a decompensated left ventricle and worsens prognosis.
However, there are only sparse data to indicate that correct-
ing MR prolongs life or even improves symptoms over an
extended time. The benefits of performing mitral valve
repair over MVR are also unclear in this subset of patients.
Percutaneous mitral valve repair provides a less invasive
alternative to surgery but is not approved for clinical use
in the United States.
Supporting References: 426,436,459
Class IIa
1. Mitral valve surgery is reasonable for patients with chronic severe
secondaryMR (stages C andD)who are undergoingCABGorAVR.
(Level of Evidence: C)
There is no proof that correction of chronic secondaryMR
at the time ofAVRor CABG is effective in prolonging life or
relieving symptoms, but it seems wise to address the mitral
valve during those operations. Although itmay be hoped that
the revascularization will recruit hibernating myocardium
and reduce chronic secondaryMRor that LVpressure reduc-
tion from relief of AS or volume reduction from relief of AR
might improve chronic secondary MR, such hopes may not
be realized. Failing to correct chronic secondary MR may
leave the patient with severe residual MR.
Class IIb
1. Mitral valve repair or replacement may be considered for severely
symptomatic patients (NYHA class III to IV) with chronic severe
secondary MR (stage D) who have persistent symptoms despite
optimal GDMT for HF.439,448-458 (Level of Evidence: B)
Although it is clear that chronic severe secondary
MR adds to the burden of HF by imposing volume overload
on an already compromised left ventricle and worsens prog-
nosis, there is remarkably little evidence that correcting
chronic severe secondary MR prolongs life or evenThe Journal of Thoracic and Caimproves symptoms for a prolonged period. This paradox
may result from the fact that mitral surgery in ischemic
MR does not prevent CAD from progressing, nor does it
prevent the continued idiopathic myocardial deterioration
in nonischemic chronic secondary MR. Furthermore,
when chronic severe secondary MR is addressed surgically,
it is not clear that repair, so valuable in treating primaryMR,
is even preferred over MVR in chronic severe secondary
MR. Small RCTs have demonstrated that mitral valve sur-
gery reduces chamber size and improves peak oxygen con-
sumption in chronic severe secondary MR. Deciding which
patients with chronic severe secondary MR will benefit
from mitral surgery awaits the results of larger RCTs.
Ischemic or dilated cardiomyopathy presents different chal-
lenges for mitral repair. Regurgitation is caused by annular
dilation as well as apical and lateral displacement of the
papillary muscles. New techniques have facilitated mitral
repair in this situation, but durability of the repair is primar-
ily dependent on regression or progression of ventricular
dilation. If the heart continues to dilate, long-term durability
of the repair is moot; the survival of the patient is limited.
Supporting References: 434,435,439,448-458
Class IIb
2. Mitral valve repair may be considered for patients with chronic
moderate secondary MR (stage B) who are undergoing other car-
diac surgery. (Level of Evidence: C)
Because MR tends to be a progressive disease, it may be
helpful to address moderate MR when other cardiac surgery
is being performed. Because adding MVR to other valve
surgery increases surgical risk, it seems logical that repair
would be preferred in such instances; however, there are
sparse data available at the time of publication to support
this concept.
Supporting Reference: 433
See Online Data Supplement 18 for more information on
intervention.
8. TRICUSPID VALVE DISEASE
8.1. Stages of TR
Trace-to-mild degrees of TR of no physiological conse-
quence are commonly detected on TTE in subjects with
anatomically normal valves. Primary disorders of therdiovascular Surgery c Volume 148, Number 1 e53
FIGURE 4. Indications for surgery for MR. AF, Atrial fibrillation; CAD, coronary artery disease; CRT, cardiac resynchronization therapy; ERO, effective
regurgitant orifice;HF, heart failure; LV, left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension;MR, mitral
regurgitation;MV, mitral valve;MVR, mitral valve replacement; NYHA, New York Heart Association; PASP, pulmonary artery systolic pressure; RF, regur-
gitant fraction; RVol, regurgitant volume; Rx, therapy. *Mitral valve repair is preferred over MVR when possible.
Clinical Guidelines Nishimura et altricuspid apparatus that can lead to more significant degrees
of TR include rheumatic disease, prolapse, congenital dis-
ease (Ebstein’s), IE, radiation, carcinoid, blunt chest wall
trauma, RV endomyocardial biopsyrelated trauma, and
intra-annular RV pacemaker or implantable cardioverter-
defibrillator leads. Approximately 80% of cases of signifi-
cant TR are functional in nature and related to tricuspid
annular dilation and leaflet tethering in the setting of RV re-
modeling due to pressure and/or volume overload. The
tricuspid annulus is a saddle-shaped ellipsoid that becomes
planar and circular as it dilates in an anterior-posterior direc-
tion and will often not return to its normal size and configu-
ration after relief of RVoverload. Table 19 shows the stages
(A through D) of primary and functional TR as defined for
other valve lesions. Severe TR (stages C andD) is associated
with poor prognosis independent of age, LV and RV func-
tion, and RV size. Patients with signs or symptoms of right
HF would fit into the stage D category even if they do not
meet other hemodynamic or morphological criteria.
Supporting Reference: 460e54 The Journal of Thoracic and Cardiovascular Surg8.2. Tricuspid Regurgitation
See Figure 5 for indications for surgery.
8.2.1. Diagnosis and Follow-up: Recommendations
Class I
1. TTE is indicated to evaluate severity of TR, determine etiology,
measure sizes of right-sided chambers and inferior vena cava, assess
RV systolic function, estimate pulmonary artery systolic pressure,
and characterize any associated left-sided heart disease. (Level of
Evidence: C)
Most TR is clinically silent. Advanced degrees of TRmay
be detected on physical examination by the appearance of
elevated ‘‘c-V’’ waves in the jugular venous pulse, a systolic
murmur at the lower sternal border that increases in intensity
with inspiration, and a pulsatile liver edge. In many patients,
characteristic findings in the jugular venous pulse are the
only clues to the presence of advanced TR, because a
murmur may be inaudible even with severe TR. Symptoms
include fatigue from low cardiac output, abdominal fullness,
edema, and palpitations, particularly if AF is also present.ery c July 2014
Nishimura et al Clinical GuidelinesProgressive hepatic dysfunction may occur due to the
elevated right atrial pressure, and thus assessment of liver
function is useful in patients with advanced degrees of TR.
TTE can distinguish primary from functional TR, define
any associated left-sided valvular and/ormyocardial disease,
and provide an estimate of pulmonary artery systolic pres-
sure. Characterization of severity of TR (Table 19) relies
on an integrative assessment of multiple parameters as rec-
ommended by the ASE and EAE. In cases of functional
TR, the tricuspid annular diameter should be measured
in the apical 4–chamber view. There is a linear relationship
between annular diameter and tricuspid regurgitant volume.
A diastolic diameter>40mm (or>21mm/m2) indicates sig-
nificant annular dilation and an increased risk of persistent or
progressive TR after isolated mitral valve surgery. With RV
remodeling, tricuspid valve leaflet tethering height and
area also contribute to functional TR and may predict the
need for repair techniques other than annuloplasty to achieve
an effective and durable operative result. Pulmonary artery
systolic pressure is estimated from the maximal tricuspid
valve regurgitant velocity using themodifiedBernoulli equa-
tion. The accuracy of this technique can be compromised in
severe TR due to the difficulty in assessing right atrial pres-
sure as well as potential inaccuracies of applying the simpli-
fied Bernoulli equation to lesions with laminar flow.
Assessment ofRV systolic function is challenged by geomet-
ric and image acquisition constraints, aswell as by variability
in RV loading conditions. Normal RV systolic function is
defined by several parameters, including tricuspid annular
plane systolic excursion>16mm, tricuspid valve annular ve-
locity (S’) >10.0 cm per second, and RV end-systolic
area<20.0 cm2 or fractional area change>35%. TEE for
tricuspid valve assessment can be considered when TTE im-
ages are inadequate, although visualization of the tricuspid
valve with TEE can also be suboptimal.
Supporting References: 5,461-469,469-471
Class IIa
1. Invasive measurement of pulmonary artery pressures and pulmo-
nary vascular resistance can be useful in patients with TR when
clinical and noninvasive data regarding their values are discordant.
(Level of Evidence: C)
When physical examination, ECG, and TTE data
regarding estimated pulmonary artery systolic pressure
are either discordant or insufficient, including when the
TR jet velocity signal is inadequate or may underestimate
pulmonary artery systolic pressure, invasive measurement
of pulmonary artery pressures and pulmonary vascular
resistance can be helpful to guide clinical decision making
in individual patients. Invasive data are essential for accu-
rate diagnosis of the cause of pulmonary hypertension and
for the assessment of pulmonary vascular reactivity
following vasodilator challenge. Direct measurements of
right atrial pressure may also be useful for clinical decisionThe Journal of Thoracic and Camaking. Right ventriculography may further aid in the eval-
uation of the severity of TR and the status of the right
ventricle. Thermodilution cardiac output measurements
may be inaccurate with severe TR, and thus a Fick cardiac
output should be measured to apply to the calculation of
pulmonary resistance.
Class IIb
1. CMR or real-time 3D echocardiography may be considered for
assessment of RV systolic function and systolic and diastolic vol-
umes in patients with severe TR (stages C and D) and suboptimal
2D echocardiograms. (Level of Evidence: C)
Assessment of RV systolic function in patients with TR
is a critical component of preoperative planning,
especially in the context of reoperative isolated tricuspid
valve repair or replacement years after left-sided valve
surgery. Impaired RV systolic function negatively impacts
early functional, late functional, and survival outcomes
following tricuspid valve surgery. Evaluation with TTE
or TEE may be suboptimal in some patients, due to poor
acoustic windows, the technical limitations of standard
echocardiographic and Doppler techniques, and dynamic
changes in RV loading conditions. Both CMR and real-
time 3D echocardiography may provide more accurate
assessment of RV volumes and systolic function, as well
as annular dimension and the degree of leaflet tethering.
CMR may be the ideal modality in young asymptomatic
patients with severe TR to assess initial and serial mea-
surements of RV size and systolic function. In addition,
echocardiographic strain imaging or CT scanning may
be useful in assessing RV function. These imaging modal-
ities are not widely used at the time of guideline publica-
tion, and outcome data are needed to determine the
incremental utility of these tests.
Supporting References: 472-481
Class IIb
2. Exercise testingmay be considered for the assessment of exercise ca-
pacity in patients with severe TR with no or minimal symptoms
(stage C). (Level of Evidence: C)
Patients with severe functional TR usually report symp-
toms referable to the responsible left-sided valve or myocar-
dial abnormality. However, in some patients with primary
TR, symptoms may not emerge until relatively late in the
course of the disease. As is the case for left-sided valve le-
sions, treadmill or bicycle testing may uncover limitations
to exercise not previously recognized by the patient and
prompt earlier evaluation for surgery. Although some clin-
ical experience has been reported for patients with Ebstein’s
anomaly, the effect on clinical outcomes of any exercise-
induced changes in RV size/function or pulmonary artery
pressures in patients with severe TR (stage C) has not
been prospectively studied.
Supporting Reference: 482rdiovascular Surgery c Volume 148, Number 1 e55
TABLE 19. Stages of TR
Stage Definition Valve anatomy Valve hemodynamics*
Hemodynamic
consequences Symptoms
A At risk of TR Primary
 Mild rheumatic change
 Mild prolapse
 Other (eg, IE with
vegetation, early carcinoid
deposition, radiation)
 Intra-annular RV
pacemaker or ICD lead
 Postcardiac transplant
(biopsy related)
Functional
 Normal
 Early annular dilation
 No or trace TR  None  None or in relation to other
left heart or pulmonary/
pulmonary vascular disease
B Progressive TR Primary
 Progressive leaflet
deterioration/destruction
 Moderate-to-severe
prolapse, limited chordal
rupture
Functional
 Early annular dilation
 Moderate leaflet tethering
Mild TR
 Central jet area<5.0 cm2
 Vena contracta width not
defined
 CW jet density and
contour: soft and parabolic
 Hepatic vein flow: systolic
dominance
Moderate TR
 Central jet area 5–10 cm2
 Vena contracta width not
defined but<0.70 cm
 CW jet density and
contour: dense, variable
contour
 Hepatic vein flow: systolic
blunting
Mild TR
 RV/RA/IVC size normal
Moderate TR
 No RV enlargement
 No or mild RA enlargement
 No or mild IVC
enlargement with normal
respirophasic variation
 Normal RA pressure
 None or in relation to other
left heart or pulmonary/
pulmonary vascular disease
C Asymptomatic,
severe TR
Primary
 Flail or grossly distorted
leaflets
Functional
 Severe annular dilation
(>40 mm or 21 mm/m2)
 Marked leaflet tethering
 Central jet area>10.0 cm2
 Vena contracta width>0.7
cm
 CW jet density and
contour: dense, triangular
with early peak
 Hepatic vein flow: systolic
reversal
 RV/RA/IVC dilated with
decreased IVC
respirophasic variation
 Elevated RA pressure with
‘‘c-V’’ wave
 Diastolic interventricular
septal flattening may be
present
 None, or in relation to other
left heart or pulmonary/
pulmonary vascular disease
D Symptomatic
severe TR
Primary
 Flail or grossly distorted
leaflets
Functional
 Severe annular dilation
(>40 mm or>21 mm/m2)
 Marked leaflet tethering
 Central jet area>10.0 cm2
 Vena contracta width>0.70
cm
 CW jet density and
contour: dense, triangular
with early peak
 Hepatic vein flow: systolic
reversal
 RV/RA/IVC dilated with
decreased IVC
respirophasic variation
 Elevated RA pressure with
‘‘c-V’’ wave
 Diastolic interventricular
septal flattening
 Reduced RV systolic
function in late phase
 Fatigue, palpitations,
dyspnea, abdominal
bloating, anorexia, edema
CW, Continuous wave; ICD, implantable cardioverter-defibrillator; IE, infective endocarditis; IVC, inferior vena cava; RA, right atrium; RV, right ventricle; TR, tricuspid regur-
gitation. *Several valve hemodynamic criteria are provided for assessment of severity of TR, but not all criteria for each category will necessarily be present in every patient.
Categorization of severity of TR as mild, moderate, or severe also depends on image quality and integration of these parameters with clinical findings.
Clinical Guidelines Nishimura et al8.2.2. Medical Therapy: Recommendations
Class IIa
1. Diuretics can be useful for patients with severe TR and signs of
right-sided HF (stage D). (Level of Evidence: C)
Patients with severe TR usually present with signs or
symptoms of right HF, including peripheral edema ande56 The Journal of Thoracic and Cardiovascular Surgascites. Diuretics can be used to decrease volume
overload in these patients. Loop diuretics are typically pro-
vided and may relieve systemic congestion, but their use
can be limited by worsening low-flow syndrome. Aldoste-
rone antagonists may be of additive benefit, especially in
the setting of hepatic congestion, which may promote sec-
ondary hyperaldosteronism.ery c July 2014
FIGURE 5. Indications for surgery. LV, Left ventricular; PHTN, pulmonary hypertension; RV, right ventricular; TA, tricuspid annular; TR, tricuspid regur-
gitation; TTE, transthoracic echocardiogram; TV, tricuspid valve; TVR, tricuspid valve replacement. *See Table 19 for definition of stages. TA dilation is
defined by>40 mm on TTE (>21 mm/m2) or>70 mm on direct intraoperative measurement.
Nishimura et al Clinical GuidelinesClass IIb
1. Medical therapies to reduce elevated pulmonary artery pressures
and/or pulmonary vascular resistance might be considered in pa-
tients with severe functional TR (stages C and D). (Level of Evi-
dence: C)
Medical therapies for management of severe TR (stages C
and D) are limited. Attention should be focused on the caus-
ative lesion in patients with functional TR. Reduction of pul-
monary artery pressures and pulmonary vascular resistance
with specific pulmonary vasodilators may be helpful to
reduce RV afterload and functional TR in selected patients
with pulmonary hypertension who demonstrate acute
responsiveness during invasive testing. Medical treatment
of conditions that elevate left-sided filling pressures, such
as systemic hypertension, should be optimized.
Supporting References: 483,484
8.2.3. Intervention: Recommendations
Class I
1. Tricuspid valve surgery is recommended for patients with severe
TR (stages C and D) undergoing left-sided valve surgery. (Level of
Evidence: C)
The indications for surgical correction of TR are most
often considered at the time of mitral or aortic valve surgery.The Journal of Thoracic and CaSevere TR of either a primary or functional nature may not
predictably improve after treatment of the left-sided valve
lesion and reduction of RV afterload; as such, severe TR
should be addressed as part of the index procedure. Reoper-
ation for severe, isolated TR after left-sided valve surgery is
associated with a perioperative mortality rate of 10% to
25%. Tricuspid valve repair does not add appreciably to
the risks of surgery and can be accomplished with a clini-
cally insignificant increase in ischemic time. There has
been a significant increase in the number of tricuspid valve
repairs performed for this indication over the past decade.
Tricuspid valve repair is preferable to replacement. When
replacement is necessary for primary, uncorrectable
tricuspid valve disease, the choice of prosthesis is individu-
alized, with the usual trade-offs between thrombosis/antico-
agulation with a mechanical valve and durability with a
tissue valve. Meta-analysis has shown no difference in over-
all survival between mechanical and tissue valves for pa-
tients undergoing tricuspid valve replacement. The risks
and benefits of tricuspid valve operation should be carefully
considered in the presence of severe RV systolic dysfunc-
tion or irreversible pulmonary hypertension, due to the pos-
sibility of RV failure after operation.
Supporting References: 485-494rdiovascular Surgery c Volume 148, Number 1 e57
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1. Tricuspid valve repair can be beneficial for patients withmild, mod-
erate, or greater functional TR (stage B) at the time of left-sided
valve surgery with either 1) tricuspid annular dilation or 2) prior
evidence of right HF.464-466,495-501 (Level of Evidence: B)
Left uncorrected at the time of left-sided valve
surgery, mild or moderate degrees of functional TR may
progress over time in approximately 25% of patients and
result in reduced long-term functional outcome and sur-
vival. Risk factors for persistence and/or progression of
TR include tricuspid annulus dilation (>40 mm diameter
or 21 mm/m2 diameter indexed to body surface area on pre-
operative TTE;>70 mm diameter on direct intraoperative
measurement); degree of RV dysfunction/remodeling;
leaflet tethering height; pulmonary artery hypertension;
AF; nonmyxomatous etiology of MR; and intra-annular
RV pacemaker or implantable cardioverter-defibrillator
leads. The cut-off of>70 mm diameter on direct intraoper-
ative measurement originated from a single center, per-
formed with the patient on cardiopulmonary bypass using
a supple ruler, taken from the anteroseptal commissure to
the anteroposterior commissure. Echocardiography is usu-
ally performed on the beating heart and examines a different
plane of the tricuspid annulus. Numerous observational
studies and 1 prospective RCT attest to the benefit on
several echocardiographic and functional parameters of
tricuspid repair at the time of mitral valve surgery for
mild-to-moderate TR (stage B) with tricuspid annulus dila-
tion. When surgery is performed for isolated severe primary
MR due to a degenerative etiology, less than moderate TR is
unlikely to progress if left untreated. A prior recent history
of right HF is also an indication for tricuspid valve repair at
the time of left-sided valve surgery. A survival benefit with
tricuspid repair in this setting has not been demonstrated.
Management of indwelling pacemaker or implantable
cardioverter-defibrillator leads may require their removal
with epicardial placement in selected patients. Other ap-
proaches, such as sequestering the leads in a commissure
or placing them in an extra-annular position, may be used.
Following repair with ring annuloplasty, residual TR is pre-
sent in approximately 10% of patients at 5 years.
Supporting References: 463-466,495-504
Class IIa
2. Tricuspid valve surgery can be beneficial for patients with symp-
toms due to severe primary TR that are unresponsive to medical
therapy (stage D). (Level of Evidence: C)
Correction of symptomatic severe primary TR (stage D)
in patients without left-sided valve disease is preferentially
performed before onset of significant RV dysfunction.
Replacement may be required because of the extent and
severity of the underlying pathology (eg, carcinoid, radia-
tion, Ebstein’s anomaly). Reduction or elimination of the
regurgitant volume load can alleviate systemic venous ande58 The Journal of Thoracic and Cardiovascular Surghepatic congestion and decrease reliance on diuretics. Pa-
tients with severe congestive hepatopathy may also benefit
from surgery to prevent irreversible cirrhosis of the liver.
Quality and duration of long-term survival are related to re-
sidual RV function.
Class IIb
1. Tricuspid valve repair may be considered for patients with moder-
ate functional TR (stage B) and pulmonary artery hypertension at
the time of left-sided valve surgery. (Level of Evidence: C)
When pulmonary artery hypertension is caused predom-
inantly by left-sided valve disease, effective surgery on the
left-sided valve lesions usually leads to a fall in RVafterload
and improvement in functional TR, especially in the
absence of significant (ie, >40 mm on TEE) tricuspid
annulus dilation. This observation dates to the early years
of mitral valve surgery. Prediction rules that account for
the relative contributions of pulmonary hypertension and
only mild-to-moderate degrees of tricuspid annulus
enlargement for the risk of progressive TR are lacking.
The benefit of routine tricuspid valve repair in this context
is less clear across broad populations but may be considered
on an individual basis.
Supporting References: 503,505,506
Class IIb
2. Tricuspid valve surgery may be considered for asymptomatic or
minimally symptomatic patients with severe primary TR (stage
C) and progressive degrees of moderate or greater RV dilation
and/or systolic dysfunction. (Level of Evidence: C)
The optimal timing of tricuspid valve surgery for asymp-
tomatic or minimally symptomatic, severe primary TR has
not been established. Extrapolation from limited experi-
ences reported for patients with stable carcinoid heart dis-
ease and patients with a flail tricuspid leaflet and
application of the management principles adopted for pa-
tients with severe MR suggest that serial assessments
of RV size and function might trigger consideration of
corrective surgery in selected patients with severe, primary
TR when a pattern of continued deterioration can be estab-
lished and the risks of surgery are considered acceptable. In
otherwise healthy patients without other comorbidities,
such as the patient with severe TR due to trauma, the risk
of tricuspid valve operation is low (<1% to 2%) in the
absence of RV dysfunction or pulmonary hypertension.
Supporting References: 507,508
Class IIb
3. Reoperation for isolated tricuspid valve repair or replacement may
be considered for persistent symptoms due to severe TR (stage D) in
patients who have undergone previous left-sided valve surgery and
who do not have severe pulmonary hypertension or significant RV
systolic dysfunction. (Level of Evidence: C)
Isolated tricuspid valve surgery for severe TR has histor-
ically been performed relatively late in the natural history ofery c July 2014
Nishimura et al Clinical Guidelinesthe disease and once patients have become symptomatic
with signs of right HF. Unadjusted mortality rates for iso-
lated tricuspid valve surgery have therefore exceeded those
reported for isolated aortic or mitral valve surgery, and this
trend has been evenmore pronounced following reoperative
tricuspid surgery late after left-sided valve surgery. This
high mortality is likely related to the advanced nature of
RV failure encountered at the time of the second procedure,
residual pulmonary hypertension, LV dysfunction, and
other valve abnormalities. Two Heart Valve Centers of
Excellence have reported perioperative mortality rates
with tricuspid valve reoperation of 4.2% and 13.2%,
respectively. Thus, the hazards imposed by reoperation
have influenced decision making for repair of functional
TR initially at the time of left-sided valve surgery. The so-
bering results seen with tricuspid valve repair at reoperation
inject a note of caution into the recommendations for its
performance and may encourage replacement with an
age-appropriate (mechanical or biological) prosthesis. The
presence of either severe and uncorrectable pulmonary hy-
pertension or significant RV dysfunction constitutes a rela-
tive contraindication to reoperation.
Supporting References: 485-489,509-512
See Online Data Supplement 19 for more information on
outcomes following tricuspid valve surgery.8.3. Stages of Tricuspid Stenosis
See Table 20 for the stages of severe tricuspid stenosis
(TS).8.4. Tricuspid Stenosis
8.4.1. Diagnosis and Follow-up: Recommendations
Class I
1. TTE is indicated in patients with TS to assess the anatomy of the
valve complex, evaluate severity of stenosis, and characterize any
associated regurgitation and/or left-sided valve disease. (Level of
Evidence: C)
Rheumatic disease is the most common etiology of TS.
Its clinical manifestations are far overshadowed by those
attributable to the associated left-sided (particularly mitral)
valve disease. Because TS is often not detected during
bedside examination, TTE is essential for diagnosis and
characterization. TS is usually accompanied by TR of vary-
ing severity. When valve and/or chordal thickening and
calcification are evident, additional findings indicative of
severe TS include mean pressure gradient>5 mm Hg, pres-
sure half-time 190 milliseconds, valve area 1.0 cm2
(continuity equation), and associated right atrial and infe-
rior vena cava enlargement. It is recognized that assessment
of TS severity with TTE is limited by several technical fac-
tors; thus, these values are less well validated than those re-
ported for MS.
Supporting Reference: 8The Journal of Thoracic and CaClass IIb
1. Invasive hemodynamic assessment of severity of TS may be consid-
ered in symptomatic patients when clinical and noninvasive data
are discordant. (Level of Evidence: C)
Hemodynamic assessment of TS is rarely undertaken
for patients with acquired disease but may be performed
in selected patients at the time of invasive study for another
indication, such as MS with pulmonary hypertension.
Direct assessment of the absolute right atrial and RV dia-
stolic pressure may be useful in determining the contribu-
tion of TS to the patient’s signs or symptoms.
8.4.2. Medical therapy
As for patients with severe TR, loop diuretics may be use-
ful to relieve systemic andhepatic congestion in patientswith
severe, symptomatic TS, although their use may be limited
by worsening low-flow syndrome. Attention to left-sided
valve disease and AF, when present, is also important.
8.4.3. Intervention: Recommendations
Class I
1. Tricuspid valve surgery is recommended for patients with severe
TS at the time of operation for left-sided valve disease. (Level of
Evidence: C)
Surgery for severe TS is most often performed at the time
of operation for left-sided valve disease, chiefly rheumatic
MS/MR. If repair is not adequate or feasible due to valve
destruction or multiple levels of pathological involvement,
replacement may be necessary. The choice of prosthesis
should be individualized. Perioperative mortality rates are
higher for mitral plus tricuspid versus either isolated mitral
or tricuspid surgery alone.
Supporting Reference: 489
Class I
2. Tricuspid valve surgery is recommended for patients with isolated,
symptomatic severe TS. (Level of Evidence: C)
Relief of severe stenosis should lower elevated right atrial
and systemic venous pressures and alleviate associated
symptoms. Tricuspid valve surgery is preferred over percu-
taneous balloon tricuspid commissurotomy for treatment of
symptomatic severe TS because most cases of severe TS are
accompanied by TR (rheumatic, carcinoid, other), and
percutaneous balloon tricuspid commissurotomymay either
create orworsen regurgitation. There is also a relative lack of
long-term follow-up data on patients managed with percuta-
neous balloon tricuspid commissurotomy for this indication.
Outcomes with surgery are dependent on RV function.
Supporting References: 513,514
Class IIb
1. Percutaneous balloon tricuspid commissurotomy might be consid-
ered in patients with isolated, symptomatic severe TS without
accompanying TR. (Level of Evidence: C)
Isolated, symptomatic severe TS without accompanying
TR is an extremely rare condition for which percutaneousrdiovascular Surgery c Volume 148, Number 1 e59
TABLE 20. Stages of severe TS
Stage Definition Valve anatomy Valve hemodynamics
Hemodynamic
consequences Symptoms
C, D Severe TS  Thickened, distorted,
calcified leaflets
 T ½ 190 ms
 Valve area 1.0 cm2
 RA/IVC enlargement  None or variable and
dependent on severity of
associated valve disease
and degree of obstruction
The transtricuspid diastolic gradient is highly variable and is affected by heart rate, forward flow, and phases of the respiratory cycle. However, severe TS usually has mean pres-
sure gradients>5 to 10 mm Hg at heart rate 70 bpm. bpm, Beats per minute; IVC, Inferior vena cava; RA, right atrium; T ½, pressure half-time; TS, tricuspid stenosis.8
Clinical Guidelines Nishimura et alballoon tricuspid commissurotomy might be considered,
recognizing its short-term limitations and the lack of
long-term outcome data.
See Online Data Supplement 19 for more information on
outcomes following tricuspid valve surgery.
9. PULMONIC VALVE DISEASE
9.1. Stages of Pulmonic Regurgitation
See Table 21 for the stages of severe pulmonic regurgita-
tion (PR).
Mild-to-moderate PR seen on echocardiography is com-
mon and does not require further follow-up or intervention
if asymptomatic with normal RV size and function. Signif-
icant PR in patients is uncommon. Primary PR that follows
in the wake of childhood surgery for tetralogy of Fallot or
other congenital lesions may progress insidiously and reach
severe proportions that threaten RV function without
adequate clinical recognition. Its evaluation and manage-
ment, including indications for valve replacement, are
comprehensively reviewed in the ‘‘2008 ACC/AHAGuide-
lines for theManagement of PatientsWith Congenital Heart
Disease.’’ The pulmonic valve is rarely involved by IE or
rheumatic disease but is susceptible to carcinoid accretion
because it also affects the tricuspid valve and results in vary-
ing degrees of stenosis and regurgitation. Surgery is consid-
ered when symptoms or signs of RV dysfunction have
intervened and PR is severe. Secondary PR from long-
standing pulmonary hypertension and annular dilation is
encountered less frequently in the modern era. Treatment
should focus on the cause(s) of elevated pulmonary artery
pressures.
Supporting Reference: 516
9.2. Stages of Pulmonic Stenosis
See Table 22 for the stages of severe pulmonic stenosis.
Pulmonic stenosis is essentially a congenital disorder.
Less common etiologies include carcinoid and obstructing
vegetations or tumors. Assessment with TTE alone is usu-
ally sufficient for diagnosis and clinical decision making.
Indications for percutaneous balloon pulmonic valve com-
missurotomy and valve replacement are contained in the
‘‘2008 ACC/AHA Guidelines for the Management of Pa-
tients With Congenital Heart Disease.’’
Supporting Reference: 516e60 The Journal of Thoracic and Cardiovascular Surg10. MIXED VALVE DISEASE
10.1. Mixed VHD
10.1.1. Diagnosis and Follow-up
For the majority of patients with mixed valve disease,
there is usually a predominant valve lesion (ie, stenosis or
regurgitation); further, the symptoms and pathophysiology
resemble those of a pure dominant lesion. However, the
presence of mixed valve disease poses limitations for nonin-
vasive and invasive techniques used to determine severity.
These limitations should be strongly considered in the eval-
uation of patients with mixed valve disease. For patients
with mixed aortic disease and predominant AS, a high
gradient and small valve area will be present. Pressure over-
load results in concentric LV myocardial hypertrophy, usu-
ally without chamber enlargement except in late stages of
the disease. Symptoms may be present in patients with pre-
dominant AS with or without alterations in chamber
morphology. Conversely, for patients with mixed aortic dis-
ease and predominant AR, the aortic velocity and gradient
may be significantly elevated due to regurgitation in the
setting of AS, but the aortic valve area is relatively large. Pa-
tients with predominant ARwill have both pressure and vol-
ume overload, resulting in marked increases in LV volume.
In these patients, symptoms may be relatively latent due to
preload recruitment with compensatory hypertrophy. For
patients with mixed mitral disease and predominant MS, a
high transmitral gradient and small valve area will be pre-
sent. Left atrial enlargement occurs with relative preserva-
tion of the LV chamber size. Conversely, in patients with
mixed mitral disease and predominant MR, LV remodeling
will occur in addition to left atrial enlargement. These pa-
tients frequently have high transmitral gradients due to
the regurgitant flow, but the valve area may be relatively
large.
For patients with mixed valve disease, there is a paucity
of data on the natural history of such coexistent conditions.
Consequently, the appropriate timing for serial evaluations
of these patients remains uncertain. For patients with pre-
dominant lesions (ie, stenosis or regurgitation), serial eval-
uations in accordance with recommendations for the
predominant valve lesion are generally recommended.
Nonetheless, it is important to recognize that the coexis-
tence of stenosis and regurgitation may have pathologicalery c July 2014
TABLE 21. Stages of severe PR
Stage Definition Valve anatomy Valve hemodynamics
Hemodynamic
consequences Symptoms
C, D Severe PR  Distorted or absent leaflets,
annular dilation
 Color jet fills RVOT
 CW jet density and
contour: dense laminar flow
with steep deceleration
slope; may terminate
abruptly
 Paradoxical septal motion
(volume overload pattern)
 RV enlargement
 None or variable and
dependent on cause of PR
and RV function
CW, Continuous wave; PR, pulmonic regurgitation; RV, right ventricular; RVOT, right ventricular outflow tract.515
Nishimura et al Clinical Guidelinesconsequences that are incremental to the effects of either of
these disease states alone. As a result, patients with mixed
disease may require serial evaluations at intervals earlier
than recommended for single valve lesions.
Supporting References: 517-521
10.1.2. Medical Therapy
Recommendations for medical therapy follow those for
single valve disease when there is a predominant valve
lesion and other management recommendations for
concomitant LV dysfunction. There are no other recommen-
dations for medical therapy specific to patients with mixed
valve disease.
10.1.3. Timing of Intervention
For patients with mixed valve disease and a predominant
lesion, the need for intervention should generally follow
recommendations for a pure dominant lesion. This consid-
eration should be undertaken with attention to symptoms,
lesion severity, chamber remodeling, operative risk, and
the expected surgical outcome. Timing of intervention
must be individualized because coexistence of stenosis
and regurgitation may have pathological consequences
that are incremental to the effects of either lesion alone.
For example, patients with mixed aortic disease will have
increased afterload due to both the regurgitant volume
and the relatively small aortic valve area. Thus, patients
with dominant AR may develop symptoms and require
surgery before severe LV enlargement develops. For pa-
tients with dominant AS, coexistent regurgitation may be
poorly tolerated by a ventricle that is noncompliant due to
pressure hypertrophy. An elevated left atrial pressure resultsTABLE 22. Stages of severe pulmonic stenosis
Stage Definition Valve anatomy Valve hemodynamic
C, D Severe PS  Thickened, distorted, possibly
calcified leaflets with systolic
doming and/or reduced
excursion
 Other anatomic abnormalities
may be present, such as
narrowed RVOT
 Vmax>4 m/s; peak
instantaneous
gradient>64 mm H
PA, Pulmonary artery; PS, pulmonic stenosis; RA, right atrium; RV, right ventricle; RVH, rig
valve jet velocity.8
The Journal of Thoracic and Cafrom both MS and regurgitation in patients with mixed
mitral disease. Thus, patients with mixed mitral disease
may develop symptoms or pulmonary hypertension at
earlier intervals than has been demonstrated in patients
with pure stenosis or regurgitation. The alterations in
loading conditions due to mixed valve disease may also
lead to cardiac symptoms and chamber remodeling in pa-
tients when there is not a predominant lesion (ie, mixed
moderate valve disease). Patients with mixed moderate
valve disease present a special management challenge, as
there is a paucity of data to guide timing of intervention
in these patients.
For those patients with symptoms of uncertain origin,
valve intervention may be considered when there are clin-
ical findings or data supportive of significant pathological
consequences of the mixed valve lesion. Supportive ab-
normalities include objective evidence of functional limi-
tation (eg, severely reduced peak myocardial oxygen
consumption attributable to impaired cardiac output)
and significantly elevated atrial or ventricular pressures.
Exercise hemodynamic studies should be considered for
those patients with symptoms that are out of proportion
to hemodynamic findings at rest. For example, patients
with mixed mitral disease and a relatively low mitral
gradient may be particularly susceptible to developing
functional MS at higher transvalvular flow rates due to
the concomitant regurgitant volume. In patients with
mixed aortic disease, the pathological contribution of
aortic regurgitant volume may lessen with exercise due
to shortening of diastole. Given the potential limitations
of noninvasive assessments, direct pressure measurement
with cardiac catheterization may be needed for assessings Hemodynamic consequences Symptoms
g
 RVH
 Possible RV, RA enlargement
 Poststenotic enlargement
of main PA
 None or variable and dependent
on severity of obstruction
ht ventricular hypertrophy; RVOT, right ventricular outflow; Vmax, maximal pulmonic
rdiovascular Surgery c Volume 148, Number 1 e61
Clinical Guidelines Nishimura et alventricular filling abnormalities at rest and with exercise
in patients with mixed valve disease. Because the indica-
tions for intervention have not been well studied in this
patient population, the decision to pursue surgical therapy
should be individualized, with consideration of patient
symptoms, severity of hemodynamic abnormalities, and
risk of surgery.
Supporting References: 517-521
10.1.4. Choice of Intervention
For patients with mixed valve disease, the appropriate
interventional therapy is determined by guidelines for
the predominant valve lesion with consideration of the
severity of the concomitant valve disease. For example,
in a patient with predominant AS, TAVR may be consid-
ered in patients with moderate but not severe AR,
whereas conventional AVR may be a therapeutic option
regardless of severity of mixed valve disease. Similarly,
percutaneous balloon mitral commissurotomy is a thera-
peutic option in patients with MS and suitable anatomy
if there is mild but not moderate or severe regurgitation.
Percutaneous aortic balloon dilation should not be per-
formed if there is moderate or severe regurgitation due
to the potential for worsening of the regurgitation with
the procedure.11. PROSTHETIC VALVES
11.1. Evaluation and Selection of Prosthetic Valves
11.1.1. Diagnosis and Follow-up: Recommendations
Patients who have undergone valve replacement are not
cured but still have serious heart disease. Patients have
exchanged native valve disease for prosthetic valve disease
and must be followed with the same care as those with
native valve disease. The clinical course of patients with
prosthetic heart valves is influenced by several factors,
including LV dysfunction; progression of other valve dis-
ease; pulmonary hypertension; concurrent coronary,
myocardial, or aortic disease; and complications of pros-
thetic heart valves. The interval between routine follow-
up visits depends on the patient’s valve type, residual heart
disease, comorbid conditions, and other clinical factors.
Management of anticoagulation should be supervised
and monitored frequently by an experienced healthcare
professional.
The asymptomatic uncomplicated patient is usually
seen at 1–year intervals for a cardiac history and physical
examination. ECG and chest x-ray examinations are not
routinely indicated but may be appropriate in individual
patients. Additional tests that may be considered include
hemoglobin and hematocrit in patients receiving chronic
anticoagulation. No further echocardiographic testing is
required after the initial postoperative evaluation in pa-
tients with mechanical valves who are stable and whoe62 The Journal of Thoracic and Cardiovascular Surghave no symptoms or clinical evidence of prosthetic valve
or ventricular dysfunction or dysfunction of other heart
valves.
Class I
1. An initial TTE study is recommended in patients after prosthetic
valve implantation for evaluation of valve hemodynamics.522-525
(Level of Evidence: B)
An echocardiographic examination performed 6weeks to
3 months after valve implantation is an essential component
of the first postoperative visit because it allows for an assess-
ment of the effects and results of surgery and serves
as a baseline for comparison should complications or
deterioration occur later. Doppler TTE provides accurate
measurements of transvalvular velocities and pressure gra-
dients as well as detection and quantitation of valvular and
paravalvular regurgitation. Normal Doppler transvalvular
velocities and gradients vary among different types and sizes
of prosthetic valves but are also affected by patient-specific
factors, including body size and cardiac output. The postop-
erative study, recorded when the patient is asymptomatic
and in a stable hemodynamic state, provides the normal
Doppler flow data for that valve in that patient. In addition
to imaging and Doppler flow data for the prosthetic valve,
TTE provides assessment of other valve disease(s), pulmo-
nary hypertension, atrial size, LV and RV hypertrophy, LV
and RV size and function, and pericardial disease.
Supporting References: 291,526,527
Class I
2. Repeat TTE is recommended in patients with prosthetic heart
valves if there is a change in clinical symptoms or signs suggesting
valve dysfunction. (Level of Evidence: C)
Bioprosthetic valves are prone to tissue degeneration or
pannus formation with development of valve regurgitation
and/or stenosis. Bioprosthetic valve dysfunction typically
presents with the insidious onset of exertional dyspnea or
with a louder systolic murmur (MR or AS) or a new
diastolic murmur (AR or MS) on physical examination.
More abrupt and severe symptoms may occur with bio-
prosthetic valve endocarditis or with degenerative rupture
of a valve cusp.
Patients with mechanical valve dysfunction present
with symptoms of HF, systemic thromboembolism,
hemolysis, or a new murmur on auscultation. Mechani-
cal valve dysfunction may be due to thrombosis, pannus
formation, or IE. Signs or symptoms of mechanical
valve dysfunction are often acute or subacute because
of more abrupt impairment of leaflet occluder opening
or closing by thrombus or pannus. Acute or chronic par-
avalvular regurgitation may also be seen due to IE or
suture dehiscence.
TTE allows evaluation of valve dysfunction based on im-
aging of leaflet structure and motion, vegetations, andery c July 2014
Nishimura et al Clinical Guidelinesthrombus and Doppler evaluation for prosthetic valve steno-
sis or regurgitation. Comparison with the baseline postoper-
ative echocardiogram is particularly helpful for detection of
prosthetic valve dysfunction.
Supporting References: 528,529
Class I
3. TEE is recommended when clinical symptoms or signs suggest
prosthetic valve dysfunction. (Level of Evidence: C)
TTE is the preferred approach for initial assessment
of suspected prosthetic valve dysfunction because it al-
lows correct alignment of the Doppler beam with trans-
valvular flow for measurement of velocity, gradient, and
valve area. TTE also allows quantitation of LV volumes
and LVEF, an estimate of pulmonary pressures, and
evaluation of right heart function. However, the left
atrial side of a prosthetic mitral valve is obscured by
acoustic shadowing from the TTE approach, resulting
in a low sensitivity for detection of prosthetic MR and
prosthetic mitral valve thrombus, pannus, or vegetation.
TEE provides superior images of the left atrial side of
the mitral prosthesis and is accurate for diagnosis of
prosthetic mitral valve dysfunction. However, both TTE
and TEE are needed for complete evaluation in a patient
with suspected prosthetic valve dysfunction, particularly
for those with prosthetic aortic valves in whom the pos-
terior aspect of the valve is shadowed on the TTE
approach and the anterior aspect of the valve is shad-
owed on the TEE approach. With suspected mechanical
valve stenosis, fluoroscopy or CT imaging of valve oc-
cluder motion is also helpful for detection of reduced
motion due to pannus or thrombus.
Supporting References: 530,531
Class IIa
1. Annual TTE is reasonable in patients with a bioprosthetic valve af-
ter the first 10 years, even in the absence of a change in clinical sta-
tus. (Level of Evidence: C)
The incidence of bioprosthetic valve dysfunction is low
within 10 years of valve implantation but increases markedly
after that point; as such, routine annual evaluation is
a reasonable approach. Earlier evaluation may also be pru-
dent in selected patients at increased risk of early bio-
prosthetic valve degeneration, including those with renal
impairment, diabetes mellitus, abnormal calcium meta-
bolism, systemic inflammatory disease, and in patients<60
years of age. Patients typically remain asymptomatic until
valve dysfunction is severe enough to result in adverse hemo-
dynamic consequences, such as LV dilation and systolic
dysfunction, pulmonary hypertension, or AF. It may be chal-
lenging to distinguish a murmur due to prosthetic MR or AS
from the normal postoperative flowmurmur, and the diastolic
murmurs of prosthetic AR and MS often are very soft and
difficult to hear on auscultation. Depending on the valveThe Journal of Thoracic and Catype and mechanism of regurgitation, some patients with
asymptomatic significant prosthetic valve regurgitation may
require surgical intervention. For example, if prosthetic
regurgitation is due to a bioprosthetic leaflet tear, more severe
acute regurgitation may suddenly occur and cause clinical
decompensation. Other asymptomatic patients with less se-
vere prosthetic valve regurgitation or with stable valve anat-
omycan bemonitored for evidence ofprogressiveLVdilation
and systolic dysfunction with the same criteria for timing of
surgical intervention as those for native valve regurgitation.
With prosthetic valve stenosis, echocardiographic diagnosis
while the patient is asymptomatic alerts the clinician to the
need for more frequent follow-up. Patients with asymptom-
atic prosthetic valve stenosis should be educated about symp-
toms, the likely need for repeat valve intervention, and the
importance of promptly reporting new symptoms.
In patients with mechanical valve prostheses, routine
annual echocardiographic evaluation is not needed if the
postoperative baseline study is normal in the absence of
signs or symptoms of valve dysfunction. However, many
of these patients require TTE for other indications, such
as residual LV systolic dysfunction, pulmonary hyperten-
sion, aortic disease, or concurrent valve disease.
Supporting References: 532,533
11.1.2. Intervention: Recommendations
See Table 23 for a summary of recommendations for
prosthetic valve choice.
Class I
1. The choice of valve intervention, that is, repair or replacement,
as well as type of prosthetic heart valve, should be a shared
decision-making process that accounts for the patient’s values and
preferences, with full disclosure of the indications for and risks of
anticoagulant therapy and the potential need for and risk of reoper-
ation. (Level of Evidence: C)
The choice of valve prosthesis in an individual patient is
based on consideration of several factors, including valve
durability, expected hemodynamics for a specific valve
type and size, surgical or interventional risk, the potential
need for long-term anticoagulation, and patient preferences.
Specifically, the tradeoff between risk of reoperation for
bioprosthetic valve degeneration and the risk associated
with long-term anticoagulation should be discussed in
detail with the patient. Surgical or interventional risk for
an individual patient is estimated by using the STS
PROM score with the online calculator (Section 3.2.4).
This information is discussed with the patient and family
to allow for shared decision making about the timing and
type of intervention. In a patient with a small aortic annulus,
patient-prosthesis mismatch of the implanted prosthetic
aortic valve may be avoided or reduced by consulting tables
of prosthetic valve hemodynamics for the valve types and
sizes being considered. Aortic annular enlarging proceduresrdiovascular Surgery c Volume 148, Number 1 e63
TABLE 23. Summary of recommendations for prosthetic valve choice
Recommendations COR LOE References
Choice of valve intervention and prosthetic valve type should be a shared decision process I C N/A
A bioprosthesis is recommended in patients of any age for whom anticoagulant therapy is contraindicated, cannot
be managed appropriately, or is not desired
I C N/A
Amechanical prosthesis is reasonable for AVR orMVR in patients<60 y of agewho do not have a contraindication
to anticoagulation
IIa B 534-536
A bioprosthesis is reasonable in patients>70 y of age IIa B 537-540
Either a bioprosthetic or mechanical valve is reasonable in patients between 60 y and 70 y of age IIa B 541,542
Replacement of the aortic valve by a pulmonary autograft (the Ross procedure), when performed by an experienced
surgeon, may be considered in young patients when VKA anticoagulation is contraindicated or undesirable
IIb C N/A
AVR, Aortic valve replacement; COR, Class of Recommendation; LOE, Level of Evidence; MVR, mitral valve replacement; N/A, not applicable; VKA, vitamin K antagonist.
Clinical Guidelines Nishimura et almay be used when patient-prosthesis mismatch cannot be
avoided with any available valve substitute.
Bioprosthetic valves avoid the need for long-term antico-
agulation with VKA, such as warfarin, but have limited
durability. The risk of need for reoperation with a bio-
prosthetic valve is inversely related to the patient’s age at
the time of implantation, with a rate of structural deteriora-
tion 15 to 20 years after implantation of only 10% in patients
70 years of age at the time of implantation compared with
90% in those 20 years of age at the time of implantation.Me-
chanical valves are durable in patients of any age with a low
risk of reoperation, and current VKA therapeutic manage-
ment strategies are associatedwith a low risk of thromboem-
bolism and bleeding. Some patients prefer to avoid repeat
surgery and arewilling to accept the risks and inconvenience
of lifelong anticoagulant therapy. Amechanical valve might
be prudent for patients in whom a second surgical procedure
would be high risk; for example, those with prior radiation
therapy or a porcelain aorta. Other patients are unwilling
to consider long-term VKA therapy due to the inconve-
nience of monitoring, the attendant dietary and medication
interactions, and the need to restrict participation in some
types of athletic activity. In women who desire subsequent
pregnancy, the issue of anticoagulation during pregnancy
is a consideration (Section 13).
In patients who are being treated with long-term VKA
anticoagulation before valve surgery, a mechanical valve
may be appropriate, given its greater durability compared
with a bioprosthetic valve and the need for continued
VKA anticoagulation even if a bioprosthetic valve is im-
planted. However, if interruption of VKA therapy is neces-
sary for noncardiac procedures, bridging therapy with other
anticoagulants may be needed if a mechanical valve is pre-
sent, whereas stopping and restarting VKA therapy for
other indications may be simpler. Specific clinical circum-
stances, comorbid conditions, and patient preferences
should be considered when deciding between a bio-
prosthetic and mechanical valve in patients receiving
VKA therapy for indications other than the prosthetic valve
itself.
Supporting References: 532,533,543-545e64 The Journal of Thoracic and Cardiovascular SurgClass I
2. A bioprosthesis is recommended in patients of any age for whom
anticoagulant therapy is contraindicated, cannot be managed
appropriately, or is not desired. (Level of Evidence: C)
Anticoagulant therapy with VKA is necessary in all pa-
tients with a mechanical valve to prevent valve thrombosis
and thromboembolic events. If anticoagulation is contrain-
dicated or if the patient refuses VKA therapy, an alternate
valve choice is appropriate.
Class IIa
1. A mechanical prosthesis is reasonable for AVR or MVR in patients
less than 60 years of age who do not have a contraindication to anti-
coagulation.534-536 (Level of Evidence: B)
In a prospective randomized study of 575 patients under-
going older-generation mechanical versus bioprosthetic
valve replacement, overall survival was similar at 15 years
in both groups. However, in patients<65 years of age un-
dergoing AVR, primary valve failure occurred in 26% of
those with a bioprosthetic valve compared with 0% of pa-
tients with a mechanical valve. Similarly, in those<65 years
of age undergoing MVR, primary valve failure occurred in
44% of patients with a bioprosthetic mitral valve compared
with 4% with a mechanical mitral valve (P ¼ .0001). In a
propensity scorematched comparison of 103 patients
<60 years of age undergoing mechanical versus biological
AVR, those with a mechanical valve had lower mortality
rates (HR: 0.243; 95%CI: 0.054 to 0.923; P¼ .038) despite
similar rates of valve-related complications. This is
possibly related to better valve hemodynamics and the
beneficial effects of anticoagulant therapy in those with a
mechanical valve.
Overall, patients<60 years of age at the time of valve im-
plantation have a higher incidence of primary structural dete-
rioration and a reoperation rate as high as 40% for patients 50
years of age, 55% for patients 40 years of age, 75% for pa-
tients 30 years of age, and 90% for patients 20 years of age.
Anticoagulation with VKA has an acceptable risk
of complications in patients<60 years of age, particularly
in compliant patients with appropriate monitoring of INR
levels. Thus, the balance between valve durability versusery c July 2014
Nishimura et al Clinical Guidelinesrisk of bleeding and thromboembolic events favors the
choice of a mechanical valve in patients<60 years of age.
Supporting References: 533,536,546
Class IIa
2. A bioprosthesis is reasonable in patients more than 70 years of
age.537-540 (Level of Evidence: B)
In patients>70 years of age at the time of bioprosthetic
valve implantation, the likelihood of primary structural
deterioration at 15 to 20 years is only about 10%. In addi-
tion, older patients are at higher risk of bleeding complica-
tions related to VKA therapy and more often require
interruption of VKA therapy for noncardiac surgical and in-
terventional procedures. In the United States, the expected
number of remaining years of life at 70 years of age is
13.6 years for a man and 15.9 years for a woman; at 80 years
of age the expected number of remaining years of life is 7.8
years for men and 9.3 years for women. Thus, it is reason-
able to use a bioprosthetic valve in patients>70 years of age
to avoid the risks of anticoagulation because the durability
of the valve exceeds the expected years of life. Data from
41,227 patients in the Society for Cardiothoracic Surgery
in the Great Britain and Ireland National database between
2004 and 2009 show that the proportion of patients>70
years of age who receive a biological prosthesis at the
time of valve replacement has increased from 87% to
96%, with no evidence for an increase in adverse events.
Supporting References: 41,533,546
Class IIa
3. Either a bioprosthetic or mechanical valve is reasonable in patients
between 60 and 70 years of age.541,542 (Level of Evidence: B)
Outcomes are similar with implantation of either a bio-
prosthetic or mechanical valve for patients between 60 and
70 years of age at the time of surgery. In the EdinburghHeart
Valve Study of 533 patients (mean age 54.410.4 years) un-
dergoing valve surgery, therewas no difference in long-term
survival between those randomized to a Bjork-Shiley me-
chanical prosthesis or a porcine prosthesis (log-rank test:
P ¼ .39). In a prospective randomized Italian study of 310
patients between 55 and 70 years of age, therewas no differ-
ence in overall survival at 13 years between those receiving a
mechanical valve compared with those who received a bio-
prosthetic valve. The linearized rates of thromboembolism,
bleeding, IE, and major adverse prosthesis-related events
were no different between the 2 valve types, but valve fail-
ures and reoperations were more frequent in the bio-
prosthetic valve group compared with the mechanical
valve group (P ¼ .0001 and P ¼ .0003, respectively).
Although the evidence supports the use of either a me-
chanical or bioprosthetic valve in patients 60 to 70 years
of age, patient preferences should also be considered. Ac-
cording to data on 41,227 patients in the Society for Cardio-
thoracic Surgery in the Great Britain and Ireland NationalThe Journal of Thoracic and Cadatabase collected between 2004 and 2009, the proportion
of patients 60 to 65 years of age who received a bio-
prosthesis at the time of valve replacement increased from
37% to 55%; in those 65 to 70 years of age, the proportion
increased from 62% to 78%.
Supporting References: 532,533,543,546
Class IIb
1. Replacement of the aortic valve by a pulmonary autograft (the Ross
procedure), when performed by an experienced surgeon, may be
considered in young patients when VKA anticoagulation is contra-
indicated or undesirable. (Level of Evidence: C)
Replacement of the aortic valve with a pulmonary auto-
graft (the Ross procedure) is a complex operation intended
to provide an autologous substitute for the patient’s
diseased aortic valve by relocating the pulmonic valve
into the aortic position and subsequently replacing the pul-
monic valve with a homograft. It is a surgical challenge and
requires an experienced surgical team with exceptional sur-
gical expertise. In the most experienced hands, hospital
mortality can be similar to mortality for a simple bio-
prosthetic or mechanical valve replacement. Expansion of
the Ross procedure to a broader group of surgeons with
less focused experience has been difficult. The failure
mode of the Ross procedure is most often due to regurgita-
tion of the pulmonary autograft (the neoaortic valve) in the
second decade after the operation. Regurgitation typically is
due to leaflet prolapse if the autograft is implanted in the
subcoronary position or to aortic sinus dilation if the auto-
graft is implanted starting at the aortic sinuses. Surgical
reinforcement techniques have been used to prevent dilation
of the neoaortic sinuses. Some surgeons have advocated
placing the pulmonic valve within a Dacron conduit. Still
others have returned to placing the neoaortic valve in a sub-
coronary position with a reinforced native aorta. The
outcome of these new procedures, with data extending
into the second decade after operation, is not yet available.
In a small (n¼228) RCT comparing pulmonary autografts
with aortic valve allografts, the HR for death at 10 years was
4.61 (P ¼ .006) in those receiving an allograft compared
with those with a pulmonary autograft AVR, with survival
in the autograft group similar to an age-matched general
population. Freedom from reoperation for the aortic sinuses
and ascending aorta was 99% in the autograft group and
82% in the allograft group. Freedom from severe regurgita-
tion of the neoaortic valve was 94% at 10 years. However,
these outstanding results have not been generally replicated.
In addition, an allograft valve is not the ideal comparator,
given current outcomes with bioprosthetic valves.
In addition to reoperation for neoaortic valve regurgita-
tion, at least half of the new pulmonic homograft valve im-
plants will require intervention during the second decade.
This is obviously a concern for young patients who began
with single valve disease and then face a lifetime of dealingrdiovascular Surgery c Volume 148, Number 1 e65
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Calcification of the homograft and adhesions between the
homograft and neoaorta may increase the difficulty of
reoperation.
The Ross procedure is an effective procedure in the hands
of a small group of focused and experienced surgeons. It is a
risky procedure in the hands of surgeons who perform it
only occasionally. The procedure should be reserved for pa-
tients in whom anticoagulation is either contraindicated or
very undesirable, and it should be performed only by sur-
geons experienced in complex surgery involving the aortic
valve, sinuses, and ascending aorta.
Supporting References: 547-549
See Online Data Supplement 20 for more information on
choice of valve prosthesis.
11.2. Antithrombotic Therapy for Prosthetic Valves
11.2.1. Diagnosis and Follow-up
Effective antithrombotic therapy in patients with me-
chanical heart valves requires continuous effective VKA
anticoagulation with an INR in the target range. It is prefer-
able to specify a single INR target in each patient, recog-
nizing that the acceptable range is 0.5 INR units on each
side of this target; this is preferable because it avoids pa-
tients having INR values consistently near the upper or
lower edge of the range. In addition, fluctuations in INR
are associated with increased incidence of complications
in patients with prosthetic valves, so patients and caregivers
should strive to attain the single INR value. The effects of
VKA anticoagulation vary with the specific medication, ab-
sorption of medication, effects of various foods and medica-
tions, and changes in liver function. Most of the published
studies on VKA therapy used warfarin, although other
coumarin agents are used on a worldwide basis. In clinical
practice, a program of patient education and close surveil-
lance by an experienced healthcare professional
with periodic monitoring of the INR is necessary. Patient
monitoring by hospital-based anticoagulation clinics results
in lower complication rates compared with standard care
and is cost-effective due to lower rates of bleeding and hem-
orrhagic complications. Periodic direct patient contact and
telephone encounters with the anticoagulation clinic phar-
macists are equally effective in reducing complication rates.
Self-monitoring with home INR measurement devices is
another option for educated and motivated patients.
Supporting References: 550-555
11.2.2. Medical Therapy: Recommendations
Class I
1. Anticoagulation with a VKA and INR monitoring is recommended
in patients with a mechanical prosthetic valve.556-558 (Level of
Evidence: A)
All patients with mechanical valves require anticoagu-
lant therapy. In addition to the thrombogenicity of thee66 The Journal of Thoracic and Cardiovascular Surgintravascular prosthetic material, mechanical valves
impose abnormal flow conditions, with zones of low
flow within their components, as well as areas of high-
shear stress, which can cause platelet activation, leading
to valve thrombosis and embolic events. Life-long therapy
with an oral VKA at an INR goal appropriate for the co-
morbidity of the patient and the type and position of the
mechanical valve prosthesis is recommended to decrease
the incidence of thromboembolism and the associated
morbidity (eg, ischemic stroke, cerebrovascular accident,
and peripheral systemic embolism). Cumulative data
show that anticoagulation with a VKA is protective
against valve thrombosis (OR: 0.11; 95% CI: 0.07 to
0.2) and thromboembolic events (OR: 0.21; 95% CI:
0.16 to 0.27).
Many centers initiate heparin early after surgery for anti-
coagulation until the INR reaches the therapeutic range.
Bridging anticoagulation is typically started once postoper-
ative bleeding is no longer an issue. Some centers use sub-
cutaneous low-molecular-weight heparin (LMWH) or
unfractionated heparin (UFH), whereas other centers
continue to prefer intravenous UFH.
Supporting References: 12,556,559,560
Class I
2. Anticoagulation with a VKA to achieve an INR of 2.5 is
recommended in patients with a mechanical AVR (bileaflet or cur-
rent-generation single tilting disc) and no risk factors for thrombo-
embolism.561-563 (Level of Evidence: B)
The intensity of anticoagulation in a patient with a me-
chanical aortic valve prosthesis should be optimized so
that protection from thromboembolism and valve throm-
bosis is achieved without excess risk of bleeding. The rate
of thromboembolism in patients with bileaflet mechanical
AVR on VKA and antiplatelet regimen is estimated to be
0.53% per patient-year over the INR range of 2.0 to 4.5.
In a large retrospective study, adverse events increased if
the INR was>4.0 in patients with mechanical AVR. In pa-
tients with the new-generation AVR without other risk fac-
tors for thromboembolism, the risk of thromboembolic
events was similar, but the risk of hemorrhage was lower
in the group with an INR of 2.0 to 3.0 versus the group
with an INR of 3.0 to 4.5 (P<.01). In a study comparing
an INR target of 1.5 to 2.5 with the conventional 2.0 to
3.0 in 396 patients with low-risk mechanical aortic pros-
thetic valves and no other risk factors, the lower INR target
was noninferior, but the quality of the evidence was low.
Thus, for bileaflet and current-generation single tilting
disc valve prostheses in the aortic position, an INR of 2.5
(between 2.0 and 3.0) provides a reasonable balance be-
tween optimal anticoagulation and a low risk of bleeding
for mechanical aortic valves with a low thromboembolic
risk.
Supporting Reference: 12ery c July 2014
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3. Anticoagulation with a VKA is indicated to achieve an INR of 3.0 in
patients with a mechanical AVR and additional risk factors for
thromboembolic events (AF, previous thromboembolism, LV
dysfunction, or hypercoagulable conditions) or an older-
generation mechanical AVR (such as ball-in-cage).564 (Level of Evi-
dence: B)
In patients with an aortic mechanical prosthesis who
are at higher risk of thromboembolic complications, INR
should be maintained at 3.0 (range, 2.5 to 3.5). These pa-
tients include those with AF, previous thromboembolism,
and a hypercoagulable state. Many would also include pa-
tients with severe LV dysfunction in this higher-risk group.
Supporting Reference: 12
Class I
4. Anticoagulation with a VKA is indicated to achieve an INR of 3.0 in
patients with a mechanical MVR.564,565 (Level of Evidence: B)
In patients with mechanical prostheses, the incidence of
thromboembolism is higher for the mitral than the aortic po-
sition, and the rate of thromboembolism is lower in patients
with a higher INR goal compared with those with a lower
target INR. In the GELIA (German Experience With Low
Intensity Anticoagulation) study of patients with a mechan-
ical mitral prosthesis, a lower INR (2.0 to 3.5) was associ-
ated with lower survival rates than a higher target INR
range (2.5 to 4.5) in those with a second mechanical valve.
Patient compliance may be challenging with higher INR
goals. In 1 study, patients with a target INR between 2.0
and 3.5 were within that range 74.5% of the time. In
contrast, patients with a target INR of 3.0 to 4.5 were within
range only 44.5% of the time. An INR target of 3.0 (range,
2.5 to 3.5) provides a reasonable balance between the risks
of under- or overanticoagulation in patients with a mechan-
ical mitral valve.
Supporting References: 12,562
Class I
5. Aspirin 75 mg to 100 mg daily is recommended in addition to anti-
coagulation with a VKA in patients with a mechanical valve pros-
thesis.566,567 (Level of Evidence: A)
Aspirin is recommended for all patients with prosthetic
heart valves, including those with mechanical prosthetic
valves receiving VKA therapy. Even with the use of
VKA, the risk of thromboemboli is 1% to 2% per year.
The addition of aspirin 100 mg daily to oral VKA anti-
coagulation decreases the incidence of major embolism or
death (1.9% vs 8.5% per year; P<.001), with the stroke
rate decreasing to 1.3% per year versus 4.2% per year
(P< .027) and overall mortality to 2.8% per year versus
7.4% per year (P < .01). The addition of low-
dose aspirin (75 mg to 100 mg per day) to VKA therapy
(INR 2.0 to 3.5) also decreases mortality due to other
cardiovascular diseases. The combination of low-doseThe Journal of Thoracic and Caaspirin and VKA is associated with a slightly increased
risk of minor bleeding such as epistaxis, bruising, and he-
maturia, but the risk of major bleeding does not differ
significantly between those who received aspirin (8.5%)
versus those who did not (6.6%; P ¼ .43). The risk of
GI irritation and hemorrhage with aspirin is dose depen-
dent over the range of 100 mg to 1,000 mg per day, but
the antiplatelet effects are independent of dose over this
range. The addition of aspirin (75 mg to 100 mg per
day) to VKA should be strongly considered unless there
is a contraindication to the use of aspirin (ie, bleeding or
aspirin intolerance). This combination is particularly
appropriate in patients who have had an embolus while
on VKA therapy with a therapeutic INR, those with known
vascular disease, and those who are known to be particu-
larly hypercoagulable.
Supporting References: 12,568-571
Class IIa
1. Aspirin 75 mg to 100 mg per day is reasonable in all patients with a
bioprosthetic aortic or mitral valve.572-575 (Level of Evidence: B)
The risk of a clinical thromboembolism is on average
0.7% per year in patients with biological valves in sinus
rhythm; this figure is derived from several studies in which
the majority of patients were not undergoing therapy with
VKA. Among patients with bioprosthetic valves, those
with mitral prostheses have a higher rate of thromboembo-
lism than those with aortic prostheses in the long term
(2.4% per patient-year versus 1.9% per patient-year,
respectively). In a prospective study of bioprosthetic valves
in patients with AVR who were in sinus rhythm and had no
other indications for anticoagulation, the incidence of
thromboembolic events, bleeding, and death was similar be-
tween those who received aspirin or aspirin-like antiplatelet
agents only versus those who received VKA. There are no
studies examining the long-term effect of antiplatelet agents
in patients with bioprosthetic MVR or mitral valve repair,
but the beneficial effects seen with bioprosthetic aortic
valves are presumed to apply to mitral valves as well.
Supporting Reference: 12
Class IIa
2. Anticoagulation with a VKA is reasonable for the first 3 months af-
ter bioprosthetic MVR or repair to achieve an INR of 2.5.576 (Level
of Evidence: C)
The risk of ischemic stroke after all types of mitral valve
surgery is about 2% at 30 days, 3% at 180 days, and 8% at
5 years. This is observed even with routine use of early hep-
arin followed by VKA in patients with a mechanical valve
or other indications for long-term anticoagulant therapy.
The risk of ischemic stroke at 5 years is lower with
mitral valve repair (6.1%0.9%) compared with bio-
prosthetic (8.0%2.1%) and mechanical valve replace-
ment (16.1%2.7%). In 1 study, patients with ardiovascular Surgery c Volume 148, Number 1 e67
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lower rate of thromboembolism than those who did not
receive therapy with VKA (2.5% per year with anticoagu-
lation versus 3.9% per year without anticoagulation;
P ¼ .05). However, another study showed that even with
routine anticoagulation early after valve surgery, the inci-
dence of ischemic stroke within the first 30 postoperative
days was higher after replacement with a biological pros-
thesis (4.6%1.5%; P< .0001) than after mitral valve
repair (1.5%0.4%) or replacement with a mechanical
prosthesis (1.3%0.8%; P<.001). Thus, anticoagulation
with a target INR of 2.5 (range, 2.0 to 3.0) is reasonable
early after bioprosthetic mitral valve implantation.
Many centers start heparin as soon as the risk of surgical
bleeding is acceptable (usually within 24 to 48 hours), with
maintenance of a therapeutic partial thromboplastin time. Af-
ter anoverlapofheparin andVKAfor 3 to 5days, heparinmay
be discontinued when the INR reaches 2.5. After 3 months,
the tissue valve can be treated like native valve disease, and
VKA can be discontinued in more than two thirds of patients
with biological valves. In the remaining patients with associ-
ated risk factors for thromboembolism, such as AF, previous
thromboembolism, or hypercoagulable condition, lifelong
VKA therapy is indicated to achieve an INR of 2 to 3.
Supporting References: 572-574,577-582
Class IIb
1. Anticoagulation, with a VKA, to achieve an INR of 2.5 may be
reasonable for the first 3 months after bioprosthetic AVR.583 (Level
of Evidence: B)
Patientswith a bioprosthetic aortic valve are at a higher risk
of ischemic stroke or peripheral embolism than the normal
population, particularly in the first 90 days after valve
replacement. Anticoagulation early after valve implantation
is intended to decrease the risk of thromboembolism until
the prosthetic valve is fully endothelialized. The potential
benefit of anticoagulation therapy must be weighed against
the risk for bleeding, particularly in patients who are at low
risk for thromboembolism (eg, those in sinus rhythm with
normal LV function, no history of thromboembolism, or his-
toryof hypercoagulable conditions). SmallRCTshave not es-
tablished benefit for anticoagulation after implantation of a
bioprosthetic AVR; however, a large observational registry
demonstrated benefit without a significantly increased
bleeding risk. In 4,075 patients undergoing isolated bio-
prosthetic AVR with a median duration of follow-up of 6.57
person-years, the estimated rate of strokes per 100 person-
years was 7.00 (95%CI: 4.07 to 12.06) in patients not treated
withVKAvs2.69 (95%CI: 1.49 to 4.87) in those treatedwith
VKA(HR: 2.46; 95%CI: 1.09 to 5.55). The lower event rates
in those on VKA persisted at 6 months, with a cardiovascular
death rate of 6.50 per 100person-years (95%CI: 4.67 to9.06)
in those not on VKA therapy compared with 2.08 (95% CI:
0.99 to 4.36) in those on VKA therapy (adjusted internale68 The Journal of Thoracic and Cardiovascular Surgrate of return: 3.51; 95% CI: 1.54 to 8.03) for events within
90 to 179 days after surgery. Thus, anticoagulation with an
INR target of 2.5 (range, 2.0 to 3.0) may be reasonable for
at least 3 months, and perhaps as long as 6 months, after bio-
prosthetic AVR.
Supporting References: 572,574,583-586
Class IIb
2. Clopidogrel 75 mg daily may be reasonable for the first 6 months
after TAVR in addition to life-long aspirin 75 mg to 100 mg daily.
(Level of Evidence: C)
During TAVR, a biological prosthesis mounted on a
metallic expandable frame is inserted transcutaneously
within the native aortic valve with stenosis. In prospective
RCTs of balloon-expandable TAVR for treatment of AS,
the research protocol included dual antiplatelet therapy
with aspirin and clopidogrel for the first 6 months to mini-
mize the risk of thromboembolism. The current recommen-
dation is based on outcomes in these published studies,
although the issue of antiplatelet therapy was not assessed.
A small prospective, RCT, single-center study of 79 patients
receiving self-expanding TAVR did not show a difference in
the composite of major adverse cardiac and cerebrovascular
events, defined as death from any cause, MI, major stroke,
urgent or emergency conversion to surgery, or life-
threatening bleeding between aspirin and clopidogrel
versus aspirin alone at both 30 days (13% versus 15%;
P ¼ .71) and 6 months (18% versus 15%; P ¼ .85).
Supporting References: 79,170,587,588
Class III: Harm
1. Anticoagulant therapy with oral direct thrombin inhibitors or anti-
Xa agents should not be used in patients withmechanical valve pros-
theses.589-591 (Level of Evidence: B)
TheU.S. FoodandDrugAdministration has approved new
anticoagulants that are direct thrombin inhibitors or factor
Xa inhibitors (dabigatran, apixaban, and rivaroxaban) for
anticoagulant prophylaxis in patients with AF not caused
byVHD. Several case reports have demonstrated thrombosis
on mechanical heart valves despite therapeutic dosing with
dabigatran. The RE-ALIGN (Randomized, Phase II Study
to Evaluate the Safety and Pharmacokinetics ofOralDabiga-
tranEtexilate in Patients afterHeartValveReplacement) trial
was stopped prematurely for excessive thrombotic complica-
tions in the dabigatran arm. After enrollment of 252 patients,
ischemic or unspecified stroke occurred in 9 patients (5%)
randomized to dabigatran compared with no patients treated
with warfarin. In the dabigatran group, 15 patients (9%)
reached the composite endpoint of stroke, transient ischemic
attack, systemic embolism,MI, or death comparedwith 4 pa-
tients (5%) in the warfarin group (HR in the dabigatran
group: 1.94; 95% CI: 0.64 to 5.86; P ¼ .24). In addition, a
major bleeding episode occurred in 7 patients (4%) in the da-
bigatran group and 2 patients (2%) in thewarfarin group, and
bleeding of any type occurred in 45 patients (27%) and 10ery c July 2014
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4.86;P¼ .01). TheFood andDrugAdministration has issued
a specific contraindication for use of this product in patients
with mechanical heart valves. These agents are also not rec-
ommended, due to lack of data on their safety and effective-
ness, in patients with bioprosthetic valves who require
anticoagulation.
Supporting References: 591-59411.3. Bridging Therapy for Prosthetic Valves
11.3.1. Diagnosis and Follow-up
The management of patients with mechanical heart
valves in whom interruption of anticoagulation therapy is
needed for diagnostic or surgical procedures should take
into account the type of procedure, risk factors, and type,
location, and number of heart valve prosthesis(es).
11.3.2. Medical Therapy: Recommendations
Class I
1. Continuation of VKA anticoagulation with a therapeutic INR
is recommended in patients with mechanical heart valves un-
dergoing minor procedures (such as dental extractions or cata-
ract removal) where bleeding is easily controlled. (Level of
Evidence: C)
Management of antithrombotic therapy must be individ-
ualized, but some generalizations apply. Antithrombotic
therapy should not be stopped for procedures in which
bleeding is unlikely or would be inconsequential if it
occurred (ie, surgery on the skin, dental cleaning, or simple
treatment for dental caries). Eye surgery, particularly for
cataracts or glaucoma, is usually associated with very little
bleeding and thus is frequently performed without alter-
ations to antithrombotic treatment.
Class I
2. Temporary interruption of VKA anticoagulation, without bridging
agents while the INR is subtherapeutic, is recommended in patients
with a bileafletmechanical AVR and no other risk factors for throm-
bosis who are undergoing invasive or surgical procedures. (Level of
Evidence: C)
The risk of increased bleeding during a procedure per-
formed with a patient receiving antithrombotic therapy
has to beweighed against the increased risk of a thromboem-
bolism caused by stopping the therapy. In patients with a bi-
leaflet mechanical aortic valve and no other risk factors for
thromboembolism, the risk of stopping VKA is relatively
slight if the drug is withheld for only a few days. In these
low-risk patients, the inconvenience and expense of
bridging anticoagulation can be avoided. When it is neces-
sary to interrupt VKA therapy, VKA is stopped 2 to 4
days before the procedure (so the INR falls to<1.5 for major
surgical procedures) and restarted as soon as bleeding risk
allows, typically 12 to 24 hours after surgery.
Supporting References: 595,596The Journal of Thoracic and CaClass I
3. Bridging anticoagulation with either intravenous UFH or subcu-
taneous LMWH is recommended during the time interval when
the INR is subtherapeutic preoperatively in patients who are under-
going invasive or surgical procedures with a; (1) mechanical AVR
and any thromboembolic risk factor; (2) older-generation mechan-
ical AVR; or (3) mechanical MVR. (Level of Evidence: C)
In patients at higher risk of thromboembolism during
interruption of VKA anticoagulation, the risk of an adverse
event can be minimized by anticoagulation with alternative
agents that can be stopped right before and restarted right
after the surgical procedure (eg, ‘‘bridging therapy’’). Pa-
tients at high risk of thrombosis include all patients with
mechanical MVR or tricuspid valve replacements and
patients with an AVR and any risk factors for thromboem-
bolism. Such risk factors include AF, previous throm-
boembolism, hypercoagulable condition, older-generation
mechanical valves, LV systolic dysfunction (LVEF
<30%), or>1 mechanical valve.
When interruption of VKA therapy is needed, VKA is
stopped 2 to 4 days before the procedure (so the INR falls
to <1.5 for major surgical procedures) and restarted as
soon as bleeding risk allows, typically 12 to 24 hours after
surgery. Bridging anticoagulation with intravenous UFH or
subcutaneous LMWH is started when INR is<2.0 (usually
about 48 hours before surgery) and stopped 4 to 6 hours (for
intravenous UFH) or 12 hours (for subcutaneous LMWH)
before the procedure. When LMWH is used, therapeutic
weight-adjusted doses are given twice daily. One study of
bridging therapy for interruption of VKA included 215 pa-
tients with mechanical valves. In the total group of 650 pa-
tients, the risk of thromboembolism (including possible
events) was 0.62%, with 95% CI: 0.17% to 1.57%. Major
bleeding occurred in 0.95% (0.34% to 2.0%). Most studies
using LMWH used enoxaparin for therapy. The use of
bridging heparin after surgery must be individualized, de-
pending on risk of bleeding and risk of thrombosis.
The acceptable level of anticoagulation in patients
undergoing cardiac catheterization depends on the specific
procedure being performed. For procedures with a low
bleeding risk, such as coronary angiography from the radial
approach, only slight modification in VKA dosing is needed.
With interventional procedures at higher risk, many clini-
cians prefer to stop VKA anticoagulation and use bridging
therapy as is done for other surgical procedures.
Supporting References: 597-599
Class IIa
1. Administration of fresh frozen plasma or prothrombin complex
concentrate is reasonable in patients with mechanical valves
receiving VKA therapy who require emergency noncardiac surgery
or invasive procedures. (Level of Evidence: C)
Because VKA inhibits production of several proteins
involved in the coagulation cascade, the anticoagulant effect
persists until adequate levels of these proteins are achievedrdiovascular Surgery c Volume 148, Number 1 e69
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48 to 72 hours. In patients with mechanical valves on long-
term warfarin therapy who require emergency surgery or
invasive procedures, anticoagulation can be reversed by
administration of fresh frozen plasma or intravenous pro-
thrombin complex concentrate. Administration of low-
dose (1 mg to 2 mg) oral vitamin K may be added because
the effect of fresh frozen plasma or prothrombin complex
has a shorter half-life than the effects of VKA therapy.
Higher doses of vitamin K are discouraged to avoid diffi-
culty in achieving a therapeutic INR after the procedure.
Supporting References: 600-602
See Online Data Supplement 21 for more information on
bridging therapy.
11.4. Excessive Anticoagulation and Serious Bleeding
With Prosthetic Valves: Recommendation
See Figure 6 for anticoagulation for prosthetic valves.
Class IIa
1. Administration of fresh frozen plasma or prothrombin complex
concentrate is reasonable in patientswithmechanical valves and un-
controllable bleeding who require reversal of anticoagulation.601,602
(Level of Evidence: B)
Excessive anticoagulation (INR5) greatly increases the
risk of hemorrhage. However, a rapid decrease in the INR
that leads to INR falling below the therapeutic level in-
creases the risk of thromboembolism. High-dose vitamin
K should not be given routinely, because this may create a
hypercoagulable condition. In most patients with an
INR of 5 to 10, excessive anticoagulation can be managed
by withholding VKA and monitoring the level of anticoagu-
lation with serial INR determinations. In patients with an
INR>10 who are not bleeding, it is prudent to administer
1 mg to 2.5 mg of oral vitamin K1 (phytonadione) in addi-
tion to holding VKA therapy. When the INR falls to a safe
level, VKA therapy is restarted with the dose adjusted as
needed to maintain therapeutic anticoagulation. In emer-
gency situations, such as uncontrollable bleeding, adminis-
tration of fresh frozen plasma or prothrombin complex
concentrate is reasonable because the onset of action of
vitamin K is very slow.
Supporting References: 600,603
11.5. Thromboembolic EventsWith Prosthetic Valves
11.5.1. Diagnosis and Follow-up
The annual risk of thromboembolic events in patients
with a mechanical heart valve is 1% to 2% versus 0.7%
with a bioprosthetic valve, even with appropriate antithrom-
botic therapy. Many complications are likely related to sub-
optimal anticoagulation; even in clinical trials, the time in
therapeutic range for patients on VKA varies from only
60% to 70%. However, embolic events do occur even in pa-
tients who are in the therapeutic range at every testing inter-
val. Annual follow-up in patients with prosthetic hearte70 The Journal of Thoracic and Cardiovascular Surgvalves should include review of the adequacy of anticoagu-
lation and any issues related to compliance with medical
therapy. Screening questions for symptoms that may be
related to embolic events are especially important if antico-
agulation has been suboptimal. Patients should be educated
about symptoms related to embolic events and instructed to
promptly report to a healthcare provider should symptoms
occur. TTE is the first step in evaluation of suspected pros-
thetic valve thromboembolism to evaluate valve hemody-
namics in comparison to previous studies, and TEE often
is needed, particularly for mitral prosthetic valves. Howev-
er, the prosthetic valve should be considered the source of
thromboembolism even if echocardiographic findings are
unchanged.
11.5.2. Medical Therapy
In patients on VKA anticoagulation and aspirin 75 mg to
100 mg daily for a mechanical valve who have a definite
embolic episode, it is important to document the adequacy
of the anticoagulation, including the timewithin therapeutic
range. If there have been periods in which the INR has been
documented to be subtherapeutic, appropriate steps to
ensure adequate anticoagulation should be taken. If embolic
events have occurred despite a therapeutic INR when other
contraindications are not present, a prudent approach to an-
tithrombotic therapy is:
 Increase the INR goal from 2.5 (range, 2.0 to 3.0) to 3.0 (range, 2.5
to 3.5) for patients with an AVR; or, increase the INR goal from 3.0
(range, 2.5 to 3.5) to 4.0 (range, 3.5 to 4.5) for patients with an
MVR.
In patients with a bioprosthetic valve with embolic events
who are only on aspirin 75 mg to 100 mg daily, a possible
approach includes consideration of anticoagulation with
a VKA.
11.5.3. Intervention
Embolic events in patients with prosthetic heart valves
should be managed by ensuring optimal anticoagulation
and antiplatelet therapy. Measures to improve patient
compliance, including patient education and more frequent
monitoring, should be instituted. Studies show that patients
on anticoagulation with VKAwho are managed by a dedi-
cated pharmacist-led anticoagulation clinic have lower rates
of bleeding and thromboembolism compared with conven-
tional monitoring by a clinician’s office. Surgical interven-
tion is rarely needed for recurrent thromboembolic events
but might be considered in some situations. In patients
with degenerated bioprosthetic valves, calcific emboli
may complicate thrombotic embolism, often in association
with prosthetic valve stenosis and/or regurgitation. In pa-
tients with mechanical valves who have recurrent serious
adverse effects of over- or underanticoagulation despite
all efforts to improve compliance, replacement of the me-
chanical valve with a bioprosthetic valve might beery c July 2014
FIGURE 6. Anticoagulation for prosthetic valves. Risk factors include AF, previous thromboembolism, LV dysfunction, hypercoagulable condition, and
older-generation mechanical AVR. AF, Atrial fibrillation; ASA, aspirin; AVR, aortic valve replacement; INR, international normalized ratio; LMWH, low-
molecular-weight heparin;MVR, mitral valve replacement; PO, by mouth;QD, every day; SC, subcutaneous; TAVR, transcatheter aortic valve replacement;
UFH, unfractionated heparin; VKA, vitamin K antagonist.
Nishimura et al Clinical Guidelinesconsidered after a discussion of the potential risks and ben-
efits of this approach.11.6. Prosthetic Valve Thrombosis
See Figure 7 for evaluation and management of suspected
valve thrombosis.
11.6.1. Diagnosis and Follow-up: Recommendations
Class I
1. TTE is indicated in patients with suspected prosthetic valve throm-
bosis to assess hemodynamic severity and follow resolution of valve
dysfunction.604,605 (Level of Evidence: B)
Obstruction of prosthetic heart valves may be caused by
thrombus formation, pannus ingrowth, or a combination of
both. Mechanical prosthetic heart valve thrombosis has a
prevalence of only 0.3% to 1.3% per patient-year in devel-
oped countries but is as high as 6.1% per patient-year in
developing countries. Bioprosthetic valve thrombosis is
less common. Differentiation of valve dysfunction due to
thrombus versus fibrous tissue ingrowth (pannus) is chal-
lenging because the clinical presentations are similar.The Journal of Thoracic and CaThrombus is more likely when there is a history of inade-
quate anticoagulation and with more acute onset of valve
dysfunction and symptoms. Although fluoroscopy or CT
imaging can be used to evaluate the leaflet motion of an ob-
structed mechanical prosthesis, the etiology and hemody-
namic impact are best evaluated by echocardiography.
TTE allows evaluation of valve hemodynamics and detec-
tion of valve stenosis or regurgitation. Leaflet motion and
thrombus may be visualized in some patients, but TEE is
more sensitive for detection of valve thrombosis, especially
of the mitral valve. Transthoracic imaging also allows mea-
surement of LV size and systolic function, left atrial size,
right heart function, and an estimation of pulmonary
pressures.
Clinical evaluation, including auscultation of diminished
or abolished clicks together with new systolic or diastolic
murmurs, is the first step in the routine assessment of pa-
tients with a prosthetic heart valve but is unreliable for
detection of valve thrombosis. TTE allows detection of
prosthetic valve dysfunction and quantitation of stenosis
and regurgitation but is inadequate for evaluation of the
presence and size of thrombus or valve occluder motion.rdiovascular Surgery c Volume 148, Number 1 e71
Clinical Guidelines Nishimura et alClass I
2. TEE is indicated in patients with suspected prosthetic
valve thrombosis to assess thrombus size and valve motion.605-607
(Level of Evidence: B)
TEE allows direct imaging of mechanical valve throm-
bosis, particularly for thrombi on the left atrial side of
the mitral valve, which is obscured by shadowing on
TTE imaging. Compared with chronic fibrous ingrowth
or pannus, thrombi tend to be larger, less dense, and more
mobile than pannus on ultrasound imaging. Thrombus
size, measured on TEE, is a significant independent predic-
tor of outcome after thrombolysis of an obstructed pros-
thetic heart valve. Multivariate analysis of 107 patients
with thrombosed heart valve prostheses revealed that prior
history of stroke (OR: 4.55; 95% CI: 1.35 to 15.38) and
thrombus area by TEE (OR: 2.41 per 1.0 cm2; CI: 1.12 to
5.19) were independent predictors of complications after
thrombolysis. A thrombus area<0.8 cm2 identified patients
at lower risk for complications from thrombolysis, irrespec-
tive of NYHA classification. TEE should be used to identify
lower-risk patients for thrombolysis.
Supporting References: 605-607
Class IIa
1. Fluoroscopy or CT is reasonable in patients with suspected valve
thrombosis to assess valve motion. (Level of Evidence: C)
Fluoroscopy and CT are alternative imaging techniques
for evaluation of mechanical valve ‘‘leaflet’’ motion, partic-
ularly in patients with prosthetic aortic valves, which
are difficult to image by either TTE or TEE. CT is best
suited for measurement of valve opening angles because
3D image acquisition allows postacquisition analysis from
multiple views. CT imaging may also allow visualization
of pannus or thrombus in patients with mechanical or bio-
prosthetic valves.
11.6.2. Medical Therapy: Recommendations
Class IIa
1. Fibrinolytic therapy is reasonable for patients with a thrombosed
left-sided prosthetic heart valve, recent onset (<14 days) of NYHA
class I to II symptoms, and a small thrombus (<0.8 cm2).605,608
(Level of Evidence: B)
Although fibrinolytic therapy of a left-sided obstructed
prosthetic heart valve is associated with an overall rate of
thromboembolism and bleeding of 17.8%, the degree of
risk is directly related to thrombus size. When thrombus
area is measured in the 2D TEE view showing the largest
thrombus size, an area of 0.8 cm2 provides a useful break-
point for clinical decision making. A mobile thrombus or a
length>5 mm to 10 mm is also associated with increased
embolic risk. Patients with a small thrombus (<1.0 cm in
diameter or 0.8 cm2 in area) have fewer thrombolysis-
related complications, whereas those with a large thrombus
(>1.0 cm diameter or 0.8 cm2 in area) have a 2.4–fold highere72 The Journal of Thoracic and Cardiovascular Surgrate of complications per 1.0 cm2 increase in size. Factors
that identify patients at risk for adverse outcomes of fibrino-
lytic therapy include active internal bleeding, history of hem-
orrhagic stroke, recent cranial trauma or neoplasm, diabetic
hemorrhagic retinopathy, large thrombi, mobile thrombi,
systemic hypertension (>200mmHg/120mmHg), hypoten-
sion or shock, and NYHA class III to IV symptoms.
With mild symptoms due to aortic or mitral valve throm-
bosis with a small thrombus burden, it is prudent to reassess
after several days of intravenous UFH. If valve thrombosis
persists, fibrinolysis with a recombinant tissue plasminogen
activator dose of a 10 mg IV bolus followed by 90 mg
infused IV over 2 hours is reasonable. Heparin and glyco-
protein IIb/IIIa inhibitors are held, but aspirin can be
continued. A lower tissue plasminogen activator dose of a
20 mg IV bolus followed by 10 mg per hour for 3 hours
may be appropriate in some situations. Alternatively, strep-
tokinase may be used with a loading dose of 500,000 IU in
20 minutes followed by 1,500,000 IU over 10 hours. Uroki-
nase is less effective than tissue plasminogen activator or
streptokinase. If fibrinolytic therapy is successful, it is fol-
lowed by intravenous UFH until VKA achieves an INR of
3.0 to 4.0 for aortic prosthetic valves and 3.5 to 4.5 for
mitral prosthetic valves. A structured institutional protocol
with indications, contraindications, and a specific timeline
for medication administration and patient monitoring is
recommended.
After treatment of the acute thrombotic event, it is impor-
tant to always determine the adequacy of anticoagulation
before the event and ensure that there is meticulous
follow-up after the event. The anticoagulation regimen
can be increased as outlined in Section 11.5.2.
Supporting References: 609,610
Class IIa
2. Fibrinolytic therapy is reasonable for thrombosed right-sided pros-
thetic heart valves.611,612 (Level of Evidence: B)
In nonrandomized, retrospective cohorts of thrombosed
mechanical or biological tricuspid valve prostheses, fibrino-
lysiswas as successful in normalization of hemodynamics as
surgical intervention. With fibrinolysis of right-sided valve
thrombosis, the resultant small pulmonary emboli appear
to be well tolerated and systemic emboli are uncommon.
See Online Data Supplement 22 for more information on
fibrinolytic therapy.
11.6.3. Intervention: Recommendations
Class I
1. Emergency surgery is recommended for patients with a thrombosed
left-sided prosthetic heart valve with NYHA class III to IV symp-
toms.610,611,613 (Level of Evidence: B)
Prompt surgical treatment of a thrombosed prosthetic
heart valve is an effective treatment to ameliorate clinicalery c July 2014
FIGURE 7. Evaluation and management of suspected prosthetic valve thrombosis. *See text for dosage recommendations. CT, Computed tomography; IV,
intravenous; NYHA, New York Heart Association; Rx, therapy; TEE, transesophageal echocardiography; TTE, transthoracic echocardiography.
Nishimura et al Clinical Guidelinessymptoms and restore normal hemodynamics, with a
success rate close to 90% in patients who do not have a
contraindication to surgical intervention. In contrast, a
meta-analysis of 7 studies that included 690 episodes of
left-sided prosthetic valve thrombosis showed a success
rate for restoring normal valve function of only about
70% in 244 cases treated with fibrinolytic therapy.
There was no difference in mortality between surgical and
fibrinolytic therapy for left-sided prosthetic valve throm-
bosis, but in addition to a higher success rate for restoring
normal valve function, surgery was associated with lower
rates of thromboembolism (1.6% vs 16%), major bleeding
(1.4% vs 5%), and recurrent prosthetic valve thrombosis
(7.1% vs 25.4%). Although RCTs have not been
performed, the weight of the evidence favors surgical
intervention for left-sided prosthetic valve thrombosis un-
less the patient is asymptomatic and the thrombus burden
is small.
Supporting References: 605,613,614The Journal of Thoracic and CaClass IIa
1. Emergency surgery is reasonable for patients with a thrombosed
left-sided prosthetic heart valve with a mobile or large thrombus
(>0.8 cm2).605,607,610 (Level of Evidence: C)
Prompt surgical treatment of a thrombosed prosthetic
heart valve is associated with a relatively low rate of mortal-
ity. In a retrospective study of 106 surgeries for obstructed
left-sided prosthetic heart valves, the mortality rate was
17.5% for patients with NYHA class IV symptoms and
4.7% in those patients with NYHA class I to III symptoms.
Mortality was similar for removing the thrombus or replac-
ing the entire prosthetic valve. Patients with large, mobile
clots that extend beyond the prosthesis are better suited
for surgical intervention than fibrinolysis, which is associ-
ated with significant risk of systemic embolism. In 1 report,
in which patients with small thrombus burden (<0.8 cm2 on
TEE imaging) had minimal thrombolysis-related complica-
tions, those with large thrombus burden (0.8 cm2) had a
2.4–fold higher rate of complications per 1.0 cm2 increaserdiovascular Surgery c Volume 148, Number 1 e73
Clinical Guidelines Nishimura et alin size, making surgery the optimal intervention. In patients
with recent hemorrhagic stroke, surgery is a better choice
because of the bleeding risks associated with fibrinolysis.
11.7. Prosthetic Valve Stenosis
11.7.1. Diagnosis and Follow-up
Reoperation to replace a prosthetic heart valve is a
serious clinical event. It is usually required for moderate-
to-severe prosthetic dysfunction (structural and nonstruc-
tural), dehiscence, and prosthetic valve endocarditis
(PVE). Causes of prosthetic valve stenosis that might
require reoperation with a mechanical valve include
chronic thrombus or pannus impinging on normal
leaflet occluder motion; for a bioprosthetic valve, leaflet
fibrosis and calcification are the most common causes. Re-
operation may also be needed for recurrent thromboembo-
lism, severe intravascular hemolysis, severe recurrent
bleeding from anticoagulant therapy, and thrombosed pros-
thetic valves.
In somepatients, the size of the prosthetic valve that can be
implanted results in inadequate blood flow to meet the meta-
bolic demands of the patient, even when the prosthetic valve
itself is functioning normally. This situation, called ‘‘patient-
prosthesismismatch’’ (defined as an indexed effective orifice
area0.85 cm2/m2 for aortic valve prostheses), is a predictor
of a high transvalvular gradient, persistent LV hypertrophy,
and an increased rate of cardiac events afterAVR.The impact
of a relatively small valve area ismost noticeablewith severe
patient-prosthesismismatch, defined as an orifice area<0.65
cm2/m2. Patient-prosthesis mismatch is especially detri-
mental in patients with reduced LVEF and may decrease
the likelihood of resolution of symptoms and improvement
in LVEF. Patient-prosthesis mismatch can be avoided or
reduced by choosing a valve prosthesis that will have an
adequate indexed orifice area, based on the patient’s
body size and annular dimension. In some cases, annular
enlargement or other approaches may be needed to
allow implantation of an appropriately sized valve or avoid-
ance of a prosthetic valve. With bileaflet mechanical valves,
patterns of blood flow are complex and significant pressure
recovery may be present; this may result in a high velocity
across the prosthesis that should not be mistaken for pros-
thetic valve stenosis or patient-prosthesis mismatch.
In patients with bioprosthetic valves who show evidence
of prosthetic valve stenosis, TTE is used to monitor the
appearance of the valve leaflets, valve hemodynamics, LV
size, and systolic function, and to estimate pulmonary
pressures. Transthoracic imaging is usually adequate, with
TEE imaging reserved for patients with poor-quality im-
ages. In patients with mechanical valves, fluoroscopy or
CT imaging can be helpful for showing disc motion.
CT may also visualize paravalvular pannus formation
with either bioprosthetic or mechanical valves.
Supporting References: 527,528,544,615,616e74 The Journal of Thoracic and Cardiovascular Surg11.7.2. Medical Therapy
There are no medical therapies known to prevent bio-
prosthetic valve degeneration other than those integrated
into the valve design. Medical therapy is not effective for
treatment of symptoms due to significant prosthetic valve
stenosis, except with valve thrombosis, but standard medi-
cal therapy may help stabilize patients before surgical inter-
vention and may be used for palliative care in patients who
are not surgical candidates.
11.7.3. Intervention: Recommendation
Class I
1. Repeat valve replacement is indicated for severe symptomatic pros-
thetic valve stenosis. (Level of Evidence: C)
The indications for surgical intervention for prosthetic
valve stenosis are the same as those for native stenosis of
the aortic or mitral valve. Surgery is primarily needed for
bioprosthetic valve degeneration. In this situation, the
choice of a new valve prosthesis depends on the same fac-
tors as those for patients undergoing a first valve replace-
ment. The use of transcatheter valve prostheses to treat
bioprosthetic valve stenosis with a ‘‘valve-in-valve’’
approach is promising but not yet fully validated.
Mechanical valve stenosis is rare and typically due to
valve thrombosis or pannus formation. If patient noncompli-
ance contributed tovalve thrombosis, it is prudent to consider
a bioprosthetic valve at the time of reoperation. With atten-
tion to optimal valve selection, a second surgical procedure
for significant patient-prosthesis mismatch is rarely needed
and should be considered only if a larger prosthetic valve
or a valve type with better hemodynamics can be implanted.
11.8. Prosthetic Valve Regurgitation
11.8.1. Diagnosis and Follow-up
In patients with bioprosthetic valves who show evidence
of prosthetic valve regurgitation, TTE is used to monitor the
appearance of the valve leaflets, valve hemodynamics, LV
size, and systolic function, and to estimate pulmonary pres-
sures. The initial approach is TTE for evaluation of ante-
grade valve velocities and pressure gradients. However,
TEE is essential for evaluation of suspected or known pros-
thetic mitral valve regurgitation. On TTE imaging, the
LA is shadowed by the valve prosthesis, obscuring
evidence of prosthetic regurgitation. TEE imaging provides
clear images of the left atrial side of the mitral prosthesis
and is particularly useful for delineation of the site and
severity of paravalvular regurgitation, evaluation of suit-
ability for a percutaneous approach, and guidance during
percutaneous closure procedures.
11.8.2. Medical Therapy
Bioprosthetic valve regurgitation is typically due to leaflet
degeneration and calcification. There are no medical thera-
pies known to prevent bioprosthetic valve degenerationery c July 2014
Nishimura et al Clinical Guidelinesother than those integrated into the valve design. Patholog-
ical regurgitation of a mechanical prosthetic valve is typi-
cally due to a paravalvular leak or pannus limiting normal
occluder closure. Medical therapy is not effective for treat-
ment of symptoms due to significant prosthetic valve regur-
gitation, but standard approaches may help stabilize patients
before surgical intervention and may be used for palliative
care in patients who are not surgical candidates.
11.8.3. Intervention: Recommendations
Class I
1. Surgery is recommended for operable patients with mechanical
heart valves with intractable hemolysis or HF due to severe pros-
thetic or paraprosthetic regurgitation.617,618 (Level of Evidence: B)
The indications for surgical intervention for prosthetic
valve regurgitation include the same indications for native
regurgitation of the aortic or mitral valve. Specifically, indi-
cators are evidence of LV systolic dysfunction, including a
low LVEF or progressive LV dilation; the same cut-off
points should be used as defined for native valve disease.
Paravalvular regurgitation may also result in hemolytic ane-
mia; often this is mild and is managed medically but may be
refractory in some patients. Paravalvular regurgitation may
be treated by replacing the dysfunctional valve with a new
valve or by repairing the paravalvular defect.
Supporting Reference: 619
Class IIa
1. Surgery is reasonable for operable patients with severe symptom-
atic or asymptomatic bioprosthetic regurgitation. (Level of Evi-
dence C)
Bioprosthetic valve degeneration results in regurgitation
due to leaflet calcification and noncoaptation or leaflet degen-
eration with a tear or perforation. Even in asymptomatic pa-
tients with severe bioprosthetic regurgitation, valve
replacement is reasonable due to the risk of sudden clinical
deterioration if further leaflet tearing occurs. The choice of
type of valve prosthesis in a patient undergoing reoperation
depends on the same factors as those for patients undergoing
a first valve replacement. The use of transcatheter valve pros-
theses to treat bioprosthetic valve regurgitationwith a ‘‘valve-
in-valve’’ approach is promising but is not yet fully validated.
Paravalvular regurgitation can also occur with a bioprosthetic
valve. New paravalvular regurgitation may be due to IE or su-
turedisruption frommechanical causes.Bloodcultures should
be obtained when new paravalvular regurgitation is detected.
Class IIa
2. Percutaneous repair of paravalvular regurgitation is reasonable in
patients with prosthetic heart valves and intractable hemolysis or
NYHA class III/IV HF who are at high risk for surgery and have
anatomic features suitable for catheter-based therapy when per-
formed in centers with expertise in the procedure.620-622 (Level of
Evidence B)
Surgery is a viable therapeutic option in many patients
with symptomatic paravalvular prosthetic regurgitation.The Journal of Thoracic and CaHowever, in some patients, surgery to replace a prosthetic
valve with significant paravalvular regurgitation may carry
significant operative risk due to the need for reoperation
and patient comorbidity. Recent studies have demonstrated
clinical success with percutaneous approaches, in which
operators use complex catheter techniques and a variety
of occluder devices to reduce paravalvular regurgitation.
Procedural success rates with percutaneous closure, typi-
cally defined by no more than mild residual regurgitation
and the absence of death and major complications, have
been reported to be 80% to 85% in centers with expertise
in the procedure. Major complications, nonetheless, occur
in 9% of patients, mainly due to vascular injury, cardiac
perforation, and bleeding (procedural death,<2%). The
degree of residual regurgitation directly affects symptom
improvement and survival free of adverse events. Treat-
ment of HF symptoms is more successful than treatment
of hemolysis. Due to the complexity of these procedures,
consideration should be given to their performance in cen-
ters of expertise under the guidance of a multidisciplinary
team.
Supporting References: 620-629
See Online Data Supplement 23 for more information on
paravalvular regurgitation.
12. INFECTIVE ENDOCARDITIS
See Online Data Supplement 24 for more information
on surgical outcomes.
12.1. IE: Overview
IE has a high mortality rate, even with appropriate
antibiotic therapy and surgical intervention, with an in-
hospital mortality rate of 15% to 20% and a 1–year mor-
tality rate approaching 40%. The overall incidence of IE
is 3 to 10 per 100,000 patient-years, with a higher preva-
lence in older patients. In underdeveloped countries, IE is
most often associated with rheumatic heart disease. In
developed countries, IE is increasingly associated with
prosthetic valve and intracardiac devices, with a risk of
IE 50 times higher in patients with a prosthetic valve
compared with the general population. IE also may be
associated with intravenous drug use, diabetes mellitus,
or immunosuppression. Despite differences in associated
risk factors and clinical outcomes, there are few differ-
ences in the recommendations for diagnosis and treatment
of NVE versus PVE. In this guideline, there is 1 set of rec-
ommendations for diagnosis and management of all types
of IE. Recommendations for prevention of IE are included
in Section 2.
Antimicrobial therapy is the cornerstone of therapy for
IE. The specific antimicrobial agents and duration of
therapy should be guided by the susceptibility profile of
the causative organism. Temporal and geographic vari-
ability in causative organisms and antimicrobialrdiovascular Surgery c Volume 148, Number 1 e75
Clinical Guidelines Nishimura et alsusceptibility profiles mandate concomitant management
with an infectious disease specialist. Details of specific anti-
microbial regimens have previously been published by the
AHA, European Society of Cardiology, and British Society
for Antimicrobial Chemotherapy and are not repeated in
this guideline.
In addition to antibiotic therapy, early surgical interven-
tion is often needed for effective treatment of infection
and to manage the sequelae of valve leaflet and paravalvular
tissue destruction. Decisions about whether surgical inter-
vention is needed and the optimal timing of intervention
are complex. Most of the indications for surgical interven-
tion are the same for NVE and PVE and are included in 1
recommendation for both when possible. Appropriate man-
agement of patients with IE requires a Heart Valve Team
approach, initiated as soon as a diagnosis of probable or def-
inite IE is confirmed, with specialists in cardiology, cardio-
thoracic surgery, and infectious disease all involved in
patient care and decision making.
Supporting References: 52,278,630-63512.2. Infective Endocarditis
See Online Data Supplement 24 for more information on
surgical outcomes.
12.2.1. Diagnosis and Follow-up: Recommendations
See Figure 8 for recommendations for imaging studies in
NVE and PVE.
Class I
1. At least 2 sets of blood cultures should be obtained in patients at risk
for IE (eg, those with congenital or acquired VHD, previous IE,
prosthetic heart valves, certain congenital or heritable heart mal-
formations, immunodeficiency states, or injection drug users) who
have unexplained fever for more than 48 hours636 (Level of Evi-
dence: B) or patients with newly diagnosed left-sided valve regurgi-
tation. (Level of Evidence: C)
Blood cultures are positive in 90% of patients with IE. In
patients with a chronic (or subacute) presentation, 3 sets of
blood cultures should be drawn>6 hours apart at peripheral
sites before initiation of antimicrobial therapy. However,
this is not feasible or safe in patients with severe sepsis or
septic shock. In this situation, 2 cultures at separate times
should allow for a secure microbiological diagnosis before
initiation of antimicrobial therapy. More important than the
time interval of the cultures is the observance of strict
aseptic technique, avoiding sampling from intravascular
lines, and ensuring adequate volume of blood for culture
sample. Routine incubation of blood cultures for>7 days
is no longer necessary in the era of continuous-monitoring
blood culture systems and nonculture-based technology.
In the 10% of patients with culture-negative endocarditis,
serologic testing to identify the etiologic agent is
appropriate.
Supporting References: 52,637-641e76 The Journal of Thoracic and Cardiovascular SurgClass I
2. The Modified Duke Criteria should be used in evaluating a patient
with suspected IE (Tables 24 and 25).642-645 (Level of Evidence: B)
TheModified Duke Criteria (Tables 24 and 25) have been
well validated in comparison to surgical or autopsy findings
and in clinical outcomes in numerous studies in a wide spec-
trum of patients, including children, the elderly, prosthetic
valve recipients, injection drug users, and nondrug users,
as well as patients in both primary and tertiary care settings.
Clinical judgment and infectious disease specialty guidance
are essential when deciding on the type and duration of anti-
biotic therapy when these criteria suggest possible IE and in
patients with unusual clinical presentations or culture-
negative endocarditis. About three fourths of patients with
IE are diagnosed within 30 days of the onset of infection,
so classic clinical features, such as embolic or vasculitic
skin lesions, renal disease due to immune complex deposi-
tion, and immunologic abnormalities of IE, are often ab-
sent. In these cases, maintaining a high level of clinical
suspicion to the possibility of IE in patients who are suscep-
tible is paramount.
Supporting References: 644,646-650
Class I
3. Patients with IE should be evaluated and managed with consulta-
tion of a multispecialty Heart Valve Team including an infectious
disease specialist, cardiologist, and cardiac surgeon. In surgically
managed patients, this team should also include a cardiac anesthe-
siologist.651 (Level of Evidence: B)
The diagnosis of IE can still be difficult and is frequently
delayed, which may cause progressive and potentially irrep-
arable structural damage to the heart and other organ sys-
tems secondary to vascular-embolic and immunologically
mediated events. The in-hospital mortality rate for patients
with IE remains high (15% to 20%), with 1–year mortality,
even in the current therapeutic era, approaching 40%. Addi-
tionally, stroke (16.9%), embolization other than stroke
(22.6%), HF (32.3%), intracardiac abscess (14.4%), and
the need for surgical therapy (48.2%) remain common.
The optimal treatment and potential timing of invasive
strategies in these patients can be quite challenging in the
individual patient. Patients with suspected IE are most opti-
mally managed in an environment that coordinates manage-
ment of specialists well attuned to various organ systems,
pathological processes, and potential treatment modalities
involved. Cardiologists provide expertise in diagnosis,
imaging, and clinical management; infectious disease spe-
cialists provide expertise in identification of the causative
organism and the choice and duration of antimicrobial ther-
apy; cardiac surgeons are essential for decisions about
timing of surgical intervention as well as the procedure it-
self; and anesthesiologists are essential for peri- and intra-
operative diagnosis and management. Because the urgent/
emergency need for surgical intervention can arise rapidly,ery c July 2014
FIGURE 8. Recommendations for imaging studies in NVE and PVE. *Repeat TEE and/or TTE re-commended for re-evaluation of patients with IE and a
change in clinical signs or symptoms and in patients at high risk of complications. CT, Computed tomography; IE, infective endocarditis; NVE, native valve
endocarditis; PVE, prosthetic valve endocarditis; S aureus, Staphylococcus aureus; TEE, transesophageal echocardiography; TTE, transthoracic echocar-
diography.
Nishimura et al Clinical Guidelinesit is strongly recommended that these patients be cared for
in centers with immediate access to cardiac surgery during
the initial observation stages of the disease. With the
emerging use of telemedicine, it may be reasonable to
manage patients with lower-acuity IE in a center without
on-site multispecialty care by telecommunication with a
Heart Valve Team and infectious disease specialists. Rapid
transfer of the patient should also be available if the need
arises. IE is a disease that is continually changing with
new high-risk patients, new diagnostic procedures, the
involvement of new micro-organisms, and new therapeutic
approaches. Despite knowledge of these changes and
considerable improvements in diagnostic and therapeutic
strategies, IE is still a potentially debilitating or fatal dis-
ease. Patients affected by the disease are often older and
sicker, and the comorbidity rate is high.
Supporting References: 652-654
Class I
4. TTE is recommended in patients with suspected IE to identify veg-
etations, characterize the hemodynamic severity of valvular lesions,
assess ventricular function and pulmonary pressures, and detect
complications.655-659 (Level of Evidence: B)
The presence of valvular vegetation is a major criterion in
the diagnosis of IE. TTE has a sensitivity of between 50%
and 90% and a specificity>90% for detection of vegeta-
tions in NVE. TTE has a sensitivity of only 36% to 69%
in PVE, but TTE still has a role in these patients for detec-
tion and quantitation of valve dysfunction (even in the chal-
lenging situation of regurgitation in the mechanicalThe Journal of Thoracic and Caprosthetic mitral valve, for which a proximal convergence
zone may provide important evidence for a paravalvular
leak), evaluation of ventricular size and systolic function,
and estimation of pulmonary pressures. TTE exhibits supe-
rior imaging over TEE for the anterior aspect of a prosthetic
aortic valve, which is commonly shadowed by the valve on
TEE. TTE also allows measurement of aortic transvalvular
velocity/gradient, which is not always possible on TEE.
Although TTE will not definitely exclude vegetations or ab-
scesses in IE, it can identify very high-risk patients and
establish the diagnosis as well as guide early treatment de-
cisions (Figure 8).
Supporting References: 655,660-664
Class I
5. TEE is recommended in all patients with known or suspected IE
when TTE is nondiagnostic, when complications have developed
or are clinically suspected, or when intracardiac device leads are
present.662,665-672 (Level of Evidence: B)
The sensitivity of TEE in NVE ranges from 90% to
100%, with sensitivity ranges slightly lower in PVE. The
positive predictive value for TEE in both NVE and PVE
is 90%. TEE is superior to TTE in the visualization
of both vegetations and perivalvular complications, which
can be anatomic or hemodynamic in nature. Examples of
such complications include valve perforation, abscesses,
and pericardial effusion. Hemodynamic complications
may include valve regurgitation, fistulae, and intracardiac
thrombi. TEE is now considered the most reliable noninva-
sive test for defining this disease. However, it may notrdiovascular Surgery c Volume 148, Number 1 e77
TABLE 24. Diagnosis of IE according to the proposed modified duke
criteria
Definite IE
Pathological criteria
 Microorganisms demonstrated by culture or histologic examination of a
vegetation, a vegetation that has embolized, or an intracardiac abscess
specimen; or
 Pathological lesions: vegetation or intracardiac abscess confirmed by
histological examination showing active endocarditis
Clinical criteria
 2 major criteria; or
 1 major criterion and 3 minor criteria; or
 5 minor criteria
Possible IE
 1 major criterion and 1 minor criterion; or
 3 minor criteria
Rejected
 Firm alternate diagnosis explaining evidence of IE; or
 Resolution of IE syndrome with antibiotic therapy for<4 d; or
 No pathological evidence of IE at surgery or autopsy, with antibiotic
therapy for<4 d; or
 Does not meet criteria for possible IE as listed above
IE, Infective endocarditis.642,644
TABLE 25. Major andminor criteria in the modified duke criteria for
the diagnosis of IE
Major Criteria
1. Blood culture positive for IE
Typical microorganisms consistent with IE from 2 separate blood cultures:
 Viridans streptococci, Streptococcus bovis, HACEK group
(Haemophilus spp., Actinobacillus actinomycetemcomitans,
Cardiobacterium hominis, Eikenella spp., and Kingella kingae),
Staphylococcus aureus; or community-acquired enterococci, in the
absence of a primary focus; or
Microorganisms consistent with IE from persistently positive blood
cultures, defined as follows:
 At least 2 positive cultures of blood samples drawn 12 h apart; or
 All of 3 or a majority of4 separate cultures of blood (with first and last
samples drawn at least 1 h apart)
 Single positive blood culture for Coxiella burnetii or antiphase I IgG
antibody titer>1:800
2. Evidence of endocardial involvement
 Echocardiogram positive for IE defined as follows:
B Oscillating intracardiac mass on valve or supporting structures, in
the path of regurgitant jets, or on implanted material in the absence
of an alternative anatomic explanation;
B Abscess; or
B New partial dehiscence of prosthetic valve
 New valvular regurgitation (worsening or changing of pre-existing
murmur not sufficient)
Minor Criteria
1. Predisposition, predisposing heart condition, or injection drug use
2. Fever, temperature>38C (100.4F)
3. Vascular phenomena, major arterial emboli, septic pulmonary infarcts,
mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages,
and Janeway lesions
4. Immunologic phenomena: glomerulonephritis, Osler’s nodes, Roth’s
spots, and rheumatoid factor
5. Microbiological evidence: positive blood culture but does not meet a
major criterion as noted above* or serological evidence of active
infection with organism consistent with IE
C, Celsius; F, Fahrenheit; IE, infective endocarditis; spp, species; TEE, transesopha-
geal echocardiography; TTE, transthoracic echocardiography.642,644 *Excludes single
positive cultures for coagulase-negative staphylococci and organisms that do not
cause IE.
Clinical Guidelines Nishimura et aldifferentiate between active and healed vegetations andmay
not discriminate between thickened valves or valvular nod-
ules and vegetations. TTE and TEE are complementary for
the comprehensive evaluation of hemodynamics and anat-
omy in patients with IE. Because TEE has a higher sensi-
tivity in detecting anatomic complications, it should be
used as an adjunct in patients with echocardiographic fea-
tures of IE on TTE to rule out the presence of findings
such as abscesses, which may alter the therapeutic approach
to themanagement of the patient. TEE also serves a vital role
in reassessment of patients with known IE with suspected
clinical complications as well as a guiding tool in the intra-
operative assessment and management of the IE patient.
The number, type, and timing of repeat examinations
depend on the clinical presentation and course as well as
the virulence of the microorganism. Vegetation size at diag-
nosis has clearly identified a higher risk of death in prospec-
tive studies. Additionally, 1 study has shown that failure to
decrease vegetation size with antibiotic treatment was asso-
ciated with an increased risk of embolism. Another study
demonstrated that most vegetations (83.8%) remain con-
stant in size under therapy and that this does notworsen prog-
nosis. In this study, both increase of vegetation size under
antibiotic therapy (observed in 10.5% of patients with IE)
and reduction of vegetation size under therapy were associ-
atedwith an increased embolic risk. Thus, increasing vegeta-
tion size under therapy must be considered a risk factor for
new embolic events, whereas unchanged or reduced vegeta-
tion size under therapy may be more difficult to interpret.
ComparedwithTTE,TEE ismore sensitive for detectionof
vegetations and thrombi associated with device leads. Theree78 The Journal of Thoracic and Cardiovascular Surgare emerging data that intracardiac echocardiography may
be an increasingly useful tool to diagnose vegetations that
may be present on right-sided pacemaker leads. It has shown
superior sensitivity over TEE in identifying these lesions.
Supporting References: 664,670,673-681
Class I
6. TTE and/or TEE are recommended for re-evaluation of patients
with IE who have a change in clinical signs or symptoms (eg, new
murmur, embolism, persistent fever, HF, abscess, or atrioventric-
ular heart block) and in patients at high risk of complications (eg,
extensive infected tissue/large vegetation on initial echocardiogram
or staphylococcal, enterococcal, fungal infections).679,682 (Level of
Evidence: B)
HF, perivalvular extension, and embolic events represent
the 3 most frequent and severe complications of IE. Theyery c July 2014
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performed in almost 50% of cases. If signs or symptoms
consistent with any of these complications exist, there
should be a very low threshold for repeat imaging in these
patients. TEE may miss initial paravalvular abscesses,
particularly when the study is performed early in the pa-
tient’s illness. In such cases, the incipient abscess may be
seen only as nonspecific paravalvular thickening, which
on repeat imaging across several days may become recog-
nizable as it expands and cavitates. Similarly, paravalvular
fistulae and pseudoaneurysms develop over time, and nega-
tive early TEE images do not exclude the potential for their
development. For patients who have IE that was diagnosed
by clinical, microbiological, or surgical criteria but for
whom results of initial TEE were false-negative, repeated
TEE has often demonstrated vegetative IE. Thus, it appears
that a single negative TEE study cannot rule out underlying
IE and that a repeat TEE study should be performed when a
suspicion of persistence of infection remains or if
complications ensue. Conversely, in the absence of clinical
deterioration or new signs/symptoms, routine follow-up
echocardiography is probably of only limited clinical
utility.
Supporting References: 52,630,665,683-685
Class I
7. Intraoperative TEE is recommended for patients undergoing valve
surgery for IE.686,687 (Level of Evidence: B)
Intraoperative TEE during cardiac surgery plays an
important role in the evaluation and quality control of
a large variety of pathologies. Clinical and echocardio-
graphic characteristics may change during an episode of
IE because of the prolonged active phase and fluctuating
course of this disease. Even if preoperative TEE has been
performed, the possibility of vegetation change/emboliza-
tion or extension of the infectious process beyond the
valve tissue may occur. In addition, other valves may
become involved as the disease timeline progresses. Intrao-
perative TEE has been invaluable for baseline reassessment
of anatomical/hemodynamic changes that may occur in the
interval between the diagnostic echocardiogram and the
time of surgery. TEE is also an important monitoring tool
for evaluation of operative complications such as air emboli
and an important adjunct to ensure the quality of the in-
tended surgical result.
Supporting References: 688,689
Class IIa
1. TEE is reasonable to diagnose possible IE in patients with Staphylo-
coccal aureus (S aureus) bacteremia without a known source.690-692
(Level of Evidence: B)
IE in patients with S aureus bacteremia frequently in-
volves normal cardiac valves and is seldom accompanied
by the physical stigmata of IE, rendering the diagnosis ofThe Journal of Thoracic and Cathe disease difficult. Reliance on physical examination find-
ings and clinical stigmata is likely to result in underdiagno-
sis of S aureus IE in a large number of cases. TEE is
cost-effective to guide duration of therapy in patients with
intravascular catheter-associated S aureus bacteremia, pa-
tients with intracardiac electronic devices, or other patients
at higher risk for IE (including those with previous pros-
thetic valve surgery) or associated complications.
Despite early diagnosis and appropriate therapy, IE
following S aureus bacteremia is frequently associated
with disabling and life-threatening sequelae. The overall
mortality of S aureus IE ranges from 19% to 65%. Other
complications include HF (20% to 50%), paravalvular car-
diac abscesses (30% to 40%), neurological manifestations
(30%), and systemic embolization (40%).
Supporting References: 652,677,693,694
Class IIa
2. TEE is reasonable to diagnose IE of a prosthetic valve in the pres-
ence of persistent fever without bacteremia or a newmurmur.695,696
(Level of Evidence: B)
When compared with NVE, PVE is characterized by
a lower incidence of vegetations (especially in mechanical
prostheses) and a higher incidence of annular abscess and
other paravalvular complications. Because cardiac auscul-
tation may also be less revealing in PVE and because ordi-
narily less virulent organisms may cause more anatomic
destruction before culture or serological detection, it is
important to use TEE early in these high-risk patients.
TEE has a lower sensitivity in detecting prosthetic IE
when compared with TEE detection rates in NVE, so the
importance of comparing serial echocardiographic studies
is paramount to making the diagnosis.
Supporting References: 697,698
Class IIa
3. Cardiac CT is reasonable to evaluate morphology/anatomy in the
setting of suspected paravalvular infections when the anatomy
cannot be clearly delineated by echocardiography.678,699-701 (Level
of Evidence: B)
Electrocardiographic-synchronized, multidetector-row
CT is emerging as an important tool for noninvasive cardiac
assessment and may be helpful in evaluating complications
of IE. CT may also be indicated in right-sided IE to demon-
strate the presence of septic pulmonary infarcts and ab-
scesses. Although CT is less accurate than TTE and TEE
for identifying valvular vegetation and valvular perfora-
tions, CT is useful for evaluating patients with equivocal
findings on TEE and for evaluating complications in pa-
tients with suspected myocardial, pericardial, and coronary
sinus extension of the infectious process. CT can also more
sensitively detect paravalvular abscess involvement and
evaluate extent and anatomic consequences of pseudoa-
neurysms and their relationship to adjacent structures. CTrdiovascular Surgery c Volume 148, Number 1 e79
Clinical Guidelines Nishimura et alimaging is particularly useful in preoperative evaluation of
patients with aortic valve IE to evaluate coronary artery and
aortic involvement.
In suspected PVE, cardiac CT is less affected by the shad-
owing of mechanical valves or bioprosthetic valve sewing
rings than ultrasound. CT also allows evaluation of motion
of mechanical valve occluders and provides visualization of
thrombus or infective material limiting valve occluder
motion. Additional imaging modalities such as cardiac
valvular fluoroscopy can be an adjunct to other clinical
and imaging information to detect the presence of obstruc-
tive disease of mechanical prosthetic valves affected by IE.
Normative values for the opening and closing angles are
known for the common valves available for patient use. A
combination of cineradiography and echocardiography
makes it possible to provide an accurate and detailed deter-
mination of the degree and extent of valvular obstruction
that may accompany mechanical PVE.
Supporting References: 699,702-706
Class IIb
1. TEE might be considered to detect concomitant staphylococcal IE
in nosocomial S aureus bacteremia with a known portal of entry
from an extracardiac source.663,707,708 (Level of Evidence: B)
Because the frequency of IE among patientswith S aureus
bacteremia is reported to be approximately 30%, with many
cases not being clinically suspected, TEE should generally
be pursued in the setting of S aureus bacteremia to rule out
IE. Even in S aureus bacteremia from a known extracardiac
source, such as an infected joint or joint prosthesis, TEE
might be considered. given known cases of seeding of valve
tissue in this type of setting. Possible exceptions are patients
who have no underlying cardiac predisposing conditions or
clinical signs of IE whose fever and bacteremia resolve
within 72 hours after removal of a likely infected focus
(such as intravascular catheter removal). In the absence of:
(1) prolonged bacteremia>4 days; (2) a permanent intracar-
diac device; (3) hemodialysis dependency; and (4) spinal
infection or nonvertebral osteomyelitis, the risk of IE is rela-
tively low, and routine TEE may not be necessary.
Supporting References: 663,691,692,709
12.2.2. Medical Therapy: Recommendations
See Online Data Supplement 24 for more information on
surgical outcomes.
Class I
1. Appropriate antibiotic therapy should be initiated and continued
after blood cultures are obtained with guidance from antibiotic
sensitivity data and infectious disease consultants.636 (Level of Evi-
dence: B)
Optimal treatment of IE is based on the appropriately
timed initiation of antimicrobial therapy that is effective
against the specific infective organism involved. Empirical
therapy may be necessary in patients with septic shock ore80 The Journal of Thoracic and Cardiovascular Surgwho show high-risk signs on presentation; however, tar-
geted antimicrobial therapy guided by minimum inhibitory
concentration is the goal. The minimum inhibitory concen-
tration is used to determine the antibiotic dosage that the pa-
tient will receive and the type of antibiotic used and can
lower the opportunity for microbial resistance to specific
antimicrobial agents. Prompt use of antibiotics significantly
reduces the incidence of emboli in patients with IE. Dura-
tion of therapy needs to be guided by those with expertise
in the field of antibiotic therapy. Although no RCTs have
been performed with the use of antibiotic therapy in IE,
the mortality rate before the antibiotic age neared 100%.
Despite advances in knowledge of mechanism of therapeu-
tic approaches to treating infections and despite a signifi-
cant expansion of the antimicrobial armamentarium, the
emergence of resistant organisms has led to continued
complexity in the approach to patients with systemic infec-
tions. Antimicrobial therapy for NVE and PVE should be
guided by the susceptibility profile of the causative organ-
ism. Specific antimicrobial regimens, depending on the
causative microorganism, have been published by the
British Society for Antimicrobial Chemotherapy and the
AHA. Given the ever-changing spectrum of antimicrobial
sensitivity, as well as regional and site-specific differences
in antimicrobial susceptibility profiles, concomitant man-
agement with the assistance of a consultant thoroughly
familiar with these patterns is imperative.
Supporting References: 633,634,636,710-713
Class IIa
1. It is reasonable to temporarily discontinue anticoagulation in pa-
tients with IE who develop central nervous system symptoms
compatible with embolism or stroke regardless of the other indica-
tions for anticoagulation.714-719 (Level of Evidence: B)
There are several potential mechanisms of stroke in pa-
tients with IE, including hemorrhagic transformation of
an ischemic infarct, septic erosion of an arteritic vessel
without aneurysm formation, and rupture of a mycotic
aneurysm. Approximately 15% to 35% of all patients
with IE develop clinically evident systemic emboli. If
more sensitive tests such as cerebral magnetic resonance
imaging are used, a much higher proportion of patients
with IE have evidence of emboli (30%). The most com-
mon cause of stroke in patients with IE in the modern anti-
microbial era is a septic embolus resulting in ischemia,
often followed by hemorrhagic transformation. Anticoagu-
lant therapy may increase the risk of an embolic infarct
converting to a hemorrhagic infarct. Hemorrhagic transfor-
mations can occur up to 11 days after an initial infarct. On
the other hand, the longer anticoagulation is withheld, the
higher the chance of recurrent embolization or valve
dysfunction in patients with PVE. The beneficial or
deleterious effect of anticoagulation in patients with IE is
determined by a multitude of clinical, bacteriologic,ery c July 2014
Nishimura et al Clinical Guidelinesradiological, and echocardiographic variables that may tilt
the balance of the risk toward early recurrent stroke or intra-
cranial hemorrhage. Patients with IE and a cerebral embo-
lism or stroke should be referred to a center with a
multispecialty Heart Valve Team. A specialist in the field
of neurology and/or neuroradiology should be added to
this team when the complication of stroke arises in IE.
The risk of bleeding complications should be included in
the assessment of patients with IE receiving anticoagulation
treatment.
Supporting References: 12,720-726
Class IIb
1. Temporary discontinuation of VKA anticoagulation might be
considered in patients receiving VKA anticoagulation at the time
of IE diagnosis.715,727-730 (Level of Evidence: B)
In patients with NVE, routine use of VKA is not recom-
mended unless a separate indication exists. There is no
conclusive evidence that prophylactic use of VKA anticoa-
gulation reduces the incidence of emboli in patients with
NVE who have no other indication for anticoagulation.
Alternatively, for patients already receiving anticoagula-
tion with VKA or aspirin for other evidence-based indica-
tions at the time of diagnosis with IE, there is little
information on the risks and benefits of continued anticoa-
gulation therapy. Continuing anticoagulant therapy in the
face of IE potentially increases the risk of hemorrhagic
transformation of an embolic stroke or accentuation of
bleeding from septic arteritis or mycotic aneurysms should
they occur. The evidence and propensity of expert
consensus would suggest that VKAs be discontinued at
the time of initial presentation with IE secondary to the
combined risk of bleeding from potentially urgent invasive
procedures and the risk of developing hemorrhagic stroke.
Early surgery is required in roughly 50% of patients with
PVE. Although there is no evidence regarding the use of
bridging therapy with intravenous or subcutaneous antico-
agulant therapy while patients are off VKAs, studies indi-
cate that there is increased risk of hemorrhagic stroke in
patients on intravenous UFH during the acute phase
of acute IE. It should be noted that the strength of this evi-
dence is low, and some institutional practices continue
VKA anticoagulation until an invasive procedure is deemed
a definitive necessity or until a neurological complication
develops or is noted on imaging studies. Decisions about
continued anticoagulation and antiplatelet therapy should
ultimately be directed by the patient’s consulting cardiolo-
gist and cardiothoracic surgeon in consultation with a
neurology specialist if neurological findings are clinically
present or noted on imaging. Although there is no strong ev-
idence base for screening neurological imaging studies and
their potential impact on management, the data are strong
that subclinical neurological abnormalities are common,
occurring in 25% of patients with IE and S aureus and upThe Journal of Thoracic and Cato 55% of critically ill patients with IE. In patients with
valvular or nonvalvular indications for continued use of
VKAs, strong consideration should be given to cerebral
magnetic resonance imaging to evaluate for subclinical ce-
rebrovascular complications to help guide anticoagulation
management. Novel oral anticoagulants have no indication
for VHD.
In patients with IE, routine antiplatelet therapy is not rec-
ommended unless a separate indication exists. There is no
evidence that routine use of aspirin in the setting of IE re-
duces risk of embolic stroke in patients who are already
receiving antibiotic therapy. However, large retrospective
studies have suggested that embolism associated with IE oc-
curs less frequently among patients who have received
continuous daily antiplatelet therapy for other indications
before the diagnosis of IE.
Supporting References: 12,728-735
Class III: Harm
1. Patients with known VHD should not receive antibiotics before
blood cultures are obtained for unexplained fever. (Level of Evi-
dence: C)
Two sets of blood cultures are the minimum for a secure
microbiological diagnosis of IE. The leading cause of ‘‘cul-
ture-negative IE,’’ which can be a significant clinical conun-
drum, is the use of antibiotics before blood cultures are
obtained. Negative blood cultures in the setting of IE can
delay diagnosis by slowing other serological and polymer-
ase chain reaction assessments; therefore, it can delay defin-
itive treatment of the patient as well as impair determination
of antimicrobial treatment duration. The identification of
the causative pathogen will improve the specificity of the
therapeutic regimen and may significantly improve patient
outcome. S aureus is the most common pathogen respon-
sible for PVE but still accounts for only 23% of cases. Anti-
biotic therapy is most effective if the identity and
sensitivities of the responsible organism are known.
Supporting References: 724,736,73712.2.3. Intervention: Recommendations
See Figure 9 for diagnosis and treatment of IE and Online
Data Supplement 24 for more information on surgical
outcomes.
Class I
1. Decisions about timing of surgical intervention should be made by a
multispecialty Heart Valve Team of cardiology, cardiothoracic sur-
gery, and infectious disease specialists.651 (Level of Evidence: B)
The in-hospital mortality rate for IE is high, at 15% to
20%, with 1–year mortality approaching 40%. Given those
rates and the complexities and uncertainties about surgical
timing/indications related to comorbid conditions in many
of these patients, it is recommended that patients with IE
be managed in an environment with ready access tordiovascular Surgery c Volume 148, Number 1 e81
Clinical Guidelines Nishimura et alspecialists in the fields of cardiology, cardiothoracic surgery,
and infectious disease. Cardiothoracic surgical consultation
should be obtained rapidly after the diagnosis of IE. A risk-
scoring system using the STS database has been developed
to predict risk of surgery in patients with IE to help better
counsel patients and more objectively define risks of sur-
gery. One trial noted that even when surgery is indicated,
women were less likely to undergo a surgical procedure
than men (26% vs 47%) and that women had higher in-
hospital and 1–year mortality rates than men despite similar
comorbidities. To prevent subjective bias in decisionmaking
for patients, it is recommended that hospitals use systempol-
icies to ensure best practices in patients with IE.
Supporting References: 738-740
Class I
2. Early surgery (during initial hospitalization before completion of
a full therapeutic course of antibiotics) is indicated in patients
with IE who present with valve dysfunction resulting in symptoms
of HF.741-746 (Level of Evidence: B)
Death may occur suddenly in patients with endocarditis-
induced HF, particularly if the aortic valve is involved. The
ICE-PCS (International Collaboration on Endocarditis-
Prospective Cohort Study) has reported a 21% in-hospital
mortality rate in patients with IE with HF treated with sur-
gery versus a 45% mortality rate in those who were medi-
cally treated. One-year mortality in this study was 29.1%
in patients undergoing valvular surgery versus 58.4% in
those not undergoing surgery. In complicated left-heart
NVE, 4 baseline features have been independently associ-
ated with 6–month mortality: abnormal mental status,
moderate-to-severe HF, bacterial etiology other than Viri-
dans streptococci, and medical therapy without valve sur-
gery. This risk stratification system has been validated in
a separate cohort, and similar findings have been repro-
duced in both retrospective propensity studies and prospec-
tive studies. Prompt surgical consultation should be
obtained in all cases of IE to assist with assessment of the
need for surgical treatment and to help judge the timing
of surgery. Further prospective randomized studies with
large study populations are necessary to more precisely
evaluate the optimal timing of surgery in patients
with NVE.
Reinfection after prosthetic valve surgery (which occurs
in 5% to 10% of patients, with a significant percentage
of these being injectable drug users) is low relative to the
risk of no surgery in patients with hemodynamic and micro-
bial indications for surgery. Repair rather than replacement
of a valve is always best; however, such repairs are possible
in only a minority of cases, such as when a leaflet perfora-
tion occurs without extensive leaflet destruction or annular
involvement. PVE is clearly associated with both higher
mortality rates (especially if associated with a new murmur,
HF, or severe valvular dysfunction or if the infectiouse82 The Journal of Thoracic and Cardiovascular Surgmicrobe is staphylococcal or fungal) and higher post-
treatment HF-related disability. Most surgical series report
a surgical rate of nearly 50% in patients with PVE. Up to
20% more would benefit from surgery if it were not for
an already developed catastrophic complication. Surgical
debridement and replacement of the infected prosthetic
valve lead to significantly lower mortality (23%) compared
with medical therapy alone (56%). Improved outcome was
seen for the surgical group even when controlling for
severity of illness at time of diagnosis. In a series of
1,025 patients with PVE, early surgery did not reduce
in-hospital or 1–year mortality when adjusted for the pro-
pensity to operate and the effect of survivor bias. However,
subgroup analysis indicated that patients with the strongest
indications for surgery (new left-sided valve regurgitation,
paravalvular abscess or fistula, prosthetic valve dehiscence,
or HF) did have a lower 1–year mortality rate with early sur-
gery (27.9% vs 50.0%; P ¼ .007).
PVE is classified into ‘‘early-,’’ ‘‘intermediate-,’’ and
‘‘late-’’ onset PVE. Early-onset PVE is defined as occurring
within the first 60 days of surgery and is typically associated
with healthcareacquired infection, with the most common
microbe during this time frame being S aureus.
Intermediate-onset PVE occurs between 60 and 365
days after surgery and is associated with a mix of both
healthcareacquired infection and community-acquired
infection. The most common microbe implicated in
intermediate-onset PVE is coagulase-negative Staphylo-
coccus. Two thirds of all reported cases of PVE occur within
the first year of valve surgery. Late-onset PVE is defined as
occurring>1 year after surgery. Although S aureus and
coagulase-negative Staphylococcus remain important in-
fecting agents, the late-onset PVE microbial spectrum
more closely resembles that of NVE.
Supporting References: 635,724,747-751
Class I
3. Early surgery (during initial hospitalization before completion of a
full therapeutic course of antibiotics) is indicated in patients with
left-sided IE caused by S aureus, fungal, or other highly resistant or-
ganisms.746,752-758 (Level of Evidence: B)
In the United States, 34% of NVE cases are due to S
aureus. Compared with patients with IE due to other organ-
isms, patients with S aureus IE were significantly more
likely to die (20% vs 12%), experience an embolic event
(60% vs 31%), have a central nervous system event
(20% vs 13%), and not undergo surgery (26% versus
39%). Although mortality rates are lower in patients
with methicillin-sensitive S aureus, the rate of embolic
events is even higher than that of methicillin-resistant S
aureus. Factors involved in the higher modern rates of S
aureus IE are a low prevalence of rheumatic heart disease
(therefore an older, less immunocompetent population
with underlying degenerative VHD), a larger populationery c July 2014
FIGURE 9. Diagnosis and treatment of IE. *Early surgery defined as during initial hospitalization before completion of a full therapeutic course of anti-
biotics. HF, Heart failure; ICD, implantable cardioverter-defibrillator; IE, infective endocarditis; NVE, native valve endocarditis; PVE, prosthetic valve en-
docarditis; Rx, therapy; S aureus, Staphylococcus aureus; TEE, transesophageal echocardiography; TTE, transthoracic echocardiography; VKA, vitamin K
antagonist.
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and a higher rate of prolonged use of an intravascular de-
vice. In hospital-acquired IE, the mortality rate has been re-
ported to be 2 times that of community-acquired IE, largely
due to resistant staphylococcal and enterococcal species.
Certain pathogens, such as Pseudomonas aeruginosa, Bru-
cella, fungi, and gram-positive cocci (especially those that
are resistant to beta-lactam antibiotics or vancomycin) are
extremely difficult to cure with medical therapy alone.
Many of these organisms are also prone to abscess/fistula
formation and other cardiac tissue destruction, which
cannot be effectively treated with medical therapy alone.
Despite high-quality imaging using 2D and even 3D TEE,
false-negative findings for intracardiac abscess are as high
as 60%. Similar to studies in S aureus IE, the mortality
rate is significantly lower in patients treated with antifungal
agents combined with surgery compared with those treated
with antifungal agents alone (42% vs 59%).
An important distinction ismade for injectable drug users.
When Staphylococcus is the bacteria, death occurs in<5%
of patients with right-sided NVE; however, in left-sidedThe Journal of Thoracic and CaNVE with the same organism, death ensues in 20% to
30% of cases. In injectable drug users with NVE, Entero-
coccus sp carries a mortality rate of 15% to 25%. Pseudo-
monas aeruginosa, Enterobacteriaceae, and fungi, though
rare, carry an overall mortality rate of>50% in this popula-
tion. Coexisting conditions that increase mortality in inject-
able drug users include HF, neurological events, renal
failure, and symptomatic HIV infection. Given the high
nonsurgical cure rates of right-sided IE combined with the
significant concern of reinfection of prosthetic material in
surgical intervention, an even more coordinated effort of
surgical and nonsurgical experts in management of NVE is
necessary for injectable drug users.
Staphylococcal PVE has been associated with a mortality
rate as high as 70%. Given the difficulty in eradicating
Staphylococcus spp when foreign and avascular material
are involved in the infection, survival rates are significantly
higher in patients who undergo surgical debridement and
have the infected valve removed and replaced. Mortality
rates remain higher in this group of patients whether treated
surgically or not when compared with every other categoryrdiovascular Surgery c Volume 148, Number 1 e83
Clinical Guidelines Nishimura et alof IE aside from fungal infections. Pseudomonas aerugi-
nosa and multiresistant enterococci, for which there is no
synergistic bactericidal regimen, are also less amenable to
medical therapy.
Supporting References: 652,724,747,753,759-766
Class I
4. Early surgery (during initial hospitalization before completion of a
full therapeutic course of antibiotics) is indicated in patients with IE
complicated by heart block, annular or aortic abscess, or destruc-
tive penetrating lesions.746,767-771 (Level of Evidence: B)
Abscess of the native valves or paravalvular structures
with or without extension to the cardiac conduction system
is a life-threatening complication that cannot be cured with
antibiotic therapy alone. Early recognition and institution of
appropriate medical and surgical therapy is necessary for
patient survival. Complete heart block in IE usually occurs
secondary to extension of infection into the atrioventricular
node. Heart block is most commonly associated with aortic
valve IE, given the high prevalence of paravalvular exten-
sion and the proximity of the conduction system to the valve
(although it has also been reported in mitral and tricuspid
valve IE) and is associated with an increased risk for sudden
cardiac death and more severe anatomical destruction of
cardiac tissues. Extensive perivalvular infections (to
include annular/aortic abscesses and destructive penetrating
lesions/fistulae) respond poorly to medical therapy and are
associated with a mortality rate of40%. Patients with par-
avalvular abscess are typically very ill by the time they are
referred for surgery. Even so, the long-term results of sur-
gery are very satisfactory, with an actuarial survival rate
of 75%6% at 5 years. Freedom from recurrent IE has
been reported to be 76% at 8 years. The 2 primary objec-
tives of surgery are total removal of infected tissues and
reconstruction of functional anatomy. Surgical series have
shown that the surgical results are more related to a sur-
geon’s ability to remove all infected tissues than to the
type of valve used for a replacement.
Patients with PVE complicated by paravalvular invasion,
as manifested by intracardiac abscesses, fistulae, or heart
block, experience high mortality rates and are rarely cured
by medical treatment alone. By contrast, surgical series
have reported surgical survival rates of 71% in this high-
risk group.
Supporting References: 724,772-775
Class I
5. Early surgery (during initial hospitalization before completion of a
full therapeutic course of antibiotics) for IE is indicated in patients
with evidence of persistent infection as manifested by persistent
bacteremia or fevers lasting longer than 5 to 7 days after onset of
appropriate antimicrobial therapy.746,756,757,776-778 (Level of
Evidence: B)
Blood cultures will typically become negative after 48
hours of appropriate antimicrobial therapy; however, ine84 The Journal of Thoracic and Cardiovascular Surgmethicillin-resistant S aureus and other resistant organ-
isms, it may take up to a week for cultures to become
negative. An ongoing infection despite antibiotic therapy
is common with aggressive micro-organisms, abscess
formation, or large vegetations. In some patients, the
only evidence of persistent infection is an elevated white
blood cell count or fevers that persist longer than 5 to 7
days. In patients with persistent bacteremia despite
appropriate susceptibility-based therapy, the clinician
must consider surgical adjunctive therapy based on mul-
tispecialty input and guidance from serial TEE and other
imaging data. Detection of abscess by TEE can be
missed in the presence of calcification in the posterior
mitral annulus or because of echocardiography artifact
from prosthetic material. CT imaging may be helpful
in this situation. Early surgery has been shown to
improve outcome in patients with an abscess. Addition-
ally, patients with persistent sepsis are at high risk of
developing multiorgan failure, and surgery may be
needed in these patients to debride infected/necrotic tis-
sues to effectively eradicate the infection. Predictors of
in-hospital mortality in patients with PVE include older
age, healthcare-associated infection, S aureus infection,
HF, stroke, intracardiac abscess, and persistent bacter-
emia. Some caution is advised in patients who develop
recurrent fever after an initially successful response to
antibiotics, because the fever could be explained by
other reasons than the endocarditic valve.
Supporting References: 724,746,747,777,779
Class I
6. Surgery is recommended for patients with PVE and relapsing infec-
tion (defined as recurrence of bacteremia after a complete course of
appropriate antibiotics and subsequently negative blood cultures)
without other identifiable source for portal of infection. (Level of Ev-
idence: C)
TEE has a reduced sensitivity for detection of abscess in
patients with prosthetic valves. If there is suspicion by a
team of cardiologists, cardiothoracic surgeons, and infec-
tious disease specialists that relapsing infections may be
due to incomplete sterilization of valvular or paravalvular
tissue secondary to a deep tissue infection, it is reasonable
to consider surgery in this situation. In the absence of
other indications for intervention, such as severe valve
dysfunction or a resistant organism, the timing of
surgical intervention cannot be strictly defined in these sit-
uations. Because the possibility of ‘‘reseeding’’ a prosthetic
valve has been reported in the setting of infection from
an origin separate from the heart, careful assessment for
the possibility of reintroduction of an infectious microbe
from another portal should be thoroughly ruled out in these
instances before consideration of cardiac surgical
reintervention.
Supporting Reference: 746ery c July 2014
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7. Complete removal of pacemaker or defibrillator systems, including
all leads and the generator, is indicated as part of the early manage-
ment plan in patients with IE with documented infection of the de-
vice or leads.780-783 (Level of Evidence: B)
Complete device and lead removal is recommended
for all patients with cardiac device infection, even if evi-
dence for infection appears to be limited to the generator
pocket site. A prospective cohort study using data from
ICE-PCS showed that among patients with cardiac device
IE, the rates of both concomitant valve infection andmortal-
ity are high, particularly if there is valve dysfunction.
Optimal therapy for cardiac device IE combines complete
device extraction and a prolonged course of parenteral anti-
biotics. A proportional hazards regression analysis showed
a survival benefit at 1 year for device removal during the
initial hospitalization; 28 of 141 patients (19.9%) who un-
derwent device removal during the index hospitalization
had died at 1 year versus 13 of 34 (38.2%) who did not un-
dergo device removal (HR: 0.42; 95% CI: 0.22 to 0.82).
Supporting References: 681,784-786
Class IIa
1. Complete removal of pacemaker or defibrillator systems, including
all leads and the generator, is reasonable in patients with valvular
IE caused by S aureus or fungi, even without evidence of device
or lead infection.780-783 (Level of Evidence: B)
The likelihood of underlying cardiac device infection
in a patient with S aureus bacteremia is relatively high
(approximately 30% to 40%) and is also likely in pa-
tients with fungal valvular IE. In patients with a normal
pocket site, it is difficult to determine if the device
should be removed. If there is evidence of valvular endo-
carditis on TEE, then the device should be removed. If
there is a lead mass without a valve lesion, device
removal has been advocated by some based on ‘‘lead en-
docarditis.’’ However, the writing committee noted that
the likelihood of finding a clot on a lead in noninfected
patients can range from 1% to 50% of patients undergo-
ing TEE.
The likelihood of underlying cardiovascular implantable
electronic device infection in someone with bacteremia due
to gram-negative bacilli is much less. Therefore, if the
pocket site appears normal, device removal is generally
not required for an initial episode of bacteremia.
Supporting References: 781,785,787
Class IIa
2. Complete removal of pacemaker or defibrillator systems, including
all leads and the generator, is reasonable in patients undergoing
valve surgery for valvular IE. (Level of Evidence: C)
In patients with an intracardiac lead who are undergoing
prosthetic valve replacement for valvular IE, the device and
lead might serve as a nidus for recurrent infection becauseThe Journal of Thoracic and Cainfection of the leads may be present even without visible
vegetations. Removal of the entire device and leads reduces
the risk of reinfection.
Class IIa
3. Early surgery (during initial hospitalization before completion of a
full therapeutic course of antibiotics) is reasonable in patients with
IE who present with recurrent emboli and persistent vegetations
despite appropriate antibiotic therapy.655,788,789 (Level of
Evidence: B)
Early surgery is associated with a reduction in the rate
of embolic complications in patients who present with
left-sided IE, severe VHD, and large vegetations (>10
mm). Embolic events are a frequent and life-threatening
complication of IE. Embolism is associated with an
increased morbidity and mortality in IE and occurs in
20% to 40% of patients with IE. Embolic incidence de-
creases to 9% to 21% after initiation of antibiotic treat-
ment. Factors associated with a new embolic event are
vegetation size>10 mm in length and marked vegetation
mobility (especially when associated with the anterior
leaflet of the mitral valve). The risk of embolism is highest
during the first days after initiation of antibiotic treatment
and decreases after 2 weeks.
Patients with PVE who are most likely to benefit from
medical therapy without surgery are those with non
Staphylococcal PVE without complications or prosthetic
valve dysfunction, as well as those who remain clinically
stable and who show clinical improvement on antibiotic
treatment. Surgical intervention is especially beneficial in
patients with Staphylococcal PVE and complicated PVE,
of which recurrent embolization is identified as a
common type of major complication (>20% of patients in
all PVE studies).
Supporting References: 679,783,789-791
Class IIb
1. Early surgery (during initial hospitalization before completion of a
full therapeutic course of antibiotics) may be considered in patients
with NVE who exhibit mobile vegetations greater than 10 mm in
length (with or without clinical evidence of embolic phenome-
non).655,788,789 (Level of Evidence: B)
With NVE, large vegetation size is associated with
a markedly higher rate of embolic phenomenon. Embolic
events are also known to be causally associated with
higher rates of mortality in IE. In an RCT of surgical inter-
vention in patients with severe left-sided valve dysfunction
and vegetations>10 mm in length (even in the absence of
clinically apparent embolic events or HF), there was no
significant difference in all-cause mortality at 6 months
in the early-surgery versus the conventional-treatment
groups (3% and 5%, respectively; P ¼ .59); however,
there was a marked reduction in the number of embolic
events, 0% in the early-surgery group compared with
21% in the conventional-treatment group (P ¼ .005).rdiovascular Surgery c Volume 148, Number 1 e85
Clinical Guidelines Nishimura et alAdditionally, 77% of the conventional group required sur-
gery in the initial hospitalization or during the follow-up
phase secondary to HF, paravalvular extension, and heart
block.
Supporting References: 652,789
13. PREGNANCYAND VHD
13.1. Native Valve Stenosis: RecommendationsClass I
1. All patients with suspected valve stenosis should undergo a clinical
evaluation and TTE before pregnancy. (Level of Evidence: C)
Patients with severe valve stenosis tolerate the hemody-
namic changes of pregnancy poorly. The increased cardiac
output, increased heart rate, and decreased afterload that
occur during pregnancy may all contribute to hemody-
namic decompensation in the presence of severe valve ste-
nosis. Thus, it is critical to identify patients who may have
suspected valve stenosis before pregnancy, because this
finding may have important implications for therapy
before conception as well as management during preg-
nancy and delivery. The most common etiology of AS in
women of childbearing age in developed countries is a
congenitally abnormal unicuspid or bicuspid valve, which
can be associated with an aortopathy. In these patients, it
is important to determine the size of the aorta before preg-
nancy, because those with a dilated aorta may be at
increased risk for further dilation during pregnancy. A
comprehensive TTE and Doppler echocardiogram should
be performed before pregnancy to diagnose the presence
of valve stenosis, severity of stenosis, and hemodynamic
consequence of the stenosis.
Supporting References: 792-794
Class I
2. All patients with severe valve stenosis (stages C and D) should un-
dergo prepregnancy counseling by a cardiologist with expertise
in managing patients with VHD during pregnancy. (Level of Evi-
dence: C)
The management of patients with valve stenosis should
ideally begin before conception. A complete assessment
of functional capacity, severity of stenosis, and the status
of the left ventricle and pulmonary pressures are necessary
to determine the risk of pregnancy and delivery in patients
with valve stenosis. The risks and benefits of proceeding
with pregnancy must be fully discussed with the patient. In-
terventions before pregnancy, such as valve replacement,
valve repair, or percutaneous aortic or mitral balloon dila-
tion should be considered, particularly in those patients
with severe stenosis, regardless of symptoms. Drugs with
potential harmful effects on the fetus must be identified.
If pregnancy is contemplated, arrangements should be
made for the patient to be monitored in a tertiary care centere86 The Journal of Thoracic and Cardiovascular Surgwith a dedicated Heart Valve Team of cardiologists, sur-
geons, anesthesiologists, and obstetricians who have exper-
tise in managing high-risk cardiac patients. Counseling
regarding all these areas should be performed by a cardiol-
ogist with expertise in managing patients with VHD during
pregnancy.
Supporting References: 792-794Class I
3. All patients referred for a valve operation before pregnancy should
receive prepregnancy counseling by a cardiologist with expertise in
managing patients with VHD during pregnancy about the risks and
benefits of all options for operative interventions, including me-
chanical prosthesis, bioprosthesis, and valve repair. (Level of Evi-
dence: C)
All prosthetic valve types pose major problems during
pregnancy. Patients with mechanical prostheses require
continued anticoagulation throughout pregnancy to prevent
valve thrombosis and systemic embolism. However, antico-
agulation has risks for both the mother and the fetus. Bio-
prostheses have a limited life span, particularly in the
younger patient, and controversy persists as to whether
there is acceleration of valve degeneration during preg-
nancy. Patients of childbearing age who undergo valve sur-
gery should be informed of the maternal and fetal risks of
anticoagulation, risk of mechanical valve thrombosis and
embolism, and risk of bioprosthetic valve degeneration dur-
ing pregnancy.
Supporting References: 793,795Class I
4. Pregnant patients with severe valve stenosis (stages C and D)
should be monitored in a tertiary care center with a dedicated
Heart Valve Team of cardiologists, surgeons, anesthesiologists,
and obstetricians with expertise in the management of high-risk
cardiac patients during pregnancy. (Level of Evidence: C)
Patients with severe stenosis are at high risk during
pregnancy. The risk increases throughout pregnancy,
given the continued hemodynamic changes, including
increased intravascular volume, decreased afterload,
and increased heart rate. Pulmonary edema, arrhyth-
mias, and even maternal death may occur. The presence
of severe valve stenosis is also associated with an
increased risk to the fetus. Management of pregnant pa-
tients with VHD requires that clinicians have knowl-
edge and experience in caring for these patients.
Cardiac diagnostics, hemodynamic monitoring, and pre-
vention of cardiovascular complications require exper-
tise beyond the standard obstetrical scope of practice.
Timing and mode of delivery should be discussed
jointly and carried out by the Heart Valve Team, with
close hemodynamic monitoring during and up to 24
hours after delivery.
Supporting References: 792-794ery c July 2014
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Class IIa
1. Exercise testing is reasonable in asymptomatic patients with
severe AS (aortic velocity 4.0 m per second or mean pres-
sure gradient 40 mm Hg, stage C) before pregnancy. (Level
of Evidence: C)
Patients with severe AS—particularly those who are
symptomatic—have an increased risk of sudden clinical
deterioration and even death during pregnancy. Exercise
testing is reasonable in asymptomatic patients with severe
AS before pregnancy to obtain an objective assessment of
exercise tolerance. Patients with symptoms provoked by
exercise testing should be considered symptomatic, espe-
cially if the clinical history is equivocal. These patients
should be treated for symptomatic severe AS and
cautioned against pregnancy or should undergo an inter-
vention such as AVR or percutaneous aortic balloon dila-
tion before conception. Although there are no data on the
prognostic value of other findings on exercise testing
before pregnancy, high-risk parameters on exercise testing
for nonpregnant patients include a limited exercise toler-
ance or a drop in BP.
Supporting References: 46,47,117,793,794
13.1.2. Medical Therapy: Recommendations
Class I
1. Anticoagulation should be given to pregnant patients with MS and
AF unless contraindicated. (Level of Evidence: C)
Systemic embolization may occur in up to 10% to 20%
of patients with MS, with the highest risk in patients
with AF. One third of embolic events occur within the first
month of the onset of AF. Anticoagulation will result in a
4– to 15–fold decrease in the incidence of embolic events
in nonpregnant patients. Pregnancy is associated with a
hypercoagulable state and is expected to further increase
the risk of thromboembolic events. Therefore, all patients
with MS and AF should receive antithrombotic therapy.
Warfarin is the most effective anticoagulant regimen in
the second and third trimester. These patients should
then be converted to continuous infusion of UFH before
planned delivery. The optimal anticoagulation regimen
during the first trimester remains controversial and is dis-
cussed further in the prosthetic valve and pregnancy sec-
tion (Section 13.3.2).
Supporting References: 310,316,796,797
Class IIa
1. Use of beta blockers as required for rate control is reasonable for
pregnant patients with MS in the absence of contraindication if
tolerated. (Level of Evidence: C)
In patients with MS, the shortening of the diastolic filling
period with the increased heart rate of pregnancy results in
a rise in LA pressure due to obstruction at the mitral valveThe Journal of Thoracic and Calevel. If stenosis is onlymild to moderate, the increase in car-
diac output further exacerbates the rise in LA pressure. IfMS
is severe, the normal rise in cardiac outputmaybeblunteddue
to the short diastolic filling period across a small mitral
orifice. Therapy targeted at reducing heart rate allows a
longer diastolic filling period with an improvement in for-
ward cardiac output and reduction in LA pressure. After the
first trimester, restricting physical activity helps with heart
rate control. In addition, beta-blocker medications are rela-
tively safe for both the mother and the fetus. The use of
beta blockers with beta-1 selectivity is preferred because
the beta-2 effects on uterine relaxation are avoided.Metopro-
lol has a lower incidence of fetal growth retardation than aten-
olol and is the preferred beta blocker for use in pregnancy.
Supporting References: 794,798-801
Class IIb
1. Use of diuretics may be reasonable for pregnant patients with MS
and HF symptoms (stage D). (Level of Evidence: C)
Diuretics may be helpful in reducing elevated LA pres-
sure in patients with MS who become symptomatic. How-
ever, they should be used with caution due to the potential
for reducing placental perfusion.
Supporting Reference: 793
Class III: Harm
1. ACE inhibitors and ARBs should not be given to pregnant patients
with valve stenosis.802-804 (Level of Evidence: B)
ACE inhibitors and ARBs are contraindicated during
pregnancy due to fetal toxicity, including renal or tubular
dysplasia, oligohydramnios, growth retardation, ossifica-
tion disorders of the skull, lung hypoplasia, and intrauterine
fetal death. If a patient with valve stenosis is taking 1 of
these medications for any reason, it should be discontinued
or replaced with an alternate medication before conception.
Supporting References: 802-804
13.1.3. Intervention: Recommendations
Class I
1. Valve intervention is recommended before pregnancy for symptom-
atic patients with severe AS (aortic velocity 4.0 m per second or
mean pressure gradient40mmHg, stageD). (Level of Evidence: C)
Patients with severe AS are at high risk for complica-
tions during the hemodynamic stress of pregnancy. Early
studies demonstrated a very poor outcome for patients
with severe AS who become pregnant, with a maternal
mortality rate of 17% and fetal and neonatal mortality
rate of 32%. Subsequent studies reported better outcomes,
but there is still a 3% to 10% risk of complication of HF
and up to a 25% risk of arrhythmia. In addition, sudden
deterioration and even death may occur, despite meticu-
lous medical care during pregnancy and delivery. Fetal
complications, including preterm birth, intrauterine growth
retardation, and low birth weight occur in up to 25% ofrdiovascular Surgery c Volume 148, Number 1 e87
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severity of stenosis and presence of symptoms are predic-
tors of poor outcomes during pregnancy in patients with
AS. Valve intervention is recommended for all patients
with severe symptomatic AS, regardless of whether or
not pregnancy is being contemplated. Women with symp-
tomatic severe AS who wish to become pregnant should
have a valve intervention before conception to prevent
the possible devastating consequences of progressive or
sudden deterioration during pregnancy and delivery.
Percutaneous aortic balloon dilation may be considered
in patients with noncalcified bicuspid aortic valves, with
the understanding that restenosis may occur within several
years of the procedure. AVR may also be considered
before pregnancy, after a detailed discussion with the pa-
tient about the risks and benefits of a bioprosthetic versus
a mechanical valve.
Supporting References: 792,805-810
Class I
2. Valve intervention is recommended before pregnancy for symptom-
atic patients with severe MS (mitral valve area 1.5 cm2, stage D).
(Level of Evidence: C)
Patients with severe MS (mitral valve area1.5 cm2) are
at increased risk for complications during pregnancy. The
increased blood volume, heart rate, and cardiac output
will more than double the transmitral gradient, significantly
increasing LA pressure. Up to 74% of patients with severe
MS will have clinical deterioration during pregnancy, man-
ifested primarily by HF symptoms and atrial arrhythmias.
The predictors of poor outcome are severity of the stenosis
and symptoms before pregnancy. Maternal mortality is un-
common but does occur with severe symptoms and critical
MS. Fetal outcome is also dependent on the severity of ste-
nosis and symptoms. The rate of premature delivery is 14%
in patients with mild MS and up to 33% in patients with se-
vereMS. If severe symptoms develop, there is a 30% risk of
fetal mortality. These complications can be minimized by
relief of MS before pregnancy. When valve morphology is
favorable, percutaneous mitral balloon commissurotomy
is the preferred intervention. In patients with calcified
immobile valves and subvalvular fusion, the choice be-
tween therapeutic intervention using percutaneous mitral
balloon commissurotomy, surgical commissurotomy, or
MVR should be made based on institutional experience.
Supporting References: 792,809-813
Class I
3. Percutaneous mitral balloon commissurotomy is recommended
before pregnancy for asymptomatic patients with severeMS (mitral
valve area1.5 cm2, stage C) who have valve morphology favorable
for percutaneous mitral balloon commissurotomy. (Level of Evi-
dence: C)
Percutaneous mitral balloon commissurotomy can be
performed with a high rate of success and low rate ofe88 The Journal of Thoracic and Cardiovascular Surgcomplications in patients with valve anatomy amenable
to this procedure. There is a high rate of clinical deteri-
oration that occurs in patients with severe MS during the
hemodynamic changes of pregnancy. There is also a
high rate of compromised fetal outcome, including
growth retardation, prematurity, and low birth weight,
which has subsequent consequences on infant morbidity,
infant mortality, and patient cardiovascular disease. If
valve anatomy is suitable for commissurotomy, percuta-
neous mitral balloon commissurotomy should be per-
formed in patients with severe MS before conception,
even in the absence of symptoms.
Supporting References: 809-814
Class IIa
1. Valve intervention is reasonable before pregnancy for asymptom-
atic patients with severe AS (aortic velocity 4.0 m per second
or mean pressure gradient 40 mm Hg, stage C). (Level of Evi-
dence: C)
Most patients with mild-to-moderate AS can tolerate the
hemodynamic changes of pregnancy without adverse car-
diovascular events. However, patients with severe AS are
at an increased risk for complications, with HF developing
in 10% to 44% of patients and arrhythmias in up to 25%,
even if they were asymptomatic before pregnancy. Pro-
gressive as well as sudden deterioration may occur in pa-
tients with severe AS during pregnancy and delivery.
There is also an increased incidence of hypertensive emer-
gencies that occur during pregnancy in patients with se-
vere AS, possibly related to poor placental perfusion.
Fetal outcomes are also worse in patients with severe
AS. These adverse outcomes can be minimized by relief
of AS. Percutaneous aortic balloon dilation may be
considered in patients with noncalcified congenital AS,
with the understanding that restenosis may occur within
several years of the procedure. When anatomy is not suit-
able for balloon aortic dilation, AVR may be considered
before pregnancy, after a detailed discussion with the pa-
tient about the risks and benefits of a bioprosthetic versus
a mechanical valve.
Supporting References: 805-810Class IIa
2. Percutaneous mitral balloon commissurotomy is reasonable for
pregnant patients with severeMS (mitral valve area1.5 cm2, stage
D) with valve morphology favorable for percutaneous mitral
balloon commissurotomy who remain symptomatic with NYHA
class III to IV HF symptoms despite medical therapy.157,815-818
(Level of Evidence: B)
Patients with severe MS have a high probability of devel-
oping progressive symptoms during the hemodynamic
changes of pregnancy, particularly during the second and
third trimesters. Percutaneous mitral balloon commissurot-
omy has been performed successfully in pregnant patientsery c July 2014
Nishimura et al Clinical Guidelineswith severe MS, primarily in those who have an anatomy
that is amenable to this intervention. Although the risk of
complications is low, there is still a risk of severe MR
requiring urgent MVR. This procedure should be reserved
only for those patients who remain symptomatic with
NYHA class III to IV HF symptoms after initial therapy
with bed rest, beta blockade, and diuretics. Percutaneous
mitral balloon commissurotomy should preferably be per-
formed after 20 weeks of gestation, the period safest for
the fetus. Percutaneous mitral balloon commissurotomy
during pregnancy should only be performed by experienced
operators who have a demonstrated low complication rate,
minimizing radiation dose to the mother and fetus. The pro-
cedure should also be done with back-up cardiac surgery,
anesthesiology, and high-risk obstetrics services in place.
Supporting References: 157,815-818
Class IIa
3. Valve intervention is reasonable for pregnant patients with severe
MS (mitral valve area 1.5 cm2, stage D) and valve morphology
not favorable for percutaneous mitral balloon commissurotomy
only if there are refractory NYHA class IV HF symptoms. (Level
of Evidence: C)
Patients with severe MS and unfavorable valve
morphology (ie, severe leaflet calcification, leaflet thick-
ening, immobility, subvalvular fusion, and commissural
calcification) are at high risk for percutaneous mitral
balloon commissurotomy. In these patients, the percuta-
neous approach may be complicated by severe MR
requiring emergencyMVR. Although percutaneous balloon
mitral commissurotomy remains an option, MVR under
controlled surgical conditions is the safest approach in
this subgroup of patients. However, valve operation during
pregnancy is high risk, with a 30% to 40% fetal mortality
rate and up to 9% maternal mortality rate. Surgery for
MS during pregnancy should be reserved for those with re-
fractory NYHA class IV HF symptoms that are not respon-
sive to medical therapy. The operation needs to be carefully
planned with a Heart Valve Team of cardiologists, cardio-
vascular anesthesiologists, surgeons, and obstetricians
specializing in high-risk obstetrics to determine optimal
timing and sequence of therapies. High pump flows and
normothermic perfusion should be used to protect the fetus
during cardiopulmonary bypass, with the shortest pump
time possible. Continued monitoring of the fetus should
be performed. There is no ideal time during pregnancy to
perform open heart surgery, so timing is based on the com-
bination of the clinical status of the mother and the fetus.
The period between the 20th and 28th weeks of pregnancy
appears to be safest for the fetus in terms of risk of malfor-
mation and premature delivery. If the mother can carry the
fetus to full maturity, a combined cesarean section followed
by cardiac surgery can be planned.
Supporting References: 816,819-822The Journal of Thoracic and CaClass IIa
4. Valve intervention is reasonable for pregnant patients with severe
AS (mean pressure gradient 40 mm Hg, stage D) only if there is
hemodynamic deterioration or NYHA class III to IV HF symp-
toms.805,823-828 (Level of Evidence: B)
Patients with severe AS may develop progressive HF or
sudden hemodynamic deterioration during the hemody-
namic stress of pregnancy. Medical therapy is of limited ef-
ficacy, as the AS is a fixed mechanical obstruction. Both
open heart surgery and percutaneous aortic balloon dilation
are high-risk procedures during pregnancy for both the
mother and the fetus and should only be performed
if there is hemodynamic deterioration or severe NYHA
class III to IV HF symptoms. The type of intervention
(AVR or percutaneous aortic balloon dilation) will be
dependent on the expertise of the center but the intervention
should always be performed in a center with a multidisci-
plinary group of cardiologists, interventionalists, cardiac
anesthesiologists, and obstetricians specializing in high-
risk obstetrics.
There have been reports of successful percutaneous
aortic balloon dilation during pregnancy. This procedure
has better results in patients with the noncalcified
bicuspid aortic valve but may result in severe AR due
to a tear in an aortic valve cusp. Limited fluoroscopy
time with appropriate lead shielding of the fetus is
necessary. Intervention is preferable after 20 weeks of
gestation because it is safer for the fetus. Percutaneous
aortic balloon dilation should only be performed by
highly experienced operators in centers with a competent
team of cardiologists and cardiovascular anesthesiolo-
gists, with back-up cardiac surgery and high-risk obstet-
rics services in place.
AVR may also be considered. High pump flows and
normothermic perfusion should be used to protect the
fetus during cardiopulmonary bypass, with the shortest
pump time possible. Continued monitoring of the fetus
should be performed. There is no ideal time during
pregnancy to perform open heart surgery, so timing is
based on the combination of the clinical status of the
mother and the fetus. The period between the 20th
and 28th weeks of pregnancy appears to be safest for
the fetus in terms of risk of malformation and premature
delivery. If the mother can carry the fetus to full matu-
rity, a combined cesarean section followed by cardiac
operation can be planned.
Percutaneous aortic balloon dilation and AVR proce-
dures need to be carefully planned with a Heart Valve
Team of cardiologists, cardiovascular anesthesiologists,
surgeons, and obstetricians specializing in high-risk ob-
stetrics to determine optimal timing and sequence of
therapies.
Supporting References: 805,816,819-828rdiovascular Surgery c Volume 148, Number 1 e89
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1. Valve operation should not be performed in pregnant patients with
valve stenosis in the absence of severe HF symptoms. (Level of Evi-
dence: C)
Valve surgery during pregnancy is high risk, with a 30%
to 40% fetal mortality rate and up to 9%maternal mortality
rate reported. It should be reserved only for patients with se-
vere, intractable symptoms unresponsive to bed rest and
medical therapy.
Supporting References: 816,819-82213.2. Native Valve Regurgitation
13.2.1. Diagnosis and Follow-up: Recommendations
Class I
1. All patients with suspected valve regurgitation should undergo
a clinical evaluation and TTE before pregnancy. (Level of
Evidence: C)
Patients with valve regurgitation tolerate pregnancy bet-
ter than do patients with valve stenosis because the decrease
in afterload that occurs throughout pregnancy allows an
appropriate increase in cardiac output without a rise in ven-
tricular filling pressures. However, patients with severe
regurgitation who are already symptom limited or have a
reduced LVEF or pulmonary hypertension may develop
HF symptoms because of the volume load of pregnancy.
Clinical and TTE evaluation before pregnancy allow deter-
mination of the cause of regurgitation, quantitation of regur-
gitant severity, measurement of LVEF, and estimation of
pulmonary pressures so that patients at high risk can be
identified.
Supporting References: 792-794,810,829-834
Class I
2. All patients with severe valve regurgitation (stages C and D) should
undergo prepregnancy counseling by a cardiologist with expertise
in managing patients with VHD during pregnancy. (Level of Evi-
dence: C)
The management of patients with valve regurgitation
should ideally begin before conception. A complete
assessment of functional capacity, severity of regurgita-
tion, pulmonary pressures, and LV size and function are
necessary to determine the risk of pregnancy and delivery
in patients with valve regurgitation. The risks and benefits
of proceeding with pregnancy must be fully discussed with
the patient. Interventions before pregnancy may be consid-
ered in the patient with severe regurgitation who is at high
risk for developing HF during pregnancy, particularly if
the valve can be repaired instead of replaced. Drugs
with potential harmful effects on the fetus must be identi-
fied. If pregnancy is contemplated, arrangements should
be made for the patient to be monitored in a tertiary
care center with a dedicated Heart Valve Team of cardiol-
ogists, surgeons, anesthesiologists, and obstetricians withe90 The Journal of Thoracic and Cardiovascular Surgexpertise in managing high-risk cardiac patients. Coun-
seling regarding all these areas should be performed by
a cardiologist with expertise in managing patients with
VHD during pregnancy.
Supporting References: 792-794,810,834
Class I
3. All patients referred for a valve operation before pregnancy should
receive prepregnancy counseling by a cardiologist with expertise in
managing patients with VHD during pregnancy regarding the risks
and benefits of all options for operative interventions, including me-
chanical prosthesis, bioprosthesis, and valve repair. (Level of Evi-
dence: C)
When intervention is indicated, valve repair is preferred
for the treatment of valve regurgitation in women of child-
bearing age. However, not all valves can be adequately re-
paired, and the decision to proceed with implantation of a
prosthetic valve is sometimes made at the time of opera-
tion. All prosthetic valve types pose major problems dur-
ing pregnancy. Mechanical prostheses require continued
anticoagulation throughout pregnancy, with risks to both
the mother and the fetus. Bioprostheses have a limited
life span, particularly in the younger patient, and contro-
versy persists as to whether there is acceleration of valve
degeneration during pregnancy. All patients of child-
bearing age being considered for a valve operation should
receive prepregnancy counseling by a cardiologist with
expertise in managing patients with VHD during preg-
nancy to discuss the risks and benefits of available treat-
ment options.
Supporting References: 793,795,810,834
Class I
4. Pregnant patients with severe regurgitation (stages C and D) should
be monitored in a tertiary care center with a dedicated Heart Valve
Team of cardiologists, surgeons, anesthesiologists, and obstetricians
with expertise in managing high-risk cardiac patients. (Level of Ev-
idence: C)
Patients with severe regurgitation may be at high risk dur-
ing pregnancy. The risk increases throughout pregnancy,
given the continued physiological hemodynamic changes,
including increased volume, decreased afterload, and
increased heart rate. Pulmonary edema, arrhythmias, and
even maternal death may occur. The presence of severe
valve regurgitation is also associated with an increased
risk to the fetus. Timing and mode of delivery should be dis-
cussed and carried out by the Heart Valve Team, with close
hemodynamic monitoring during and up to 24 hours after
delivery. Management at a tertiary care center with a dedi-
cated Heart Valve Team of cardiologists, surgeons, anesthe-
siologists, and obstetricians who have expertise in the care
of high-risk cardiac patients will ensure optimal maternal
and fetal outcomes in women with severe valve
regurgitation.
Supporting References: 792-794,810,834ery c July 2014
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1. Exercise testing is reasonable in asymptomatic patients with severe
valve regurgitation (stage C) before pregnancy. (Level of Evidence: C)
Asymptomatic patients with severe valve regurgitation
usually tolerate the hemodynamic changes of pregnancy,
unless there is concurrent ventricular systolic dysfunction
or pulmonary hypertension. Exercise testing may identify
apparently asymptomatic patients at higher risk of compli-
cations during pregnancy. Exercise parameters suggesting a
higher risk include limited exercise tolerance, exercise-
induced pulmonary hypertension, or abnormal symptoms.
Patients with symptoms provoked by exercise testing
should be considered symptomatic.
Supporting References: 793,810,834
13.2.2. Medical Therapy: Recommendation
Class III: Harm
1. ACE inhibitors and ARBs should not be given to pregnant patients
with valve regurgitation.802-804 (Level of Evidence: B)
ACE inhibitors and ARBs are contraindicated during
pregnancy due to fetal toxicity, including renal or tubular
dysplasia, oligohydramnios, growth retardation, ossification
disorders of the skull, lung hypoplasia, and intrauterine fetal
death. If a patient with valvular regurgitation is taking 1 of
these medications for any reason, it should be discontinued
or replaced with an alternate medication before conception.
Supporting References: 802-804
13.2.3. Intervention: Recommendations
Class I
1. Valve repair or replacement is recommended before pregnancy for
symptomatic women with severe valve regurgitation (stage D).
(Level of Evidence: C)
Symptomatic women with severe valve regurgitation are
at high risk for developing HF during pregnancy. All pa-
tients with symptomatic severe valve regurgitation should
undergo surgery to repair or replace the valve, regardless
of whether they wish to become pregnant. The operation
will improve long-term outcomes and prevent progressive
ventricular dysfunction from the long-standing volume
overload. Although the ideal operation would be valve
repair, not all valves can be successfully repaired. Potential
problems associated with the different types of prosthetic
valves during pregnancy must be discussed in detail with
all women before operation.
Supporting References: 793,810,834
Class IIa
1. Valve operation for pregnant patients with severe valve regurgita-
tion is reasonable only if there are refractory NYHA class IV HF
symptoms (stage D). (Level of Evidence: C)
Valve operation during pregnancy is high risk for both the
mother and the fetus, with a 30% to 40% fetal mortalityThe Journal of Thoracic and Carate and up to 9% maternal mortality rate reported. Thus,
it should be reserved for the very rare patient with severe
valve regurgitation who has severe refractory HF symp-
toms. The operation needs to be carefully planned with
the multidisciplinary Heart Valve Team of cardiologists,
cardiovascular anesthesiologists, surgeons, and high-risk
obstetricians to determine optimal timing and sequence of
therapies. High pump flows and normothermic perfusion
should be used to protect the fetus during cardiopulmonary
bypass, with the shortest pump time possible. Continuous
monitoring of the fetus should be performed. There is no
ideal time during pregnancy to perform open heart surgery,
so timing is based on the combination of the clinical status
of the mother and the fetus. The period between the 20th
and 28th weeks of pregnancy appears to be safest for the
fetus in terms of risk of malformation and premature deliv-
ery. If the mother can carry the fetus to full maturity, a com-
bined cesarean section followed by cardiac operation can be
planned.
Supporting References: 819-822
Class IIb
1. Valve repair before pregnancy may be considered in the asymptom-
atic patient with severe MR (stage C) and a valve suitable for valve
repair, but only after detailed discussion with the patient about the
risks and benefits of the operation and its outcome on future preg-
nancies. (Level of Evidence: C)
The threshold for valve operation for valve regurgitation
should be higher in the asymptomatic patient who wants to
become pregnant as opposed to conventional criteria in pa-
tients who are not likely to become pregnant. Although a
successful mitral valve repair will result in a low-risk
pregnancy and delivery, not all valves can be successfully
repaired with complete certainty. If surgery is undertaken
and valve repair is unsuccessful, the implantation of a
mitral valve prosthesis increases the risks during preg-
nancy, regardless of whether a mechanical or bioprosthetic
valve is used. Most patients with asymptomatic severe MR
tolerate pregnancy, and there is no evidence for accelera-
tion of LV dysfunction during pregnancy. Thus, it may
be prudent to manage these patients medically rather
than recommending valve surgery before pregnancy. In pa-
tients with MR who are at higher risk for the development
of HF during pregnancy, including those with depressed
LV systolic function or pulmonary hypertension (pulmo-
nary artery systolic pressure>50 mm Hg), the decision
to operate before pregnancy should take into consideration
the mitral valve morphology, chance of successful repair
in the institution, estimated surgical risk, and issues
related to possible MVR. This may require referral to a
Heart Valve Center of Excellence if the expected rate of
a successful and durable valve repair at the institution
does not exceed 95%.
Supporting References: 793,810,834rdiovascular Surgery c Volume 148, Number 1 e91
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1. Valve operations should not be performed in pregnant patients with
valve regurgitation in the absence of severe intractable HF symp-
toms. (Level of Evidence: C)
Valve surgery during pregnancy is high risk, with a 30%
to 40% fetal mortality rate and up to 9%maternal mortality
rate reported. It should be reserved only for patients with se-
vere, intractable symptoms unresponsive to bed rest and
medical therapy.
Supporting References: 819-822
13.3. Prosthetic Valves in Pregnancy
13.3.1. Diagnosis and Follow-up: Recommendations
Class I
1. All patients with a prosthetic valve should undergo a clinical evalu-
ation and baseline TTE before pregnancy. (Level of Evidence: C)
Major complications can occur during pregnancy in pa-
tients with prosthetic valves. The increased hemodynamic
burden of pregnancy can lead to HF if there is prosthetic
valve thrombosis, stenosis, regurgitation, or patient-
prosthesis mismatch. Clinical evaluation and baseline
TTE allow determination of valve function and hemody-
namics under normal loading conditions and help identify
valve dysfunction that might require treatment before preg-
nancy. In addition, there is an increased risk of valve throm-
bosis in patients with a mechanical prosthesis due to the
hypercoagulable state of pregnancy. The baseline TTE
serves as the reference standard for the patient if
valve thrombosis is suspected during pregnancy.
Supporting References: 793,795
Class I
2. All patients with a prosthetic valve should undergo prepregnancy
counseling by a cardiologist with expertise in managing patients
with VHD during pregnancy. (Level of Evidence: C)
The management of the pregnant patient with a prosthetic
valve may significantly differ from that of the patient who is
not pregnant, specifically in relation to antithrombotic
therapy. There is a much higher risk of valve thrombosis for
patients with a mechanical prosthesis due to the hypercoagu-
lable state of pregnancy. Certain drugs are contraindicated
during pregnancy. Prepregnancy counseling by a cardiologist
with expertise in managing patients with VHD during preg-
nancy should be performed to determine the risk of preg-
nancy, discuss potential complications, and outline an
approach for anticoagulation at the time of conception.
Supporting References: 793,795
Class I
3. TTE should be performed in all pregnant patients with a prosthetic
valve if not done before pregnancy. (Level of Evidence: C)
Although it is preferable to perform a baseline echocardio-
gram before pregnancy in women with prosthetic heart
valves, if a baseline study is not available during the timee92 The Journal of Thoracic and Cardiovascular Surgthe patient has been clinically stable, TTE during pregnancy
still provides evaluation of prosthetic valve function, as well
as ventricular function and pulmonary pressures. Due to an
increase in cardiac output that occurs during pregnancy, the
mean pressure gradient across all prostheses will increase
throughout thefirst and second trimesters and remain elevated
in the third trimester. Other hemodynamic parameters such as
diastolic half-time (for amitral prosthesis) and dimensionless
index (the ratio of the LVoutflow timevelocity divided by the
peak aortic valve velocity for an aortic prosthesis) must be
used to determine the function of the prosthesis.
Supporting References: 793,795
Class I
4. Repeat TTE should be performed in all pregnant patients with a
prosthetic valve who develop symptoms. (Level of Evidence: C)
If there are changes in clinical status with either the onset
of symptoms of dyspnea or change in the clinical examina-
tion, a repeat echocardiogram is indicated to look for
changes in ventricular function and in the hemodynamics
of the prosthetic valve. Bioprosthetic valves are at risk for
tissue degeneration; bioprosthetic valve stenosis typically
develops slowly, but bioprosthetic regurgitation may be
acute due to a leaflet tear adjacent to an area of calcification.
Mechanical valves are prone to acute stenosis or regurgita-
tion during pregnancy due to valve thrombosis limiting disc
opening or closure. TTE should be performed initially
because both aortic and mitral transvalvular flows can be re-
corded from this approach. However, TEE is needed if pros-
thetic MR is suspected. Although radiation exposure should
be minimized, fluoroscopy of mechanical valves may be
helpful in evaluating disc motion.
Supporting References: 793,795
Class I
5. TEE should be performed in all pregnant patients with a mechani-
cal prosthetic valve who have prosthetic valve obstruction or expe-
rience an embolic event. (Level of Evidence: C)
If thrombotic obstruction is suspected or if an embolic
event occurs in a pregnant patient with a mechanical pros-
thesis, TEE is indicated to look at valve function and disc
motion and to determine the thrombus burden. Subsequent
therapeutic decisions will depend on the clinical state of the
patient, gestational age of the child, degree of valve
dysfunction, and thrombus burden. TEE is especially
important for detection of prosthetic mitral valve dysfunc-
tion, and an apparently normal transthoracic study should
not dissuade clinicians from proceeding with TEE. With a
prosthetic aortic valve, both TTE and TEE are needed for
a complete examination. Chest CT imaging can also diag-
nose prosthetic valve thrombosis and limitations of me-
chanical valve motion but should be avoided during
pregnancy due to radiation exposure.
Supporting References: 605,793,795,835-837ery c July 2014
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6. Pregnant patients with a mechanical prosthesis should be moni-
tored in a tertiary care center with a dedicated Heart Valve Team
of cardiologists, surgeons, anesthesiologists, and obstetricians with
expertise in the management of high-risk cardiac patients. (Level
of Evidence: C)
Women with mechanical valves are at high risk of devas-
tating complications during pregnancy. There is an
increased risk for thrombosis of mechanical valves due
to the hypercoagulable state of pregnancy, particularly
those with a prosthetic valve in the mitral position. Antico-
agulation regimens to prevent valve thrombosis require in-
depth knowledge of the risks and benefits of each approach.
Valve thrombosis may result in acute, severe HF and/or
embolic events, with a high-resultant maternal and fetal
mortality. The occurrence of valve thrombosis during
pregnancy constitutes a medical and sometimes surgical
emergency. Integrated care by a Heart Valve Team of cardi-
ologists, surgeons, anesthesiologists, and obstetricians with
expertise in the management of high-risk cardiac patients is
needed.
Supporting References: 793,795
13.3.2. Medical Therapy: Recommendations
See Figure 10 for anticoagulation of pregnant patients
with mechanical valves.
Class I
1. Therapeutic anticoagulation with frequent monitoring is recom-
mended for all pregnant patients with a mechanical pros-
thesis.838,839 (Level of Evidence: B)
There is a high risk of valve thrombosis in patients with
mechanical prostheses who are pregnant due to the hyper-
coagulable state that occurs during pregnancy. All anticoag-
ulant regimens carry an increased risk to the fetus, with fetal
abnormalities, an increased risk of miscarriage, and hemor-
rhagic complications, including retroplacental bleeding,
leading to premature birth and fetal death. However,
without any anticoagulation, maternal mortality is high
(up to 5%), and there is a high risk of thromboembolic
events (up to 24%) and valve thrombosis. Because of the
physiological effects of pregnancy, there are constantly
changing requirements for antithrombotic regimens. Effec-
tive anticoagulation with frequent monitoring of its sys-
temic effect is critical throughout the pregnancy.
Supporting References: 838,839
See Online Data Supplement 25 for more information on
pregnancy.
Class I
2. Warfarin is recommended in pregnant patients with a mechanical
prosthesis to achieve a therapeutic INR in the second and third tri-
mesters.840-845 (Level of Evidence: B)
Warfarin is the most effective anticoagulant for prevent-
ing maternal thromboembolic events during pregnancy.The Journal of Thoracic and CaAlthough warfarin has potential fetal teratogenic effects
in the first trimester, there is little teratogenic effect in the
second and third trimesters. Use of UFH throughout preg-
nancy has the highest risk of thromboembolic events and
maternal death in patients with a mechanical prosthesis,
with reported instances of massive thrombosis of prosthetic
valves. Although there are no RCTs comparing the different
antithrombotic regimens, the risk of thromboembolic events
using warfarin throughout pregnancy is<4%, compared
with 33% with the use of UFH throughout pregnancy.
Use of UFH throughout pregnancy is also associated with
maternal complications of thrombocytopenia and osteopo-
rosis. LMWH given at a fixed dose has resulted in fatal
valve thrombosis. When monitored with anti-Xa levels,
LMWH has a lower rate of valve thrombosis compared
with UFH. Even with meticulous monitoring of anti-Xa
levels, there have been cases of valve thrombosis with
LMWH used throughout pregnancy. There is no ideal anti-
coagulant regimen for pregnant women with mechanical
valves. However, during the second and third trimesters of
pregnancy, the benefits of warfarin for the mother appear
to outweigh the slightly increased risk to the fetus.
Supporting References: 838,840-847
See Online Data Supplements 25 and 26 for more infor-
mation on pregnancy.
Class I
3. Discontinuation of warfarin with initiation of intravenous UFH
(with an activated partial thromboplastin time [aPTT]>2 times
control) is recommended before planned vaginal delivery in preg-
nant patients with a mechanical prosthesis. (Level of Evidence: C)
Warfarin crosses the placental barrier and results in an-
ticoagulation of the fetus as well as the mother. There is a
higher risk of intracranial hemorrhage for the fetus if the
mother is fully anticoagulated during vaginal delivery. It
is recommended that the mother be hospitalized before
planned delivery with discontinuation of warfarin and
initiation of intravenous continuous infusion of UFH
to keep aPTT >2 times control levels. Then heparin is
stopped just before delivery. Patients with mechanical
prostheses are at increased risk for premature labor, so
careful planning with a Heart Valve Team of
cardiologists, anesthesiologists, and obstetricians is
required before anticipated delivery. Alternative ap-
proaches to delivery include elective cesarean section after
a shorter cessation of warfarin.
Supporting References: 848,849
Class I
4. Low-dose aspirin (75 mg to 100 mg) once per day is recommended
for pregnant patients in the second and third trimesters with either
a mechanical prosthesis or bioprosthesis. (Level of Evidence: C)
Although there are no data regarding the addition of
aspirin to anticoagulation in pregnant patients with pros-
thetic valves, the addition of aspirin is effective in loweringrdiovascular Surgery c Volume 148, Number 1 e93
Clinical Guidelines Nishimura et althe thromboembolic risk in nonpregnant patients. Aspirin is
safe in the second and third trimesters of pregnancy from
the obstetric standpoint.
Supporting References: 567,568,850
Class IIa
1. Continuation of warfarin during the first trimester is reasonable for
pregnant patients with a mechanical prosthesis if the dose of
warfarin to achieve a therapeutic INR is 5 mg per day or less after
full discussion with the patient about risks and bene-
fits.838,839,844,845,848,851 (Level of Evidence: B)
The optimal anticoagulant used during the first trimester
in pregnant patients with mechanical prosthetic valves re-
mains controversial. Oral anticoagulation with warfarin is
the safest regimen for the mother, but there is an increased
risk of embryopathy. Anticoagulation with UFH or LMWH
has been recommended to avoid the risk of embryopathy,
but it is not as effective as warfarin in preventing thrombo-
embolic events. The risk of embryopathy is dose dependent,
with a low risk (<3%) if the dose of warfarin is 5 mg per
day. The risk of abortion and fetal loss are increased with
any anticoagulant regimen but may be similar in women
exposed to oral anticoagulants versus heparin in the first
trimester, especially at low doses of warfarin. Continuation
of warfarin during the first trimester is reasonable after a full
discussion with the patient and family about the risks and
benefits when a therapeutic INR can be maintained with a
daily warfarin dose of 5 mg.
Supporting References: 838,839,844,845,848,851-854
See Online Data Supplements 25 and 26 for more infor-
mation on pregnancy.
Class IIa
2. Dose-adjusted LMWH at least 2 times per day (with a target anti-
Xa level of 0.8 U/mL to 1.2 U/mL, 4 to 6 hours postdose) during
the first trimester is reasonable for pregnant patients with a me-
chanical prosthesis if the dose of warfarin is greater than 5 mg
per day to achieve a therapeutic INR.840-843,855,856 (Level of
Evidence: B)
In patients whose dosage of warfarin is>5 mg per day,
the risk of embryopathy is >8% (compared with <3%
with a warfarin dosage of 5 mg per day). It is reasonable
to consider heparin anticoagulation instead of warfarin dur-
ing the first trimester of pregnancy, because heparin does
not cross the placental barrier and is not associated with
fetal embryopathy. LMWH may be a better alternative
than UFH with potential advantages of better subcutaneous
absorption and bioavailability, longer half-life, and a more
predictable anticoagulation response. Anti-Xa levels should
be monitored because dosage requirements may increase
by as much as 50% over the course of pregnancy. The target
anti-Xa level should be 0.8 U/mL to 1.2 U/mL, measured 4
to 6 hours after injection.With use of this meticulous dosing
regimen, the incidence of valve thrombosis is lower than
with UFH, but there are still reports of valve thrombosis,e94 The Journal of Thoracic and Cardiovascular Surgeven with the newer-generation mechanical prostheses.
The data for use of LMWH in pregnancy are incomplete,
with unresolved questions to be addressed, including
optimal anti-Xa levels, use of peak and trough levels,
optimal timing of dosage, and compliance issues with
dosing 2 times a day and sometimes 3 times a day. If the pa-
tient chooses not to be on an oral anticoagulant in the first
trimester, dose-adjusted LMWH is a reasonable choice of
anticoagulation.
Supporting References: 840-843,846,855-857
See Online Data Supplements 25 and 26 for more
information on pregnancy.
Class IIa
3. Dose-adjusted continuous intravenous UFH (with an aPTTat least 2
times control) during the first trimester is reasonable for pregnant
patients with a mechanical prosthesis if the dose of warfarin is
greater than 5 mg per day to achieve a therapeutic INR.838,839,848
(Level of Evidence: B)
If the decision is made to use UFH during the first
trimester of pregnancy, it is reasonable that the patient
receive a continuous infusion of heparin, with carefully
monitoring of aPTT and a goal of at least 2 times control.
Prior studies have shown that the use of subcutaneous
UFH is associated with a high incidence of valve throm-
bosis, especially with older-generation valve prostheses.
Disadvantages of intravenous UFH include an increased
risk of serious infection and a risk of osteoporosis.
Supporting References: 838,839,848
See Online Data Supplements 25 and 26 for more infor-
mation on pregnancy.
Class IIb
1. Dose-adjusted LMWH at least 2 times per day (with a target anti-
Xa level of 0.8 U/mL to 1.2 U/mL, 4 to 6 hours postdose)
during the first trimester may be reasonable for pregnant patients
with a mechanical prosthesis if the dose of warfarin is 5 mg per
day or less to achieve a therapeutic INR.840-843,855-857 (Level of
Evidence: B)
The choice of type of anticoagulation during the first
trimester requires a detailed discussion with the patient
about the risks and benefits of the different regimens. The
use of warfarin during the first trimester is associated
with an increased risk of warfarin embryopathy, but the
risk is low (<3%) if the daily dose of warfarin is 5 mg.
The use of heparin will avoid the risk of embryopathy but
is associated with an increased risk of valve thrombosis
and embolic events. If the patient decides not to continue
warfarin during the first trimester, after a full discussion of
the risks and benefits of the different regimens, dose-
adjusted LMWH appears to be the safest choice in terms
of prevention of thromboembolic events. However, this
does require meticulous monitoring of anti-Xa levels, as
dosing requirements change throughout pregnancy. Theery c July 2014
FIGURE 10. Anticoagulation of pregnant patients with mechanical valves. aPTT, Activated partial thromboplastin time; ASA, aspirin; INR, international
normalized ratio; LMWH, low-molecular-weight heparin; QD, once daily; UFH, unfractionated heparin.
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1.2 U/mL at 4 to 6 hours postdose, given at least 2 times a
day.
Supporting References: 840-843,846,855-857
See Online Data Supplements 25 and 26 for more infor-
mation on pregnancy.
Class IIb
2. Dose-adjusted continuous infusion of UFH (with aPTT at least 2
times control) during the first trimestermay be reasonable for preg-
nant patients with a mechanical prosthesis if the dose of warfarin is
5 mg per day or less to achieve a therapeutic INR.838,839,848 (Level of
Evidence: B)
If the patient on a dose of warfarin5mg per day decides
not to continuewarfarin during the first trimester, after a full
discussion of the risks and benefits of the different regi-
mens, dose-adjusted LMWH appears to be the safest choice
in terms of prevention of thromboembolic events. If the de-
cision is made to use UFH during the first trimester of preg-
nancy, it is reasonable that the patient receive a continuous
infusion of heparin, with careful monitoring of aPTTwith a
goal of at least 2 times control. Subcutaneous UFH is asso-
ciated with a high incidence of valve thrombosis, especially
with the older-generation valve prostheses. Intravenous
UFH is associated with an increased risk of infection
from the prolonged use of intravenous catheters and a risk
of osteoporosis.
Supporting References: 838,839,848
See Online Data Supplements 25 and 26 for more infor-
mation on pregnancy.
Class III: Harm
1. LMWH should not be administered to pregnant patients with me-
chanical prostheses unless anti-Xa levels are monitored 4 to 6 hours
after administration.841,842,847,855,856 (Level of Evidence: B)
Initial studies using subcutaneous LMWH at a fixed dose
without monitoring of anti-Xa levels in pregnant patients
with a mechanical prosthesis were associated with a high
risk of valve thrombosis, leading to maternal deaths. Since
the requirements of LMWH increase throughout pregnancy,
there should be meticulous monitoring of anti-Xa levels 4 to
6 hours after administration if dose-adjusted administration
of LMWH is to be used.
Supporting References: 841,842,847,855,856
14. SURGICAL CONSIDERATIONS
14.1. Evaluation of Coronary Anatomy:
Recommendations
See Figure 11 for evaluation and management of CAD in
patients undergoing valve surgery.
Screening coronary angiography to assess associated
CAD should be considered in selected patients before car-
diac surgery or transcatheter intervention for VHD. Invasive
selective coronary angiography remains the gold standard.
Fractional flow reserve may better delineate thee96 The Journal of Thoracic and Cardiovascular Surgphysiological significance of a coronary lesion, but there
are no outcome data for its utility in patients undergoing
valve surgery. Due to its high negative predictive value, cor-
onary CTangiography to exclude CAD may be an option in
patients with low or intermediate pretest probability of
CAD. If significant epicardial CAD is present, concomitant
CABG should be considered at the time of valve surgery.
The presence of severe CAD may also be helpful in deter-
mining whether a surgical or transcatheter approach is
optimal in patients with AS.
Class I
1. Coronary angiography is indicated before valve intervention in pa-
tients with symptoms of angina, objective evidence of ischemia,
decreased LV systolic function, history of CAD, or coronary risk
factors (including men age>40 years and postmenopausal women).
(Level of Evidence: C)
Knowledge of the coronary anatomy contributes to risk
stratification and determines if concomitant coronary
revascularization is indicated. Coronary angiography can
be avoided in young patients (men<40 years of age and
premenopausal women) with no atherosclerotic risk
factors and in patients in whom the risks outweigh the
benefits, such as in patients with acute aortic dissection,
large aortic valve vegetation, or occlusive prosthetic
thrombosis.
Supporting References: 858-871
Class I
2. Coronary angiography should be performed as part of the evalua-
tion of patients with chronic severe secondary MR. (Level of Evi-
dence: C)
In patients with chronic secondary MR, the valve leaflets
and chordae are structurally normal and the MR results
from the geometrical distortion of the mitral apparatus.
This is due to multiple factors that can cause displacement
of the papillary muscles, tethering of the leaflets, annular
dilation, and decreased closing forces from reduced
contractility. Because CAD and accompanying myocardial
ischemia may contribute to chronic secondary MR, the
assessment of coronary anatomy status is necessary to com-
plete the diagnosis and allow evaluation of revasculariza-
tion options.
Supporting References: 309,872-875Class IIa
1. Surgery without coronary angiography is reasonable for patients
having emergency valve surgery for acute valve regurgitation, dis-
ease of the aortic sinuses or ascending aorta, or IE. (Level of Evi-
dence: C)
Assessment of coronary artery anatomy is rarely required
in patients undergoing emergency valve surgery for acute
AR, aortic dissection, or IE with hemodynamic instability.
Supporting References: 188,876-879ery c July 2014
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2. CT coronary angiography is reasonable to exclude the presence of
significant obstructive CAD in selected patients with a low/interme-
diate pretest probability of CAD. Apositive coronaryCTangiogram
(the presence of any epicardial CAD) is confirmedwith invasive cor-
onary angiography.880-886 (Level of Evidence: B)
In select patients who are at low-to-intermediate pre-
test probability of CAD and who are being considered
for angiography before valve surgery, coronary CT angi-
ography is a reasonable alternative. This does not
include patients who have active symptoms of angina,
those with documented ischemia, or those with a prior
history of CAD, all of whom should have selective cor-
onary angiography. Several small studies have reported
high diagnostic accuracy of coronary CT angiography
in select patients with VHD. One study of 98 consecu-
tive patients with significant VHD and guideline-based
indications for coronary angiography underwent CT cor-
onary angiography if their coronary calcium score
was <1000. Invasive coronary angiography was per-
formed in patients with at least 1 of the following:
>50% stenosis, calcium artifacts, or motion artifacts.
CT coronary angiography excluded the presence of sig-
nificant CAD in 80.6% of patients without the need for
invasive angiography. Conventional coronary angiog-
raphy was required in 19.4% of patients because of
>50% stenosis in 13.3%, calcium artifact in 2%, and
motion artifact in 1%. In another study of 70 patients,
31 had AS (44%), 24 had MR (34%), 9 had AR
(13%), and the remainder had other valvular or congen-
ital lesions. On a per-patient basis, sensitivity was 100%
(18 of 18 patients with significant CAD) and specificity
was 92% (48 of 52 patients without significant CAD).
The corresponding negative likelihood ratio is 0.01,
which means a negative test would be associated with
a very low posttest probability of disease for patients
with low and intermediate pretest probabilities.
Assuming that all patients would have previously been
referred for invasive angiography, coronary CT angiog-
raphy allowed the 48 patients (69%) in the study cohort
with negative CT findings to avoid this procedure. How-
ever, a positive coronary CT angiogram, defined as the
presence of epicardial CAD, requires confirmation with
invasive coronary angiography to establish the need for
and extent of CABG. The risk of radiation exposure
and renal failure due to the contrast injection should
be taken into consideration.
Supporting References: 880-88714.2. Concomitant Procedures
14.2.1. Intervention for CAD: Recommendation
In patients undergoing AVR who also have significant
CAD, the combination of CABG and AVR reduces the rates
of perioperative MI, perioperative mortality, late mortality,The Journal of Thoracic and Caand morbidity when compared with patients not undergoing
simultaneous CABG, even though the combined operation
carries a small but real increased risk of mortality. The alter-
native in some patients of a hybrid approach of surgical
valve replacement and PCI is attractive, but there are no
data at this time to support this approach.
Supporting References: 859,888
Class IIa
1. CABG or PCI is reasonable in patients undergoing valve repair or
replacement with significant CAD (70% reduction in luminal
diameter in major coronary arteries or50% reduction in luminal
diameter in the left main coronary artery). (Level of Evidence: C)
Several studies have reported the outcomes of patients
undergoing combined CABG and valve operation.
Although combined myocardial revascularization and valve
operation increases cross-clamp time and has the potential
to increase perioperativeMI and early postoperativemortal-
ity compared with patients without CAD undergoing iso-
lated valve surgery, in several series, combined CABG
had little or no adverse effect on operative mortality. More-
over, combined CABG and valve operation reduces the
rates of perioperative MI, operative mortality and late mor-
tality, and morbidity compared with patients with signifi-
cant CAD who do not undergo revascularization at the
time of valve operation. Incomplete revascularization
is associated with greater postoperative LV systolic
dysfunction and reduced survival rates after surgery
compared with patients who receive complete revasculari-
zation. For more than a decade, improved myocardial pres-
ervation techniques have been associated with reduced
overall operative mortality, and it has become standard
practice to bypass all significant coronary artery stenoses
when possible in patients undergoing valve surgery. In pa-
tients with a significant stenosis of the left anterior descend-
ing artery, a left internal thoracic artery graft should be
used if possible. No RCTs fully support the use of concom-
itant coronary revascularization in all patients with asymp-
tomatic CAD undergoing valve operation.
Supporting References: 889-895
14.2.2. Intervention for AF: Recommendations
Class IIa
1. A concomitant maze procedure is reasonable at the time of mitral
valve repair or replacement for treatment of chronic, persistent
AF. (Level of Evidence: C)
The addition of arrhythmia surgery to valve procedures
has been advocated on the basis of evidence that persistent
AF is an independent risk factor for cerebrovascular acci-
dent and mortality following surgery for VHD. When AF
has been present for>1 year, stable sinus rhythm is unlikely
with mitral repair alone. Arrhythmia procedures span a
spectrum from pulmonary vein isolation to the full maze
and a variety of intermediate procedures. The term ‘‘mazerdiovascular Surgery c Volume 148, Number 1 e97
FIGURE 11. Evaluation and management of CAD in patients undergoing valve surgery. CABG, Coronary artery bypass graft; CAD, coronary artery dis-
ease; CT, computed tomography; IE, infective endocarditis; LV, left ventricular; PCI, percutaneous coronary intervention.
Clinical Guidelines Nishimura et alprocedure’’ properly refers to a specific biatrial procedure
creating a defined set of conduction block lesions per-
formed ‘‘cut and sew’’ (‘‘maze III’’) or with tissue ablation
technologies including cryoablative or radiofrequency
(‘‘maze IV’’). The requisite lesions or incisions include
complete encirclement of the pulmonary veins en bloc, an
incision or lesion to the mitral annulus from this encircling
lesion, and a lesion to the stump of the ligated or amputated
left atrial appendage on the LA. On the right atrium, an
ablation line or incision extends in the tubular portion
from superior vena cava to inferior vena cava and along
the right atrial free wall from this lateral incision across
the body of the right atrium to the tricuspid annulus. A sepa-
rate incision or lesion extends across the right atrial
appendage down to the tricuspid annulus. As originally
described, the septum is opened into the fossa ovalis,
although this lesion or incision is increasingly omitted in
current practice. When performed in this manner, combined
with mitral valve repair or replacement, RCTs have shown
that the surgical maze procedure affords superior freedom
from AF at discharge and at 1 year (with success rates
ranging from 75% to 95% with ablation versus 10%e98 The Journal of Thoracic and Cardiovascular Surgto 40% without ablation). Combining the maze
procedure with a mitral valve procedure adds little
complexity because the LA is already open. As such, the
procedure does not appear to significantly increase opera-
tive risk of mortality in properly selected patients. In
RCTs, long-term survival and stroke risk have not been
improved by addition of the maze procedure.
Ligation or amputation of the left atrial appendage is
commonly performed in patients with AF with or without
such arrhythmia procedures with the aim of reducing the
risk of thromboembolic events, although no RCTs have
demonstrated a beneficial impact.
Supporting References: 420,896-912
Class IIa
2. A full biatrial maze procedure, when technically feasible, is reason-
able at the time ofmitral valve surgery, comparedwith a lesser abla-
tion procedure, in patients with chronic, persistent AF.907,908 (Level
of Evidence: B)
A large variety of less extensive procedures, commonly
referred to as ‘‘mini-maze’’ procedures, have been devel-
oped and promulgated, ranging from pulmonary veinery c July 2014
Nishimura et al Clinical Guidelinesisolation alone to single atrial procedures. The clinical effi-
cacy of these procedures falls below that of the full maze
procedure, although the full maze procedure may be associ-
ated with more bradycardia requiring pacemaker implanta-
tion. Although the less extensive ‘‘mini-maze’’ procedure
may be preferable in specific circumstances in which one
is willing to trade efficacy for invasiveness, when feasible,
the full maze is preferable. These less extensive procedures
are more often advocated when the AF is paroxysmal, rather
than persistent, and when combined with procedures other
than those on the mitral valve.
Supporting References: 907,908
Class IIb
1. A concomitant maze procedure or pulmonary vein isolation may be
considered at the time of mitral valve repair or replacement in pa-
tients with paroxysmal AF that is symptomatic or associated with a
history of embolism on anticoagulation. (Level of Evidence: C)
RCTs have shown that the surgical maze procedure af-
fords superior freedom from AF at discharge and at
1 year, defined as sinus rhythm at last follow-up (75% to
95% with ablation versus 10% to 40% without ablation).
When the maze procedure is added to mitral valve proce-
dures, it adds little complexity because the LA is already
open. As such, this procedure does not appear to increase
operative risk of mortality in properly selected patients. In
RCTs, neither long-term survival nor stroke risk appears
to be improved by addition of the procedure. Several non-
randomized studies, however, have suggested a reduction
in stroke risk with the addition of the maze procedure to
mitral valve repair or MVR even when a mechanical pros-
thesis is used.
Other surgical approaches to prevention of recurrent AF,
including less extensive procedures such as pulmonary vein
isolation or a left-sided-only maze, have been less success-
ful than the full maze procedure in converting the patient to
sinus rhythm. Although less effective, these less extensive
procedures are also less invasive and, accordingly, are
more often advocated when the AF is paroxysmal rather
than persistent and when combined with procedures other
than those on the mitral valve.
Supporting References: 898,900-902,904-906,913,914
Class IIb
2. Concomitant maze procedure or pulmonary vein isolation may be
considered at the time of cardiac surgical procedures other than
mitral valve surgery in patients with paroxysmal or persistent AF
that is symptomatic or associated with a history of emboli on anti-
coagulation. (Level of Evidence: C)
The addition of arrhythmia surgery to valve
procedures other than mitral valve disease has been advo-
cated on the basis of evidence that persistent AF is an inde-
pendent risk factor for cerebrovascular accident and
mortality following surgery for mitral VHD. Limited data
suggest an increased risk of HF and stroke after AVRThe Journal of Thoracic and Caas well. When combined with aortic valve surgery, the addi-
tion of the maze procedure has been shown in observational
studies to improve conversion to sinus rhythm over aortic
valve surgery alone. This occurs in the setting of chronic
AF without a statistically significant increase in operative
risk of mortality, although the potential impact of selection
bias cannot be ignored. Limited evidence suggests pulmo-
nary vein isolation is equivalent to maze in the presence
of paroxysmal AF.
Supporting References: 420,896,897,915
Class III: No Benefit
1. Catheter ablation for AF should not be performed in patients with
severe MR when mitral repair or replacement is anticipated, with
preference for the combined maze procedure plus mitral valve
repair.916 (Level of Evidence: B)
A single randomized study of patients with rheumatic
mitral valve disease compared catheter ablation with surgi-
cal maze and demonstrated superior conversion to sinus
rhythm (82% versus 55%) in the surgical group. Accord-
ingly, if surgical repair or replacement of the mitral valve
is anticipated, catheter ablation should be deferred in favor
of surgical maze.
Supporting References: 916
See Online Data Supplement 27 for more information on
the maze procedure.
15. NONCARDIAC SURGERY IN PATIENTS WITH
VHD
15.1. Diagnosis and Follow-up
The risk of noncardiac surgery is increased in patients
with significant VHD. AS is present in 1% to 2% of all pa-
tients>65 years of age and 3% to 8% of all patients>75
years of age. Severe AS is associated with an increased
risk for noncardiac surgery, depending on the specific de-
gree of valve narrowing, LV systolic function, concurrent
CAD, and other risk factors for surgery. The estimated
rate of cardiac complications in patients with undiagnosed
severe AS undergoing noncardiac surgery is 10% to
30%. Thus, TTE is appropriate in patients being evaluated
for noncardiac surgery when a systolic murmur suggestive
of AS is present for evaluation of stenosis severity and LV
systolic function to allow optimization of perioperative
management. Evaluation for concurrent CAD in patients
with AS is problematic, and standard ECG exercise testing
is not adequate. A stress echocardiographic or nuclear im-
aging study may be helpful if resting LV systolic function
is normal and AS is only mild to moderate in severity.
With severe AS, coronary angiography may be necessary
if risk factors or symptoms that might be due to coronary
disease are present.
MS may also be poorly tolerated with the altered hemo-
dynamics of anesthesia and noncardiac surgery. Left-sided
regurgitant lesions are better tolerated but still conveyrdiovascular Surgery c Volume 148, Number 1 e99
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geon are unaware of the diagnosis or severity of valve dis-
ease. Thus, whenever the clinical history or physical
examination suggests valve disease might be present, TTE
is helpful to detect valve dysfunction and quantitate the
severity of stenosis and regurgitation. Other echocardio-
graphic data useful in operative planning include LV sys-
tolic function and an estimate of pulmonary artery
systolic pressure.
Supporting References: 917-923
15.2. Medical Therapy
Anesthetic management of patients with VHD undergo-
ing noncardiac surgery should take into account the under-
lying valvular abnormality, its effect on the systolic and
diastolic function of the heart, and any comorbidities,
such as CAD or pulmonary hypertension. In noncardiac
surgical patients with AS, the reduced LV compliance
that results from the chronic pressure overload makes ven-
tricular filling dependent on preload and atrial contraction.
In the patient with AS, arrhythmias are poorly tolerated.
Specifically, tachycardia should be particularly avoided,
because the combination of a shortened diastolic filling
period and a stiff left ventricle results in inadequate LV
filling and a fall in cardiac output. If possible, sinus
rhythm should be maintained and the ventricular rate
controlled. A typical example is the patient with AS
with acute onset supraventricular tachycardia or AF, in
whom synchronized cardioversion should be applied
immediately if the patient becomes hypotensive. The atrial
contribution to LV filling is often significant, particularly
with AS and diastolic dysfunction. Intravascular volume
should be titrated at a level that ensures an adequate for-
ward cardiac output without an excessive rise in left atrial
pressure. This can be achieved by ensuring adequate vol-
ume replacement with guidance from central venous or
pulmonary pressures or dynamic pulsatility indices, and
monitoring LV chamber size with intraoperative TEE
may be particularly useful. A drop in systemic vascular
resistance may reduce diastolic BP and coronary blood
flow, leading to myocardial ischemia, and this may be
particularly detrimental in the patient with coexisting
CAD or peripheral artery disease. The anesthetic approach
and anesthetic agents should be chosen to avoid systemic
hypotension. Potential detrimental effects of the anesthetic
approach should be considered, such as acute increases in
afterload-induced laryngoscopy, tracheal intubation, or
surgical stimulation. Either phenylephrine or norepineph-
rine can be used to raise the BP; both were found to not
adversely affect LV systolic and diastolic function. In-
stances of systemic hypertension should be treated prefer-
entially with arterial dilators, such as short-acting calcium
channel blockers instead of preload-reducing agents such
as nitroglycerin. General anesthetics are well tolerated,e100 The Journal of Thoracic and Cardiovascular Surand the choice of anesthetic agents should be carefully
titrated to maintain normotension and sinus rhythm. It is
equally important to modify epidural or spinal anesthetic
interventions so that systemic pressure changes do not
occur or occur gradually. For example, only high-
dilution neuraxial local anesthetic agents in combination
with opioids should be used.
The patient with MS undergoing noncardiac surgery
should be treated in a manner similar to the patient
with AS, because the pathophysiology of the disease and
its implications are similar. Maintenance of normal
LV preload and sinus rhythm, and avoidance of tachycardia
and systemic hypotension should be the targets in the peri-
operative period. Of particular concern is judicious intrave-
nous fluid administration so as to avoid increases in the left
atrial pressure and pulmonary capillary pressure that may
precipitate acute pulmonary edema.
Patients with AR or MR present with chronic LV volume
overload. In either disease, a decrease in systemic afterload
will augment the systemic LVoutput and reduce the regur-
gitant volume. Patients with regurgitant valve lesions are
better suited to receive a regional anesthetic, because the
combination of neuraxial local anesthetics and opioids pro-
duces a favorable systemic vasodilation. However, preload
should be maintained, particularly in the chronic regurgita-
tion lesions, because there is a larger LV volume and in-
crease in diastolic compliance. Monitoring of central
venous or pulmonary pressures and size and function of
the left ventricle should be done with invasive catheters or
echocardiography.
Changes in fluid balance continue to occur postopera-
tively, so these intraoperative considerations are applicable
in the 48- to 72–hour postoperative period as well as during
the procedure.
Supporting References: 924-929
15.3. Intervention: Recommendations
When VHD is diagnosed in patients being considered
for elective noncardiac surgery, the first step is to re-
view the standard criteria for intervention of the specific
valve lesion. If the patient meets standard criteria for
intervention, it is usually prudent to defer the elective
noncardiac procedure and proceed to valve intervention
instead.
In patients with significant asymptomatic valve disease
who do not meet standard criteria for intervention, the
risk of the noncardiac procedure can be minimized by: (1)
having an accurate diagnosis of the type and severity of
valve dysfunction; (2) choosing an anesthetic approach
appropriate to the valve lesion; and (3) ensuring a higher
level of intraoperative monitoring.
In emergency situations, noncardiac surgery may be
necessary in the presence of uncorrected severe valve dis-
ease. In patients with severe AS or MS, volume shifts andgery c July 2014
Nishimura et al Clinical Guidelinesrhythm disturbances associated with the surgical stress
and cardiovascular side effects of the anesthetic medica-
tions may lead to hypovolemia and tachycardia and
further hemodynamic compromise. Thus, patients with
severe left-sided valve stenosis requiring emergency
noncardiac surgery should be managed by a cardiovascu-
lar anesthesiologist with invasive hemodynamic or TEE
imaging monitoring intraoperatively and remain in an
intensive monitoring setting for 48 to 72 hours
postoperatively.
Class IIa
1. Moderate-risk elective noncardiac surgery with appropriate
intraoperative and postoperative hemodynamic monitoring is
reasonable to perform in patients with asymptomatic severe
AS.917,920-922 (Level of Evidence: B)
The hemodynamic effects of anesthesia and surgery are
poorly tolerated in patients with severe AS. AVR is recom-
mended in all patients with symptomatic severe AS and
should be performed before other surgical interventions to
avoid hemodynamic instability during, as well as after,
noncardiac surgery.
In patients with moderate-to-severe AS, 30–day mortal-
ity is higher for patients with AS (2.1%) compared
with propensity scorematched controls (1.0%) with a
higher risk of postoperative MI in patients with AS. Predic-
tors of adverse outcomes include severity of AS, high-risk
surgery, cardiac symptoms, coexisting MR, and CAD.
However, these comorbidities also increase the risk of
AVR. The risk–benefit ratio continues to favor managing
patients with severe AS undergoing moderate-risk noncar-
diac surgery with hemodynamic monitoring and optimiza-
tion of loading conditions rather than considering
prophylactic AVR.
Adverse outcomes in the setting of aortic valve obstruc-
tion are due to the combination of the anesthetic proce-
dure (general, regional, or monitored anesthesia care)
and surgical stress. Systemic hypotension and tachycardia
may result in decreased coronary perfusion pressure,
development of arrhythmias or ischemia, myocardial
injury, cardiac failure, and death. These complications
can be avoided by periprocedural hemodynamic moni-
toring with a right-heart catheter or intraoperative TEE
to allow continuous optimization of loading conditions.
Intra- and postoperative monitoring of BP and intracar-
diac volume are implemented starting in the preoperative
period and continuing until hemodynamics are stable,
which may be as long as 24 to 48 hours after the proce-
dure. Maintenance of normal coronary perfusion pressure
with the administration of alpha-adrenergic agents, such
as phenylephrine, may be helpful early in the procedure
to avoid the detrimental consequences of myocardial
hypoperfusion.
Supporting References: 917,920-922The Journal of Thoracic and CarClass IIa
2. Moderate-risk elective noncardiac surgery with appropriate intra-
operative and postoperative hemodynamic monitoring is reason-
able to perform in patients with asymptomatic severe MR. (Level
of Evidence: C)
In patients with severe MR undergoing noncardiac sur-
gery, the overall hemodynamic goals are avoidance of
both increased afterload and bradycardia by choosing the
appropriate anesthetic scheme. Invasive hemodynamic
and/or TEE monitoring allows for continuous optimization
of loading conditions during and after the operative proce-
dure, with these patients admitted to an intensive moni-
toring setting for up to 24 to 48 hours after the procedure.
Supporting Reference: 930
Class IIa
3. Moderate-risk elective noncardiac surgery with appropriate intra-
operative and postoperative hemodynamic monitoring is reason-
able to perform in patients with asymptomatic severe AR and a
normal LVEF. (Level of Evidence: C)
Patients with severe AR are prone to hemodynamic insta-
bility because of the detrimental effects of increased vol-
ume on myocardial wall stress. The perioperative stress
associated with noncardiac surgery may lead to hypoten-
sion, arrhythmias, HF, or even death. It is especially impor-
tant to avoid bradycardia when AR is present due to the
increase in total diastolic time. These patients should be
monitored with invasive systemic arterial and venous cath-
eters and/or TEE and admitted postoperatively to an inten-
sive monitoring setting. Patients with severe AR and a
decreased LVEF, elevated serum creatinine>2 mg/dL, or
who are undergoing intermediate- to high-risk noncardiac
surgery have the highest risk of cardiopulmonary complica-
tions and death.
Supporting Reference: 931Class IIb
1. Moderate-risk elective noncardiac surgery in patients with appro-
priate intraoperative and postoperative hemodynamic monitoring
may be reasonable to perform in asymptomatic patients with severe
MS if valve morphology is not favorable for percutaneous balloon
mitral commissurotomy. (Level of Evidence: C)
Patients with asymptomatic severe MS and valve anat-
omy favorable for percutaneous balloon mitral commissur-
otomy who are undergoing elective noncardiac surgery
should be evaluated and treated pursuant to the recommen-
dations for MS (Section 4.2.3). If valve anatomy is not
favorable or if there are other contraindications to percuta-
neous balloon mitral commissurotomy, elective noncardiac
surgery may be considered with invasive hemodynamic
monitoring to optimize loading conditions. Preload should
be maintained high enough to allow an adequate forward
cardiac output across the stenotic mitral valve but low
enough to avoid pulmonary edema. Maintaining preloaddiovascular Surgery c Volume 148, Number 1 e101
Clinical Guidelines Nishimura et alin this narrow range can be challenging and requires mea-
surement of cardiac output and pulmonary wedge pressure.
Tachycardia should be avoided due to the shortened dia-
stolic LV filling time across the stenotic mitral valve, result-
ing in an increase in left atrial pressure.
Supporting References: 924,932
See Online Data Supplement 28 for more information on
noncardiac surgery.16. EVIDENCE GAPS AND FUTURE DIRECTIONS
Current recommendations for evaluation and
management of VHD are largely based on clinical experi-
ence and observational studies, with few prospective
RCTs. We recommend that research on valve disease span
the spectrum from basic science to prospective randomized
trials and that studies focus on each stage of the disease pro-
cess from the patient at risk to the patient with end-stage
disease.16.1. Prevention of Valve Disease—Stage A
On a worldwide basis, rheumatic fever remains the pri-
mary cause of VHD; global health systems outcomes
studies are needed to identify impediments to successful
primary and secondary prevention of rheumatic heart dis-
ease. Other approaches to prevention (such as vaccine
development) and delaying disease progression once valve
damage is present should also be explored. Disease preven-
tion in patients at risk of other types of valve disease is
needed. Some subgroups at risk of calcific AS can be iden-
tified, such as those with a congenital bicuspid aortic valve
or elevated lipoprotein(a) levels. However, there are no
known therapies to prevent valve dysfunction in these pa-
tients. Basic science studies on the genetic and pathobiolog-
ical causes of valve dysfunction will provide insight into
mechanisms of disease initiation and progression that might
be amenable to medical therapy.
Supporting References: 933-93816.2. Medical Therapy to Treat or Prevent Disease
Progression—Stage B
In patients with early VHD, including those with calcific
or myxomatous disease, there are currently no therapies to
prevent disease progression in the valve leaflets. Instead,
our recommendations are all directed toward patient moni-
toring with the intent to intervene once severe disease is pre-
sent that results in symptoms or abnormal cardiovascular
function. Again, basic science studies are needed to identify
potential targets for prevention of progressive VHD that
then can be translated into prospective clinical trials. Addi-
tional studies are needed for therapies that might prevent the
adverse consequences of VHD, such as LV dysfunction and
pulmonary hypertension.
Supporting Reference: 939e102 The Journal of Thoracic and Cardiovascular Sur16.3. Optimal Timing of Intervention—Stage C
Current approaches to identifying the optimal timing of
intervention in patients with progressive valve disease are
suboptimal. Symptom onset is a subjective measure and
may occur too late in the disease course for optimal long-
term outcomes. Despite the availability of sophisticated
approaches for measurement of LV volumes, systolic func-
tion, diastolic function, and other measures of myocardial
performance, recommendations rely only on simple linear
dimensions used in published series with data that may
not reflect contemporary clinical outcomes. We urgently
need studies evaluating the value of newer measures of
LV size, function, and myocardial structure in predicting
outcomes after valve intervention. However, LV enlarge-
ment and dysfunction are late consequences of valve
dysfunction; as more durable approaches to restoring
normal valve function are developed, the balance of bene-
fitrisk for intervention will shift to earlier in the disease.
Studies examining the role of earlier markers of
myocardial dysfunction such as strain and strain-rate imag-
ing, diastolic dysfunction, serum markers, and other novel
approaches to defining the optimal timing of intervention
also are needed.
Few studies have included adequate numbers of older
adults to make specific recommendations for this group of
patients in whom particular concerns, such as cognitive
function, frailty, and mobility challenges, may change the
decision algorithms.
Given the relatively low risk of intervention in otherwise
healthy patients and the improved options for valve repair or
replacement, RCTs of intervention for severe asymptomatic
VHD are needed. Examples of specific conditions where
clinical equipoise exists are asymptomatic severe AS in
otherwise healthy patients, asymptomatic severe AR with
normal LV systolic function, and severe primary MR with
normal LV function and a high likelihood of valve repair.
Data from large, carefully designed registries are also
needed for defining and improving quality of care.
16.4. Better Options for Intervention—Stage D
We need better options for valve repair and replacement.
The timing of intervention is based on the balance between
outcomes with native valve disease and the risk and long-
term durability of the valve after intervention. As valve
repair and replacement options improve, the balance will
shift toward earlier intervention. We need a valve substitute
that can be safely and reliably implanted, is nonthrombo-
genic, has hemodynamics similar to a normal native valve,
and is durable. Transcatheter valve procedures offer the
promise of safe implantation and excellent hemodynamics,
but long-term durability is not yet known. In patients who
require mechanical valve replacement, we need oral therapy
that provides effective anticoagulation with a low risk of
complications and no negative impact on quality of life.gery c July 2014
Nishimura et al Clinical GuidelinesModerate-to-severe VHD is present in 2.5% of the U.S.
population and increases in prevalence with age. The dis-
ease affects between 4% and 9% of those 65 to 75 years
of age and 12% to 13% of those>75 years of age. Many
of these patients require surgical or interventional proce-
dures. However, even with intervention, overall survival is
lower than expected, and the risk of adverse outcomes
due to VHD is high, both because of limited options for
restoring normal valve function and failure to intervene at
the optimal time point in the disease course. We urgently
need research on almost every aspect of VHD to ensure
that patients who already have VHD receive optimal ther-
apy and to prevent VHD in those at risk. Approaches to
improving outcomes in patients with VHD include: (1) na-
tional and international registries and RCTs; (2) continuous
evaluation of outcomes data at each Heart Valve Center of
Excellence; and (3) a focus on patient-centric care with
involvement of the patient in the decision-making process.
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 Bracco None None None  None None
Nancy M. Albert Content Reviewer—
ACC/AHATask
Force on Practice
Guidelines
Cleveland Clinic
Foundation—Senior
Director of Nursing
Research and Clinical
Nursing Specialists,
Kaufman Center for
Heart Failure
 Medtronic None None None  None None
Jeffrey L. Anderson Content Reviewer—
ACC/AHATask
Force on Practice
Guidelines
Intermountain Medical
Center—Associate
Chief of Cardiology
 Sanofi-aventis None None  GlaxoSmithKline  None None
Robert H. Beekman Content Reviewer—
Adult Congenital
and Pediatric
Cardiology Section
Cincinnati Children’s
Hospital Medical
Center—Division of
Cardiology
 St. Jude
Medical
None None None  None None
Vera A. Bittner Content Reviewer—
Prevention of
Cardiovascular
Disease Committee
University of Alabama at
Birmingham—
Professor of Medicine;
Director, Cardiac
Rehabilitation
 Novartis None None  Amgen
 AstraZenecay
 Eli Lillyy
 GlaxoSmithKline*
 NIH/Joint Abbott*
 Sanofi-aventisy
 Schering Ploughy
 Pfizer None
Biykem Bozkurt Content Reviewer—
ACC/AHATask
Force on Practice
Guidelines
Michael E. DeBakey VA
Medical Center—Mary
and Gordon Cain Chair
and Professor of
Medicine
None None None  Forest
Pharmaceuticals—
PI*
 Amgen
 Corthera
 Novartis
None
Joseph Cleveland Content Reviewer—
Heart Failure
and Transplant
Council
University of Colorado
Anschutz Medical
Center—Professor of
Surgery; Surgical
 Sorin None None  Heartware  None None
(Continued)
APPENDIX TABLE 2. Continued
N
ish
im
u
ra
et
a
l
C
lin
ica
l
G
u
id
elin
es
T
h
e
J
o
u
rn
a
l
o
f
T
h
o
ra
cic
a
n
d
C
a
rd
io
v
a
scu
la
r
S
u
rg
ery
c
V
o
lu
m
e
1
4
8
,
N
u
m
b
er
1
e1
2
7
Reviewer Representation Employment Consultant
Speaker’s
bureau
Ownership/
partnership/
principal
Personal
research
Institutional,
organizational, or
other financial benefit Expert witness
Director, Cardiac
Transplantation and
Mechanical Circulatory
Support
Salvatore P. Costa Content Reviewer Geisel School of Medicine
at Dartmouth—
Associate Professor of
Medicine; Dartmouth-
Hitchcock Medical
Center Section of
Cardiology—Medical
Director,
Echocardiography Lab
None None None  Edwards
Lifesciences
(PARTNERS 2
Trial)—Co-PIy
 None None
Lesley Curtis Content Reviewer—
ACC/AHATask
Force on Practice
Guidelines
Duke University School of
Medicine—Associate
Professor in Medicine
None None None  GE Healthcare*
 GlaxoSmithKline*
 Johnson and
Johnson*
 None None
Larry S. Dean Content Reviewer—
Intervention Council
University of Washington
School of Medicine—
Professor of Medicine
and Surgery; Director,
UW Medicine Regional
Heart Center
 Philips
Medical
 Daiichi-
Sankyo
 Eli Lilly
 Emageon  Edwards
Lifesciences*
 None None
Jeanne M. DeCara Content Reviewer—
Council on Clinical
Practice
University of Chicago
Medicine—Associate
Professor of Medicine,
Section of Cardiology
None None None None  None None
Susan Farkas Content Reviewer—
ACC Board of
Governors
Sanford Medical Center
Fargo—Cardiologist
None None None None  None None
Frederico Gentile Content Reviewer Centro Medico
Diagnostico
None None None None  None None
Linda Gillam Content Reviewer Morristown Medical
Center—Professor of
Cardiology; Vice Chair,
Cardiovascular
Medicine
None None None  Edwards
Lifesciencesy
 Edwards
Lifesciencesy
None
Charles Hogue, Jr. Content Reviewer Johns Hopkins University
School of Medicine—
Professor of
Anesthesiology &
Critical Care Medicine;
Chief, Division of Adult
Anesthesia
None None None None  Merck (DSMB)  Defendant,
Operative
Mortality,
2012
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Pei-Hsiu Huang Content Reviewer—
Content Lifelong
Learning Oversight
Committee
(Educational)
Sutter Medical Center—
Interventional
Cardiologist
None None None  St. Jude Medical
 Boston Scientific
 Abbott Vascular
 None None
Judy W. Hung Content Reviewer Harvard Medical School—
Associate Professor of
Medicine;
Massachusetts General
Hospital—Associate
Director,
Echocardiography
None None None None  None None
Bernard Iung Content Reviewer Bichat Hospital—
Professor of Cardiology
 Abbott
 Boehringer
Ingelheim
 Edwards
Lifesciences
 Valtech
None None None  Archives of
Cardiovascular
Disease (Associate
Editor)y
 Boehringer
Ingelheimy
None
Amar Krishnaswamy Content Reviewer—
Content Lifelong
Learning Oversight
Committee
(Educational)
Cleveland Clinic—
Associate Staff, Robert
and Suzanne Tomsich
Department of
Cardiovascular
Medicine
None None None None None None
David Lanfear Content Reviewer—
Heart Failure and
Transplant Council
Henry Ford Hospital—
Assistant Professor,
Heart and Vascular
Institute in the Center
for Health Services
Research
 Thoratec None None  Amgen*
 Biocontrol*
 CardioRentis
 None None
Richard Lange Content Reviewer University of Texas Health
Science Center at San
Antonio—Professor of
Medicine
None None None None  None None
M. Regina
Lantin-Hermoso
Content Reviewer—
Adult Congenital
and Pediatric
Cardiology Section
Texas Children’s Hospital
Heart Center—
Associate Professor of
Pediatrics, Section of
Cardiology; Medical
Director, Cardiology
Clinics
None None None None  None None
D. Craig Miller Content Reviewer Stanford University
Medical Center,
Cardiothoracic Surgery
 Abbott
Vascular
 Medtronic*
None None  Edwards
Lifesciencesy
 None None
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Clinic—Professor of
Cardiovascular Surgery
 Medtronic
Heart Valve
Division
 MitraClip
 Edwards
Lifesciencesy
 St. Jude
Medical
Tom C. Nguyen Content Reviewer—
Content Lifelong
Learning Oversight
Committee
(Educational)
University of Texas Health
Science Center at
Houston—Assistant
Professor of
Cardiovascular Surgery
None None None None  None None
Philippe Pibarot Content Reviewer Laval University—
Professor, Department
of Medicine; University
of Cardiology and
Pneumology of
Quebec—Chair,
Canada Research Chair
in Valvular Heart
Diseases
None None None  Edwards
Lifesciences*
 None None
Geetha Raghuveer Content Reviewer—
ACC Board of
Governors
University of Missouri-
Kansas City School of
Medicine— Associate
Professor of Pediatrics;
Pediatric Cardiologist
None None None None  None None
Michael J. Reardon Content Reviewer Methodist DeBakey Heart
& Vascular Center—
Professor of
Cardiothoracic Surgery
 Medtronic None None  Medtronic  None None
Raphael Rosenhek Content Reviewer Medical University of
Vienna—Associate
Professor, Department
of Cardiology
None  Abbott
 Edwards
Lifesciences
None None  None None
Hartzell V. Schaff Content Reviewer Mayo Clinic—Stuart W.
Harrington Professor of
Surgery
None None None None  None None
Allan Schwartz Content Reviewer Columbia University—
Chief, Division of
Cardiology
None None None None  None None
Frank W. Sellke None None None  CLS Behring  CLS Behring None
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Content Reviewer—
ACC/AHATask
Force on Practice
Guidelines
Rhode Island Hospital—
Chief, Division of
Cardiothoracic Surgery
and Lifespan Heart
Center
 The Medicines
Company
 The Medicines
Company
Dipan Shah Content Reviewer—
Cardiovascular
Section Leadership
Council
Houston Methodist
DeBakey Heart &
Vascular Center—
Director,
Cardiovascular MRI
Laboratory; Weill
Cornell Medical
College—Assistant
Professor of Medicine
None  AstraZeneca*
 Lantheus
Medical
Imaging
None  Astellas*
 Siemens Medical
Solutions*
 None None
Win-Kuang Shen Content Reviewer—
ACC/AHATask
Force on Practice
Guidelines
Mayo Clinic Arizona,
Phoenix Campus—
Professor of Medicine;
Consultant
None None None None  None None
Adam Skolnick Content Reviewer—
Geriatric Cardiology
Section Leadership
Council
NYU School of
Medicine— Assistant
Professor of Medicine,
Leon H. Charney
Division of Cardiology;
Associate Director,
Health Care Center
None None None None  None None
Craig R. Smith Content Reviewer Columbia University
College of Physicians
and Surgeons—
Professor of Surgery;
Chair, Department of
Surgery; New York-
Presbyterian Hospital/
Columbia University
Medical Center—
Surgeon-in-Chief
None None None  Edwards
Lifesciences—PI
 None None
Ruth H. Strasser Content Reviewer—
AIG
Heart Centre,
University Hospital,
University of
Technology, Dresden—
Professor, Director, and
Chair, Internal
Medicine and
Cardiology Clinic;
None None None None  Abbotty
 AstraZenecay
 Bayery
 Biosensorsy
 Pfizery
None
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Medical Director, Heart
Centre
Rakesh Suri Content Reviewer Mayo Clinic—Associate
Professor of Surgery
None None None None  Edwards
Lifesciencesy
 Soriny
 St. Jude Medicaly
None
Vinod Thourani Content Reviewer—
Surgeon Council
Emory University  Edward
Lifesciences
 Sorin
 St. Jude
Medical
None  Apica
Cardiovasculary
 Maquet  None None
Alec Vahanian Content Reviewer Hospital Bichat—
Department de
Cardiologie
 Abbott
Vascular
 Edwards
Lifesciences
 Medtronic
 St. Jude
Medical
 Valtech
None None None  None None
Andrew Wang Content Reviewer Duke University Medical
Center—Professor of
Medicine
None None None  Abbott Vascular*
 Edwards
Lifesciences*
 None  Defendant,
Sudden death,
2012
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